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Abstract 
Urothelial cell carcinoma of the bladder is characterized by multifocality. 
Identification of molecular events associated with multifocal disease will 
increase understanding of disease pathogenesis, aid development of 
targeted therapies and ultimately lead to reduced morbidity, mortality and 
healthcare costs. In the first part of the project, I determined genome-wide 
copy number alterations and mutations in key genes in synchronous 
multifocal non-invasive tumours in order to: 
 • Assess monoclonal or oligoclonal origin. 
• Assess molecular heterogeneity of tumours within one patient as this might 
imply differential response to treatment. 
• Identify specific features of multifocality i.e. is multifocal disease different 
from solitary disease matched for grade and stage. 
 
One-way hierarchical cluster analysis of copy number and mutational data of 
FGFR3, PIK3CA and RAS genes from 66 tumours was performed to assess 
the relationships between the individual tumours of each patient. Tumours 
separated into 3 main clusters with tumours from the same patient tending to 
group together. The majority of tumours from the same patient shared at 
least a few copy number alterations indicating monoclonal origin. 
Comparison of multifocal and solitary tumours of the same grade and stage 
revealed that multifocal tumours exhibited higher frequencies of 
chromosomal alterations than solitary counterparts. 
In the second part of the project I used immunohistochemistry on tissue 
microarrays to assess whether the FGFR3 expression status of a primary 
bladder tumour can serve as a surrogate for the related metastases. 
Expression levels in two evaluable tissue spots from the primary tumour (n= 
97) or the lymph node metastases (n = 90) showed a high level of 
concordance (primary tumour: OR=8.6, p=0.000003; metastases: OR=16.7, 
p=0.0000002). 
With few exceptions, the levels of FGFR protein expression were the same 
in matched primary and metastatic lesions (p=0.78), suggesting that 
expression in the primary tumour can be used to select FGFR-targeted 
therapy for disseminated disease.  
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Aims 
 
 
Bladder cancer is commonly characterized by development of multifocal 
tumours in the same patient and tumour multifocality is associated with 
poorer outcomes. Cytogenetic studies have provided evidence of non-
random chromosomal aberrations, which can vary from few changes in low 
stage and/or grade tumours to highly deranged karyotypes in advanced, 
muscle-invasive disease [1]. Strong association between tumour’s 
karyotypic complexity and stage and grade has been noted in multiple 
studies [2]. This might indicate that tumours progressively accumulate 
genetic alterations on bladder carcinogenesis pathway. Analysis of bladder 
tumours and cell lines with aCGH described multiple genomic changes 
underlying neoplastic development [3-5].  These studies provided detailed 
evidence on deleted or amplified regions of tumours of different stage and 
grade with no distinction of tumours multifocality. In our study I aimed to 
determine genome-wide copy number alterations and mutations in key 
genes in synchronous multifocal tumours in order to: assess tumour 
monoclonality or oligoclonality; assess the molecular heterogeneity of 
tumours; identify unique features related to multifocality as opposed to 
solitary disease matched for grade and stage. I hypothesise that tumours 
multifocality might represent a significant risk factor for tumours progression 
and/or recurrence in superficial bladder cancers. Non-muscle invasive 
multifocal tumours at the cytogenetic level might resemble more advanced 
disease than non-multifocal tumours matched for stage and grade. One of 
the methods chosen to test the hypothesis was aCGH. This technique 
enables the characterisation of large chromosomal aberrations as well as 
amplified and deleted regions to the level of specific candidate genes. 
In the second part of the project I used immunohistochemistry on tissue 
microarrays to assess whether the FGFR3 expression status of a primary 
bladder tumour can serve as a surrogate for the occurrence of related 
metastases. 
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Chapter 1 
Introduction 
 
1.1  Bladder cancer 
 
Bladder cancer is the most frequently occurring tumour of the urinary tract. 
Worldwide an estimated 386,000 new cases of bladder cancer were 
diagnosed in 2008 representing about 3.2% of all cancers. Transitional cell 
carcinoma is the most common type of bladder cancer in Europe, comprising 
90-95% of cases in the UK, bladder cancer is the seventh most common 
cancer, accounts for approximately 1 in 30 new cases of cancer each year. It 
is more common in males than in females (3.7:1) and represents the sixth 
cause of death in males and the thirteenth in females [6]. The high incidence 
rates of bladder cancer are observed in Western Europe, North America and 
Australia. The areas associated with endemic schistosomiasis in Africa and 
the Middle East are also reported to have a high incidence rate of bladder 
cancers, majority of which are squamous cell carcinomas. The median age 
for diagnosis is 65 years old, and the disease is seldom diagnosed before 40 
years old.  
 
1.1.1  Histology, presentation and survival 
 
At initial presentation over 70% of patients have low-grade tumours confined 
to the urothelium or submucosa (Ta, T1, Cis). This is depicted in Figure 1.1 
and 1.2 and described in text below. The primary treatment for these 
patients consists of transurethral resection and in the majority cases 
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Figure 1.1: The staging of TCC 
Ta: Superficial papillary tumour that has not invaded the lamina propria 
(i.e. not breached the basement membrane) 
T1: Invasion of the lamina propria 
T2: Tumour invades the superficial (T2a) or deep muscle (T2b) 
T3: Tumour invades the peri-vesical fat microscopically (T3a) or 
macroscopic (T3b) 
T4: Invades the pelvic viscera (T4a invade the prostatic stroma, rectum, 
vagina or uterus; T4b tumours extend to the pelvic sidewall or 
abdominal walls). Adapted from Turo, 2012 [7] 
 
 
 
Figure 1.2: Comparison of the 1973 and 2004 WHO grading system [8, 
9]. The 1973 WHO grade 1 and grade 2 carcinomas are not 
interchangeable with the 2004 WHO PUNLMP and low grade carcinoma 
category. Some grade 1 carcinomas are assigned to the PUNLMP 
category, and some to the low-grade carcinoma category. Similarly, 
grade 2 carcinomas are assigned, some to the low-grade carcinoma 
category, and others to the high-grade carcinoma category. All grade 3 
tumours are assigned to the high-grade carcinoma category. WHO = 
World Health Organization; PUNLMP = papillary urothelial neoplasm of 
low malignant potential. Adapted from MacLennan, 2007 [8] 
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additional administration of intravesical immuno- or chemo-therapy to reduce 
the risk of disease recurrence and/or progression. Fifteen to thirty per cent of 
these tumours show grade and stage progression, eventually requiring 
radical treatment [10]. However, these tumours despite being classified as 
‘lower risk’ tumours tend to re-occur after primary treatment and therefore 
require intensive clinical follow up, in the form of cystoscopic surveillance . 
The risk of recurrence in these patients with superficial disease can be as 
high as 70% [11]. Due to an extensive follow up regime , transurethral 
resections of recurrences and treatment with intravesical instillations bladder 
cancer is the most expensive malignancy to treat per patient [12]. Two large 
studies identified that the average cost of treatment per patient was $65,158 
(US dollars).The estimated lifetime costs for patients averaged $99,270 in 
the best-case scenario and$120,684 in the worst-case scenario [13].The 
calculated 5-year net cost of bladder cancer was one billion dollars (one of 
the highest among all cancers) in 2008 [14]. Therefore bladder cancer is a 
major public health issue and development of diagnostic, treatment and 
surveillance methods is required. The need for better prognostic tools to 
individualize management and care is also of high priority. 
Twenty to thirty per cent of patients with bladder cancer present with muscle 
invasive disease, which has a less than 50% disease specific survival at 5 
years. Lymph node involvement reduces the 5- and 10-year recurrence-free 
survival rates to 35 and 34%, respectively [15, 16].  
Current gold standard treatment for muscle invasive bladder cancer is 
bilateral pelvic lymphadenectomy and radical cystoprostatectomy in men 
and anterior exenteration in women. This treatment can offer long-term 
disease free survival in up to 70% in patients with organ-confined disease 
[17]. 
Pelvic lymphadenectomy is performed for staging and prognostic purposes, 
but also potentially offers a therapeutic role. It has been reported that up to 
30% of patients with pelvic lymph node metastasis remained recurrence free 
5 years after cystectomy and pelvic lymphadenectomy. The optimal extent of 
lymphadenectomy still has not been determined and numerous approaches 
to assess the subject have been applied (overall lymph node count, number 
of positive lymph nodes, lymph node density) [18-23]. 
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In the majority of cases of muscle invasive bladder cancer or lymph node 
positive bladder cancer surgical resection is not sufficient and additional 
systemic therapy is required. Therefore, from the therapeutic point of view, it 
is more important to eradicate the micro-metastasis that often cannot be 
identified by preoperative imaging rather than increase local curability by 
improving radical cystectomy results. Systemic chemotherapy using drug 
combination regimens is the standard therapy for metastatic transitional cell 
carcinoma of the bladder. The gold standard treatment was considered the 
combination of four drugs: methotrexate, vinblastine, doxorubicin and 
cisplatin (MVAC) as described by Sternberg et al [24] and Chester et al [25]. 
The median survival for patients on this regime is 11-13 months with a 5 
year progression free survival of only 3% [26]. Subsequent studies revealed 
significant toxicity associated with MVAC including serious complications of 
neutropenia, mucositis and toxic death in 3-4% of cases. Therefore MVAC 
regime has subsequently been replaced with the combination of gemcitabine 
and cisplatin (GC) [24, 27-29]. A large randomized study comparing both 
regimes demonstrated similar response rates (GC, 49% and MVAC, 46%;  p 
= 0.51), progression-free survival (GC, 7.7 months and MVAC, 8.3 months; p 
= 0.63), and median survival (GC, 14 months and MVAC, 15.2 months; p = 
0.66), with significantly improved tolerability and safety profile for the GC-
treated patients with locally advanced or metastatic TCC. However, cisplatin-
containing chemotherapy is only suitable for patients with good performance, 
adequate renal function and no comorbidity that prevents high-volume 
hydration [30, 31]. 
 
1.1.2  Prognostic factors 
 
At present there are limited number of established prognostic factors for 
recurrence, progression, and overall survival based on histological and 
anatomical appearance of the bladder cancer. These include: tumour grade, 
T stage classification, associated carcinoma in situ (Cis), multifocality and 
the presence of lymph node metastasis. Based on these factors, the 
European Organization for Research and Treatment of Cancer (EORTC) 
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has published risk tables to assist clinicians in creation of individualised 
management plans and surveillance protocols according to calculated risk of 
recurrence and progression [32]. Despite the efforts to identify patients that 
are at high risk of progression and/or recurrence and reduce the frequency 
of patients’ clinical visits, nearly 75% of cystoscopies at follow up are normal 
[33]. As a consequence there is an on-going search for novel markers to 
predict the chance of recurrence and guide therapeutic interventions on an 
individual basis.  
 
1.1.3  Molecular features of bladder cancer 
 
Bladder cancer is a heterogenous disease that significantly differs with 
regards to histopathological characteristics and clinical presentation. 
Improvements in classification that lead to better bladder cancer 
management, together with extensive characterization of the molecular 
alterations will lead to improved understanding of this disease and ultimately 
enhance prognostication and treatment modalities. There has already been 
significant progress in identification of various epigenetic and genetic 
alterations that are involved in the development and progression of bladder 
tumours [34]. Our knowledge has been improved on the nature of different 
molecular events that occur most frequently and are associated with a 
specific type of tumour. Based on tumours’ molecular characteristics a new 
subcassification can be achieved in the near future. 
Molecular features of invasive and non-muscle invasive bladder (NMIBC) 
cancer are distinct and commonly present different spectrum of genetic and 
epigenetic changes. Alterations identified and correlated with NMIBC include 
those involving oncogenes NRAS (1p13), HRAS (11p15), KRAS2 (12p12), 
FGFR3 (4p16), PIK3CA (3q26), CCND1 (11q13), MDM2 (12q13) and 
tumour suppressor genes DBC1 (9q32–33), PTCH (9q22), CDKN2A (9p21). 
Genomic alterations reported in MIBC frequently involve CDKN2A (9p21), 
PTEN (10q23), RB1 (13q14), TSC1 (9q34) and TP53 (17p13). 
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1.1.4  Role of FGFR3 receptor in bladder cancer 
 
Over 50% of primary bladder tumours harbour activating mutations in the 
FGFR3 gene [35, 36]. The majority of these somatic mutations are similar to 
germ line mutations responsible for skeletal disorders such as 
achondroplasia, hypochondroplasia, severe achondroplasia with 
developmental delay and acanthosis nigricans (SADDAN) and thanatophoric 
dysplasia [37]. The early study of FGFR3 mutations in bladder cancer, was  
performed by Capellen and colleagues who  identified mutations in 35% of 
bladder carcinomas that were identical to two lethal forms of dwarfism [35]. 
This rather unexpected finding led to further extensive investigations on 
FGFR3 receptor in bladder cancer and associated mutations of FGFR3. To 
date, studies have identified 11 mutations of this receptor [35, 38-47]. It has 
also become evident that these are associated with superficial bladder 
cancer rather than muscle invasive disease [39, 45]. The overall frequency 
and distribution of these is shown in Table 1.1. Among the most frequent 
mutations are S249C (66.6%) and Y375C (15.1%); and the least frequent 
are: S373C (0,1%), G282R (0,1%), K652Q (0,1%).  
The mutation S249C causes ligand independent dimerization and signalling 
by producing cysteines in the extracellular domain of the receptor. This 
process is mediated by conversion of a serine residue between 
immunoglobulin domains II and III and thus preventing the formation of 
normal disulphide bonds within the chains or by enabling the formation of 
bonds between chains [48]. FGFR3 mutations are also found in benign skin 
conditions, including seborrheic keratoses, benign skin lesions commonly 
seen in elderly patients [49, 50] and in epidermal nevi [51], and seem to be 
absent in other studied malignancies such as breast, prostate, skin, brain, 
ovarian, lung, renal, oesophageal and stomach. The only other malignancy 
where FGFR3 mutations were found is multiple myeloma and cervical 
carcinoma [51, 52]. 
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Mutation Frequency (%) Exon Part of receptor 
S249C 66.6 7 Extracellular 
R248C 9.7 7 Extracellular 
G372C 4.3 10 Transmembrane 
S373C 0.1 10 Transmembrane 
Y375C 15.1 10 Transmembrane 
G282R 0.1 10 Transmembrane 
A393E 1.2 10 Transmembrane 
K652M 1.0 15 Kinase domain 
K652Q 0.1 15 Kinase domain 
K652E 1.4 15 Kinase domain 
K652T 0.4 15 Kinase domain 
 
Table 1.1 Relative frequencies and positions of FGFR3 mutations in 
bladder cancer (all grades and stages). Frequencies are the percentage 
of all FGFR3 mutations described to date. Adapted from Knowles, 2005 
[53] 
 
Four out of five family members of FGF receptors (FGFR1-5) harbour 
tyrosine kinase function. They play a significant role in cells differentiation, 
apoptosis, growth, adhesion and mobility [54] and activation of these 
receptors by gene overexpression or mutation may lead to tumour 
development. Once FGFR is activated, signal is transduced through three 
pathways: phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein 
kinases (MAPK) and phospholipase C-gamma (PLC-γ); and this leads to the 
regulation of critical processes within the cell such as migration, survival, 
growth and differentiation [55]. (Figure 1.3). 
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Figure 1.3: The FGFR signaling pathway. Once FGFR3 is activated by 
ligand binding, signal is transduced through three pathways: 
phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinases 
(MAPK) and phospholipase C-gamma (PLC-γ), which then activates 
RAS and downstream RAF and MAPK pathways 
 
FGFRs consist of an extracellular domain that includes an amino terminal 
hydrophobic signal peptide, three immunoglobulin-like domains, a 
hydrophobic transmembrane domain, and an intracellular tyrosine kinase 
domain, Figure 1.3 [56]. The FGFR family is highly conserved throughout 
evolution. The receptor’s ligands (fibroblast growth factors) bind to 
extracellular Ig-like domains II and III, leading to downstream signalling [57]. 
It has been confirmed that the ligand-receptor binding is not only dependent 
on the specific receptor but also by alternative RNA splicing of FGF 
receptors in the Ig domain. This generates to two alternative isoforms 3b and 
3c [56, 58-60]. 
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Figure 1.4: FGFR3 receptor structure. IgI, IgII, IgIII, immunoglobulin-like 
domains; TK-1, TK-2, split tyrosine kinase domain, TM 
Transmembrane. Frequent mutations occur in three regions of the 
FGFR3 gene, located in exons 7, 10 and 15 
 
Studies explaining the role of FGFR3 mutation status in tumour development 
have been performed in urothelial hyperplasia, which is thought to be an 
early bladder cancer precursor. Hyperplastic lesions are commonly found 
adjacent to bladder cancer of different stages and grades.The study 
examining these lesions in 30 patients with simultaneous or consecutive 
papillary tumours, it was found that FGFR3 mutation was present in 23% of 
hyperplasias and simultaneous chromosome 9 LOH in 30%. In 7% of 
patients, FGFR3 mutation alone was present, and in 20% of cases 
chromosome 9 LOH alone was found. The authors of this study concluded 
that chromosome 9 losses might occur earlier than FGFR3 mutation during 
the development of papillary TCC [61]. Further evidence confirming an early 
role of FGFR3 mutation in bladder tumorigenesis has come from studies 
examining  papillomas, which are considered by the majority of 
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histhopathologists regarded as precursors of TCC. In one study, examining 
12 samples of urothelial papillomas, FGFR3 mutation was found in 75% [46]. 
Another way of assessing the role of FGFR3 mutation status and examining 
its time of appearance along the tumour development pathway, is the 
examination of different areas that represent different tumour stages within 
the same tumour from the same patient. Knowles and colleagues showed 
that mutation status was found to be different in different regions of tumour 
blocks from 8 of 158 patients [62]. Interestingly in most of the cases the 
mutation was found in the non-invasive component of the tumour. Two out of 
8 samples were also reported as multifocal. It might be suggested that 
FGFR3 mutations occur early in tumour development and the allele 
containing the FGFR3 mutation is lost in the high stage region at later stage 
or that a small subset of FGFR3 wild-type cells present in the low stage 
tumour had progressed and overgrown the remaining part of the tumour. 
When the presence of FGFR3 mutation was examined in relation to other 
molecular abnormalities it was found that RAS gene mutations and FGFR3 
mutations are mutually exclusive [63]. This mutual exclusivity phenomenon 
of both mutations may be explained by activation of the same RAS-MAPK 
pathway by either event [64] and this may represent an alternative means of 
contributing to the same phenotype on urothelial cancer cells. 
 
1.1.5  Role of RAS genes  in bladder cancer 
 
In humans more than 100 members of small Ras proteins have been 
identified [65]. The majority of them do not exceed 30 kDa and they bind and 
hydrolyze guanosine triphosphate (GTP), cycling between a GTP active 
state and an inactive guanosine diphosphate (GDP) state, Figure 1.5. In 
cells they act as mediators in signal transduction and membrane trafficking 
playing important role in cell cycle control, apoptosis regulation, involvement 
in endocytosis and exocytosis, adhesion regulation, cell cycle progression  
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Figure 1.5: GTP/GDP cycle of Ras proteins. Monomeric G proteins 
cycle through GTP bound and GDP bound. This cycle is regulated by 
GEFs, which stimulate exchange of GDP for GTP, by GAPs, which 
stimulate hydrolysis of GTP, and by GDIs, which bind to GDP bound 
form and inhibit nucleotide exchange. GTP bound form is capable of 
stimulating various downstream effectors. Guanine nucleotide 
exchange factors (GEFs), guanosine triphosphate (GTP), guanosine 
diphosphate (GDP), guanine nucleotide dissociation inhibitors (GDIs), 
guanosine triphosphatase activating proteins (GAPs). Effectors 
regulate: cell cycle, apoptosis, involvement in endocytosis and 
exocytosis, adhesion, cell cycle progression and cell motility.  
 
and cell motility [66]. The RAS family is divided into 11 members, including 5 
RAS (N-RAS, K-RAS2, H-RAS, M-RAS, and R-RAS), 4 Rap and 2 Ral 
proteins. RAS proteins in mutated and/or overexpressed form are relatively 
common in human cancers, present in about 30% of tumours [67]. Activating 
mutations in RAS genes result in a constitutively active GTP bound form of 
the protein. Three RAS genes (H-RAS, K-RAS and N-RAS) encode highly 
homologous proteins with only significant amino acid differences at the C-
terminal (40 amino acids). The function of this region is primarily in localizing 
these proteins inside the cell. All 3 proteins, encoded by these genes are 
associated with the plasma membrane. H-RAS and N-RAS are also found in 
significant amounts on endomembranes [68]. The three well characterized 
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effectors of RAS are RAF - protein kinases involved in mitogen activated 
protein (MAP) kinase signalling cascades, PI3 - lipid kinases that play role in 
inositol phospholipid signalling by generating PIP3 from PIP2 and a family of 
GEFs (RALGDS) (Figure 1.6). Point mutation of RAS gene leads to 
subsequent oncogenic activation of the phosphatidylinositol 3-kinase (PI3K) 
signalling pathway through the interaction of RAS with p110α unit [69]. 
Activating HRAS mutations were first discovered in bladder cancer [70]. The 
frequency of HRAS mutations in bladder cancer has been assessed in 
multiple studies, which reported a widerange of frequencies from 3% to 84% 
[70-73]. This range may be potentially due to various methods involved, 
differences of sensitivities or potential methodology errors. It is generally 
accepted that activating mutations in HRAS or KRAS2 occur in 
approximately 13% of human bladder tumours [63, 74]. 
There was no correlation between tumour’s stage/grade and RAS mutation 
status. To my knowledge there is no reported literature on the RAS mutation 
status in multifocal bladder cancer. 
 
 
 
Figure 1.6: Common Ras effectors. Three best characterized effectors 
stimulated by Ras-GTP are Raf, which is protein kinase linked to MAP 
kinase cascades; RalGDS, exchange factor (GEF) for RalA and RalB, 
which stimulates their activation to GTP bound form, and lipid kinase 
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PI3K, which drives production of PIP3, contributing to activation of 
many cellular proteins by recruiting them to plasma membrane 
 
1.1.6  Role of PI3K pathway and PIK3CA in bladder cancer 
 
The PI3K pathway plays a significant role in cell proliferation, growth, and 
survival [75]. Multiple genes altered along this pathway  are involved in 
tumorigenesis, including tumour suppressor genes (eg. PTEN) and proto-
oncogenes  (eg. PIK3CA) [76-81]. Commonly signalling is up-regulated in 
this pathway by mutation, deletion or amplification in sporadic cancers [82, 
83]. Mutations of PIK3CA have been recently discovered in bladder cancer, 
which seems to correlate with low stage and grade tumours [84]. PIK3CA 
and Ras commonly interact with each other [69, 85] and when both 
mutations are present two pathways, mitogen-activated protein kinase and 
PI3K pathway, are activated [39]. When Knowles and colleagues  analysed 
mutation frequencies of PIK3CA, it was discovered that the overall mutation 
frequency was 25.3% in tumours and cell lines [86]. In previous studies the 
overall frequency rate was reported as 13% and the mutation presence 
correlated with tumour stage: 65.5% of Ta, 11.5% of T1 and 23% of ≥T2 
stage tumours [84]. The most frequent mutations in bladder cancer were 
E545K and E542K as opposed to several other types of cancer, where 
H1047R was most common [87]. Similarly, a study performed by Sjödahl et 
al. found 17% of mutated cases in the extended series of tumours (n = 218) 
[88] with a significantly higher proportion of PIK3CA mutations seen in Ta 
cases compared to T1 (p=0.05). However there was no difference observed 
between T1 and ≥T2. Also positive association was noted with low-grade 
tumours (p=0.01).  
The PI3K pathway is altered through several different mechanisms in 
bladder tumorigenesis. As suggested by Platt et al. different pathway 
members may have additive or synergistic effects through non-canonical 
functions and therefore a single-agent PI3K-targeted therapy may not be 
successful in these cancers [86]. Structural studies defined that PI3Ks are 
heterodimeric lipid kinases composed of a catalytic (p110) and a regulatory 
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subunit (p85) and 110α. The  110α subunit is regulated through an inhibitory 
effect of p85. However this effect may be lost by the stimulation of upstream 
receptors and thus bringing PI3K to the membrane. The inhibition of p110α 
by p85 seems to be mediated by interaction of the N-terminal domain of p85 
with the helical domain of p110α [89, 90]. A study recently performed by 
Zhao et al. has revealed that helical domain and kinase domain mutations 
(E545K, E542K, H1047R) in p110α of PI3K induce gain of function by 
different mechanisms and through interaction with RAS [91]. However, it is 
not clear why there is predominance of helical mutations in bladder cancer. It 
might be related to the dual activation of the RAS–mitogen-activated protein 
kinase pathway either through RAS mutation or signalling though epidermal 
growth factor receptor during tumorigenesis or through other mechanisms 
[86]. The coexistence of both RAS and PIK3CA mutations in the same 
tumour might be compatible with this hypothesis. In one study, 7 out of 92 
tumours showed both mutations in the same patient [86].  
 
1.1.7  Molecular features of muscle invasive bladder tumours 
 
In muscle invasive bladder tumours both p53 and Rb pathways are more 
frequently inactivated [92-94]. Inactivation of TP53 commonly occurs by 
missense point mutations (80%), which leads to production of non-functional 
protein. p53 nuclear overexpression is often associated with a wide 
distribution of reported different mutations (more than 1000). There is 
mounting evidence from large, multi-institutional analyses that the p53 
overexpression is associated with high stage and grade bladder tumours 
[95, 96]. Study performed by George et al. on TP53 mutation and protein 
status showed that p53 molecular information was an independent predictor 
in lymph node negative disease [97]. Upregulation of Rb protein expression 
and associated loss of the p16 tumour suppressor [98], has been found in 
over half of the muscle invasive bladder tumours [99]. These finding are 
infrequent in non-muscle invasive bladder tumours [100, 101]. Together with 
inactivation of Rb pathway there is coexistent overexpression of genes on 
6p22, seen in 9% of T2 bladder cancers [102]. Two candidate genes were 
-15 - 
 
identified within the minimum region of amplification E2F3 and CDKAL1 
[102-105]. Multiple studies showed that over 30% of muscle-invasive 
tumours show loss of expression of Rb [100, 101, 106]. 
Another alterations commonly associated with MIBC are losses, 
amplifications and rearrangement of chromosome arm 8p [107-110], and 
less frequently involving short arm 8q [4]. 
Deletions of 10q, including region of the tumour suppressor gene PTEN, are 
found frequently in higher stage and grade bladder cancers [111-113]. 
Studies on bladder tumour cells reported that PTEN has a significant effect 
on the invasive properties of bladder tumour cells in a mouse model [114]. 
Commonly associated with more aggressive and muscle invasive bladder 
tumours is the receptor tyrosine kinase gene HER2 [115-119], which is 
amplified and/or overexpressed at the protein level in many bladder tumours. 
There is emerging evidence for a tumour suppressor role of the tuberous 
scle- rosis gene TSC1 in bladder cancer. TSC1 mutations show no clear 
correlation with tumour’s stage and grade, however Hirao and colleagues 
reported that LOH at the region close to TSC1 has been associated with 
tumour invasion [120]. Chromosome 9 alterations are very frequent (>50%) 
in bladder cancer [121-123]. Chromosome 9 is the most studied genomic 
region in bladder tumours and its deletion was one of the first alterations 
identified cytogenetically in bladder cancer. On the short arm of 
chromosome 9, there is a single region including the known cell-cycle 
regulators and tumour suppressor genes CDKN2A and CDKN2B [123-127]. 
This locus is frequently homozygously deleted in bladder tumours and 
associated with high stage and grade tumours [128]. 
 
1.1.8  Targeted therapies 
 
During the last decade cancer therapy has rapidly evolved. Limited 
effectiveness and side effects of systemic chemotherapy resulted in interest 
in developing drugs that would interfere specifically with pathways that are 
genetically altered in tumour cells only. This would allow sparing normal cells 
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that do not display the tumour-specific target. As opposed to cytotoxic 
therapies where mechanisms of action are based on the theory that cancer 
is basically a disease of growing cells, targeted therapies interfere in specific 
pathways altered in tumour cells only [129]. To predict response to such 
therapies, the molecular profile of the target cells needs to be characterised. 
For example, the selective application of anti-HER2 therapy in breast cancer 
patients requires the identification of human epidermal growth factor 
receptor-2 (HER2) amplification.  
 
1.1.8.1  Receptor Tyrosine Kinase Inhibitors (TKIs) 
 
One of the receptors commonly used as a target in many cancers including 
colorectal and head and neck cancers, is EGFR [130].  It has been shown 
that EGFR is also overexpressed in TCC and it is associated with poor 
prognosis [131]. In preclinical studies it was demonstrated that cetuximab 
(anti-EGFR monoclonal antibody) inhibited tumour expansion and 
metastasis in combination with paclitaxel by blocking neovascularization and 
inducing apoptosis [130]. Currently a randomised phase two trial is 
evaluating cetuximab in combination with gemcitabine and cisplatin in 
patients with locally advanced or metastatic urothelial carcinoma [132]. A 
group of drugs (gefitinib, erlotinib, lapatinib) targeting EGFR has been 
evaluated as a treatment option in many cancers with good response. The 
phase two trial of Cancer and Leukemia Group (NCT00041106), sought to 
determine the efficacy of cisplatin, standard infusion of gemcitabine and 
gefitinib in patients with advanced urothelial carcinoma. The results of this 
trial showed 40% of objective responses, the median survival time was 15.1 
months (95% CI$11.1–21.7 months) and the median time to progression was 
7.4 months (95% CI 5.6–9.2 months) [133]. Another oral EGFR TKI used 
commonly in the treatment of non-small cell lung cancer has been assessed 
in treatment of muscle invasive bladder cancer in the neoadjuvant setting 
before cystectomy (NCT00749892). Patients are scheduled to receive 
erlotinib for four weeks and undergo cystectomy, followed by adjuvant 
erlotinib. Effects on targeted pathways are examined by detailed evaluation 
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of tumour tissue together with microarray analysis to define predictive factors 
and to determine the effects of therapy on gene expression. 
Successful reports of treatment of breast cancer patients with an oral TKI 
which targets both EGFR and HER2 (lapatinib), has led to a phase two trial 
in advanced urothelial cancer [134].  Preliminary report of 59 patients with 
EGFR and/or HER2 overexpression, showed activity of lapatinib as salvage 
therapy for advanced UC, with partial responses in 3% and clinical benefit in 
12% of patients. The median time to progression was 8.6 weeks and there 
was also a trend towards clinical benefit in those in whom overexpressed 
EGFR or HER2. Similarly a UK based trial with lapatinib (NCT00949455) in 
patients with advanced bladder cancer is currently on-going and finished 
recruiting patients [135].  
The expression of HER2 oncoprotein in invasive bladder cancer was 
examined by immunohistochemical staining in a study performed by 
Matsubara et al. who found that 50% of lymph node positive patients were 
HER-2 positive. These patients also had corresponding HER 2-positive 
primary tumours [136]. In a more recent study, 42 paired lymph node 
metastases where examined to determine frequency of HER2 
overexpression, HER2/MYC coamplification, and association between HER2 
and MYC status and clinicopathologic features. The results revealed that 
HER2 overexpression occurred in 19 primary tumours (36%) and 14 
metastases (30%), with an 88% concordance rate between primary and 
matched metastases [137]. The results of this study also indicate that HER2-
targeted therapy may be a valuable treatment option for metastatic bladder 
cancer. Furthermore, studies in other cancer types have shown that 
coamplification of HER2 and MYC may impact tumour growth and influence 
response to HER2- directed therapy and this could be relevant in bladder 
cancer [137, 138]. 
Sorafenib is another drug that is currently being assessed in treatment of 
advanced UC as a second line therapy and also as a first line therapy in 
combination with chemotherapeutic agents. It has got multitargeting 
properties, inhibiting BRAF and CRAF in the RAS/MAPK signalling pathway 
inhibiting tumour cell proliferation and angiogenesis (targeting VEGFR and 
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PDGFR). Sorafenib also blocks other TKs receptors including VEGFR-2, 
platelet-derived growth factor receptor (PDGFR)-β, c-KIT and Flt-3.  
Another multitargeted receptor TKI is drug called sunitinib which is currently 
approved for the treatment of renal cell carcinoma. It work is mainly based 
on targeting VEGFR-2, PDGFR-β, KIT and Flt3 receptors. There is evidence 
emerging from preclinical studies that it is effective as a single agent and in 
combination with cisplatin [139, 140]. There are few phase two trials 
currently undergoing with sunitinib either as a the salvage therapy [141], in 
patients with stable disease [142], in combination with GC [143] or in 
neoadjuvant setting [144]. To some extent similar in action multitargeted 
receptor TKI-axitinib, showed some promising pre-clinical results. Axitinib on 
xenografts revealed inhibition of angiogenesis and VEGFR-2 and PDGFR-α 
phosphorylation together with overall regression of the graft [145]. 
 
1.1.8.2  VEGF targeted therapy 
 
Vascular endothelial growth factor (VEGF) is responsible for mediating 
angiogenesis in TCC of bladder. Several studies have shown that its levels 
are associated with bladder tumour stage, grade, vascular invasion and 
carcinoma in situ [146-149]. Patients with metastatic disease also had a 
significantly higher levels of VEGF than those with localized disease [150]. 
Based on the rationale that antiangiogenic drugs in urothelial cancer may 
play a significant role, a phase two trial was designed to assess the activity 
of sunitinib as first-line treatment in patients with metastatic urothelial cancer 
ineligible for cisplatin [151]. Sunitinib is a multitargeted tyrosine kinase 
inhibitor that selectively inhibits VEGF receptors -1, - 2, and - 3; platelet-
derived growth factor (PDGF) receptors -α and -β; stem cell receptor (kit); 
Fms-like tyrosine kinase-3 receptor (FLT3); the receptor tyrosine kinase 
encoded by the ret proto-oncogene (RET); and the receptor for M-CSF 
(CSF-1R) [141]. It showed promising initial results: on intention-to-treat 
analysis, 3 out of 38 patients (8%) showed partial responses and 19 (50%) 
presented with stable disease, 17 (45%) of them at 3 months. Clinical benefit 
was estimated at 58%. Median time to progression was 4.8 months and 
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median overall survival 8.1 months. Relying on preclinical evidence that 
supports the antitumour efficacy of targeting VEGF receptors expressed on 
bladder cancer in combination with chemotherapy [152], several other phase 
two trials have been initiated with bevacizumab [153].  
 
1.1.8.3  FGFR3 targeted therapy 
 
The FGFR family of receptors are considered potential theraupetic targets in 
bladder cancer. FGFR3 mutations in bladder carcinogenesis [61, 74] are 
strongly associated with low stage and grade [74]. While FGFR3 mutations 
are not associated with invasive bladder tumours,  FGFR3 protein 
expression is significantly increased in muscle invasive disease [62]. FGFR1 
is over-expressed in human bladder cancer cell lines and tumour samples, 
independently of the stage and grade [154]. In pre-clinical studies FGFR1 
knock-down inhibited tumour growth, suggesting FGFR1 as a potential 
therapeutic target in UC. Small molecules  work against the cytoplasmic 
domain containing the tyrosine kinase site (small molecule) or against the 
extracellular domain (mAb) of the receptor [155]. These small molecules 
induce direct cytostatic effect in FGFR3 mutant cells. It has been also 
discovered that human antibody anti-FGFR3 (PRO-001) inhibits the 
proliferation of cells and induces apoptosis [156]. PRO-001 binds to FGFR3 
expressed cells and inhibits FGFR3 autophosphorylation and downstream 
signalling. It potently inhibited FGFR3-dependent solid tumour growth in a 
mouse xenograft model. An antibody (R3Mab) developed by Qing et al 
inhibited WT FGFR3 and various mutants of the receptor [157]. By binding to 
FGFR3 receptor it exerted potent antitumor activity against bladder 
carcinoma and multiple myeloma xenografts in mice. Also the inhibition of 
FGFR3 expression has been reported by interference with iRNA by 
decreasing the levels of proteins MCL-1 and Bcl-2, which play anti-apoptotic 
role in the cell [155]. The anti tumour activity of mAb has been also shown in 
both multiple myeloma xenograft tumour models (harbouring either WT or 
mutant FGFR3) and in vitro, in human bladder cancer [157, 158]. Several 
FGFR3 small molecule inhibitors have been recently tested in vivo and in 
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vitro. Examples are PD173074, TKI258 and SU5402 inhibitors [159]. 
PD173074 selectively inhibits FGFR3 and FGFR1 competing for ATP 
binding and inhibiting autophosphorylation [160]. TKI258 and SU5402 are 
inhibitors, which target both FGFRs and VEGFR [161, 162]. All three 
inhibitors were shown to be cytoxic and/or cytostatic on bladder cancer cell 
lines [163, 164]. However, only PD173074 revealed no toxicity on normal 
bladder cells. When tested in vivo it inhibited tumour growth and induced 
regression and the response seemed to be related to the level of FGFR 
expression and dependence [163, 164]. These investigations imply that anti-
FGFR3 treatment should be considered for targeted therapy of cancer and 
possibly other diseases where the receptor is involved. Currently Hoosier 
Oncology Group is recruiting patients to a phase two trial of dovitinib in 
Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma in patients 
with tumour FGFR3 mutations or over-expression (Trial: NCT01732107) 
[165]. Dovitinib (TKI258) is an inhibitor of FGFR1, FGFR2, and FGFR3, and 
has shown antitumor activity in FGFR-amplified breast cancers [166]. The 
results of a multicentre phase two study with dovitinib in FGFR3 mutated 
and WT advanced UC are awaited (Trial: NCT00790426) [167]. Although the 
majority of these studies are preliminary, the interim findings from these 
trials are encouraging. Despite the fact that no targeted therapy agents are 
ready for routine use in advanced bladder cancer these trials are 
exceptionally important and may lead in future to significant improvement in 
bladder cancer management. 
 
1.1.9  Targeted therapies and relationship of primary and matched 
metastasis 
As more research is being conducted on targeted cancer therapies we have 
learned the need to understand the molecular features of cancer in order to 
predict response to specific agents. For example, one of prerequisites for an 
anti-EGFR antibody response is prior knowledge of the molecular activation 
of the EGF-receptor pathway either by mutation or amplification as well as 
absence of KRAS, BRAF or PI3K mutations [168-170]. 
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Similarly, prior to breast cancer treatment with trastuzumab or lapatinib, the 
status of HER2 must be examined [171, 172]. However the major target 
tissue in disseminated disease is metastatic tumour and a potential problem 
is the possibility that systemic tumour differs at the molecular level from the 
primary tumour that is available for analysis. Whilst this is widely 
acknowledged, few studies to date have assessed metastatic tumours 
tissues or compared primary tumours with related metastatic lesions. 
Studies comparing primary and matched metastasis were performed on non-
bladder cancers and have demonstrated similarities between them [173-
175].  
One of the widely used methods to characterize human cancers is gene 
expression analysis based on genome-wide microarrays. MicroRNAs 
(miRNAs) are a class of non-coding RNA molecules contributing to cancer 
onset and progression. A miRNA array study performed on breast, lung and 
bladder cancer and their corresponding metastases overexpression of miR-
148a was found in lung and breast, miR-148b in lung, and miR-126 in 
bladder cancer metastases, and down-regulation of miR-373 in lung and 
miR-143 in bladder cancer metastases. The signature analysis of miRNAs 
may also help to identify the organ of origin, in difficult cases of unknown 
metastases [176]. A study that characterized primary and metastatic bladder 
cancer defined MAGE-A4 and MAGE-A9 expression. It was discovered that 
expression of both antigens was high in primary tumours compared to 
metastases. Characterization of the expression of various cancer-testis (CT) 
genes in bladder cancer has shown that members of the MAGE-A family are 
frequently expressed in these tumours making them a target of choice for 
bladder cancer immunotherapy [177].  
Recent molecular studies of bladder cancer indicate that FGF receptors 
together with PI3K pathway components may be important therapeutic 
targets [178-180]. However, no studies to date have compared the 
expression and/or mutation of these targets in paired primary and metastatic 
cancers. 
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1.1.10  Molecular analyses of matched primary and metastatic 
bladder cancer 
Metastasis is the major cause of death in bladder cancer patients. The 
spread of tumour cells from a primary tumour to secondary sites within the 
body is a complex process and involves: cell migration, invasion, adhesion, 
proliferation and angiogenesis. An understanding of metastasis at the 
cellular and molecular levels is an important objective in cancer research. 
Detailed molecular and genetic ships between primary tumours and their 
paired metastatic lesions have not been characterized well in patients with 
urothelial carcinoma.  
Understanding of the relationship between primary and matched bladder 
tumours may become significantly more important in the near future as 
targeted therapies become widely used in clinical practice.  
The majority of published data on bladder cancer has described studies 
performed on primary bladder tumours. Relatively few molecular studies 
have analysed metastatic bladder cancer lesions. It is unknown whether 
distant or lymph node bladder metastases originate from separate, 
genetically different subclones from within the primary tumour,  whether 
these metastatic lesions arise from an identical cell of origin and whether 
changes in expression of therapeutic targets occur in metastatic sites. In the 
past it has been hypothesized that metastases were due to a small set of 
cells within the primary neoplasm that acquired a set of genetic modifications 
allowing them to leave the original site and grow in another organ. The 
findings of recent studies using DNA array analysis suggest that most of the 
cells in a primary tumour are capable of metastasizing [181, 182]. This may 
indicate that metastatic potential is determined by the bulk of the primary 
tumour [183]. Compatible with this Hovey et al. performed CGH on matched 
urothelial cancer primary and metastasis samples and revealed that there is  
minimal clonal evolution occurring in the metastatic tumour cell population 
after the metastatic event [184]. There is an on going debate addressing the 
mechanisms of metastatic progression, which has resulted in various models 
[185, 186]. In relation to targeted therapy, a critical issue is whenever 
primary tumours may serve as surrogates for the genetics and expression 
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profile of disseminated metastases. Currently there are two fundamental 
concepts of systemic cancer progression, which aim to find an explanation to 
this question [187]. The first model of linear progression is based on the 
concept that metastasis founder cells within the primary tumour disseminate 
as fully malignant cells. Once at the secondary sites they grow, expand and 
go through the process of adaptation to the new microenvironment. During 
this adaptation process these cells ‘adjust’ to the new ectopic 
microenvironment and hence no new genetic development is necessary 
though changes in gene expression may occur. In the second parallel 
progression model, less genetically evolved cells within the primary tumours 
disseminate at the earlier stage and undergo extensive somatic progression 
at the ectopic site. This adaptation is fundamental to ‘survival’ at the ectopic 
site and includes mutation, selection and inheritance [188]. Both models 
could potentially co-exist and play simultaneous roles in systemic cancer 
progression, however it is important to note the key difference in both of 
them. According to the linear progression model it is possible to predict the 
genotype of the metastasis by characterizing the primary tumour. In contrast, 
the parallel progression model emphasises the genetic disparity between 
primary and metastasis, making it almost impossible to find any similarities 
between primary and matched metastases. This could have important 
clinical implications. The ability to predict genotype and phenotype by 
sampling and characterization of the primary tumour may allow selection of 
targeted therapies, so that therapy can be limited only to patients with the 
potential for effectiveness and responsiveness to the drug. 
In a study performed on cystectomy samples and their matched lymph node 
metastases obtained from 24 patients, LOH and X-chromosome inactivation 
assays showed that they had the same clonal origin [189]. Eleven tumours 
demonstrated identical allelic loss patterns at all DNA loci for 3 microsatellite 
polymorphic markers on chromosome 9p21, 9q32 and 17p13 (TP53, the p53 
locus) both in the primary carcinoma and in all corresponding lymph node 
metastases. Unfortunately the results of this study do not explain whether 
each focus of lymph node metastasis originated from independent cell 
populations in the primary tumour or metastases were descendants of one, 
single altered cell population in the primary [189]. In a similar study, the 
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authors examined the pattern of allelic loss with polymorphic microsatellite 
markers on chromosome 9p21, a region which contains the tumour 
suppressor gene p16, and on chromosome 17p13, and found an identical 
pattern of allelic imbalance (allelic loss or retention) at multiple DNA loci in 8 
(88%) cases [190]. These findings suggest that allelic loss of these 
chromosome regions most likely occurs prior to the metastatic spread. Miyao 
et al. performed experiments on 14 paired samples of primary and 
metastases of the bladder and found complete concordance between 
genetic defects in the primary and metastatic sites [191]. Shariat et al. 
evaluating the association between p53, p21, p27 and Rb expression and 
pathological features and clinical outcomes of advanced bladder cancer, 
concordance between marker expression in the lymph nodes and matched 
radical cystectomy specimens was 92, 82, 70 and 86% for p53, pRB, p21 
and p27, respectively. It was also reported that p27 expression was strongly 
associated with bladder cancer presence, progression, metastasis and 
mortality [192].  
A study performed by Byrne et al. analysed the expression of E-cadherin in 
bladder TCC, areas of carcinoma in situ and corresponding lymph node 
metastases [193]. In this study samples were obtained from  77 patients 
including 17 patients with lymph node metastasis. They found high (88% and 
85%) concordance  of E-cadherin status in metastatic lymph nodes and 
carcinoma in situ areas with the primary tumours. They also reported that E-
cadherin expression was significantly associated with disease progression 
(p=0.0219) and bladder cancer specific survival (p=0.037) and suggested 
that loss of expression of this protein plays an important role in increased 
cellular invasiveness and metastasis.  
An interesting study characterizing early metastatic progression of bladder 
cancer from the primary tumour to the first lymph node was performed by 
Malmström et al. [194] In this study, 8 patients were included with sentinel 
lymph node metastasis and underwent immunohistochemical analysis of 
p53, pRB, Ki67 and E-cadherin expression. The sentinel lymph node 
metastasis had very similar molecular profile.  However, in half of the cases 
signs of clonal evolution appeared and immunohistochemical non-
concordance was observed between primary and corresponding metastasis.  
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Two studies compared expression profiles of HER2 in the primary tumour 
and corresponding metastasis and found contradictory results [195, 196]. 
The study conducted by Jimenez et al on 39 patients with evaluable 
histological material from both locations showed that over-expression in the 
primary tumour predicted over-expression in regional or distant metastasis 
[195]. Researchers also noted that HER2-negative primary tumours may 
show over-expression in their corresponding metastasis (45% of lymph 
nodes and 67% of distant metastases). However, the other study performed 
on large cohort of patients and using HercepTest™ (Dako Ltd, Ely, UK) 
staining revealed that 36% of the patients had negative metastases despite 
positive primary tumours, and in 5% the metastases were positive even 
though the primary tumours were negative. Differences in obtained results 
may be attributed to different immunohistochemical retrieval and staining 
protocols that were used in both studies.  
Recently, a group from Switzerland performed analysis of over 150 patients 
with bladder TCC and matched metastasis [197]. They have determined 
HER2 status at the gene level by FISH and at the protein level by IHC. They 
showed that HER2 amplification was significantly more frequent in lymph 
node metastases (15.3%) than in matched primary bladder cancers (8.7%; p 
= 0.003) and there was a high concordance in HER2 FISH results between 
the primary tumour (κ = 0.853) and metastases (κ = 0.930). However, IHC 
results were less concordant (κ = 0.539 and 0.830, respectively). The same 
group evaluated expression of MMP-2 and MMP-9 in tissue microarrays 
constructed of corresponding samples from primary tumours and lymph-
node metastases [198]. Matrix metalloproteinases (MMP) participate in 
tumour progression and metastasis in various cancers. The results of this 
study however, failed to show positive correlation between expression levels 
of the primary tumour and metastasis suggesting an infiltration strategy 
independent of MMP-2 and MMP-9 activity. The same cohort of patients was 
investigated for CCND1 amplification and CyclinD1 expression with regard 
to tumour heterogeneity, correlation of amplification and protein expression 
as well as association with histopathological tumour characteristics, survival 
and response to chemotherapy [199]. The results showed that CCND1 
amplification status and the percentage of IHC positive cancer cells were 
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correlated with histopathological tumour characteristics, cancer-specific 
survival and response to adjuvant chemotherapy. CyclinD1 expression and 
CCND1 amplification status were independent risk factors in metastasizing 
bladder cancer. Also, high CyclinD1 expression in lymph node metastases 
predicted favorable response to chemotherapy. 
 
1.2  Multifocal bladder cancer 
 
1.2.1  Multifocal bladder cancer and its origin 
 
Bladder cancer is commonly characterized by development of multifocal 
tumours in the same patient. Approximately 30% of all patients with 
urothelial carcinoma present with multifocal tumours [200]. Tumour 
multifocality is associated with poorer outcomes. Patients presenting with 
multiple, separate tumours are at higher risk for recurrence, progression and 
cancer-specific death [201]. During recent years, two theories have been 
proposed to explain urothelial tumour multifocality, the monoclonal and 
polyclonal theories. The monoclonal theory suggests that all of the 
coexisting tumours are descendants of a single progenitor cell that has 
undergone malignant transformation [202]. This cell proliferates and spreads 
throughout the urothelium by intra-epithelial spread or intraluminal seeding 
with secondary implantation at different sites within the urinary tract resulting 
in genetically related tumours. The second concept of field-cancerization 
suggests that multifocal tumours are derived from multiple cells that become 
transformed as a result of carcinogenic insults and acquire independent 
genetic alterations leading to the development of genetically unrelated 
tumours. The establishment of clonal origin of multifocal bladder cancer may 
have significance in the application of different therapeutic approaches such 
as targeted gene therapy. These new treatments may be more efficacious 
against a monoclonal population of cells all expressing the relevant target 
than against cells in tumours that are not genetically related. Whatever the 
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clonal origin, subclonal evolution may lead to diversity in expression of 
therapeutic targets. 
The difficulty in interpreting published results on multifocal disease is 
associated with the fact that clonality has not always been defined in the 
same way. For example, clonality could mean that two tumours A and B 
share common origin and evolved from single progenitor cell or they could 
have evolved from each other later during pathogenesis (e.g. because they 
share the same FGFR3 mutation) (Figure 1.7). In studies involving only a 
few markers, unless markers that identify events that occur early in tumour 
development are used, it is difficult to exclude monoclonality. The more 
detailed the analysis e.g. genome wide, the easier it is to assess clonality. 
 
 
Figure 1.7: Different clonality interpretations described in literature. 
Clonality could mean that tumours A,B and C have clonal origin as all 
are descendants of common progenitor cell. Alternatively the term may 
be used to denote that tumour B has evolved from tumour A thus 
sharing the same FGFR3 mutation. 
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1.2.2  Multifocal bladder cancer as a monoclonal disease 
 
One of the early studies investigating clonality of multifocal tumours was 
performed by Sidransky et al. [203] where the authors analysed by 
chromosome X-inactivation analysis in 13 tumours from four different female 
patients. X-chromosome inactivation occurs early in female development 
and as it is a random process can be used as a marker for determining 
common origin of transformed cells. Once an X chromosome’s DNA is 
inactivated by methylation, all its daughter cells remain inactivated 
throughout their life span. Sidransky and colleagues reported that for each 
patient all the tumours had inactivation of the same X chromosome 
indicating tumours monoclonal origin. Studies using these techniques were 
performed by Li et al. [204] and Cheng et al. [205] and they both determined 
monoclonal origin of the majority of synchronous multifocal tumours. 
However Cheng et al. in two cases showed different non-random X-
chromosome inactivation patterns in different sites suggesting an oligoclonal 
origin. The majority of accumulated published data on chromosomal 
changes, and gene mutations indicates that most of multifocal bladder 
tumours are of monoclonal origin. However, multifocal tumours may have 
undergone significant changes during tumorigenesis with extensive 
subclonal evolution. Takahashi et al. examined LOH at 10 microsatellite loci 
in pathologically normal mucosa and associated multifocal bladder tumours 
from six patients. Findings of this study indicated that multifocal bladder 
cancer derived from single cell in monoclonal fashion. Multifocal tumours 
originated from single foci that had spread along normal urothelium rather 
than occurred as independent polyclonal events [206, 207].  
Researchers who were not able to definitely determine the clonal origin of all 
syn- or metachronous multifocal tumours were mostly using LOH analysis as 
primary method [202, 205, 208, 209]. Because LOH of some genomic 
regions can occur late in the tumour development findings of these studies 
cannot totally exclude a clonal relationship among these tumours. LOH 
reveals regions carrying tumour suppressor genes. An interesting study, 
which combined three methods, FISH, LOH and genomic sequencing was 
-29 - 
 
performed by Denzinger et al. with the aim of determining the clonality status 
of multifocal lesions within cystectomy specimens [210]. In addition, it used 
extensive histopathologic whole-organ mapping of the cystectomy 
specimens as an important prerequisite for a comprehensive molecular 
characterization of multifocal tumours and adjacent normal and dysplastic 
urothelium. In all 7 analysed tumour samples LOH analysis showed losses 
of the same alleles and identical TP53 mutation. The mapping of TP53 
mutated samples revealed continuous spread and outgrowth of the tumour 
within the bladder. This study supported not only monoclonality of tumours 
but also supported the hypothesis of extensive intraurothelial migration of 
preneoplastic and tumour cells rather than intraluminal seeding. In 
intraluminal seeding a random distribution of mutant patches instead of 
TP53 mutant patches in adjacent regions, would be evident.  
One of the criticisms of studies performed in the past using chromosomal 
alteration and single gene mutation in clonality analysis was the fact that 
they detected alterations that may not be clone specific and could arise in 
unrelated tumours under similar carcinogenic pressures. In an attempt to 
overcome these problems, a study using microsatellite instability (MSI) was 
performed by Catto et al. [211]. There are multiple detectable mutations in 
tumours with high MSI, which persist during tumour development due to 
mismatch repair deficiency [212]. These mutations include the development 
of new alleles or alterations in the number of DNA repeats in an allele and 
are best observed in the repetitive microsatellite regions. MSI arises in the 
daughter cell during cell replication therefore it represents a reliable measure 
of clonal expansion. By characterizing MSI (its predictability and prevalence) 
it is also possible to estimate a tumour’s age in cell divisions [213]. In the 
study performed by Catto et al. researchers investigated 32 lower and upper 
urinary tract TCCs with high MSI [211]. The results suggested that in all 
patients there was a single progenitor cell with subsequent expansion of one 
or more tumour subclones. MMR deficiency (the first event on the MSI 
carcinogenic pathway) was a characteristic feature of the progenitor cell. 
Normal urothelium and multifocal TCCs were also found to show MMR 
deficiency. Methylation analysis along with the distribution of MSI, all 
suggested monoclonality. For four of the patients with multifocal tumours 
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they were able to draw phylogenetic trees. Interestingly, these trees showed 
that the order in which the tumours were detected clinically did not match 
with the order in which they developed molecularly. Similar findings were 
also reported by van Tilborg et al. [214] with LOH and FGFR3 mutation 
analysis. The disparities between clinical presentation of bladder cancer and 
evolutionary development occurred also in a study performed  by Catto et al 
[211]. In one patient, MSI was greater in extent and frequency in the ureteric 
tumour than in the bladder cancer. Clinically bladder cancer presented 
several months after the ureteric tumour was removed. However, it is 
apparent that malignant cells were already present in the bladder at the time 
of nephroureterectomy despite having normal cystoscopy 3 months 
postoperatively. In another patient, tumours that were considered to be 
earliest on the evolutionary tree, with fewest alterations, did not present until 
a few years after the initial tumour. Findings of this important study may also 
suggest that all of these patients had a population of tumour cells in situ 
despite surgical removal of the primary lesion. It may have important clinical 
implications. Currently the administration of post-operative intravesical 
adjuvant chemotherapy is only used routinely after transurethral resection of 
bladder tumours as it has been shown to decrease recurrence rates [215].  
However, this is not standard practice following nephroureterectomy. The 
data of this study suggest that intravesical chemotherapy given after 
nephroureterectomy may be of benefit in an attempt to treat residual tumour 
cells in the bladder, which are clonally related to the primary tumour. 
In a study performed by Steidl et al. the authors examined the urothelium 
surrounding tumours and the role it might play in spreading the cancer cells. 
They performed FISH for common genetic changes on chromosomes 1, 8, 
9, 11 and 17 [216] and detected chromosomal aberrations in 73% of normal 
or dysplastic samples. In these samples the highest number of aberrations 
were observed in samples adjacent to high-grade tumours. Moreover, the 
level of genomic instability was proportional to the stage and grade of the 
tumour. This finding may support the hypothesis that high-grade tumours do 
not  develop directly from low-grade tumours. Another interesting finding of 
this study was the presence of chromosomal aberrations in urothelial cells 
but not in adjacent tumours. This may indicate that clonal evolution is 
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already happening in clinically normal looking urothelium and leading to 
creation of different sub-clones. However, only one of these sub-clones 
becomes a source of the tumour. Similar findings were confirmed by other 
groups [217-219]. Using FISH, Hartmann et al. found copy number 
variations in 50% of histopathologically normal urothelium and in 71% of 
hyperplasias [217]. By examining these results one may hypothesize that the 
area of clonally related aberrant cells surrounds and precedes bladder 
cancer development. Similar hypothesis were made when examining other 
cancers such as lung and oral cavity [220-223]. 
 
1.2.3  Bladder cancer characterized by aCGH 
 
To date most studies of multifocal bladder cancer have examined only a few 
molecular characteristics in each tumour. The most complex analysis was 
performed by Simon et al. [224] using conventional CGH to metaphase 
chromosomes,TP53 mutation and IHC analyses to examine 32 multifocal 
tumours from six patients. Typically the resolution of conventional CGH is 
between 5-10 Mb depending on how condensed the chromosomes are. 
Array comparative genomic hybridization (aCGH) is a microarray based 
technique for the detection of genome wide copy number alterations in the 
tumour genome. This method enables detection of whole chromosome gain 
or loss, partial or complete chromosome arm changes, high-level 
amplification, and homozygous deletions at high resolution. The resolution of 
aCGH is limited only by the clone insert size and the density of the mapped 
sequences used. For a resolution of 1Mb approximately 3,500 clones are 
required. 
aCGH has allowed the high-resolution mapping of DNA copy number 
alterations in TCC of bladder and in other malignancies [3, 5, 225, 226]. This 
technology has been successfully applied in clinical research to identify new 
therapeutic targets and has been shown to be a robust method for 
identifying new oncogenes and tumour suppressor genes. High throughput 
technologies also have been recently applied in routine clinical practice for a 
more comprehensive assessment of biological characteristics of each 
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individual tumour [227, 228]. The unique arrangements of copy number 
alterations identified by aCGH have been reported to aid in differentiating 
tumours into more clinically and biologically relevant subtypes. Moreover, 
the higher resolution of aCGH has led to precise mapping of the boundaries 
of amplified and deleted regions indicating potential candidate genes 
relevant to cellular control pathways. The degree, type, and locations of 
chromosomal changes identified by aCGH may have prognostic and 
therapeutic implications, and thus the next wave of medical advances in 
oncology might come from the use of these technologies and from the 
development of new software to aid in identification which molecular 
aberrations should be targeted in each patient. Among other advantages of 
aCGH is that it allows a unique and precise view of the genomic instability in 
a tumour with both the amount of genomic copy number alteration and the 
specific loci involved defined in one relatively quick analysis. Therefore 
aCGH enables the detection of multiple genomic events in a single sample. 
However, the high diversity of genetic changes encountered by aCGH in one 
sample makes it almost impossible to analyse steps of bladder 
tumorigenesis with a simple algorithm.  
The majority of published literature on evolutionary processes in cancer has 
been based only on data from a single time point in cancer progression (the 
time of surgery) and therefore it was the standard to reveal different steps in 
tumorigenesis by comparing genetic alterations in tumours from various 
patients with cancers of different histological stages and grades. This was 
based on the hypothesis that chromosomal aberrations and mutations that 
occur are consistent with a model of clonal evolution [218]. The changes 
characteristic for all stages were defined as early alterations, whereas the 
late events were associated exclusively in advanced stages of tumour 
development. One of the first models based on this hypothesis was 
proposed in 1990 in colorectal cancer [229] and it included only 5 general 
steps. Currently, in view of whole genome analyses with extremely high 
numbers of genomic alterations encountered, computational methods were 
developed to aid in identification of unique pathways and subgroups of 
tumours during tumour development. In this project we have utilised the 
computational method TuMult to reveal the succession of steps in cancer 
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development and analysed samples from a single patient at different 
locations or different time points during the disease process. This type of 
approach allows reconstruction of the sequence of alterations occurring in 
an individual, rather than a theoretical model generated by the comparison 
of heterogeneous samples. This sort of analysis is only possible in two 
scenarios: if several biopsy specimens are available for the same patient 
either because neoplastic condition led to prospective biopsies or because 
of availability of multiple recurrences following excision of the primary 
tumour. Bladder cancer seems to be a particularly useful model for such an 
approach due to its frequent multifocal recurrences. In the past, authors 
were able to conclude the monoclonal origin of tumours based on 
chromosomal aberrations common to several samples, and manually 
reconstruct the relationships between samples. This was possibly due to the 
fact that only few events were involved. However, nowadays with high 
definition copy number analyses on several samples automated approaches 
are required. 
 
1.2.4  Bladder cancer characterized by SNaPshot 
 
At present, investigations of bladder cancer are expensive, time consuming 
and invasive and usually involve cystoscopy, ultrasound and CT urography 
and cytology. Therefore, there is an urgent need for development of quick, 
non-invasive, inexpensive and simple investigation, which at the same time 
is highly specific and sensitive for detection of bladder cancer. Numerous 
molecular assays have been developed to aid in detection, monitoring 
urothelial cancer and to predict tumour progression, recurrence, 
development of metastasis, response to therapy or patient survival. To 
enhance the sensitivity of cytology the analysis of FGFR3 gene has been 
performed [42, 44]. In order to facilitate application of FGFR3 mutation 
analysis in clinical practice, quick and reliable test needed to be developed. 
One of the methods which easily identifies common bladder hot spot 
mutations, in relatively labour-free manner, is a SNaPshot assay. Some 
investigators have reported it to be a more sensitive method than analysis by 
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single-stranded conformation polymorphisms (SSCP) or sequencing [42]. 
This method allows simultaneous detection of nine common FGFR3 
mutations, four PIK3CA and all mutations in hotspot codons 12, 13 and 61 of 
the HRAS, KRAS and NRAS genes. It is also fast and relatively inexpensive. 
In one cost analysis it has been estimated to be nine times cheaper when 
compared to sequencing methodology [230]. It can be applied on both fresh 
and archival samples with very little DNA required. It has been proven to be 
more sensitive than SSCP and mutations are easy to score, with no 
interobserver variability [230, 231]. In comparison to other PCR-based 
mutation screening methods such as high resolution melting analysis, 
ARMS/Scorpion assays and direct sequencing of PCR products, SNaPshot 
provides  high turnover of samples in a short space of time [231]. The other 
advantage of this assay is its high sensitivity. Researchers from our group 
were able to detect PIK3CA mutations when mutant DNA represented 5–
10% of the total input DNA with the observed sensitivity results equate to 
being able to detect one mutant allele in a background of 5% or 10% wild 
type alleles in bladder cancer [231]. Similar sensitivity results were reported 
by other group using SNaPshot assay for detection of FGFR3 mutations, 
where they showed that one mutant allele could still be detected against a 
background of up to 39 wild-type alleles [232]. 
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Chapter 2 
Materials and Methods 
 
Multifocal Study 
 
2.1 Study participants, sample collection and clinical             
information 
 
2.1.1 Study participants and consent procedure 
The study was approved by the Local Research Ethics Committee (Leeds-
East 99/156), and informed consent was obtained from all patients. Study 
participants were selected from patients listed for transurethral resection of 
bladder tumour (TURBT), cystoscopy and/or bladder biopsy and cystectomy. 
Patients were recruited to the study if they had multifocal disease classified 
as superficial transitional cell carcinoma (TCC) of the bladder and the 
samples collected met the following selection criteria: 
 
- samples collected from at least two visually separate tumours from 
consented adults 
- sufficient quantity of the tissue collected to perform experiments described 
in the study 
- confirmed superficial (stage < T2) TCC on pathological examination 
 
All operative lists from Pyrah Urology Department (St James’s University 
Hospital, Leeds) were accessed one-week prior to the procedure and 
reviewed by a Senior Scientific Officer (SSO) and Rafal Turo (RT) on a daily 
basis. Patients’ clinical information was reviewed with particular emphasis on 
information obtained from flexible cystoscopy procedure (i.e. number and 
characteristics of bladder tumours). Informed consent and a discussion with 
the patient regarding the research were carried out on the morning of 
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surgery and/or one day prior to the procedure. At consultation patients were 
supplied with a descriptive protocol of the study and all necessary contact 
details of the persons involved. A copy of informed consent was always 
offered to the participants together with an occupational risk factor and 
smoking questionnaire (Appendix 2.1). Once consent was obtained, the 
surgeon carrying out the procedure and operating theatre (OT) staff were 
informed about participants.  
 
2.1.2 Sample collection and transportation of tissue from the OT 
to the sample processing department  
 
Initially we have encountered problems in collecting sufficient number of 
samples. However, after improved communication with clinicians our 
recruitment rate improved significantly. Due to difficulties in obtaining large 
number of samples statistical power calculations were not performed.  
The sample collection procedure (Figure 2.1) was explained to clinicians and 
nursing staff in detail by RT.  All clinicians and nursing staff were informed 
and the study protocol was presented to them during two departmental audit 
meetings held on 09.12.2010 and 12.02.2010. 
 
Nursing staff placed each resected tumour sample in a separate container 
containing 10 ml RPMI 1640 (Sigma R0883) and a protease inhibitor tablet 
(Roche 1836153) and labelled it accordingly. Immediately after being notified 
by OT, the SSO retrieved the specimen from the OT suite and delivered the 
specimen to the sample processing department. When transporting tissue, 
the samples were kept cool by placing the specimens on ice. At the same 
time tissue from the same tumours were sent to the pathology department 
for assessment via the standard diagnostic procedures for this hospital. A 
blood sample (3-5 mls) was also collected from each patient in 
ethylenediamine tetraacetic acid (EDTA) tubes and stored at -20°C until 
DNA was extracted (Figure 2.1). 
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Figure 2.1. Flow chart of the sample collection procedure. TURBT – 
transurethral resection of bladder tumour, OCT compound – optimal cutting 
temperature compound. 
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2.1.3 Tumour sample processing 
 
 
All specimens were generally processed/frozen within 20-30 min from 
resection. Once accessioned, the bladder tumour specimen was handled 
according to conventional sample processing techniques for our institution. 
At our institution, the SSO performed processing. Cold cup biopsies were 
rinsed in Dulbecco’s PBS (Sigma D8537).  Each biopsy was then embedded 
in optimal cutting temperature compound (OCT) on a specimen chuck 
cooled on dry ice, wrapped in labelled foil and snap-frozen in liquid nitrogen. 
A 5 µm section was taken using a cryostat and haematoxylin and eosin 
(H&E) stained for stage and grade assessment by an experienced 
Pathologist (Dr Patricia Harnden) according to the WHO 1973 and UICC, 
1978 classification systems. The biopsies were stored in liquid nitrogen until 
used. 
 
2.1.4 Patient information 
A summary of patient information is given in Table 2.1. Twenty-two patients 
were recruited. The median age for all patients was 77 years. The majority of 
patients (19 patients) were referred to the flexible cystoscopy clinic for 
diagnosis of macroscopic haematuria. There were sixteen male patients and 
6 female. Seventeen patients were smokers with a median of 20 pack-years 
of smoking (smoking pack history range: 3-75 per patient). Four patients 
were exposed to occupational hazards such as printing, dyes, paints and 
diesel fumes. 
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Patient 
Number 
Stage/Grade 
Number 
of 
tumours 
Sex (Age) 
Smoker (S)  / 
Non-smoker (N) 
/Occupational 
hazards 
 
Smoking
-pack-
years 
Primary (P) / 
Recurrent 
(R) 
 
1 TaG2 all tumours 3 Male (69) S / Printing, Diesel fumes 75 R 
2 TaG2 all tumours 3 Female (81) S 45 R 
3 T1G3 all tumours 3 Male (74) S 3 R 
4 TaG3 all tumours 6 Male (72) S 20 R 
5 TaG2 all tumours 2 Male (90) S / Laboratories 35 P 
6 T1G3 all tumours 3 Male (79) S 15 P 
7 TaG2 all tumours 2 Male (81) S 26 R 
8 TaG2 all tumours 3 Female (69) S / Printing, Dyes & Paints 30 R 
9 T1G3 all tumours 2 Male (94) N - P 
10 TaG3 all tumours 2 Male (75) S 10 P 
11 
TaG2 tumour 1 
T1G3 tumour 2 
2 Female (79) N - R 
12 
T1G3 tumour 1-3 
TaG3 tumour 4 
4 Female (81) N - P 
13 TaG3 all tumours 4 Male (60) S 23 P 
14 TaG3 all tumours 4 Female (89) S 5 P 
15 TaG2 all tumours 2 Male (70) S 5 P 
16 TaG2 all tumours 4 Male (50) N -  R 
17 TaG2 all tumours 3 Male (81) N -  R 
18 T1G3 all tumours 4 Male (81) S 10 P 
19 TaG2 all tumours 3 Female (66) S 11 P 
20 
TaG2 tumour 1 
T1G3 tumour 2-3 
3 Male (85) S / Printing 10  P 
21 TaG2 all tumours 2 Male (69) S 20 R 
22 TaG2 all tumours 2 Male (69) S 35 P 
 
 
Table 2.1. Patients’ characteristics. The histopathological stages and 
grades of all initial multifocal tumours used in the study are shown. For each 
patient, it was also noted whether multifocal disease was primary or 
recurrent. Patients’ sex, age, smoking status and history of occupational 
exposure to risk factors are also shown.  
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2.1.5 Histopathological details 
 
A summary of the histopathological details of tumours collected in this study 
is presented in Table 2.1. Sixty-six bladder tumours of transitional histology 
were collected from twenty-two patients. These included 14 stage pTa (3 
grade 3 and 11 grade 2) and eight stage T1 (all grade 3). In two patients (11 
and 20) tumours of different stage and/or grade were present in the same 
patient. The number of tumours from a single patient varied from 2 to 6. 
Tumours from twelve patients were primary and tumours from 10 patients 
were recurrent. Tumours from one patient (patient 12) recurred twice during 
the course of the study and samples were available for comparisons with the 
initial tumours (Table 2.2). 
 
 
 
Patient number 
 
Stage / Grade 
 
Number of tumours 
 
second recurrence of 
patient 12 
 
T1G3 all tumours 
 
2 
 
third recurrence of 
patient 12 
 
T1G3 all tumours 
 
5 
 
 
Table 2.2. Histopathological stage and grade of recurrences that 
occurred in multifocal bladder cancer patients during the course of the 
study. 
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2.2 Extraction and quantification of DNA 
 
2.2.1 Extraction of DNA from tumour tissues 
 
Tumour biopsies embedded in OCT were sectioned in a cryostat (Leica 
Microsystems Ltd, Milton Keynes, UK). An initial 5 µm section was stained 
with haematoxylin and inspected for at least 70% tumour purity, then 10 x 20 
µm sections were cut and transferred into a 1.5 ml micro-centrifuge tube for 
DNA extraction. A 5 µm section was cut after each set of 10 sections and 
stained with haematoxylin and eosin to ensure the purity of the sample was 
maintained throughout. 
 
DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Crawley, UK) 
tissue protocol according to the manufacturer’s instructions. The method is 
based on specific binding of DNA to a silica-gel membrane in the QIAamp 
Mini spin column while contaminants pass through. Briefly, 180 µl of ATL 
buffer was added to 10 x 20 µM tissue sections in a 1.5 ml microcentrifuge 
tube and mixing was performed using a vortex. 20 µl of proteinase K was 
then added and the sample was incubated at 56°C until the tissues were 
completely lysed (2 – 3 hours). 200 µl of AL buffer was added and the 
samples were mixed using a vortex then incubated at 70°C for 10 min. 
Samples were then mixed with 200 µl of 96% ethanol, and applied to a 
QIAamp Mini spin column. The column was subsequently centrifuged at 
8,000 rpm for 1 min then washed with 500 µl of AW1 buffer and re-
centrifuged at 8,000 rpm for 1 min. Then, 500 µl of AW2 buffer was applied 
and the column was centrifuged at 14,000 rpm for 3 min. To remove residual 
wash solution, the column was then placed in a fresh collection tube and 
centrifugation was performed at 13,000 rpm for 1 min. Finally, to elute the 
DNA from the column 20 µl of AE buffer was added and the column was 
incubated at room temperature for 5 min. The DNA containing solution was 
then collected by centrifugation (8,000 rpm for 1 min). The elution step was 
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repeated using another 20 µl of AE buffer and the combined eluates were 
stored at -80°C. 
 
2.2.2 Extraction of DNA from blood samples 
 
DNA was extracted from venous blood samples using a Nucleon DNA 
extraction kit (Nucleon Biosciences, Lanarkshire, UK) or by a salt-
precipitation method carried out in the DNA Laboratory at St. James’s 
University Hospital. The extracted DNA samples were stored at -20°C. 
 
2.2.3 Extraction of DNA from laser capture micro-dissected 
tumour  
 
When samples consisted of less than 70% tumour cells on examination of 
hematoxylin stained fresh samples, laser-assisted microdissection of the 
neoplastic cells was performed. H&E stained 10 µm sections mounted on 
polyethylene naphthalate (PEN) membrane slides (Arcturus Engineering, 
Mountain View, USA) were dissected using a Pix-Cell II Laser-Capture 
Microdissection (LCM) system (Arcturus Engineering, Mountain View, USA). 
Neoplastic cells from each tumour tissue section were captured on 
CapSure® Macro LCM (0211) Caps (Applied Biosystems, Warrington, UK) 
by LCM and using a 7.5-mm laser beam at 50 to 100 mV. The laser causes 
the film on the cap to melt adhering to targeted cells. In each cap multiple 
area of neoplastic cells were collected from individual tumours. Films 
containing the cells were removed from the caps and transferred to 1.5 ml 
micro-centrifuge tubes. The DNA was extracted using a QIAamp DNA Mini 
kit (Qiagen, Crawley, UK) according to manufacturer’s instructions except 
that after the overnight lysis step and prior to addition of buffer AL, the lysate 
was transferred away from the film into a fresh 1.5 ml micro-centrifuge tube 
(empty films were discarded). DNA was eluted in 2 x 20 µl of buffer AE. The 
DNA samples were stored at -80°C until required. 
-43 - 
 
2.2.4 Quantification of DNA 
 
A PicoGreen dsDNA Quantitation kit (Invitrogen Ltd. Paisley, UK) was used 
to quantify DNA extracted from tumour and blood samples according to the 
manufacturer’s instructions. PicoGreen is an ultrasensitive fluorescent 
nucleic acid stain that binds selectively to dsDNA thus circumventing 
problems associated with contaminating proteins, free nucleotides and RNA.  
 
A high range assay was performed to detect DNA at a concentration 
between 1 ng/ml and 1000 ng/ml. The provided λ DNA standard was diluted 
with 1x TE to a concentration of 2 ng/ml, 20 ng/ml, 200 ng/ml and 2000 
ng/ml. Dilutions of tumour DNA samples were prepared by transferring 1 µl 
DNA into 999 µl of 1 x TE. Duplicate aliquots of 100 µl of each tumour DNA 
sample and standard were transferred into wells of a 96 well optical plate 
(BMG Labtech Ltd., Aylesbury, UK). A blank sample consisting of 1 x TE 
was also applied to the plate. PicoGreen reagent was diluted 100 fold in 1 x 
TE then 100 µl of diluted reagent was added to each well. The plate was 
covered and incubated for 2-5 min in the dark. Fluorescence intensity was 
measured on a FLUOstar Galaxy fluorescence plate reader (BMG Labtech 
Ltd., Aylesbury, UK) at an emission wavelength of 520 nm and excitation of 
480 nm. The accuracy of the standard curve was assessed. The DNA 
concentration of the sample was then determined from the standard curve 
and by taking the initial dilution factor into account. 
 
2.3 Whole genome DNA amplification 
 
Low yields of genomic DNA were obtained for three tumour samples (11 
tumour 1, 10 tumour 1, 4 tumour 2). In order to generate sufficient genomic 
DNA for the analysis of these samples, whole genome amplification was 
performed using a REPLI-g® Mini Kit (Qiagen, Crawley, UK). This method 
allows the generation of high yields of genomic DNA from a low amount of 
template DNA. It is a one-temperature amplification method employing the 
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use of exonuclease-resistant random primers and Phi 29 DNA polymerase 
that has great processivity. Figure 2.2 illustrates the mechanism of action of 
Phi 29 DNA polymerase. The process consists of three major steps: 1) a 
denaturation step in order to open up the helix to allow the random primers 
to access DNA; 2) a neutralisation step involving the addition of a 
neutralising buffer which enables primer annealing; 3) a polymerisation step 
during which polymerase and buffers are added to allow the process of 
amplification to start. 
 
 
 
 
Figure 2.2: Mechanism of action of Phi 29 polymerase during WGA. 
Primers (red arrows) anneal to the template DNA and are extended by Phi 
29 polymerase. The polymerase moves along the DNA template strand, 
displacing the complementary strand, which then becomes a template itself 
for replication. Adapted from Dean, 2001[233]. 
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Whole genome amplification was performed according to the manufacturer’s 
instructions. Briefly, 2.5 µl of the sample (containing 25ng of the tumour 
template DNA) was mixed with 2.5 µl of denaturation buffer and incubated at 
room temperature for 3 min. Five microliters of neutralization buffer was 
added, and finally, 40 µl of master mix consisting of 1 µl REPLI-g Mini DNA 
Polymerase and 39 µl Mini Reaction Buffer was added to the neutralised, 
denatured sample DNA. The mixture was incubated at 30°C overnight (10–
16 hours). At the end of the incubation, the DNA polymerase was inactivated 
by heating the sample at 65°C for 3 min. One microlitre of the whole genome 
amplified sample diluted 1:100 with water was used in each subsequent 
polymerase chain reaction (PCR). For array comparative genomic 
hybridization (aCGH) 2 µl of neat whole genome amplified product (tumour 
and reference) was used for each array. 
 
2.4 SNaPshot-based mutation detection assays 
 
Three separate SNaPshot assays for the detection of hotspot codon 
mutations in FGFR3, PIK3CA and the three RAS genes (HRAS, KRAS and 
NRAS) were used in this study. The SNaPshot assay combines a single or 
multiplex PCR amplification with a multiplex primer extension assay to allow 
targeted detection of several mutations in one reaction. The SNaPshot 
assay workflow is shown in Figure 2.3.  
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Figure 2.3: The SNaPshot assay workflow. 
* SAPEX treatment = treatment with Shrimp Alkaline Phosphatase and 
Exonuclease I 
** SAP treatment = treatment with Shrimp Alkaline Phosphatase 
  
 
Perform multiplex PCR 
Remove excess primers/dNTPs 
by SAPEX* treatment 
SAP** treat SNaPshot products 
to remove excess ddNTPs 
Separate SNaPshot products on 
basis of size on a capillary 
sequencer 
Perform SNaPshot extension 
reactions using probes adjacent 
to mutation hotspots 
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2.4.1 Multiplex PCR primers and SNaPshot probes 
 
Multiplex PCR primers and SNaPshot probes used in these assays, were as 
described in van Oers et al. and Hurst et al. [231, 232]. Primers were 
selected for multiplex PCR amplification of exon 9 and exon 20 of PIK3CA 
(Table 2.3). SNaPshot probes for the detection of PIK3CA hotspot codon 
mutations (E542K, E545G, E545K and H1047R/L) were designed to anneal 
on the sense strand immediately adjacent to the mutation site. Each probe 
was synthesised with a different length of poly(dT) tail to allow separation of 
SNaPshot products on the basis of size (Table 2.4). Similarly, primers were 
designed for the amplification of three regions of the FGFR3 gene, located in 
exons 7, 10, and 15 (Table 2.3). These regions cover the following potential 
codon mutations: R248C and S249C (exon 7), G372C, Y375C, G382R, and 
A393E (exon 10), and K652E, K652Q, K652M, and K652T (exon 15). The 
sequences of the probes designed to detect these hotspot mutations are 
shown in Table 2.4. In a third assay, primers were selected for multiplex 
amplification of exons 1 and  2 of the HRAS, KRAS and NRAS genes (Table 
2.3). These regions cover potential mutations in hotspot codons 12, 13 and 
61 of each gene. Two sets of probes were designed to detect hotspot codon 
mutations in the three RAS genes (Table 2.4).  
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Gene Primer ID Sequence (5'->3') Strand 
Concentration 
in primer mix 
(µM) 
PCR 
product 
sizes 
(bp) 
PIK3CA 
Exon 9 F AGTAACAGACTAGCTAGAGA Forward 10 138 
 Exon 9 R ATTTTAGCACTTACCTGTGAC Reverse 10 
Exon 20 F GACCCTAGCCTTAGATAAAAC Forward 10 109 
 Exon 20 R GTGGAAGATCCAATCCATTT Reverse 10 
FGFR3 
Exon 7 F AGTGGCGGTGGTGGTGAGGGAG Forward 18 115 
 Exon 7 R GCACCGCCGTCTGGTTGG Reverse 18 
Exon 10 F CAACGCCCATGTCTTTGCAG Forward 7.5 135 
 Exon 10 R AGGCGGCAGAGCGTCACAG Reverse 7.5 
Exon 15 F GACCGAGGACAACGTGATG Forward 10 
161 
Exon 15 R GTGTGGGAAGGCGGTGTTG Reverse 10 
RAS 
HRAS exon 1 F CAGGAGACCCTGTAGGAGG Forward 9  
139 HRAS exon 1 R TCGTCCACAAAATGGTTCTG Reverse 9 
HRAS exon 2 F GGAGACGTGCCTGTTGGA Forward 5  
140 HRAS exon 2 R GGTGGATGTCCTCAAAAGAC Reverse 5 
KRAS exon 1 F GGCCTGCTGAAAATGACTG Forward 5 
163 
KRAS exon 1 R GGTCCTGCACCAGTAATATG Reverse 5 
KRAS exon 2 F CCAGACTGTGTTTCTCCCTT Forward 5 
155 
KRAS exon 2 R CACAAAGAAAGCCCTCCCCA Reverse 5 
NRAS exon 1 F GGTGTGAAATGACTGAGTAC Forward 5 
128 
NRAS exon 1 R GGGCCTCACCTCTATGGTG Reverse 5 
NRAS exon 2 F GGTGAAACCTGTTTGTTGGA Forward 5 
103 
NRAS exon 2 R ATACACAGAGGAAGCCTTCG Reverse 5 
 
Table 2.3. Primers for multiplex PCR amplification of PIK3CA (exons 9 
and 20), FGFR3 (exons 7, 10 and 15) and the three genes RAS (exons 1 
and 2) 
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Gene Probe* Sequence (5'->3') 
Size 
(bp) 
Mutation 
Concentration 
in probe mix 
(µM) 
PIK3CA 
E542K T(19)TACACGAGATCCTCTCTCT 38 G->A 0.8 
E545G T(29)TCCTCTCTCTGAAATCACTG 49 A->G 2.3 
E545K T(34)ATCCTCTCTCTGAAATCACT 54 G->A 1.5 
H1047R/L T(46)TGAAACAAATGAATGATGCAC 67 A->G/T 1.5 
FGFR3 
R248C T(46)CGTCATCTGCCCCCACAGAG 66 C->T 2 
S249C T(36)TCTGCCCCCACAGAGCGCT 55 C->G 1.2 
G372C T(29)GGTGGAGGCTGACGAGGCG 48 G->T 0.4 
Y375C T(43)ACGAGGCGGGCAGTGTGT 61 A->G 1.2 
A393E T(34)CCTGTTCATCCTGGTGGTGG 54 C->A 2.4 
K652M/T T(20)CACAACCTCGACTACTACAAGA 42 A->T/C 0.8 
K652E/Q T(50)GCACAACCCGACTACTACAAG 72 A->G/C 0.6 
S373C T(19)GAGGATGCCTGCATACACAC 39 T->A 0.5 
G382R T(56)GAACAGGAAGAAGCCCACCC 76 C->T 1.2 
RAS  
Set 1 
HRAS pos.34 T(17)CTGGTGGTGGTGGGCGCC 35 G->C/T/A 0.5 
HRAS pos.182 T(18)GCATGGCGCTGTACTCCTCC 38 T->G/C/A 1 
HRAS pos.35 T(31)CGCACTCTTGCCCACACCG 50 C->G/A/T 0.5 
HRAS pos.37 T(55)CAGCGCACTCTTGCCCACAC 75 C->G/A/T 7 
HRAS pos.181 T(46)CATCCTGGATACCGCCGGC 65 C->C/T 0.4 
KRAS pos.34 T(25)GGCACTCTTGCCTACGCCAC 45 C->G/A/T 2 
KRAS pos.181 T(41)CTCATTGCACTGTACTCCTCTT 63 C->A/G 0.4 
KRAS pos.35 T(49)AACTTGTGGTAGTTGGAGCTG 70 G->C/T/A 0.5 
NRAS pos.182 T(33)GACATACTGGATACAGCTGGAC 55 A->G/C/T 0.2 
NRAS pos.34 T(62)CTGGTGGTGGTTGGAGCA 80 G->C/T/A 0.5 
RAS  
Set 2 
KRAS pos.37 T(15)CAAGGCACTCTTGCCTACGC 35 C-> G/A/T 7 
NRAS pos.181 T(18)CTCATGGCACTGTACTCTTCTT 40 G->T/C 0.2 
NRAS pos.37 T(26)GGTGGTGGTTGGAGCAGGT 45 G->C/T/A 0.1 
KRAS pos.183 T(29)CCTCATTGCACTGTACTCCTC 50 T->A/G 0.4 
KRAS pos.38 T(33)CTTGTGGTAGTTGGAGCTGGTG 55 G->C/T/A 0.5 
NRAS pos.183 T(38)CTCTCATGGCACTGTACTCTTC 60 T->G/C/A 0.7 
NRAS pos.38 T(44)GTCAGTGCGCTTTTCCCAACA 65 C->G/A/T 0.5 
NRAS pos.180 T(49)GGACATACTGGATACAGCTGG 70 A->T 0.3 
KRAS pos.182 T(56)ATTCTCGACACAGCAGGTC 75 A->T/C/G 1 
HRAS pos.183 T(62)CCTGGATACCGCCGGCCA 80 G->C/T/A 0.4 
HRAS pos.38 T(64)GTCAGCGCACTCTTGCCCACA 85 C->A/T 0.5 
NRAS pos.35 T(71)CTGGTGGTGGTTGGAGCAG 90 G->C/A/T 0.3 
 
Table 2.4. SNaPshot probes for the detection of PIK3CA, FGFR3 and 
RAS mutations. * Position refers to nucleotide position in the cDNA with 
numbering from the first base of the ATG start codon. 
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2.4.2 Multiplex PCR amplification 
 
Multiplex PCR was performed in a volume of 15 µl containing 1 × PCR 
buffer, 1.5 mM MgCl2, 0.17 mM dNTPs, 1 µl of primer mix (see Table 2.3 for 
primer concentrations in each of the primer mixes), 5% glycerol, 1 unit 
GoTaq DNA polymerase and 20 ng of template DNA. Thermal cycler 
conditions for FGFR3 and PIK3CA were: 95°C for 5 min then 35 cycles of 
95°C for 45 sec, 60°C for 45 sec, then 72°C for 45 sec followed by 72°C for 
10 min. Thermal cycler conditions for RAS were essentially the same except 
an annealing temperature of 55°C was used. 
 
2.4.3 Agarose gel electrophoresis of PCR products 
 
Multiplex PCR products were checked for quality and yield by agarose gel 
electrophoresis, using Sub-Cell Systems electrophoresis tanks (Bio-Rad, 
Hemel Hempstead, UK) containing 1 x Tris Borate EDTA running buffer 
(0.089M Tris, 0.089 M Boric Acid, 0.0025 M EDTA, pH 8.3; MP Biomedicals, 
LCC). Three microliters of PCR product were mixed with 6 µl water and 1 µl 
loading buffer (40% w/v sucrose, 0.25% w/v bromophenol blue) and loaded 
onto 2% w/v agarose gels, containing 0.7 µg/ml ethidium bromide (Severn 
BioTech Ltd, Kidderminster, UK). Samples were electrophoresed at 6 V/cm 
for 30 min alongside 0.5 µg of a 100 bp DNA ladder (New England Biolabs, 
Hitchin, UK). Fractionated PCR products were visualized under short-
wavelength UV illumination using a ChemiDoc XRS system  (Bio-Rad, 
Hemel Hempstead, UK) and imaged with Quantity One software (Bio-Rad). 
The sizes of the fractionated amplicons were compared to the anticipated 
PCR product sizes (Tables 2.3 and 2.4).  
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2.4.4 SNaPshot probe extension reactions 
 
The remaining PCR products (12 µl) were treated with 3 units of shrimp 
alkaline phosphatase (GE Healthcare Life Sciences, Buckinghamshire, UK) 
and 2 units of exonuclease I (GE Healthcare Life Sciences) to 
dephosphorylate unincorporated deoxyribonucleotide triphosphates (dNTPs) 
and degrade residual primers, respectively, that might interfere with 
subsequent steps. Samples were incubated at 37°C for 60 min, followed by 
15 min at 72°C. 
 
SNaPshot probe extension reactions were performed using an Applied 
Biosystems SNaPshot Multiplex Kit. The SNaPshot probe extension step is 
illustrated in Figure 2.4. Reactions were performed in a volume of 9 µl 
containing 2.5 µl of SNaPshot Multiplex Ready Reaction Mix, 1 × BigDye 
sequencing buffer, 1 µl of probe mix (see Table 2.4 for probe concentrations) 
and 1 µl of shrimp alkaline phosphatase/ exonuclease I-treated multiplex 
PCR product. Extension reactions were performed in a thermal cycler and 
consisted of 35 cycles of denaturation at 95°C for 10 sec and 
annealing/extension at 58.5°C for 40 sec. Labelled extension products were 
treated with shrimp alkaline phosphatase (1 unit per sample) to 
dephosphorylate unincorporated dideoxynucleotides (ddNTPs) then diluted 1 
in 10 with water. One microlitre of the diluted extension product was mixed 
with 9.8 µl of HiDiTM formamide and 0.2 µl of GeneScan-120LIZ®  size 
standard (Applied Biosystems). Products were denatured at 95°C for 5 min 
then separated using an ABI PRISM 3100 Genetic Analyser with a 36 cm 
length capillary and POP-7™ polymer. Analysis was performed using 
GeneMapper 3.7 Software, which colour codes peaks according to the dye 
label on the incorporated ddNTP. Genotypes were scored manually based 
on the peak colour and position relative to the GeneScan™ 120 LIZ® internal 
size standards. Slight shifts in the molecular weights of mutant alleles are 
observed due to mobility differences in the fluorophores used to detect each 
of the bases.  
-52 - 
 
 
Figure 2.4: The SNaPshot probe extension step. SNaPshot probes are 
designed to anneal adjacent to hotspot mutations and are extended by one 
base only. They are tailed with differing lengths of Ts at their 5’-terminus to 
allow separation of SNaPshot products according to size. The dye labels on 
each of the ddNTPs are shown in the table.  
 
2.5 Array Comparative Genomic Hybridization 
 
Array Comparative Genomic Hybridization (aCGH) is a microarray-based 
technique used for genome-wide screening of DNA copy number alterations. 
The microarrays are created by positioning and immobilising fragments of 
DNA (probes) on a solid support (glass slide) in a predetermined, ordered 
fashion. The level of resolution is determined by both probe size and 
genomic distance between DNA probes. The basic methodology is 
illustrated in Figure 2.5.  
 
ddNTP Dye label Colour 
A dR6G Green 
C dTAMRA Black 
G dR110 Blue 
T dROX Red 
G"C"
A"G"
T"
SNaPshot probe 
5’T(n) 3’ 
PCR amplified template 
Fluorescently labelled ddNTPs 
+ polymerase 
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Figure 2.5. Diagram illustrating the aCGH process. In aCGH, DNA from a 
tumour sample (green) and a normal reference sample (red) are labelled 
differentially, and co-hybridized to probes which are printed onto a glass 
slide. The fluorescence intensities of the test and reference samples is 
measured and the ratio (test/reference) is used to determine copy number 
alterations in the tumour sample. Adapted from Memorial Hospital, Turkey, 
2014 
 
In the current study, BAC (Bacterial Artificial Chromosome) arrays with 1-Mb 
resolution (Centre for Microarray Resources, Department of Pathology, 
University of Cambridge, Cambridge, UK) were used.  The BACs contain 
copies of human DNA, the positions of which are known. 1-Mb resolution 
means that the human sequences represented on the array are spaced at 
approximately 1-Mb intervals throughout the genome.  DNA extracted from a 
tumour sample (test) and the corresponding blood sample (reference) are 
differentially labelled with the fluorescent dyes Cy5 and Cy3, respectively. 
Both the microarray and labelled DNA samples are pre-treated using herring 
sperm DNA and COT1 DNA to reduce general non-specific hybridisation and 
binding to repetitive sequences that are found at numerous locations 
throughout the genome, respectively. The differentially-labelled genomic 
DNAs from tumour and blood samples are then mixed together, denatured 
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and allowed to competitively hybridise to the single-stranded probes on the 
microarray. Following a series of washing steps to remove unincorporated 
and non-specifically bound labelled DNAs, slides are scanned using a high 
resolution microarray laser scanner. The scanner measures the intensity of 
the two dyes on the labelled DNAs simultaneously allowing the relative 
fluorescence intensity of hybridisation at each probe to be determined. Thus, 
the ratio of fluorescence signals from the test and reference is determined at 
different positions along the genome, thereby  providing information on the 
relative copy number of sequences in the tumour genome as compared to 
the control genome.  
 
In the current study, hybridization to arrays was essentially as described by 
Fiegler et al. and Hurst et al. [5, 234]. Reference samples were matched 
blood DNA or DNA extracted from an EBV immortalized lymphocyte cell line 
(J82 EBV) where blood was not available (patient 5, 7, 9, 13, 22). Briefly, 
tumour and reference genomic DNAs were labelled with Cy5-dCTP or Cy3-
dCTP respectively, using random-primer labelling (BioPrime DNA Labelling 
Kit, Invitrogen Ltd, Paisley, UK) (Figure 2.6). A reaction mix consisting of 
random-primers (20µl), Cy5-dCTP or Cy3-dNTP  (5 µl), template DNA 
(400ng) and molecular biology grade water to a total volume 45 µl was heat-
denatured for 5 mins at 94°C, then snap-cooled on ice. Next, 1µl of Klenow 
was added to each tube and the reactions were incubated at 37°C for 16-20 
hrs.  
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Figure 2.6. DNA labelling by the random primer method. Double-
stranded DNA (blue) is heat denatured then snap-cooled allowing annealing 
of random primers (red). New strands are then synthesized by Klenow DNA 
polymerase. During the synthesis step, labelled dNTPs such as Cy3-dNTP 
5’# # # # # # # # # # # ##########3’###3’## denaturation#and#annealing## # # ##################################################5’###############with#random#primers# # ############5’# # # # # # # # # # # ##########3’## # # # # ## ##########################################################3’## # # # # # # # # # # ##########5’#############Cy3/Cy5#are#incorporated#############into#the#newly#synthesized#############complementary#DNA#strand####5’## ## # # # # # ##########3’#### ## # # # # # ## ## # # # # # #3’## ### # # # # # ##########5’##################################################denaturation######### labelled#probes##################################random#primer##################################################################################################################5’##############################################################################################################################3’###DNA#template###############################################newly#synthesized#DNA#strand#complementary#to#template###
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or Cy5-dNTP (green) are incorporated resulting in uniformly labelled DNA on 
both DNA strands. Adapted from Invitrogen Ltd, 2014. 
Unincorporated nucleotides were separated from labelled DNA using Micro-
spin G50 columns (GE Healthcare, Buckinghamshire, UK) according to 
manufacturer’s instructions. Unincorporated dye adheres to the resin whilst 
labelled DNA passes through the column into the collection tube. The 
labelled genomic DNAs from tumour and reference sample were then 
combined, giving a total volume of 100 µl, then precipitated using 10 µl of 3 
M sodium acetate (pH 5.5) and 250 µl of ice-cold absolute ethanol. Samples 
were centrifuged and the supernatant removed. The pellets were dried and 
re-suspended in 25 µl of hybridization buffer (50% formamide, 10% dextran 
sulphate, 0.1% Tween 20, 2 x SSC, 10 mM Tris-HCl pH 7.5) containing 62.5 
µg Cotl I DNA and 375 µg herring sperm DNA then left to prehybridize at 
37°C for 2h. This prehybridization step enables the blocking of repetitive 
sequences by Cotl I DNA and blocking of general non-specific binding by 
herring sperm DNA. 
 
Slides containing arrays were prehybridized to block non specific binding by 
the addition of 30 µl of hybridization buffer containing denatured herring 
sperm DNA (9-12 µg/ml, Sigma-Aldrich Company Ltd., Dorset, UK). A Hybri-
Slip was placed on top of the array to prevent drying out. The slides were 
then incubated at 37°C for 2h in a humid chamber containing tissues 
saturated with 2 x saline-sodium citrate buffer (SSC)!(3 M NaCl in 0.3 M 
sodium citrate, pH 7.0) and 50% formamide. Slides were then washed twice 
in Phosphate Buffered Saline (PBS) solution (H2O, 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1. 8 mM KH2PO4, pH 7) (Sigma-Aldrich Company 
Ltd., Dorset, UK) and dried by centrifugation at 150 x g for 3 min.  
 
The prehybridized labelled DNA was then added to the prehybridized slide, a 
Hybri-Slip was placed on top and the slides were incubated for 20-24h at 
37°C in a humid chamber to prevent drying out. Slides were washed in 
PBS/0.05% Tween 20 for 10 min at room temperature, then 50% formamide/ 
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2 x SSC for 30 min at 42°C, and finally PBS/0.05% Tween 20 for 10 min at 
room temperature, and then dried by centrifugation at 150 x g for 3 min. 
 
2.5.1 Image acquisition and data processing 
 
Slides were scanned at 532 nm and 633 nm with a resolution of 10 µm using 
an Agilent G2565CA Microarray Scanner (Agilent Technologies, Stockport, 
UK). High-resolution TIFF images were generated and these were used as 
input for analysis using BlueFuse software (BlueGnome, Cambridge, UK).  
 
BlueFuse software was used to define spots, subtract background, and 
calculate normalised fluorescence intensities. The software (1) excludes 
data values below the fluorescence intensity values of Drosophila control 
spots and empty buffer spots on the array, (2) adjusts for differences in 
overall signal intensity between Cy3 and Cy5 channels by normalizing all 
signal intensities to a 1:1 ratio on autosomal chromosome clones, (3) 
calculates mean log2 (test/reference) ratios for triplicates spots, and (4) 
excludes controls, excludes replicate clones >0.2 SD apart and excludes 
spots with <0.1 confidence (i.e. poor quality spots). 
 
BlueFuse produces a log2 ratio (test/reference) value for each clone on the 
array which can be exported. This log2 ratio data was transferred to an Excel 
spreadsheet to produce graphical outputs in the form of individual 
chromosome plots of mean log2 ratio (y-axis) against distance along the 
chromosome (Mb) (x-axis). Physical positions were according to hg19/NCBI 
Build 37. The same data was also transferred to another Excel spread sheet 
and presented as a graph where the whole genome of each tumour could be 
visualized. This graphical presentation (tiled data) of the whole genome 
allowed tumours from the same patient to be aligned thus enabling the 
comparison of breakpoints and altered regions between tumours (including 
the modified scoring mentioned below). 
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Normal thresholds of experimental variation for the array used in this study 
have been previously determined by observation of normal samples and 
samples with known changes by Hurst et al [235]. Regions of gain and loss 
and breakpoints were detected initially by the BlueFuse software aCGH-
Smooth algorithm [236] with calling thresholds for copy number gains and 
losses set to +0.15 or -0.15 log2 ratio of test/reference respectively. The 
algorithm gives an average log2 score across regions defined as altered.  
 
Subtle changes not scored by the BlueFuse software but relevant to the 
study were included manually upon visual inspection. Modified scoring 
criteria for the purpose of this study included incorporation of the alterations 
in tumours which were shared by other tumours in the same patient but did 
not reach the BlueFuse thresholds and low level single clone alterations 
below the BlueFuse threshold but common to all other tumours from the 
patient. In order to do this the whole genome plots for all tumours from a 
patient were tiled and used as a guide to modify the scoring where 
necessary. 
 
2.5.2 Fraction of genome altered (FGA) 
 
Fraction of genome altered (FGA) was calculated for each tumour sample. 
FGA provides a measure of chromosomal instability and was defined as the 
percentage of clones reporting significantly altered copy number. FGA was 
classified into four groups: A<1%, B 1≤10%, C 10≤30%, and D>30% of 
clones altered. 
 
2.5.3 Constructing patient representative data 
 
In order to facilitate comparisons of patients’ copy number data, each patient 
had to have a single set of representative data from all of its tumours. To 
construct representative data (merged data) for each patient, data from all 
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tumours in a given patient were combined together so every copy number 
alteration within the patient was included to give a view of the total 
complexity Table 2.5. The only exception being if a given region was both 
gained and lost within the patient in different tumours in which case such 
conflicts were excluded from the analysis. Conflicts were reported as no 
change. The highest level gain/loss in the patient was reported for each 
clone. The merging of data for representative group could potentially have 
some disadvantages. This could have resulted in some small tumour 
differences being ‘lost’ in the representative profile. Differences in only a few 
clones could also have been under represented.  
 
Prior to generating the merged data, the smoothed scored data for each 
tumour was manipulated using Excel formula work sheets so that each clone 
was assigned a copy number class (0 = no copy number aberration; 1 = 
gain; -1 = loss; 2 = high-level gain (>+1.2 log2 threshold) -2 = high-level loss 
(<-1.2 log2 threshold)). Conflicts, as described above, were assigned a value 
of 0. 
 
For the purpose of merged data analysis, if multifocal tumours were of 
different stage and/or grade then the highest stage and/or grade within the 
patient was applied. A similar rule was applied in patients where there was a 
conflict with respect to mutation status. If one tumour was mutant then the 
patient was classified as mutant in merged data set. FGA value per patient 
was calculated based on merged copy number data for each patient. 
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Number Stage and grade 
FGA 
group 
FGFR3 
mutation 
status 
PIK3CA 
mutation 
status 
RAS 
mutation 
status 
1 TaG2 B WT Mutant WT 
2 TaG2 C Mutant WT WT 
3 T1G3 C WT WT Mutant 
4 TaG3 C Mutant Mutant WT 
5 TaG2 D Mutant WT WT 
6 T1G3 D WT WT WT 
7 TaG2 C WT WT WT 
8 TaG2 C Mutant Mutant WT 
9 T1G3 A WT WT WT 
10 TaG3 D WT WT WT 
11 T1G3 C WT WT WT 
12 T1G3 D WT WT WT 
13 T1G3 D WT WT WT 
14 TaG3 D WT WT WT 
15 TaG2 C Mutant Mutant WT 
16 TaG2 C WT WT Mutant 
17 TaG2 B Mutant Mutant WT 
18 T1G3 D WT WT WT 
19 TaG2 C Mutant WT WT 
20 T1G3 D WT WT WT 
21 TaG2 C Mutant WT WT 
22 TaG2 C WT WT WT 
 
Table 2.5. Representative data (merged data) for each patient.  
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2.5.4 Copy number frequency plot visualisation and statistical 
comparisons 
 
The merged copy number class data described in section 3.5.2 was used as 
the input for frequency plot visualization and statistical comparisons 
performed within the Nexus Copy Number Professional 6 software package 
(BioDiscovery). 
Using the Comparisons function of the Nexus software a Fisher’s Exact test 
with a p-value cutoff of 0.05 and a differential threshold of 25% was 
performed to determine significant differences in the copy number data for 
specified sample sub-groups. Comparisons of copy number alterations were 
made with respect to: 
- stage 
- grade 
- FGFR3 mutation status 
- smoking status 
- CDKN2A copy number loss 
2.5.5 Multifocal (merged) vs single tumour comparisons 
aCGH data for 160 tumours from Hurst et al. [235] was available for 
comparison with the data from the current study.  One hundred and three of 
these tumours were single. This subset consisting of 28 TaG2, 10 TaG3, 7 
T1G2, 29 T1G3 and 29 ≥ T2G3 tumours had no known multifocality at the 
time of sample collection and were used in comparisons with the multifocal 
data from the current study.  
The single tumour data of Hurst et al. was imported into Nexus for 
comparison with the multifocal data. For this to occur, multifocal tumour data 
had to be made compatible by converting it to hg18/NCBI Build 36 using 
Excel. Copy number alterations in the merged multifocal and single tumour 
datasets were compared with respect to: 
 - stage and grade, 
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- FGFR3 mutation status and stage, 
- FGFR3 mutation status and stage and grade 
- CDKN2A copy number loss 
 
2.5.6 Other statistics 
Associations between non-parametric data (stage and grade, mutation 
status, CDKN2A copy number loss, FGA) were tested using the chi-square 
(X2) test within the Prism software package (GraphPad Software, Inc.). The 
chi-square test compares observed with expected numbers, with the null 
hypothesis being that there is no significant difference between the expected 
and observed result. Significance was taken as a probability value P < 0.05.  
 
2.5.7 Clustering  
One-way unsupervised hierarchical cluster analysis was performed to reveal 
relationships between samples using Partek Genomics Suite 6.6 (Partek 
Inc.). One-way unsupervised hierarchical cluster analysis was performed 
using copy number class data with Euclidean distance and the Ward method 
of linkage. Cluster analysis was performed for the individual multifocal 
tumours (n=66), for merged multifocal patient data (n=22) and for merged 
multifocal patient data combined with the single tumour data of Hurst et al. 
(n=74). 
 
2.5.8 Construction of phylogenetic trees 
For the analysis of copy number alterations and break points in tumour 
samples from the same patient and reconstruction of the relationships 
between them (both similarity and differences), the computational TuMult 
[237] algorithm was applied. During tumorigenesis cells that are 
descendants from one cancerous cell are characterized by having common 
genetic alterations and unique alterations characteristic only to the given 
cell. The common changes are hypothesised to occur before clone 
separation and the unique alterations after clone separation. Hence, the 
comparison of these changes can lead to the reconstruction of the sequence 
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of chromosomal events giving rise to each tumour. This concept is applied in 
the TuMult methodology, as is the reasoning that clones separating later in 
the tumorigenesis process should have more genetic events in common 
than those separating earlier in this process. Tumult uses an iterative 
grouping of the two closest nodes according to chromosome breakpoints, to 
reconstruct the tumour lineage from the leaves (tumours) to the root (normal 
cell). 
The TuMult algorithm is implemented through the R software environment. 
The input data for TuMult was copy number class data (as described above) 
and log2 data for each tumour. All tumours from each individual patient were 
included in the analyses. For patients with prequel or recurrent tumours a 
second analysis was performed that included these samples. Phylogenetic 
trees produced by TuMult were exported in .dot format. Images were then 
generated from the .dot files using the open source graph visualization 
software Graphviz (http://www.graphviz.org). 
 
Matched Primary and Metastatic Bladder Cancer Study 
2.1 Patients, follow-up, surgical technique and pathology 
 
The cohort comprised 150 bladder cancer patients without preoperative 
evidence of metastases (i.e., physical examination, chest x-ray, intravenous 
urography, bone scan, and pelvic computed tomography, when available) 
but with lymph node metastases on pathologic examination. All patients 
underwent extended pelvic lymphadenectomy with cystectomy as a single 
procedure between January 1985 and April 2008 at the Department of 
Urology, University of Bern according to standard protocols described 
previously in detail [238, 239]. The surgical specimens were processed as 
described previously [239]. The tumours were staged according to the 7th 
Union Internationale Contre le Cancer classification [240]. No neoadjuvant 
therapy was given. Postoperatively, the patients were followed prospectively 
according to a standard protocol with examinations at the Department of 
Urology or by urologists in private practice at 3 months and 6 months, then 
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at 6-monthly intervals until 5 year, and then at yearly intervals thereafter. 
Patients’ clinicopathological data included in the study is shown in Table 2.6. 
 
Patient!data!(n!=!150)! !!!!Age!at!surgery,!yr,!median!(range)! 67!(35–89)!!!!Female/male,!No.! 29/121!!!!FollowBup,!yr,!median! 7.1!Cystectomy!data! !Tumour!stage,!No.! !!!!pT1! 4!!!!pT2! 17!!!!pT3! 92!!!!pT4! 37!Lymphadenectomy!data! !!!!Evaluated!nodes!per!patient,!median!(range)! 27!(10–56)!!!!Positive!nodes!per!patient,!median!(range)! !!3!(1–46)!Extracapsular!extension!of!metastases,!No.! !!!!No! 71!!!!Yes! 79!
 
Table 2.6 Clinicopathologic data of patients included in the study 
 
2.2 Construction of the tissue microarray (TMA) 
  
The TMA was constructed in Bern, Switzerland by experienced technician. 
Briefly, the TMA [241] was constructed with six tissue cores (0.6-mm 
diameter) per patient: two each from normal urothelium, primary tumour 
(centre and invasion front), and a nodal metastasis. Biopsies were placed on 
slides with 17 columns and 9 rows with one liver biopsy as a control sample 
(Figure 2.7).  
 
-65 - 
 
 
Figure 2.7: Tissue microarray. A microarray contains many small 
representative tissue samples from different patients assembled on a 
single slide. This allows high throughput analysis of multiple 
specimens at the same time. 
 
2.3 Immunohistochemistry  
 
FGFR3 protein expression was assessed in sections of TMAs of formalin-
fixed paraffin wax-embedded tumours in two blocks. Briefly, 3 µm sections 
were deparaffinised in xylene (four times for 5 min.), rehydrated through 
graded ethanols (100%, 90%, and 70%, samples were immersed for 2 min.) 
and endogenous peroxidase activity blocked in 3% hydrogen peroxide 
(Sigma-Aldrich Company Ltd., Dorset, UK) for 20 min. The graded ethanols 
were in order: 100%, 90%, and 70% and samples were immersed for 2 min. 
Next, running cold tap water was used to rinse for 10 min. For antigen 
retrieval, sections were boiled in 10mM citric acid buffer (pH6) for 2 min, and 
non-specific binding was blocked for 15 min. with avidin/biotin solution 
(Vector Laboratories, Peterborough, UK) followed by 10% normal serum 
(Dako, Ely, UK) for 20 min. Primary antibody (FGFR3 B9, 1:100; Santa Cruz, 
CA, USA) was applied for 1 h at room temperature and detected with a 
biotinylated secondary antibody and 3,3- diaminobenzidine 
terahydrochloride (DAB; Vector Laboratories, Peterborough, UK). Slides 
were counterstained with Mayer’s haematoxylin for 20 seconds, rinsed for 1 
min with tap running water. Then dehydrated with absolute alcohol for 3 min. 
-66 - 
 
dried for 5 min and immersed in Xylene for 2 min. Following this coverslips 
were mounted on the slides with DEPEX (Fisher Scientific UK Ltd, 
Loughborough, UK). Immunostaining was assessed by three independent 
observers (Prof. M. Knowles, Dr P. Harnden, Mr R. Turo), who were blinded 
to mutational status and clinical outcomes. A semi-quantitative scoring 
system was adopted: 0, all tumour cells negative; 1, faint but detectable 
positivity in some or all cells; 2, weak but extensive positivity; 3, strong 
positivity (regardless of extent). (Figure 2.8, 2.9, 2.10, 2.11). For the 
statistical analysis, tumours with the score 0 and 1 were grouped as low (L) 
and tumours scored 2 and 3 as high (H). Scanned images were viewed on a 
computer using different magnifications. 
 
2.3.1 Statistical analysis of TMA 
 
FGFR3 expression was tested for association with categorical clinical data 
using a Fisher’s exact test, and overall survival (OS) and recurrence free 
survival (RFS) using Kaplan-Meier analysis. Significance of predictors in 
survival analysis was assessed using the log-rank test for univariate 
analysis. For analysis of metastatic tumour phenotype the ratios have been 
calculated of total and lower metastases’ diameter, and total number of 
metastases. All statistical calculations were carried out with SPSS for 
Windows ® version 20.
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Figure 2.8: Detection of FGFR3 
by IHC. Strong FGFR3 
expression (score 3), (x10 
magnification), Size bar = 
100µm 
 
 
 
 
Figure 2.10: Detection of FGFR3 
by IHC. Faint but detectable 
positivity (score 1), (x10 
magnification), Size bar = 
100µm 
 
 
 
Figure 2.9: Detection of FGFR3 
by IHC. Absence of staining 
(score 0), (x10 magnification), 
Size bar = 100µm 
 
 
 
 
 
Figure 2.11: Detection of FGFR3 
by IHC. Weak but extensive 
positivity (score 2), (x10 
magnification), Size bar = 
100µm
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Chapter 3 
Copy number alterations and mutation analysis 
 
In this chapter we have aimed to describe detailed molecular 
characterization and comparison of genetic alterations in clinically and 
morphologically distinct multifocal tumour cell populations. This information 
would serve to reveal the clonal evolution of carcinoma of the urinary 
bladder. Also our enhanced knowledge of the molecular genetic 
characteristics of multifocal bladder tumours may offer a combined 
molecular and histo-pathological approach to classification and thus improve 
clinical management and the decision-making process of this common 
cancer. By combing copy number and mutation data we aimed to assess the 
molecular heterogeneity of tumours within and between patients, and to 
identify specific features related to multifocality. In most of the published 
studies on multifocal bladder cancer, conventional CGH, LOH analysis, FISH 
and mutation scanning of TP53 and FGFR3 have been applied to the study 
of small sets of tumours [184, 242-247].  To our knowledge, this study is the 
first to use aCGH to analyse such a large panel of superficial multifocal 
bladder tumours. 
This chapter describes the results of experiments in which aCGH and 
SNaPshot analysis were used to determine copy number alterations and 
mutations, respectively, in 66 tumours from 22 patients with non muscle-
invasive multifocal bladder cancer. As described in detail in the Materials 
and Methods (see Section 2), in order to facilitate comparisons of patients’ 
copy number data, each patient had to have a single set of representative 
data from all tumours. To construct representative data (merged data) for 
each patient, data from all tumours in a given patient were combined 
together so every copy number alteration within the patient was included to 
give a view of the total complexity. Relationships between copy number 
alterations, mutation status and clinico-pathologic data have been assessed. 
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3.1  Copy number alterations 
3.1.1 Frequencies of copy number alterations 
 
1Mb-resolution aCGH was used to assess copy number alterations in 66 
tumours from 22 patients. All copy number data is available in the Appendix 
3.1. Copy number alterations involving whole chromosomes, chromosome 
arms and smaller regions were detected. Representative data (merged) data 
was constructed for each patient using the individual tumour copy number 
data. The frequencies of copy number alterations by chromosome arm were 
then calculated using the merged copy number data for each patient (Table 
3.1). The most common region gained was 20q (68.2%), and the most 
common region lost was 9q (81.8%). The most frequent gains observed in 
≥50% of the patients were on 8q (63.6%) and 1q (50%). The most frequent 
deletions were observed on 9p (77.3%), 10q (63.6%), 5q (54.5%), 8p (50%) 
and 2q (50%). The mean number of chromosomal gains per patient was 
29.02 (range 0-66.7) and mean number of chromosomal deletions was 30.1 
(range 0-56.4).  
 
 Chromosome arm (frequency in patients %) 
Gains 20q (68.2%), 8q (63.6%), 1q (50%), 20p (45.5%), 13q (45.5%), 
10q (40.9%), 6p (40.9%), 17q (36.4%), 12q (36.4%), 9p 
(36.4%), 7q (36.4%), 2p (36.4%), 1p (36.4%), 15q (31.8%), 11q 
(31.8%), 5p (31.8%), 19q (27.3%), 14q (27.3%), 4p (27.3%), 3q 
(27.3%), 3p (27.3%), 21q (22.7%), 18q (22.7%), 18p (22.7%), 
16p (22.7%), 7p (22.7%), 2q (22.7%), 4q (22.7%), 17p (18.2%), 
16q (18.2%), 12p (18.2%), 10p (18.2%), 8p (18.2%), 22q 
(13.6%), 19p (13.6%), 11p (13.6%), 9q (13.6%), 6q (13.6%), 5q 
(9.1%) 
Deletions 9q (81.8%), 9p (77.3%), 10q (63.6%), 5q (54.5%), 8p (50%), 2q 
(50%), 22q (40.9%), 17p (40.9%), 14q (40.9%), 13q (40.9%), 
12q (36.4%), 11p (36.4%), 19p (31.8%), 16q (31.8%), 6q 
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(31.8%), 19q (27.3%), 16p (27.3%), 11q (27.3%), 8q (27.3%), 
4q (27.3%), 4p (27.3%), 3q (27.3%), 18p (22.7%), 17q (22.7%), 
15q (22.7%), 7p (22.7%), 1q (22.7%), 1p (22.7%), 18q (18.2%), 
12p (18.2%), 7q (18.2%), 2p (18.2%), 21q (13.6%), 10p 
(13.6%), 5p (13.6%), 3p (13.6%), 20q (4.5%), 6p (4.5%) 
 
Table 3.1 The frequencies of copy number alterations by chromosome 
arm in 22 patients. 
 
3.1.2 Copy number alterations and stage and grade 
Genome-wide frequency plots of copy number alterations were constructed 
for all 22 patients and according to stage and grade (Figure 3.1). The 
proportions of the different types of copy number alterations (whole 
chromosome, chromosome arms or smaller regions) did not significantly 
differ between stages or grades, but the frequencies of copy number events 
increased with stage and grade (Figure 3.1). 
 
The frequencies of copy number alterations by chromosome arm in stage Ta 
and T1 tumours are shown in Table 3.2. Ta and T1 tumours showed 
alterations on 18% and 30% of chromosome arms respectively. The most 
frequent alterations in Ta tumours were losses of 5q (50%), 9p (78.6%), 9q 
(85.7%) and gains of 8q (57.1%) and 20q (57.1%). In T1 tumours, frequent 
losses were observed of 2q (75%), 9p (75%), 9q (75%), 10q (87.5%), 22q 
(75%) and gains of 2p (75%), 6p (75%), 8q (75%), 20p (75%) and 20q 
(87.5%). 
 
Using the Comparisons function of the Nexus software package, a Fishers 
Exact test (0.05 p-value cut off; 25% differential threshold) was used to 
compare the frequencies of copy number alterations in patients with Ta 
(n=14) versus T1 (n=8) tumours (Figure 3.1, Appendix 3.2). Gains on 1p, 2p, 
6p, 7p, 7q, 9q, and 16p were significantly more frequent in stage T1 
tumours. Deletions on 2q, 6q, 10q, 12p, 12q, 14q and 22q were also 
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significantly more frequent in patients with stage T1 tumours. The region 
showing the biggest difference in the frequency of deletion between Ta and 
T1 tumours was a region on 10q extending from 10q23.32 to 10q23.33 . This 
region contains the following genes: CPEB3, SDHCP2, EIF4A1P8, NHP2P1, 
MARCH5, MARK2P9, IDE, KIF11, RPL11P4, EIF2S2P3, HHEX, EXOC6, 
CYP26C1, CYP26A1, and NIP7P1. 
 
 
 
Stage Losses (frequency %) Gains (frequency %) 
Ta  
 
 
n=14 
1p (21.4), 1q (21.4), 2p (21.4), 2q (35.7), 
3p (14.3), 3q (21.4), 4p (21.4), 4q (21.4), 
5p (7.1), 5q (50), 6q (21.4), 7p (28.6), 7q 
(28.6), 8p (42.9), 8q (35.7), 9p (78.6), 9q 
(85.7), 10p (7.1), 10q (50), 11p (28.6), 
11q (21.4), 12p (7.1), 12q (28.6), 13q 
(35.7), 14q (28.6), 15q (14.2), 16p 
(21.4), 16q (28.6), 17p (35.7), 17q 
(35.7), 18p (21.4), 18q (14.3), 19p 
(21.4), 19q (28.6), 20q (7.1), 21q (14.3), 
22q (21.4) 
1p (28.6), 1q (42.9), 2p (14.3), 2q (14.3), 
3p (21.4), 3q (28.6), 4p (28.6), 4q (14.3), 
5p (28.6), 6p (21.4), 6q (7.1), 7p (7.1), 
7q (21.4), 8p (14.3), 8q (57.1), 9p (35.7), 
10p (28.6), 10q (35.7), 11p (7.1), 11q 
(21.4), 12p (7.1), 12q (28.6), 13q (42.9), 
14q (21.4), 15q (28.6), 16p (7.1), 16q 
(14.3), 17 p (14.3), 17q (35.7), 18p 
(21.4), 18q (14.3), 19p (14.3), 19q 
(21.4), 20p (28.6), 20q (57.1), 21q 
(21.4), 22q (7.1) 
T1 
 
 
n=8 
 
1p (25), 1q (25), 2q (75), 3q (37.5), 4p 
(37.5), 4q (37.5), 5p (25), 5q (62.5), 6q 
(50), 8p (62.5), 9p (75), 9q (75), 10p 
(25), 10q (87.5), 11p (50), 11q (37.5), 
12p (37.5), 12q (50), 13q (50), 14q 
(62.5), 15q (37.5), 16p (37.5), 16q 
(37.5), 17p (50), 18p (25), 18q (25), 19 
(50), 19q (25), 22q (75) 
1p (50), 1q (62.5), 2p (75), 2q (37.5), 3p 
(37.5), 3q (25), 4p (25), 4q (37.5), 5p 
(37.5), 5q (25), 6p (75), 6q (25), 7p (50), 
7q (62.5), 8p (25), 8q (75), 9p (37.5), 9q 
(37.5), 10q (50), 11p (25), 11q (50), 12p 
(37.5), 12q (50), 13q (50), 14q (37.5), 
15q (37.5), 16p (50), 16q (25), 17p (25), 
17q (37.5), 18p (25), 18q (37.5), 19q 
(37.5), 20p (75), 20q (87.5), 21q (25), 
22q (25) 
 
Table 3.2 Recurrent genomic alterations by chromosome arm in 22 
patients according to stage. 
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The frequencies of copy number alterations by chromosome arm in grade 2 
and grade 3 tumours are shown in Table 3.3. Grade 2 tumours showed a 
lower average frequency of alterations (10%) than grade 3 tumours (27%). 
Grade 3 tumours exhibited frequent losses of 2q (72.7%), 5q (72.7%), 9p 
(72.7%), 9q (81.8%), 10q (81.8%) and 22q (81.8%), and gains of 1q 
(63.6%), 2p (63.6%), 6p (63.6%), 8q (63.6%), 20p (63.6%) and 20q (90.9%). 
In grade 2 tumours,  losses of 9p (81.8%) and 9q (81.8%), and gains of 8q 
(63.6%), 13q (45.5%) and 20q (45.5%) predominated.  
 
 
Stage Losses (frequency %) Gains (frequency %) 
G2 
 
n=11 
1q (9.1), 2p (18.2), 2q (27.3), 3q (18.2), 
4p (9.1), 4q (18.2), 5p (9.1), 5q (36.4), 
6q (18.2), 7p (9.1), 7q (27.3), 8p (36.4), 
8q (27.3), 9p (81.8), 9q (81.8), 10p (9.1), 
10q (45.5), 11p (18.2), 11q (9.1), 12p 
(9.1), 12q (9.1), 13q (36.4), 14q (18.2), 
15q (18.2), 16p (27.3), 16q (36.4), 17p 
(27.3), 17q (27.3), 18p (27.3), 18q 
(18.2), 19p (9.1), 19q (18.2), 20q (9.1) 
1p (27.3), 1q (36.4), 2p (9.1), 2q (9.1), 
3p (9.1), 3q (18.2), 4p (18.2), 4q (9.1), 
5p (18.2), 6p (18.2), 7q (18.2), 8p (9.1), 
8q (63.6), 9p (36.4), 10p (27.3), 10q 
(36.4), 11q (9.1), 12q (27.3), 13q (45.5), 
14q (18.2), 15q (18.2), 17p (18.2), 17q 
(27.3), 18p (18.2), 18q (9.1), 19p (9.1), 
19q (18.2), 20p (27.3), 20q (45.5), 21q 
(18.2), 22q (9.1) 
G3 
 
 
n=11 
1p (45.5), 1q (36.4), 2p (18.2), 2q (72.7), 
3p (27.3), 3q (36.4), 4p (45.5), 4q (36.4), 
5p (18.2), 5q (72.7), 6p (9.1), 6q (45.5), 
7p (36.4), 7q (9.1), 8p (63.6), 8q (27.3), 
9p (72.7), 9q (81.8), 10p (18.2), 10q 
(81.8), 11p (54.5), 11q (45.5), 12p 
(27.3), 12q (63.6), 13q (45.5), 14q 
(63.6), 15q (27.3), 16p (27.3), 16q 
(27.3), 17p (54.5), 17q (18.2), 18p 
(18.2), 18q (18.2), 19p (54.5), 19q 
(36.4), 21q (27.3), 22q (81.8) 
1p (45.5), 1q (63.6), 2p (63.6), 2q (36.4), 
3p (45.5), 3q (36.4), 4p (36.4), 4q (36.4), 
5p (45.5), 5q (18.2), 6p (63.6), 6q (27.3), 
7p (45.5), 7q (54.5), 8p (27.3), 8q (63.6), 
9p (36.4), 9q (27.3), 10p (9.1), 10q 
(45.5), 11p (27.3), 11q (54.5), 12p 
(36.4), 12q (45.5), 13q (45.5), 14q 
(36.4), 15q (45.5), 16p (45.5), 16q 
(36.4), 17p (18.2), 17q (45.5), 18p 
(27.3), 18q (36.4), 19p (18.2), 19q 
(36.4), 20p (63.6), 20q (90.9), 21q 
(27.3), 22q (18.2) 
 
Table 3.3 Recurrent genomic alterations by chromosome arm in 22 
patients according to grade. 
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A comparison of the frequencies of copy number alterations in grade 2 and 
grade 3 patients was performed Appendix 3.3. Deletions on 2q, 4q, 4p, 10q, 
11p, 14q, 19p, 22q and gains on 2p, 3p, 5p, 7p, 7q, 15q, 16p and 20q were 
more frequent in patients with grade 3 tumours (Figure 3.1). Only deletion of 
9q was more frequent in grade 2 patients, however it was not statistically 
significant (p> 0.05) (Figure 3.1). 
 
 
Figure 3.1: Genome-wide frequency plots of copy number  
alterations identified in all 22 patients. The x-axis corresponds to  
chromosomes 1 to 22 and the y-axis corresponds to the  
percentage of gains and losses. Copy number gains are shown in  
blue and losses in red. Frequencies of copy number alterations  
are shown for all 22 patients and according to stage and grade. 
-74 - 
 
The frequencies of copy number alterations by chromosome arm were also 
calculated according to stage and grade (i.e. TaG2, TaG3 and T1G3 
tumours). Copy number alterations that occurred at frequencies of ≥15% in 
TaG2, TaG3 and T1G3 tumours are shown in Table 3.4. The most frequent 
alterations in TaG2 tumours were losses of 9p (81.8%) and 9q (81.8%) and 
gains of 8q (63.4%), 13q (45.5%) and 20q (45.5%). Losses of 1p (100%), 5q 
(100%), 7p (100%), 9q (100%), 22q (100%) and gains of 1q (66.7%), 3p 
(66.7%), 4p (66.7%), 5p (66.7%), 11q (66.7%), 15q (66.7%), 16q (66.7%), 
17q (66.7%) and 20q (100%) were the most frequent events in TaG3 
tumours. In T1G3 tumours losses of 2q (75%), 9p (75%), 9q (75%), 10q 
(87.5%), 22q (75%) and gains of 2p (75%), 6p (75%), 8q (75%), 20p (75%), 
20q (87.5%) were most frequent. Low-grade Ta and T1 tumours had fewer 
copy number alterations than high-grade tumours Table 3.4. 
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Stage/grade Losses (frequency %) Gains (frequency %) 
TaG2 
 
(n=11) 
2p (18.2), 2q (27.3), 3q (18.2), 4q 
(18.2), 5q (36.4), 6q (18.2), 7q 
(27.3), 8p (36.4), 8q (27.3), 9p 
(81.8), 9q (81.8), 10q (45.5), 11p 
(18.2), 13q (36.4), 14q (18.2), 15q 
(18.2), 16p (27.3), 16q (36.4), 17p 
(27.3), 17q (27.3), 18p (27.3), 18q 
(18.2), 19q (18.2) 
1p (27.3), 1q (36.4), 3q (18.2), 4p 
(18.2), 5p (18.2), 6p (18.2), 7q (18.2), 
8q (63.4), 9p (36.4), 10p (27.3), 10q 
(36.4), 12q (27.3), 13q (45.5), 14q 
(18.2), 15q (18.2), 17p (18.2), 17q 
(27.3), 18p (18.2), 19q (18.2), 20p 
(27.3), 20q (45.5), 21q (18.2) 
TaG3 
 
(n=3) 
1p (100), 1q (66.7), 2p (33.3), 2q 
(66.7), 3p (66.7), 3q (33.3), 4p 
(66.7), 4q (33.3), 5q (100), 6q 
(33.3), 7p (100), 7q (33.3), 8p 
(66.7), 8q (66.7), 9p (66.7), 9q 
(100), 10q (66.7), 11p (66.7), 11q 
(66.7), 12q (100), 13q (33.3), 14q 
(66.7), 17p (27.3), 17q (66.7), 19p 
(66.7), 19q (66.6), 21q (66.7), 22q 
(100) 
1p (33.3), 1q (66.7), 2p (33.3), 2q 
(33.3), 3p (66.7), 3q (66.7), 4p (66.7), 
4q (33.3), 5p (66.7), 6p (33.3), 6q 
(33.3), 7p (33.3), 7q (33.3), 8p (33.3), 
8q (33.3), 9 p (33.3), 10p (33.3), 10q 
(33.3), 11p (33.3), 11q (66.7), 12p 
(33.3), 12q (33.3), 13q (33.3), 14q 
(3.33), 15q (66.7), 16p (33.3), 16q 
(66.7), 17q (66.7), 18p (33.3), 18q 
(33.3), 19p (33.3), 19q (33.3), 20p 
(33.3), 20q (100), 21q (33.3) 
T1G3 
 
(n=8) 
1p (25), 1q (25), 2q (75), 3q 
(37.5), 4p (37.5), 4q (37.5), 5p 
(25), 5q (62.5), 6q (50), 8p (62.5), 
9p (75), 9q (75), 10p (25), 10q 
(87.5), 11p (50), 11q (37.5), 12p 
(37.5), 12q (50), 13q (50), 14q 
(62.5), 15q (37.5), 16p (37.5), 16q 
(37.5), 17p (50), 18p (25), 18q 
(25), 19 (50), 19q (25), 22q (75) 
1p (50), 1q (62.5), 2p (75), 2q (37.5), 
3p (37.5), 3q (25), 4p (25), 4q (37.5), 
5p (37.5), 5q (25), 6p (75), 6q (25), 7p 
(50), 7q (62.5), 8p (25), 8q (75), 9p 
(37.5), 9q (37.5), 10q (50), 11p (25), 
11q (50), 12p (37.5), 12q (50), 13q 
(50), 14q (37.5), 15q (37.5), 16p (50), 
16q (25), 17p (25), 17q (37.5), 18p 
(25), 18q (37.5), 19q (37.5), 20p (75), 
20q (87.5), 21q (25), 22q (25) 
 
Table 3.4 Recurrent genomic alterations by chromosome arm in 22 
patients according to stage and grade. Only those alterations that 
occurred at frequencies > 15% are shown. 
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3.1.3 Whole genome profiles of all tumours from individual 
patients  
 
Construction of whole genome plots for all tumours in a given patient 
enables the overall chromosomal instability to be assessed and the 
visualisation of genetic alterations that are unique to individual tumours. 
Analysis of whole genome profiles revealed that some patients had tumours 
that shared all or the majority of copy number events (patient 2, 3, 4, 7, 11, 
13, 14, 17, 20, 21) (e.g. Figure 3.2), whilst others had tumours that shared 
some common copy number events but were otherwise highly divergent 
(patient 6, 10, 12, 15, 18, 19, 22) (e.g. Figure 3.3). In 6 patients (1, 5, 8, 9, 
13, 16) there was at least one tumour in a given patient where a monoclonal 
origin could not clearly be confirmed. Patient 1 had two tumours with no 
copy number events while third synchronous tumour had copy number 
alterations (Figure 3.4). Patient 9 had no copy number alterations. Two 
tumours from patient 5 did not share copy number events. Genome plots for 
all tumours are available in Appendix 3.1. 
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Figure 3.2: Whole genome plots of array CGH data for 6 tumours from 
patient 4 that shared the majority of copy number events. Shared copy 
number events on chromosomes 1 and 9 are highlighted in green. The Y-
axis represents the log2 ratio (test / reference) for each BAC clone on the 
array. BAC clone genome order is plotted on the X-axis from chromosome 1 
to chromosome 22.  
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Figure 3.3: Whole genome plots of array CGH data for 3 tumours from 
patient 6 that shared some common copy number events but were 
otherwise highly divergent. Shared copy number events on chromosome 
5 are highlighted in green and unique changes on chromosome 8 are 
highlighted in red.  
 
 
 
Figure 3.4: Whole genome plots of array CGH data for 2 tumours from 
patient 5 that did not share copy number events. 
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3.1.4 Transition of breakpoints 
 
Whole genome plots for each tumour were aligned with others from the 
same patient, thus enabling the identification of breakpoints and alterations 
between tumours. The majority of identified breakpoints had the same 
transition from loss of copy number to gain or from gain to loss. In some 
patients a difference in the transition of breakpoint regions was seen in 
different tumours i.e. in some tumours the transition was up whilst in others 
the transition was down. Figure 3.5. This was identified in 15 patients. 
 
 
 
Figure 3.5: Difference in the transition of breakpoint regions  
(marked in red and green) between tumours from the same  
patient. Y-axis: log2 ratio (test / reference), X-axis: distance along  
chromosome (Mb) 
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3.1.5  Tumours exhibiting no copy number alterations 
 
The majority of tumours exhibited at least some chromosome alterations. 
Seven tumours (patient 1 tumours 2 and 3; patient 8 tumour 3; patient 9 
tumours 1 and 2; patient 16 tumours 1 and 3) exhibited no copy number 
alterations. Among these tumours with ‘flat’ profiles tumours 8_3, 1_1, 1_3 
and 16_3 had been deemed not ‘pure’ enough and these had been laser 
micro-dissected prior to performing aCGH to ensure >70% tumour purity 
(Figure 3.6). The other tumours with ‘flat’ profiles were specifically visually 
re-checked for tumour purity in the resected samples. On visual inspection it 
was confirmed that these samples consisted of > 70% tumours cells. Figure 
3.7. 
 
 
Figure 3.6: Laser micro-dissection of tumour 3 from patient 8. The black 
line distinguishes between the collected (pure tumour cells) and uncollected 
parts of the tissue sample. 
Uncollected)cells)(stroma,)white)blood)
cells))
Uncollected)cells))
Collected)cells)
(tumour)))
Collected)cells)
(tumour)))
Collected)cells)
(tumour)))
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Figure 3.7: A representative example of a tumour (9_1) which showed 
no copy number alterations by aCGH but demonstrated >70% tumour 
purity. 
 
 
3.1.6 Regions of homozygous deletion (HD) and high-level  
amplification 
 
Sixty-nine high-level amplifications were detected in 66 tumours from 22 
patients. The number of amplicons per tumour ranged from 1 to 9.  
Amplifications were more common in higher stage and grade tumours 
(p=0.0014) (Figure 3.8). Those found in two or more patients are shown in 
Appendix 3.4.  
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Figure 3.8: Numbers of amplifications in each stage according to grade 
for all 66 tumours. The y-axis corresponds to the number of amplicons and 
the x-axis corresponds to tumour grade. 
 
The most frequently amplified regions were 11q13.2 - q13.4 and 6p22.3 - 
p22.2. Amplification of 11q13.2 - q13.4 (containing MYEOV, CCND1, 
ORAOV1, FGF19, FGF4, FGF3) was detected in 10 tumours (3_1, 12_1, 
12_2, 12_3, 12_4, 14_1, 14_2, 14_3, 14_4, 18_3) from four different patients 
(patient 3, 12, 14, 18). Amplification of 6p22.3 - p22.2 (containing MBOAT1, 
E2F3, CDKAL1, SOX4, PRL) was detected in 8 tumours (12_1, 12_2, 12_3, 
12_4, 13_1, 13_2, 13_3, 18_2) from three patients (patient 12, 13, 18). 
Other regions of amplification were 12q14.3 - q21.1 and 17q11.2 - q12, with 
amplifications being detected in 7 (12_1, 12_2, 12_3, 12_4, 20_1, 20_2, 
20_3) and 5 (6_2, 14_1, 14_2, 14_3, 14_4) tumours respectively of two 
different patients (patient 12 and 20) and (patient 6 and 14). Amplification of 
p16.3 - p16.1 (containing FGFR3) on chromosome 4 was detected in two 
tumours (10_2, 21_2). The full lists of genes in these regions are shown in 
Appendix 3.4. 
 
Forty-four homozygous deletions were detected in 15 tumours (2_1, 2_3, 
4_1, 4_5, 10_2, 12_1, 12_2, 12_3, 14_1, 14_2, 14_3, 17_1, 17_2, 17_3, 
21_2) from seven different patients (patient 2, 4, 10, 12, 14, 17, 21). Those 
found in two or more patients are shown in Table 3.5. A region on 
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chromosome 10 (103.28-104.34Mb) was HD in five tumours (tumour 4_1, 
14_1, 14_2, 14_3, 17_3) from three different patients (patient 4, 14, 17). It 
contained 29 possible candidate genes: ACTR1A, BTRC, C10orf76, 
C10orf95, CUEDC2, DPCD, ELOVL3, FBXL15, FBXW4, FGF8, GBF1, 
HPS6, KCNIP2, KCNIP2-AS1, LDB1, LOC101927445, MGEA5, MIR146B, 
MIR3158-1, MIR3158-2, NFKB2, NOLC1, NPM3, PITX3, POLL, PPRC1, 
PSD, RPARP-AS1, SUFU, and TMEM180. 
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Table 3.5 Recurrent regions of homozygous deletions detected in all 66 
tumours. 
1Physical position is according to hg19/NCBI build 37. 
2Deletions were classified as those regions where the normalized log2 ratio 
was ≤1.2 detected in 2 or more tumours are listed. 
3The frequency of loss across candidate regions was estimated as the 
percentage of samples with log2ratio ≤0.15 
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3 p21.2 - 
p21.1 
51.56 - 
52.66 
39 ABHD14A, ABHD14A-ACY1, ABHD14B, ACY1, ALAS1, 
ALDOAP1, BAP1, DNAH1, DUSP7, GLYCTK, GPR62, 
GRM2, IQCF1, IQCF2, IQCF3, IQCF4, IQCF5, IQCF5-AS1, 
IQCF6, LINC00696, LOC101929029, LOC101929054, 
LOC101929702, MIR135A1, MIRLET7G, NISCH, NT5DC2, 
PARP3, PCBP4, PHF7, POC1A, PPM1M, PPP2R5CP, 
RAD54L2, RNA5SP132, RPL29, RRP9, SEMA3G, SMIM4, 
STAB1, TEX264, TLR9, TNNC1, TWF2, WDR82 
4_1, 
14_2 
4.55 2 
7 p21.1 16.21 - 
17.76 
10 AGR2, AG 3, AHR, ANKMY2, BZW2, ISPD, ISPD-AS1, 
LOC3 7727, LOC100131425, LOC100287613, 
LOC101927585, LOC101927609, LOC101927630, LRRC72, 
RAD17P1, RPL36AP29, SOSTDC1, TSPAN13 
4_1, 
14_1 
9.1 2 
10 q24.32 103.28 - 
104.34 
29 ACTR1A, BTRC, C10orf76, C10orf95, CUEDC2, DPCD, 
ELOVL3, FBXL15, FBXW4, FGF8, GBF1, HPS6, KCNIP2, 
KCNIP2-AS1, LDB1, LOC101927445, MGEA5, MIR146B, 
MIR3158-1, MIR3158-2, NFKB2, NOLC1, NPM3, PITX3, 
POLL, PPRC1, PSD, RPARP-AS1, SUFU, TMEM180 
4_1, 
14_1, 
14_2, 
14_3, 
17_3 
4.55 5 
12 q21.31 78.75 - 
80.26 
11 LOC642550, LOC100420794, LOC100507498, 
LOC101928252, MIR1252, MRPL11P3, PAWR, PPP1R12A, 
SYT1 
4_5, 
17_1, 
17_2 
9.1 3 
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3.1.7 Fraction of genome altered 
 
 
Fraction of genome altered (FGA) (the percentage of clones reporting 
significantly altered copy number) provides a measure of chromosomal 
instability. FGA was calculated using the individual copy number data for all 
66 tumours and the merged copy number data for each patient. Samples 
were assigned to FGA groups A (≤1%), B (1-≤10%), C (10-<30%) or D 
(≥30%). The majority of the individual tumours fell into FGA groups C or D 
(Table 3.6). Only 10 of the individual tumours had an FGA value of ≤1%.  
When FGA was examined within patients, the majority (8 patients in group 
D, 11 in group C, 2 in group B and 1 patient in group A) were in group C or D 
(Table 3.6). Three patients belonging to groups A (patient 9) and B (patient 1 
and 17) revealed minimal (FGA 4.9%) or no copy number alterations. Within 
this group 4 tumours (1_2, 1_3, 9_1, 9_2) had no copy number alterations. 
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Patient Stage and grade 
FGA 
group 
Patients 
FGA Tumour 
Tumours 
FGA 
FG
A 
1 TaG2 B 4.9 1_1 5 B 
    
1_2 0 A 
    
1_3 0 A 
2 TaG2 C 10.7 2_1 10.1 C 
    
2_2 7.7 B 
    
2_3 7.4 B 
3 T1G3 C 19.1 3_1 13.1 C 
    
3_2 12.4 C 
    
3_3 11.4 C 
4 TaG3 C 14.5 4_1 12.9 C 
    
4_2 8.44 B 
    
4_3 9.01 B 
    
4_4 8.17 B 
    
4_5 8.44 B 
    
4_6 7.92 B 
5 TaG2 D 60.1 5_1 0 A 
    
5_2 60.07 D 
6 T1G3 D 72.4 6_1 57.77 D 
    
6_2 63.42 D 
    
6_3 69.58 D 
7 TaG2 C 11.9 7_1 11.7 C 
    
7_2 12.1 C 
8 TaG2 C 12.7 8_1 0.39 A 
    
8_2 12.4 C 
    
8_3 0 A 
9 T1G3 A 0.03 9_1 0 A 
    
9_2 0 A 
10 TaG3 D 60.7 10_1 28.38 C 
    
10_2 53.58 D 
11 T1G3 C 19 11_1 16.51 C 
    
11_2 15.42 C 
12 T1G3 D 61.6 12_1 42.68 D 
    
12_2 45.26 D 
    
12_3 58.95 D 
    
12_4 40.59 D 
13 T1G3 D 63.1 13_1 57.13 D 
    
13_2 48.18 D 
    
13_3 56.43 D 
    
13_4 0.36 A 
14 TaG3 D 54.7 14_1 49.57 D 
    
14_2 42.38 D 
    
14_3 39.58 D 
    
14_4 44.29 D 
15 TaG2 C 18.2 15_1 15.85 C 
    
15_2 7.44 B 
16 TaG2 C 20 16_1 15.76 C 
    
16_2 7.95 B 
    
16_3 0 A 
    
16_4 0.15 A 
17 TaG2 B 3.1 17_1 1.21 B 
    
17_2 2.19 B 
    
17_3 1.28 B 
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Table 3.6 Stage, grade and FGA in patients and tumours 
 
 
3.1.8 Relationship of FGA to stage and grade 
 
The relationship of FGA to stage and grade was examined for the 66 
individual tumours and for the 22 patients. 
 
Overall, grade 3 tumours had a higher median FGA than grade 2 tumours 
(grade 2 = 7.4 and grade 3 = 42.4, p=0.0001, X2 analysis) (Figure 3.9).  
Stage Ta tumours had lower median FGA than stage T1 tumours (stage Ta 
= 9.6 and stage T1 = 45.14, p=0.0001, X2 analysis) (Figure 3.10). 
 
 
Patient Stage and grade 
FGA 
group 
Patients 
FGA Tumour 
Tumours 
FGA 
FG
A 
18 T1G3 D 70.5 18_1 47.87 D 
    
18_2 45.02 D 
    
18_3 40.47 D 
    
18_4 50.49 D 
19 TaG2 C 18 19_1 3.34 B 
    
19_2 6.16 B 
    
19_3 13.4 C 
20 T1G3 D 73.3 20_1 45.69 D 
    
20_2 52.82 D 
    
20_3 54.28 D 
21 TaG2 C 15.3 21_1 13.81 C 
    
21_2 13.33 C 
22 TaG2 C 17.9 22_1 16.39 C 
    
22_2 5.19 B 
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Figure 3.9: Numbers of tumours in each FGA group according to grade 
for all 66 tumours. The y-axis corresponds to the number of tumours and 
the x-axis corresponds to tumour grade. 
 
Figure 3.10: Numbers of tumours in each FGA group according to 
stage for all 66 tumours. The y-axis corresponds to the number of tumours 
and the x-axis corresponds to tumour stage. 
 
Table 3.7 and Figure 3.11 show the numbers of tumours in each of the FGA 
groups according to combined stage and grade for the 66 individual 
tumours. TaG2 tumours were predominantly FGA groups A and B. The 
majority of TaG3 and T1G3 tumours were FGA group D. 
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                          FGA 
    Stage/grade 
A 
(<1%) 
B 
(1-<10%) 
C 
(10-<30%) 
D 
(≥30%) 
Total 
 
TaG2 7 11 11 2 31 
TaG3 1 5 2 9 17 
T1G3 2 0 4 12 18 
Total 10 16 17 23 66 
 
Table 3.7 FGA group according to stage and grade for 66 tumours. 
 
 
 
 
Figure 3.11: Numbers of tumours in each FGA group according to 
stage and grade for all 66 tumours. The y-axis corresponds to the number 
of tumours and the x-axis corresponds to tumour stage and grade. 
 
Median FGA was also examined in the 66 tumours. TaG2 tumours had a 
lower median FGA (7.4%) than TaG3 (39.6%; p=0.001, X2 analysis) and 
T1G3 (59.6%; p<0.001, X2 analysis) tumours Figure 3.12. 
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Figure 3.12: FGA (%) in all 66 multifocal tumours according to stage 
and grade. The y–axis corresponds to FGA (%) and the x–axis corresponds 
to stage and grade. Green lines indicate median FGA values (%) for TaG2 
(7.4%), TaG3 (39.6 %) and T1G3 (59.6 %). 
 
Some tumours exhibited few or no copy number alterations and these 
tumours had correspondingly low FGA values. Fifteen tumours (1_1, 1_2, 
1_3, 5_1, 8_1, 8_3, 9_1, 9_2, 13_4, 16_3, 16_4, 17_1, 17_2, 17_3, 19_1) 
had <5% FGA and 10 of these (1_2, 1_3, 5_1, 8_1, 8_3, 9_1, 9_2, 13_4, 
16_3, 16_4) had <1% FGA. The majority of these genomically stable 
tumours were of low stage and grade (TaG2 n=12; TaG3 n=1; T1G3 n=2). 
 
Next, we examined FGA according to stage and grade in merged data for 
the 22 patients. Most of the patients with grade 2 disease were FGA group C 
(Figure 3.13). Patients with grade 3 tumours were mainly FGA group D with 
no patients in group B. Most of the patients with stage Ta disease were FGA 
group C (Figure 3.14). Stage T1 patients were mainly FGA group D. Table 
3.8 and Figure 3.15 show the numbers of patients in each of the FGA groups 
according to combined stage and grade for the 22 patients. One patient with 
T1G3 was FGA Group A and two patients with TaG2 tumours were FGA 
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group B. The majority of TaG3 and T1G3 tumours were FGA group D. The 
majority of patients with TaG2 tumours were FGA group C.  
  
 
 
 
Figure 3.13: Numbers of tumours in each FGA group according to 
grade for 22 patients. The y-axis corresponds to the number of tumours 
and the x-axis corresponds to tumour grade. 
 
 
 
 
Figure 3.14: Numbers of tumours in each FGA group according to 
stage for 22 patients. The y-axis corresponds to the number of tumours 
and the x-axis corresponds to tumour stage. 
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                         FGA               
 Stage/grade 
A 
(<1%) 
B 
(1-<10%) 
C 
(10-<30%) 
D 
(≥30%) 
Total 
 
TaG2 0 2 8 1 11 
TaG3 0 0 1 2 3 
T1G3 1 0 2 5 8 
Total 1 2 11 8 22 
 
Table 3.8 FGA group according stage and grade for 22 patients. 
 
 
 
 
Figure 3.15: Numbers of tumours in each FGA group according to 
stage and grade for 22 patients. The y-axis corresponds to the number of 
tumours and the x-axis corresponds to tumour stage and grade. 
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3.2 Mutation analysis 
 
The mutation status of FGFR3, PIK3CA and the 3 RAS genes (HRAS, 
KRAS and NRAS) was determined for all 66 tumours by SNaPshot analysis 
(Table 3.9, Figure 3.16). These genes play an important role in many cellular 
processes. Mutations in FGFR3, PIK3CA and Ras genes have been 
identified in a variety of human cancers including bladder cancer. The 
assays used covered all hotspot mutation codons. 
 
FGFR3 mutations were detected in 23 of 66 tumours (34.8%). S249C 
mutations were detected in 16 tumours from 5 patients (Figure 3.17). The 
second commonest FGFR3 mutation was Y375C which was detected in 5 
tumours from 2 patients. K652T mutations were detected in two tumours 
from 1 patient. PIK3CA mutations were detected in 16 (24.2%) tumours. The 
most common mutation was E542K, which was detected in 7 tumours from 3 
patients. An E545Q mutation was detected in all 6 tumours from 1 patient 
(Figure 3.18). In three tumours from one patient, H1047R mutations were 
detected. RAS gene mutations were detected in 7 tumours (10.6%). HRAS 
Q61R mutations were detected in three tumours from 1 patient, and HRAS 
G12C mutations were detected in four tumours from 1 patient. 
 
In eleven patients none of the screened mutations were detected. Eleven 
patients had at least one mutation detected. All tumours from the same 
patient shared the same mutation status except in two cases (patient 1 and 
patient 19) where PIK3CA and FGFR3 mutations, respectively, were not 
present in all tumours from the same patient. Where RAS mutations were 
detected, they were shared by all tumours from the same patient. RAS and 
FGFR3/PIK3CA mutations were mutually exclusive. Four patients had 
concomitant mutation of both FGFR3 and PIK3CA. In one patient (4), two 
tumours shared mutations in FGFR3 (S249C) and PIK3CA (E545Q) and 
shared the majority of copy number alterations (Table 3.9 and 3.10).  
  
-94 - 
 
Table 3.9 FGFR3, PIK3CA and RAS gene mutations detected in 66 individual tumours from 22 patients with multifocal 
bladder cancer.  
 
Tumour Number 
 
Stage & grade 
 
Primary/ Recurrent 
FGFR3 
Mutation 
Status 
PIK3CA 
Mutation 
Status 
Ras gene Mutation 
Status 
1_1 Ta G2 Recurrence WT E542K WT 
1_2 Ta G2 Recurrence WT E542K WT 
1_3 Ta G2 Recurrence WT WT WT 
2_1 Ta G2 Recurrence S249C WT WT 
2_2 Ta G2 Recurrence S249C WT WT 
2_3 Ta G2 Recurrence S249C WT WT 
3_1 T1 G3 Recurrence WT WT HRAS:Q61R 
3_2 T1 G3 Recurrence WT WT HRAS:Q61R 
3_3 T1 G3 Recurrence WT WT H:Q61R 
4_1 Ta G3 Recurrence S249C E545Q WT 
4_2 Ta G3 Recurrence S249C E545Q WT 
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Tumour Number 
 
Stage & grade 
 
Primary/ Recurrent 
FGFR3 
Mutation 
Status 
PIK3CA 
Mutation 
Status 
Ras Mutation 
Status 
4_3 Ta G3 Recurrence S249C E545Q WT 
4_4 Ta G3 Recurrence S249C E545Q WT 
4_5 Ta G3 Recurrence S249C E545Q WT 
4_6 Ta G3 Recurrence S249C E545Q WT 
5_1 Ta G2 Primary S249C WT WT 
5_2 Ta G2 Primary S249C WT WT 
6_1 T1 G3 Primary WT WT WT 
6_2 T1 G3 Primary WT WT WT 
6_3 T1 G3 Primary WT WT WT 
7_1 Ta G2 Recurrence WT WT WT 
7_2 Ta G2 Recurrence WT WT WT 
8_1 Ta G2 Recurrence S249C H1047R WT 
8_2 Ta G2 Recurrence S249C H1047R WT 
8_3 Ta G2 Recurrence S249C H1047R WT 
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Tumour Number 
 
Stage & grade 
 
Primary/ Recurrent 
FGFR3 
Mutation 
Status 
PIK3CA 
Mutation 
Status 
Ras Mutation 
Status 
9_1 T1 G3 Primary WT WT WT 
9_2 T1 G3 Primary WT WT WT 
10_1 Ta G3 Primary WT WT WT 
10_2 Ta G3 Primary WT WT WT 
11_1 Ta G2 Recurrence WT WT WT 
11_2 T1 G3 Recurrence WT WT WT 
12_1 T1 G3 Primary WT WT WT 
12_2 T1 G3 Primary WT WT WT 
12_3 T1 G3 Primary WT WT WT 
12_4 Ta G3 Primary WT WT WT 
13_1 Ta G3 Primary WT WT WT 
13_2 Ta G3 Primary WT WT WT 
13_3 Ta G3 Primary WT WT WT 
13_4 Ta G3 Primary WT WT WT 
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Tumour Number 
 
Stage & grade 
 
Primary/ Recurrent 
FGFR3 
Mutation 
Status 
PIK3CA 
Mutation 
Status 
Ras Mutation 
Status 
14_1 Ta G3 Primary WT WT WT 
14_2 Ta G3 Primary WT WT WT 
14_3 Ta G3 Primary WT WT WT 
14_4 Ta G3 Primary WT WT WT 
15_1 Ta G2 Primary S249C E542K WT 
15_2 Ta G2 Primary S249C E542K WT 
16_1 Ta G2 Recurrence WT WT HRASG12C 
16_2 Ta G2 Recurrence WT WT HRASG12C 
16_3 Ta G2 Recurrence WT WT HRASG12C 
16_4 Ta G2 Recurrence WT WT HRASG12C 
17_1 Ta G2 Recurrence Y375C E542K WT 
17_2 Ta G2 Recurrence Y375C E542K WT 
17_3 Ta G2 Recurrence Y375C E542K WT 
18_1 T1 G3 Primary WT WT WT 
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Tumour Number 
 
Stage & grade 
 
Primary/ Recurrent 
FGFR3 
Mutation 
Status 
PIK3CA 
Mutation 
Status 
Ras Mutation 
Status 
18_2 T1 G3 Primary WT WT WT 
18_3 T1 G3 Primary WT WT WT 
18_4 T1 G3 Primary WT WT WT 
19_1 Ta G2 Primary Y375C WT WT 
19_2 Ta G2 Primary Y375C WT WT 
19_3 Ta G2 Primary WT WT WT 
20_1 Ta G2 Primary WT WT WT 
20_2 T1 G3 Primary WT WT WT 
20_3 T1 G3 Primary WT WT WT 
21_1 Ta G2 Recurrence K652T WT WT 
21_2 Ta G2 Recurrence K652T WT WT 
22_1 Ta G2 Primary WT WT WT 
22_2 Ta G2 Primary WT WT WT 
-99 - 
 
 
 
 
 
Figure 3.16: Heatmap of mutations detected in all 66 tumours. Orange: 
mutant, green: WT. 
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Figure 3.17: SNaPshot detection of a FGFR3 S249C mutation in a 
tumour from patient 4. Top panel: Wildtype SNaPshot profile obtained 
using DNA extracted from patient 4’s blood sample. Bottom panel: Profile 
showing a FGFR3 S249C mutation (indicated by the red arrow). Bases are 
represented by the following colours: A = green; C = black; G = blue; T = 
red. Positions of codons are indicated next to peaks. Orange peaks (S) 
represent the internal size standard (Genescan-120LIZ). 
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Figure 3.18: SNaPshot detection of a PIK3CA E545Q mutation in a 
tumour from patient 4. Top panel: Wildtype SNaPshot profile obtained 
using DNA extracted from patient 4’s blood sample. Bottom panel: Profile 
showing a PIK3CA  E545Q mutation (indicated by the red arrow). 
 
3.2.1 Mutation status and stage and grade 
 
X2 tests were conducted to test for associations of mutation status with stage 
and grade in all 66 tumours. FGFR3 mutation was associated with low stage 
and grade (p=0.0001) (Figure 3.19). PIK3CA mutation was associated with 
low stage and grade (p=0.02) and RAS gene mutations were associated with 
high stage and grade tumours (p<0.0001) (Figure 3.20 and Figure 3.21). 
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Figure 3.19: FGFR3 mutations in all 66 tumours according to stage and 
grade. The y-axis corresponds to the number of tumours and the x-axis 
corresponds to tumour stage and grade. 
 
 
 
Figure 3.20: PIK3CA mutations in all 66 tumours according to stage 
and grade. The y-axis corresponds to the number of tumours and the x-axis 
corresponds to tumour stage and grade.  
FGFR3
Stage and grade
N
um
be
r o
f t
um
ou
rs
TaG2 TaG3 T1G3
0
5
10
15
20
FGFR3mut
WT
PIK3CA
Stage and grade
N
um
be
r o
f t
um
ou
rs
TaG2 TaG3 T1G3
0
5
10
15
20
25
PIK3CAmut
WT
-103 - 
 
 
Figure 3.21: RAS gene mutations in all 66 tumours according to stage 
and grade. The y-axis corresponds to the number of tumours and the  x-axis 
corresponds to tumour stage and grade. 
When the same comparisons were made per patient, only FGFR3 mutation 
analysis reached statistical significance (p=0.002) due to the low number of 
patients. This analysis revealed that FGFR3 mutations were more prevalent 
in TaG2 patients. Figure 3.22  and Table 3.10 shows the distribution of 
mutations according to stage and grade for the 22 patients. 
 
 
Figure 3.22: FGFR3 mutations in 22 patients according to stage and 
grade. The y-axis corresponds to the number of patients and the x-axis 
corresponds to tumour stage and grade. 
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Table 3.10 Mutations in 22 patients according to stage and grade. In 
brackets: number of tumours with mutation/total number of tumours in the 
patient. 
 
 
3.2.2 Relationships between FGA, mutation status, copy number 
alterations and risk factor data 
 
A comparison of mutation status and FGA (%) revealed a lower median FGA 
in tumours with an FGFR3 mutation (7.9%) as compared to wildtype tumours 
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(39.6%) (Figure 3.23). The distribution pattern of WT tumours was an 
interesting one. These tumours tended to group into two separate groups 
(one with lower and second with higher FGA status). In the first group 9 out 
of 13 tumours were stage Ta and 6 were of grade 2. 
 
 
 
Figure 3.23: FGA (%) in 66 multifocal tumours according to FGFR3 
mutation status. The y–axis corresponds to the percentage of FGA and the 
x–axis corresponds to FGFR3 mutation status. Green lines indicate median 
FGA values (%) for WT tumours (39.6%) and tumours with FGFR3 mutation  
(7.9%). 
 
 
Figure 3.24 shows the distribution of FGA (%) across different stages and 
grades of tumours according to FGFR3 mutation status. The majority of 
tumours with FGFR3 mutations had <15% of FGA and these were mainly 
TaG2 tumours. Only one FGFR3 mutant tumour (tumour 2 from patient 5) 
exhibited a significant number of copy number alterations and this was 
reflected in the high FGA value (60.1%) obtained for this tumour. 
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Figure 3.24: FGA (%) and FGFR3 mutation status in 66 multifocal 
tumours according to stage and grade. The y–axis corresponds to the 
percentage of FGA and the x–axis corresponds to stage and grade. Red 
triangles FGFR3 mutant; blue diamond, wildtype for FGFR3 
 
A comparison of mutation status and FGA (%) revealed a lower median FGA 
in tumours with an PIK3CA mutation (7.7%) as compared to wild-type 
tumours (16.5%) Figure 3.25. Similarly to FGFR3 WT tumours, the 
distribution pattern of PIK3CA WT tumours was an interesting one. These 
tumours tended to group into two separate groups (one with lower and 
second with higher FGA status). 
 
0"
10"
20"
30"
40"
50"
60"
70"
80"
FG
A$
TaG2$$$$$$$$$$$$$$TaG3 $$$$$$$$$T1G3$
WT"
FGFR3"mut"
-107 - 
 
 
Figure 3.25: FGA (%) in 66 multifocal tumours according to PIK3CA 
mutation status. The y–axis corresponds to the percentage of FGA and the 
x–axis corresponds to PIK3CA mutation status. Green lines indicate median 
FGA values (%) for WT tumours (16.5%) and tumours with PIK3CA mutation  
(7.7%). 
 
Figure 3.26 shows the distribution of FGA (%) across different stages and 
grades of tumours according to PIK3CA mutation status. The majority of 
tumours with PIK3CA mutations had <10% of FGA and these were mainly 
TaG2 tumours. Only one patient (patient 4) had PIK3CA mutations in all 
tumours and these were all stage TaG3. All tumours with T1G3 disease 
were wildtype for PIK3CA.   
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Figure 3.26: FGA (%) and PIK3CA mutation status in 66 multifocal 
tumours according to stage and grade. The y–axis corresponds to the 
percentage of FGA and the x–axis corresponds to stage and grade. Red 
triangles PIK3CA mutant; blue diamond, wildtype for PIK3CA. 
 
Due to low number of tumours with RAS gene mutations similar 
comparisons were not performed. 
 
3.3 Mutation status and copy number alterations 
 
Using the Comparisons function of the Nexus software package, a Fishers 
Exact test (0.05 p-value cut off; 25% differential threshold) was used to 
compare the frequencies of copy number alterations in patients according to 
FGFR3 mutation status (Appendix 3.5, Figure 3.27). FGFR3 wildtype 
tumours commonly showed gains of 2 regions on the long arm of 
chromosome 7 (7q21.11 - 7q21.3 and 7q22.1 - 7q36.3, p=0.017). Gain of 
discrete regions on the long arm of chromosome 8 (8q24.22 and q24.3) was 
also more frequent in FGFR3 wildtype tumours (p=0.003 and p=0.02) 
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(Figure 3.27). These minimal regions on chromosome 8, contained 5  
(EFR3A, HHLA1, KCNQ3, LOC100420215, OC90) and 7 genes (COMMD5, 
LOC101929051, RPL8, ZNF7, ZNF34, ZNF250, ZNF517), respectively. Gain 
of a region on 20q (20q11.21) was also associated with FGFR3 wild-type 
tumours (p=0.03). 
  
 
 
Figure 3.27: FGFR3 mutation status and copy number alterations in 22 
patients. Genome-wide frequency plots of copy number alterations in 
FGFR3 wildtype (n=14) and FGFR3 mutant (n=8) tumours. The x-axis 
corresponds to chromosomes 1 to 22 and the y-axis corresponds to the 
percentage of copy number gains (blue) and losses (red). 
 
3.3.1 FGA and smoking status 
 
When comparing FGA with patient smoking status, the majority of smokers 
(17 patients) were classified into FGA groups C and D (Table 3.11). 
However due to low patients’ numbers included the comparisons did not 
reach statistical significance, Chi-square test (p=0.2). Due to small number 
of patients with occupational risk exposure (n=4) no statistically significant 
conclusions could be drawn from a comparison of occupational risk 
exposure and FGA.  
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                             FGA 
   Smoking status 
A 
(<1%) 
B 
(1-<10%) 
C 
(10-<30%) 
D 
(≥30%) 
Smokers (≥20 packs year) 0 1 6 2 
Smokers (< 20 packs year) 0 0 3 5 
Non smokers 1 1 2 1 
 
Table 3.11 Distribution of FGA group among smokers (≥20 packs a year 
and <20 packs a year) and non-smokers. 
 
When smokers were divided into two groups (group one consisting of 
patients (n=8) who smoked <20 packs a year and group two consisting of 
patients (n=9) who smoked ≥20 packs a year) significant differences in the 
frequencies of copy number alterations in these two groups were observed 
(Figure 3.28). Patients who smoked <20 packs per year had a higher level of 
chromosomal instability. Patients in first group had tumours which commonly 
showed gains of one region on chromosome 20 (p11.1 - q11.21, p=0.05) 
and two regions on the short arm of chromosome 2 (p16.2 - p14 and p13.3 - 
p13.1, p=0.002). Gain of a discrete region on the long arm of chromosome 
19 (q13.12) was also more frequent in these patients (p=0.015). Deletions 
on chromosome 5 (q34 - q35.3), chromosome 8 (p23.3 - q11.1) and 
chromosome 9 (p21.3) were more frequent in first group of patients 
(p=0.015). Similar comparisons with non-smokers were not performed due to 
small number of non-smokers (n=5). 
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Figure 3.28: Smoking status and copy number alterations in 22 
patients. Genome-wide frequency plots of copy number alterations in 
patients with <20 packs a year (n=8) and with ≥20 packs a year (n=9). The 
x-axis corresponds to chromosomes 1 to 22 and the y-axis corresponds to 
the percentage of copy number gains (blue) and losses (red). 
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 Chapter 4 
Hierarchical clustering and phylogenetic analysis of copy 
number data from multifocal tumours 
 
By combing copy number and mutation data and creating the phylogenic 
trees we aimed to assess whether multifocal tumours from the same patient 
are monoclonal or oligoclonal in origin. Copy number data for the individual 
tumours from each patient was used to reconstruct the probable sequence 
of events, which gave rise to each tumour. This further confirmed the 
monoclonal origin of tumour samples from the same patient. Our data has 
also shown a significant intra-patient heterogeneity which could have 
important prognostic and therapeutic implications. Application of copy 
number data into risk stratification tables might further enhance the accuracy 
of calculating the risk for progression and/or recurrence.  
In this chapter, one-way unsupervised hierarchical analysis on copy number 
data is used to assess the relationships between individual multifocal 
tumours from the same patient and to assess the heterogeneity of copy 
number alterations in different patients with multifocal disease. Copy number 
data for the individual tumours from each patient is also used in phylogenetic 
analysis to reconstruct the probable sequence of events which gave rise to 
each tumour. 
4.1  Hierarchical cluster analysis of 66 individual multifocal 
tumours 
One-way unsupervised hierarchical cluster analysis of copy number data 
from all 66 tumours was performed to assess the relationships between the 
individual multifocal tumours of each patient.  
 
Tumours separated into 3 main clusters which varied in chromosomal 
complexity in the order Cluster  1 < Cluster 2 < Cluster 3 (Appendix 4.1, 
Figure 4.1). All tumours from the same patient tended to group together 
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within the same cluster except in 4 cases (Patients 5, 8, 13 and 16). In 
patient 5, tumours 1 and 2 separated into Clusters 1 and 3 respectively, 
reflecting the minimal copy number alterations exhibited by tumour 1.  A 
similar situation was observed for patient 13 in which the chromosomally 
stable tumour 4 was found in Cluster 1 whilst the 3 other tumours from this 
patient were in Cluster 3. In patient 8, two tumours with minimal copy 
number alterations (8_1 and 8_3) separated into Cluster 1 whilst tumour 2 
which exhibited additional copy number alterations including loss of two 
regions on chromosome 9 was found in Cluster 2. A similar situation was 
seen for patient 16 in which tumours 3 and 4 separated into Cluster 1 whilst 
tumours 1 and 2, which both exhibited several copy number alterations 
including losses on chromosome 9, were found in Cluster 2. For 3 patients 
(5, 8, 13) evidence of possible non-clonality was seen based on cluster 
analysis of copy number events. In patient 5, two tumours had no shared 
copy number events and grouped in two separate Clusters (1 and 3). 
However, all tumours from patient 5 shared FGFR3 mutation. In patient 13 
tumour 4 did not share any copy number events with the other 3 
synchronous tumours and separated into Cluster 1. Tumours from patient 13 
were all wildtype for FGFR3, PIK3CA and the RAS genes. Tumour 2 from 
patient 8 remained separated into Cluster 2 while other tumours grouped in 
Cluster 1. All tumours in this patient shared mutations in PIK3CA and 
FGFR3. 
The distribution of tumours amongst the clusters was examined in relation to 
stage, grade, FGA and mutation status. The 31 TaG2 tumours were found 
mainly in Clusters 1 (n=11) and 2 (n=18) with only two TaG2 tumours 
separating into Cluster 3 (5_2 and 20_1). T1G3 tumours were predominantly 
found in Cluster 3 (n=12) with only two and four T1G3 tumours being found 
in Clusters 1 and 2, respectively. TaG3 tumours were mainly in Clusters 2 
(n=6) and 3 (n=10), with only one TaG3 tumour (13_4) separating into 
Cluster 1. 
Cluster 1 contained 14 tumours exhibiting minimal copy number alterations 
(Figure 4.1). These tumours were mainly FGA group A (n=10) with the 
remaining 4 tumours (1_1, 17_1, 17_2, 17_3) being FGA group B. Most 
tumours in this cluster had at least one mutation in PIK3CA, FGFR3 or the 
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RAS genes, with only 4 out of 14 tumours being wildtype for all of the genes. 
Ten tumours in Cluster 1 were from patients with recurrent disease and four 
were from patients with primary disease. 
Cluster 2 contained 28 tumours, which were either FGA group B (n=12) or C 
(n=16) (Figure 4.1). Most tumours from this cluster displayed a characteristic 
loss of 9q. Apart from this characteristic feature, there was a prevalence of 
gains over losses in this cluster.  Six tumours (all from patient 4)  exhibited 
concomitant gain of 1p and 9p and loss of 9q. As observed for Cluster 1, 
most tumours in Cluster 2 had at least one mutation in PIK3CA, FGFR3 or 
RAS. Only seven out of 28 tumours were wildtype for all genes.  There was 
also a prevalence of tumours in this cluster from patients with recurrent 
(n=21) as compared to primary (n=7) disease. 
 
Cluster 3 contained tumours (n=23) with the highest number of copy number 
alterations (Figure 4.1). Twenty-two tumours in this cluster were FGA group 
D, with the remaining tumour (10_1) being FGA group C. Tumours in this 
cluster were wildtype for all genes apart from tumour 2 from patient 5 which 
carried an FGFR3 mutation. Closer inspection revealed that some tumours 
formed separate sub-clusters based on characteristic copy number 
alterations. In one sub-cluster, all tumours (8 tumours: 12_1-4, 14_1-4) 
displayed characteristic losses on chromosome arms 2q, 4q and gain in 20q. 
Similar losses on chromosome arm 2q but limited to smaller region (214.9-
242.1 Mb) were observed in 10 tumours (5_2, 6_2-3, 18_1-4, 10_1-2, 20_2) 
from another sub cluster. Tumours in Cluster 3 exhibited multiple copy 
number alterations. Loss of 2q was a common event in all except 1 tumour 
(6_1), with loss being limited to a small region extending from 2q24-2q37.3 
(214.9-242.1 Mb) in 10 tumours (5_2, 6_2-3, 18_1-4, 10_1-2, 20_2). The 
region contains 77 genes including CUL3, DNER, XRCC5, and the UGT1A 
gene cluster. A full list of genes in the region is shown in Appendix 4.1B. 
Losses on chromosome 9 and gains on chromosome 20 were also frequent 
events in tumours from this cluster. All of the tumours in Cluster 3 were from 
patients with primary disease.
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Figure 4.1: Unsupervised hierarchical cluster analysis of aCGH data 
from 66 individual multifocal tumours. Each column of the heat map 
represents 1 sample and each row represents the genomic position of 
individual clones on the array. Blue, copy number gain; red, copy number 
loss. Chromosome number is shown on the left-hand side of the heat map. 
Three main clusters of tumours were identified and these are indicated by 
the colour bars on the top of panel: cluster 1, yellow; cluster 2, green; cluster 
3, pink. The grade and stage of each tumour is shown at the top of the figure 
(black box, T1 or G3; white box, Ta or G2). The FGFR3, PIK3CA and RAS 
gene mutation status is also shown at the top of the figure (black box, 
mutant;  white box, wild type), along with FGA group (A–D) and whether the 
multifocal tumour was from a patient with primary or recurrent disease (black 
box, recurrence; white box, primary). 
-116 - 
 
4.2  Hierarchical cluster analysis of merged copy number 
data from 22 patients 
 
To assess the heterogeneity of copy number alterations in multifocal 
disease, the same one-way hierarchical clustering approach was applied to 
the merged copy number data for the 22 patients. Patients separated into 2 
main clusters, primarily according to stage and grade (Table 4.1, Figure 4.2).  
The majority of patients withTaG2 samples (n=10) were found in Cluster 1, 
with only the TaG2 patient 5 separating into Cluster 2. T1G3 patients were 
predominantly found in Cluster 2 (n=5) with only 3 patients (3, 9 and 11) 
being found in Cluster 1. TaG3 patients 10 and 14 were in Cluster 2 and the 
TaG3 patient 4 was in Cluster 1. 
 
Paitents in Cluster 1 (n=14) exhibited fewer copy number alterations than 
those in Cluster 2 (n=8). This cluster was characterized by a high frequency 
of chromosome 9 loss which was observed in 12 patients. Eleven patients in 
Cluster 1 were FGA group C, 2 were FGA group B and 1 was FGA group A. 
All except 4 patients (7, 9, 11 and 22) in Cluster 1 carried at least one 
mutation in FGFR3, PIK3CA or the three RAS genes. Ten patients in Cluster 
1 were patients with recurrent disease and 4 were patients with primary 
disease.  
 
Cluster 2 contained patients whose samples exhibiting a high level of 
chromosomal instability with all being FGA group D.  All patient samples in 
Cluster 2, except the sample from patient 5, were wildtype for FGFR3, 
PIK3CA and the three RAS genes. The patients in Cluster 2 were all patients 
with primary disease. 
 
Using the Comparisons function of the Nexus software package, a Fishers 
Exact test (0.05 p-value cut off; 25% differential threshold) was used to 
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compare the frequencies of copy number alterations in Clusters 1 and 2 
(Figure 4.3 and Appendix 4.2). Loss on 10q was a frequent event in Cluster 
2. The majority of patients (87.5%) in Cluster 2 exhibited loss of a region at 
10q23.32 containing PTEN (Appendix 4.3). Loss of 2q including the 
previously discussed region extending from 2q24-2q37.3 also occurred at 
high frequency (>75% difference) in tumours from Cluster 2 (Appendix 4.3). 
Patients in Cluster 2 also exhibited a high frequency (>75%) of gains on 
chromosomes 1, 2, 5, 7 and 20 (Appendix 4.4). 
 
Tumours in Cluster 2 exhibited higher frequencies of chromosomal  
alterations than those in Cluster 1 indicating high inter-patient heterogeneity 
between patients from the two clusters. 
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Figure 4.2: Unsupervised hierarchical cluster analysis of aCGH data 
from 22 patients. Each column of the heat map represents 1 patient  and 
each row represents the genomic position of individual clones on the array. 
Blue, copy number gain; red, copy number loss. Chromosome number is 
shown on the left-hand side of the heat map. Two main clusters of patients 
were identified and these are indicated by the colour bars on the top of 
panel: cluster 1, yellow; cluster 2, green. The grade and stage of each 
tumour is shown at the top of the figure (black box, T1 or G3; white box, Ta 
or G2). The FGFR3, PIK3CA and RAS gene mutation status is also shown 
at the top of the figure. (black box, mutant;  white box, wild type), along with 
FGA group (A–D) and whether multifocal tumours were from patients with 
primary or recurrent disease (black box, recurrence; white box, primary). 
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1 Ta G2 B Recurrence WT Mutant WT 1 
2 Ta G2 C Recurrence Mutant WT WT 1 
3 T1 G3 C Recurrence WT WT Mutant 1 
4 Ta G3 C Recurrence Mutant Mutant WT 1 
7 Ta G2 C Recurrence WT WT WT 1 
8 Ta G2 C Recurrence Mutant Mutant WT 1 
9 T1 G3 A Primary WT WT WT 1 
11 T1 G3 C Recurrence WT WT WT 1 
15 Ta G2 C Primary Mutant Mutant WT 1 
16 Ta G2 C Recurrence WT WT Mutant 1 
17 Ta G2 B Recurrence Mutant Mutant WT 1 
19 Ta G2 C Primary Mutant WT WT 1 
21 Ta G2 C Recurrence Mutant WT WT 1 
22 Ta G2 C Primary WT WT WT 1 
5 Ta G2 D Primary Mutant WT WT 2 
6 T1 G3 D Primary WT WT WT 2 
10 Ta G3 D Primary WT WT WT 2 
12 T1 G3 D Primary WT WT WT 2 
13 T1 G3 D Primary WT WT WT 2 
14 Ta G3 D Primary WT WT WT 2 
18 T1 G3 D Primary WT WT WT 2 
20 T1 G3 D Primary WT WT WT 2 
 
Table 4.1. Details of samples in the two main clusters obtained by 
hierarchical cluster analysis of merged copy number data from 22 
patients. Grade and stage is the highest reported for tumours form 
each patient 
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Figure 4.3: Genome-wide frequency plots of copy number alterations in 
the 2 main clusters obtained by hierarchical cluster analysis of merged 
copy number data from 22 patients. The x-axis corresponds to 
chromosomes 1 to 22 and the y-axis corresponds to the percentage of copy 
number gains and losses. Copy number gains are shown in blue and losses 
in red. Frequencies of copy number alterations are shown for cluster 1 (top 
panel) and cluster 2 (bottom panel). 
 
4.3  Phylogenetic tree analysis 
 
The relationships between tumours from the same patient were also 
assessed using phylogenetic analysis. The probable sequence of events 
that gave rise to each tumour was reconstructed based upon similarities and 
differences in breakpoint regions and copy number events using the TuMult 
computational method (see section 2.5.8, Materials and Methods). A 
phylogenetic tree was constructed for each patient where all tumours are 
shown as descendants of common hypothetical ancestors. Mutation status 
was also added to the graphical output of each phylogenetic tree in order to 
give a full picture of events in each patient. All phylogenetic trees not 
illustrated in this chapter can be viewed in Appendix 4.5. 
For 16 patients (2, 3, 4, 6, 7, 10, 11, 12, 14, 15, 17, 18, 19, 20, 21, 22) 
evidence for a monoclonal origin of all tumours in a given patient was 
obtained based on phylogenetic analysis of copy number events. In all 
patients except patient 4, tumours were linked via a ‘common precursor’ that 
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had a set of copy number events present in all tumours. Each tumour then 
acquired it’s own set of characteristic copy number events. 
Tree reconstruction revealed differences in the level of diversity of copy 
number alterations in different patients. In some cases trees were relatively 
simple and involved minimal copy number differences between tumours. A 
representative example of this is shown for patient 2 (Figure 4.4). 
 
Figure 4.4. Phylogenetic tree showing the relationships between all 
tumours from patient 2. 
 
In some patients many copy number alterations were acquired following 
divergence from a common precursor. A representative example of this is 
shown for patient 6 (Figure 4.5). 
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Figure 4.5. Phylogenetic tree showing the relationships between all 
tumours from patient 6. 
In patient 4, tumour 4 appeared to be the common precursor for all other 
tumours (Figure 4.6). 
 
Figure 4.6. Phylogenetic tree showing the relationships between all 
tumours in patient 4.  
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Patient 19 represented an interesting case.  All 3 tumours from this patient 
shared a common precursor based on copy number losses on 4q and 9p. 
Tumour 3 then appeared to diverge away from the other two tumours and 
accumulated it’s own set of characteristic copy number alterations. It also 
lacked an FGFR3 Y375C mutation detected in the other two tumours (Figure 
4.7).   
 
Figure 4.7.  Phylogenetic tree showing the relationships between 
tumours from patient 19. 
 
In 6 cases (patients 1, 5, 8, 9, 13 and 16) a monoclonal origin for all tumours 
in a given patient could not clearly be confirmed. Each of these cases is 
discussed below. 
A monoclonal origin of tumours from patient 1 could not be determined 
based on copy number data as two of the three tumours (1_2 and 1_3) 
exhibited no copy number alterations (Figure 4.8). Evidence of a monoclonal 
origin could perhaps be inferred for tumours 1_1 and 1_2 as both carried 
PIK3CA E545K mutations. Also it could be hypothesised that tumours 1_2 
and 1_3 were predecessors of tumour 1_1.  
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Figure 4.8. Phylogenetic tree for Patient 1. 
Two tumours from patient 5 did not share copy number events (Figure 4.9). 
Circumstantial evidence for a monoclonal origin of these tumours could be 
inferred from the fact that both tumours carried an FGFR3 S249C mutation. 
However, this should be viewed with caution as this mutation is frequent in 
superficial bladder cancer. 
 
Figure 4.9. Phylogenetic tree showing the relationship between 2 
tumours from Patient 5 
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Two tumours (8_1) and (8_2) from patient 8 shared a common copy number 
gain on 22q, and both carried FGFR3 S249C and PIK3CA H1047R 
mutations, confirming a monoclonal origin for these tumours. Tumour 3 from 
this patient exhibited no copy number alterations and therefore the 
relatedness of this tumour to the other two tumours could not be assessed 
based on copy number. This tumour did, however, carry both mutations 
seen in tumours 1 and 2 making it more likely that all 3 tumours are related 
and tumour 8_3 represents the precursor for the other 2 tumours (Figure 
4.10). 
 
 
Figure 4.10. Phylogenetic tree showing the relationships between 3 
tumours from patient 8. 
 
Tumours from patient 9 exhibited no copy number alterations and did not 
carry mutations in FGFR3, PIK3CA or the 3 RAS genes. Therefore, based 
on this evidence a monoclonal origin of tumours from this patient cannot be 
confirmed. 
 
A monoclonal origin for three tumours (13_1, 13_2 and 13_3) from patient 
13 was confirmed based on copy number events, however tumour 13_4 did 
not share any of the copy number events in the other 3 tumours and 
exhibited characteristic losses on 10q and 19p (Figure 4.11). A common 
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origin for all tumours in this patient cannot therefore be confirmed based on 
copy number alterations. All tumours from this patient were wildtype for 
FGFR3, PIK3CA and the 3 RAS genes therefore no further assessment of 
relatedness between tumour 13_4 and the other tumours  could be made 
based on this data. 
 
 
 
Figure 4.11. Phylogenetic tree showing the relationships between 4 
tumours from patient 13.  
 
A monoclonal origin could not be inferred for 4 tumours from patient 16 
based on copy number data. Tumour 16_3 carried no copy number 
alterations and the other 3 tumours carried but did not share copy number 
events. The only evidence for a monoclonal origin of tumours in this patient 
was that they all carried the same HRAS G12C mutation.  
 
The copy number events and mutations occurring at the top of each tree 
were analysed to find the most frequently occurring events in all trees. 
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These were loss and gain of 9p, 9q, 2p, 2q, 4p, 4q, 6p, 6q, 8p, 8q, 10q, 11q, 
11p, 12p, 12q, 13q, 14q, 16p, 16q, 19p, 22q. As these events are at the top 
of the tree it may be that they represent early events in tumorigenesis. 
 
 
 
-128 - 
 
Chapter 5 
Comparison of multifocal and solitary tumours 
 
This chapter describes the comparison of the merged copy number dataset 
for the 22 multifocal patients with an existing dataset of copy number 
alterations in 103 solitary tumours (data from Hurst et al. 2012) comprising 
28 TaG1/G2, 10 TaG3, 7 T1G2, 29 T1G3 and 29 ≥ T2 tumours. One-way 
hierarchical cluster analysis was performed to assess the relationships 
between multifocal and solitary tumours. Frequency plot comparisons were 
made to assess differences in copy number alterations in multifocal versus 
solitary disease. Frequency plots were constructed of copy number events in 
stage and grade matched tumours from the two datasets. Multifocal tumours 
exhibited higher frequencies of chromosomal alterations than solitary 
tumours.  
 
 
5.1  Hierarchical cluster analysis of copy number data from 
multifocal and solitary tumours excluding stage ≥ T2 tumours 
 
One-way unsupervised hierarchical cluster analysis of copy number data 
was initially performed to assess the relationships between multifocal 
tumours and solitary tumours from patients with superficial disease only. The 
solitary tumour dataset consisted of  28 TaG1/G2, 10 TaG3, 7 T1G2, and 29 
T1G3 tumours. 
 
Tumours separated into 4 main clusters which varied in chromosomal 
complexity in the order Cluster 1 < Cluster 2 < Cluster 3 < Cluster 4 (Figure 
5.1). The distribution and features of multifocal and single tumours in each of 
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the clusters is summarised in Appendix 5.1. Figure 5.2 shows genome-wide 
frequency plots of copy number events in each of the clusters. 
 
  
Figure 5.1. Unsupervised hierarchical cluster analysis of aCGH data 
from 22 patients with multifocal disease and 96 patients with solitary 
superficial bladder tumours. Each column of the heat map represents 1 
patient and each row represents the genomic position of individual clones on 
the array. Blue, copy number gain; red, copy number loss. Chromosome 
number is shown on the left-hand side of the heat map. Multifocal tumours 
are highlighted in yellow and solitary tumours in green. Four main clusters of 
patients were identified and these are indicated by the colour bars at the top 
of the panel: cluster 1, yellow; cluster 2, green; cluster 3, pink; cluster 4, 
brown. The grade and stage of each tumour is shown at the top of the figure 
(black box, T1 or G3; white box, Ta or G1/G2). The FGFR3, PIK3CA and 
-130 - 
 
RAS gene mutation status is also shown at the top of the figure (black box, 
mutant;  white box, wildtype),  along with FGA group (A–D) and whether the 
tumour was from a patient with primary or recurrent disease (black box, 
recurrence; white box, primary). 
 
Figure 5.2. Genome-wide frequency plots of copy number alterations in 
the 4 main clusters obtained by hierarchical cluster analysis of copy 
number data from multifocal and solitary superficial bladder tumours. 
The x-axis corresponds to chromosomes 1 to 22 and the y-axis corresponds 
to the percentage of copy number gains and losses. Copy number gains are 
shown in blue and losses in red. 
 
Cluster 1 contained 26 tumours that exhibited minimal copy number 
alterations with all tumours being either FGA groups A or B (Figure 5.2). 
Most of the tumours in Cluster 1 were solitary. Only tumours from 2 
multifocal patients (9 and 17) separated into this cluster (Appendix 5.1). 
Tumour 9 was a T1G3 tumour exhibiting no copy number alterations and 
tumour 17 was a TaG2 tumour that exhibited minimal copy number 
alterations (<5% FGA). TaG1/2 tumours predominated in Cluster 1 (n=18), 
with only 1 T1G2, 4 TaG3 and 3 T1G3 tumours being found in this cluster. 
Most tumours in this cluster carried at least one mutation in FGFR3, PIK3CA 
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or the RAS genes, with only 4 tumours (including multifocal patient 9) being 
wildtype for all genes.  
Cluster 2 contained 36 tumours that also exhibited a limited number of copy 
number alterations but were more chromosomally unstable than those from 
Cluster 1. T1G3 (n=15) and TaG1/G2 (n=12) tumours predominated in 
Cluster 2. The other samples in the cluster were 5 T1G2s and 4 TaG3s. Six 
tumours in Cluster 2 were from multifocal patients (2, 4, 8, 11, 15, 21) and 
four of these were TaG2 tumours. All tumours were FGA groups B or C. A 
characteristic feature of this cluster was loss of chromosome 9 with a region 
from 71.1 to 128.3Mb (9q21.11-q33.3) containing PTCH1 and DBC1 being 
lost in all but one tumour (from the solitary sample set). The other most 
frequent events in this cluster were gains of 1q (observed in 7 tumours) and 
15q (in 9 tumours). Thirty-one of the tumours in this cluster carried at least 
one mutation in FGFR3, PIK3CA or the RAS genes, with only 5 tumours 
(including multifocal patient 11) being wildtype for all genes.  
 
Tumours in Cluster 3 (n=24) exhibited a higher frequency of copy number 
alterations than those from Cluster 2. Cluster 3 contained 8 TaG2, 4 TaG3, 1 
T1G2 and 11 T1G3 tumours. Nineteen tumours were FGA group C, 2 were 
FGA group B and 3 were FGA group D. Tumours from seven multifocal 
patients (1, 3, 7, 14, 16, 19, 22) separated into this cluster. Five of these 
multifocal tumours were TaG2s (patients 1, 7, 16, 19, 22) and the other 2 
were T1G3 (patient 3) and TaG3 (patient 14) tumours. Losses of 8p, 9q and 
17p, and gains of 8q, 11q and chromosome 20 were most frequent in this 
cluster.  The region of gain on 11q13.2-q13.3 (68.7-69.3 Mb) was found in 
33% of samples (8 samples). It included 4 genes: MYEOV, CCND1, 
ORAOV1 and FGF19. Twelve tumours carried at least one mutation in 
FGFR3, PIK3CA or the RAS genes, with the other 12 tumours (including 
multifocal patients 7, 14 and 22) being wildtype for all genes.  
 
Cluster 4 samples (n=10) exhibited the highest level of chromosomal 
instability with all tumours being FGA group D. T1G3 tumours predominated 
in this cluster (n=8), with the stages and grades of the other two samples 
-132 - 
 
being TaG2 and TaG3. Seven out of the ten tumours were multifocal and 5 
of these were T1G3s. Only one tumour from multifocal patient 5 carried a 
mutation  (FGFR3 S249C) with all the remaining tumours being wildtype for 
FGFR3, PIK3CA and the RAS genes. Copy number gains and losses were 
frequent across most chromosomes in tumours from this cluster with the 
most frequent losses involving 2q, 5p, 8p, 9p, 10q and 13q, and the most 
frequent gains involving 1q, 5p, 6p, 7q 8q and 20q. 
Overall, hierarchical cluster analysis revealed that TaG2 multifocal tumours 
tended to cluster with solitary tumours of higher stage and grade. T1G3 
multifocal tumours clustered with different subsets of T1G3 solitary tumours 
and interestingly formed the majority in a highly chromosomally unstable 
subset of tumours.  
 
5.2  Comparisons of copy number alterations in multifocal and solitary 
superficial bladder tumours 
In order to identify specific features related to multifocality, a Fishers Exact 
test (0.05 p-value cut off; 25% differential threshold) was used to compare 
the frequencies of copy number alterations in multifocal and solitary 
superficial bladder tumours matched for stage, grade and FGFR3 mutation 
status.  
 
5.2.1 Comparisons of copy number events in multifocal and solitary 
superficial tumours according to stage and grade  
 
Comparisons were initially made between multifocal and solitary superficial 
tumours matched for stage or grade.  
 
Using the Comparisons function of the Nexus software package, a Fishers 
Exact test (0.05 p-value cut off; 25% differential threshold) was used to 
compare the frequencies of copy number alterations in patients with 
multifocal or solitary stage Ta tumours. (Figure 5.3, Appendix 5.2). Overall, 
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multifocal stage Ta tumours were more chromosomally unstable than stage 
Ta solitary tumours. A difference of >40% in the frequency of copy number 
events was identified for several regions including gains of 8q24.13  
(ANXA13, FBXO32, KLHL38), 13q12.11 - q12.3 and 20q11.23 - q12, and 
losses of 8p21.2  - p12 (including NRG1), 9p21.3 (CDKN2A, CDKN2A-AS1, 
CDKN2B, CDKN2B-AS1, DMRTA1, ERVFRD-3, MTAP, TUBB8P1, 
UBA52P6) and 9q12 - q34.3 (including PTCH, DBC1 and TSC1) which were 
more common in multifocal patients.  
A similar comparison was made in patients with multifocal or solitary stage 
T1 tumours (Figure 5.4, Appendix 5.3). A difference of >40% in the 
frequency of copy number events was identified for several regions. This 
comparison revealed that tumours from multifocal patients had a higher 
prevalence of gains on 1p12 - q24.3 (TAGLN2), 2p25.3 - q11.1, 6p22.3 - 
p22.1 (E2F3, CDKAL1, SOX4, PRL), 7p11.2 - q36.3, 16p12.1 - q11.2, 
19q13.11 - q13.2, 20p13 - q13.33, (including PHACTR3, SYCP2, PPP1R3D, 
CDH26, C20orf197, miR-646,CDH4) and losses on 2q33.3 - q37.3 (SGC2, 
AP1S3, WDFY1, MRPL44, SERPINE2, FAM124B, CUL3, DOCK10, 
KIAA1486), 5q11.2 - q12.3, 6q27, 8p23.2 - p12, chromosome 10 (q22.3 and 
q23.1 - q26.3), 3q14.2 - q14.3, 14q23.1 and 22q11.1 - q13.33. Overall, stage 
T1 multifocal tumours exhibited more copy number events than their solitary 
counterparts. 
 
 
Figure 5.3: Comparison of genome-wide copy number alterations in 
stage Ta tumours from patients with multifocal and solitary disease. 
The frequencies of copy number events are shown for multifocal tumours 
(top panel; n=14) and solitary tumours (bottom panel; n=38). The x-axis 
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corresponds to chromosomes 1 to 22 and the y-axis corresponds to the 
percentage of copy number gains and losses. Copy number gains are 
shown in blue and losses in red. 
 
Figure 5.4. Comparison of genome-wide copy number alterations in 
stage T1 tumours from patients with multifocal and solitary disease. 
The frequencies of copy number events are shown for multifocal tumours 
(top panel; n=8) and solitary tumours (bottom panel; n=36). The x-axis 
corresponds to chromosomes 1 to 22 and the y-axis corresponds to the 
percentage of copy number gains and losses. Copy number gains are 
shown in blue and losses in red. 
A comparison of copy number events in tumours from patients with 
multifocal or solitary grade 1/2 disease, was also made.(Figure 5.5, 
Appendix 5.4). Grade 1/2 multifocal tumours exhibited more copy number 
events than their solitary counterparts. A difference of >40% in the frequency 
of copy number events was identified for several regions including gains on 
8 q13.2 - q13.3 , 8q22.1 – 24.3, 13q12.11 - q12.3, 13q21.32 - q21.33, and 
losses on 9q13.3 – 9q 21.33, 9q31.2. - q34.12 (DBC1) and 9p21.3 (MTAP, 
CDKN2AS) with these events being more common in multifocal tumours.  
 
Figure 5.5. Comparison of genome-wide copy number alterations in 
grade 1/2 tumours from patients with multifocal and solitary disease. 
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The frequencies of copy number events are shown for multifocal tumours 
(top panel; n=11) and solitary tumours (bottom panel; n=35). 
 
In a comparison of the frequencies of copy number alterations in patients 
with multifocal or solitary grade 3 tumours, significant differences were 
identified for several regions (Figure 5.6, Appendix 5.5). Alterations 
exhibiting a difference of >50% were gains on chromosome 1 (p12 - q21.1), 
chromosome 2 (p11.2 - q11.1, p13.3 - p13.1 and p16.3 - p14), and 
chromosome  20 (p13 - q11.1, q11.21 - q12 and q13.2 -13.33) and losses on 
chromosome 2 (q33.3 - q37.3), chromosome 8 (q23.2 – q23.32, q23.33 – 
q25.3, q26.11, q26.13 and q26.2 - q26.3) and chromosome 22 (q11.1 - 
q11.21). These alterations were more frequent in multifocal tumours 
(Appendix 5.5). 
 
 
Figure 5.6. Comparison of genome-wide copy number alterations in 
grade 3 tumours from patients with multifocal and solitary disease. The 
frequencies of copy number events are shown for multifocal tumours (top 
panel; n=11) and solitary tumours (bottom panel; n=39). The x-axis 
corresponds to chromosomes 1 to 22 and the y-axis corresponds to the 
percentage of copy number gains and losses. Copy number gains are 
shown in blue and losses in red. 
 
Comparisons of the frequencies of copy number alterations were next made 
between multifocal and solitary superficial tumours matched for stage and 
grade (i.e. TaG1/G2, TaG3, T1G3).  
A comparison of copy number events in multifocal and solitary tumours from  
patients with TaG1/G2 disease was performed (Figure 5.7, Appendix 5.6). 
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Gains of large regions on chromosome 1 (p12 - q22and q23.1 - q31.3), 
chromosome 8 (p11.21 - q12.3, q13.2 - q21.11, q22.1 - q24.3), chromosome 
10 (p15.1 - p14, q22.1 - q23.2), chromosome 13 (q12.11 - q13.1 and q14.3 - 
q34), chromosome 19 (q12 - q13.43) and chromosome 20 (q11.23 - q13.33) 
were more common in multifocal patients. Other smaller regions which 
reached statistical significance included gains on chromosome 6 (q26) and 
chromosome 9 (p24.3). Losses of large regions on chromosomes 8 (p23.3 - 
p11.21) and 9 (p21.3, q12 - q34.12 and q34.3) and losses of discrete 
regions on chromosome 10 (q24.32), chromosome 13 (q13.3 - q14.2), 
chromosome 16 (p13.3, q23.3 - q24.1 and q24.3) and chromosome 17 (q12 
- q21.2) were also more prevalent in multifocal tumours.  
 
 
Figure 5.7. Comparison of genome-wide copy number alterations in low 
stage and low grade (TaG1/2) tumours from patients with multifocal 
and solitary disease. The frequencies of copy number events are shown 
for multifocal tumours (top panel; n=11) and solitary tumours (bottom panel; 
n=28). The x-axis corresponds to chromosomes 1 to 22 and the y-axis 
corresponds to the percentage of copy number gains and losses. Copy 
number gains are shown in blue and losses in red. 
 
A comparison of copy number events in tumours from patients with 
multifocal or solitary T1G3 disease, was also made (Figure 5.8, Appendix 
5.7). Large regions of gain on chromosome 1 (p12 - q12 and q23.3), 
chromosome 2 (p11.2 - q12.3, q13 - q24.1 and q24.3), chromosome 3 
(p12.1 - q13.13 and q22.1 - q25.32), chromosome 4 (q13.2 - q21.1 and 
q35.1), chromosome 7 (p11.2 - q36.3), chromosome 9 (p13.1 - q34.3), 
chromosome 16 (p11.2 - q11.2), chromosome 19 (p12 - q12, q13.11 - 
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q13.41, q13.42 and q13.43), and chromosome 20 (p11.1 - q13.33) were 
more commonly seen in multifocal tumours. Discrete regions of gain on 
chromosome 5 (p15.33), chromosome 6 (p22.3 - p21.32, p25.1 - p24.3 and 
q11.1 - q12), chromosome 10 (q22.1 - q22.3), chromosome 11 (q13.5 - 
q14.1), chromosome 14 (q24.3) and chromosome 17 (p12) were significantly 
more prevalent in multifocal patients. Regions of deletion more common in 
multifocal patients included deletions on chromosome 1 (q31.1 - q31.2 and 
q31.3 - q44), chromosome 2 (q11.1 - q11.2, q22.3 - q37.3), chromosome 3 
(q13.33 - q21.1 and q23 - q26.33), chromosome 4 (p15.2 - p12, p16.3 - 
p15.33 and q21.21 - q34.3), chromosome 5 (q11.2 - q12.3, q21.1 - q21.3 
and q31.2 - q35.3), chromosome 6 (q27), chromosome 8 (p11.22 - p11.1 
and p23.2 - p22), chromosome  9 (q34.3), chromosome 10 (p11.21 - p11.1, 
q22.3, q23.1 - q26.3), chromosome 11 (p11.12 - q12.2), chromosome 12 
(p11.1 - q13.13, q15 - q21.1 and q22 - q24.31), chromosome 13 (q14.2 - 
q14.3), chromosome 14 (q12 - q24.2), chromosome 15 (q11.2 - q14 and 
q22.31 - q26.3), chromosome 16 (p13.3 and p11.2 - q24.3), chromosome 19 
(p13.3 - p12) and chromosome 22 (q11.1 - q13.33). Overall, multifocal T1G3 
tumours were more chromosomally unstable than their solitary counterparts. 
 
 
Figure 5.8. Comparison of genome-wide copy number alterations in 
stage T1 and grade 3 (T1G3) tumours from patients with multifocal and 
solitary disease. The frequencies of copy number events are shown for 
multifocal tumours (top panel; n=8) and solitary tumours (bottom panel; 
n=29). The x-axis corresponds to chromosomes 1 to 22 and the y-axis 
corresponds to the percentage of copy number gains and losses. Copy 
number gains are shown in blue and losses in red. 
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Comparisons of copy number events in TaG3 patients could not be made 
due to low number of patients in the multifocal dataset (n=3). 
 
5.2.2 Comparisons of copy number events in multifocal and solitary 
superficial tumours according to FGFR3 mutation status  
 
The relationship of FGFR3 mutation status to copy number events in stage 
and grade matched multifocal and solitary tumours was examined.  
A comparison of copy number events in FGFR3 mutant TaG1/G2 multifocal 
and solitary tumours was made (Figure 5.9, Appendix 5.8). Deletions on 
chromosome 5 (q34 - q35.3), chromosome 9 (p21.3 and q21.33), 
chromosome 10 (q24.2 - q25.1) and chromosome 16 (p13.3), and gains on 
chromosome 1 (p12 - q31.3), chromosome 6 (q26), chromosome 8 (q13.2 - 
q13.3), chromosome 13 (q12.11 - q12.3 and q21.32 - q21.33), chromosome 
19 (q12 - q13.43) and chromosome 20 (q11.23 - q13.33) were more frequent 
in mutant FGFR3, TaG2, multifocal tumours.  
 
 
Figure 5.9. Comparison of genome-wide copy number alterations in 
FGFR3 mutant TaG1/2 tumours from patients with multifocal and 
solitary disease. The frequencies of copy number events are shown for 
multifocal tumours (top panel; n=7) and solitary tumours (bottom panel; 
n=19). The x-axis corresponds to chromosomes 1 to 22 and the y-axis 
corresponds to the percentage of copy number gains and losses. Copy 
number gains are shown in blue and losses in red. 
 
In FGFR3 wildtype TaG1/G2 tumours gain on chromosome 8 (q22.1 - q24.3) 
and deletions on chromosome 9 (p21.1 - q12) and chromosome 17 (q12 - 
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q21.2) were more frequent (p=0.024) in multifocal tumours (Figure 5.10, 
Appendix 5.9). However, the number of patients in each group was too low 
to make any further statistically significant conclusions. 
 
Figure 5.10. Comparison of genome-wide copy number alterations in 
FGFR3  wildtype TaG1/2 tumours from patients with multifocal and 
solitary disease. The frequencies of copy number events are shown for 
multifocal tumours (top panel; n=4) and solitary tumours (bottom panel; n=9). 
The x-axis corresponds to chromosomes 1 to 22 and the y-axis corresponds 
to the percentage of copy number gains and losses. Copy number gains are 
shown in blue and losses in red. 
 
A comparison of the frequencies of copy number alterations in FGFR3 
wildtype T1G3 tumours from patients with multifocal and solitary disease 
was performed (Figure 5.11, Appendix 5.10). Gains on chromosome 1 
(p34.1, p32.3 - p31.1 and p12 - q12), chromosome 2 (p14 - q11.1, p23.3 - 
p16.3, p25.3 - p24.1), 3p (p12.1), 4q (q13.3 - q21.1), 6p (p22.3 - p22.1), 7q 
(q11.21 - q11.22 and q35), chromosome 9 (q21.32 - q21.33 and p24.3), 
chromosome 16 (p13.2 - q11.2 ), 19q (q12 and q13.11 - q13.32) and 
chromosome 20 (p13 - q13.33) and losses on 2q (q24.3 - q37.3), 
chromosome 4 (p15.2 - p12, p16.3 - p15.33 and q25 - q34.3), 5q (q11.2 - 
q12.3), 6q (q27), 10q (q23.1 - q26.3), chromosome 11 (p11.2 - q12.1), 
chromosome 12 (p11.1 - q13.11), 13q (q14.2 - q14.3), 14q (q13.1 and 
q23.1), 15q (q22.31 - q25.2, q25.3 and q26.1 - q26.3), 16q (q11.2 - q21), 
19p (p13.3) and 22q (q11.1 - q11.23 and q12.2 - q13.2) were more frequent 
in multifocal tumours. 
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Figure 5.11. Comparison of genome-wide copy number alterations in 
FGFR3 wildtype T1G3 tumours from patients with multifocal and 
solitary disease. The frequencies of copy number events are shown for 
multifocal tumours (top panel; n=8) and solitary tumours (bottom panel; 
n=16). The x-axis corresponds to chromosomes 1 to 22 and the y-axis 
corresponds to the percentage of copy number gains and losses. Copy 
number gains are shown in blue and losses in red. 
 
5.3  Hierarchical cluster analysis of copy number data from 
multifocal and solitary tumours including stage ≥ T2 tumours 
 
In all comparisons with superficial solitary tumours, multifocal tumours were 
more chromosomally unstable. Also, in cluster analysis, multifocal tumours 
constituted the majority of highly chromosomally unstable tumours present in 
Cluster 4. With this in mind we performed one-way unsupervised hierarchical 
cluster analysis again and included 29 ≥ T2 tumours to assess whether the 
multifocal tumours in Cluster 4 exhibited characteristics of ≥ T2 tumours. 
 
As previously observed, tumours separated into 4 main clusters which varied 
in chromosomal complexity in the order Cluster 1 < Cluster 2 < Cluster 3 < 
Cluster 4 (Figure 5.12). The distribution and features of multifocal and single 
tumours in each of the clusters is summarised in Appendix 5.11. Figure 5.13 
shows genome-wide frequency plots of copy number events in each of the 
clusters. The features of each of the clusters was essentially as described in 
Section 5.1.  
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Figure 5.12. Unsupervised hierarchical cluster analysis of aCGH data 
from 22 patients of multifocal data set and 103 patients with solitary 
disease including 29 stage ≥ T2 tumours. Each column of the heat map 
represents 1 patient (labelled on the top) and each row represents the 
genomic position of individual clones on the array. Blue, copy number gain; 
red, copy number loss. Chromosome number is shown on the left-hand side 
of the heat map. Multifocal tumours are highlighted in yellow and solitary 
tumours in green. Four main clusters of patients were identified and these 
are indicated by the colour bars on the top of panel: cluster 1, yellow; cluster 
2, green; cluster 3, pink; cluster 4, brown. The grade and stage of each 
tumour is shown at the top of the figure (grey box, T1; black box T2, or G3; 
white box, Ta or  G2). The FGFR3 PIK3CA and RAS gene mutation status is 
also shown at the top of the figure (black box, mutant;  white box, wildtype),  
along with FGA group (A–D) and whether the tumour was from a patient with 
primary or recurrent disease (black box, recurrence; white box, primary). 
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Cluster 1 tumours were chromosomally stable with low stage and low grade 
tumours constituting the majority of tumours in this cluster. Tumours were 
FGA groups A or B and exhibited a high frequency of FGFR3, PIK3CA and 
RAS gene mutations. Only 2 ≥ T2 tumours separated into Cluster 1. As 
previously observed, multifocal tumours 9 and 17 separated into this cluster. 
Tumour 1, which previously separated into Cluster 3, was now part of 
Cluster 1. 
 
Cluster 2 contained tumours that also exhibited a limited number of copy 
number alterations but were more chromosomally unstable than those from 
Cluster 1. TaG2 and T1G3 tumours predominated in Cluster 2 with all 
tumours being FGA groups B or C. A characteristic feature of this cluster 
was loss of chromosome 9 with other frequent events in this cluster being 
gains of 1p and 15q. FGFR3, PIK3CA and RAS gene mutation was also 
frequent in Cluster 2. Only 1 ≥ T2 tumour separated into this cluster. 
Multifocal tumours 2, 4, 8, 11, 15 and 21 separated into this cluster as 
previously observed. Two other multifocal tumours (7, 22) that had 
previously been in Cluster 3, also separated into Cluster 2 following inclusion 
of the ≥ T2 tumours. 
 
Tumours in Cluster 3 exhibited a higher frequency of copy number 
alterations than those from Cluster 2. Cluster 3 contained 5 TaG2, 3 TaG3 
and 11 T1G3 tumours. Nineteen of the ≥ T2 tumours separated into this 
cluster. Thirty tumours were FGA group C and 8 were FGA group D. Losses 
of 8p, 9p, 9q and 17p, and gains of 1q, 6p, 8q and chromosome 20 were 
most frequent in this cluster.  Sixteen tumours carried at least one mutation 
in FGFR3, PIK3CA or the RAS genes, with the other 22 tumours being 
wildtype for all genes. Only 3 of the multifocal tumours (3, 16, 19) that 
previously separated into this cluster were still present in this cluster. 
 
Cluster 4 samples (n=18) exhibited the highest level of chromosomal 
instability with all tumours being FGA group D. T1G3 (n=8) and ≥ T2 (n=7) 
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tumours predominated in this cluster, with the other tumours being 1 TaG2 
sample (multifocal tumour 5) and 2 TaG3 samples (multifocal samples 10 
and 14). All 8 of the multifocal tumours that had previously separated into 
this cluster were still present. Apart from the tumour from multifocal patient 5 
which carried an S249C mutation in FGFR3, all of the tumours in Cluster 4 
were wildtype for FGFR3, PIK3CA and the RAS genes. Copy number gains 
and losses were frequent across most chromosomes in tumours from this 
cluster with the most frequent losses involving 2p, 2q, 5q, 6q, 8p, 9p, 9q, 
10q, 13p, 15q, 16q, 17p, and the most frequent gains involving 1p, 1q, 2p, 
3p, 3q, 5p, 7p, 7q, 8q, 17q, 19q, 20p and 20q.  Analysis of this cluster 
revealed similarities in the characteristics of a subset of multifocal tumours 
and a subset of ≥ T2 tumours.  
 
Figure 5.13. Genome-wide frequency plots of copy number alterations 
in the 4 main clusters obtained by hierarchical cluster analysis of copy 
number data from multifocal and solitary bladder tumours including 29 
≥ T2 tumours. The x-axis corresponds to chromosomes 1 to 22 and the 
y-axis corresponds to the percentage of copy number gains and 
losses. Copy number gains are shown in blue and losses in red. 
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Chapter 6 
Immunohistochemical analysis of FGFR3 expression in 
matched primary and metastatic bladder cancer samples 
 
FGFR3 is considered a good therapeutic target for bladder cancer. However, 
to our knowledge it is unknown whether the FGFR3 status of primary 
tumours is a surrogate for related metastases, which must be targeted by 
FGFR targeted systemic therapies. We assessed FGFR3 protein expression 
in primary bladder tumours and matched nodal metastases. FGFR3 
expression in matched primary and metastasized bladder cancer specimens 
showed good but not absolute concordance. Thus, in most patients primary 
tumour FGFR3 status can guide the selection of FGFR targeted therapy.  
This chapter describes the results of experiments in which 
immunohistochemistry was used to determine the expression of the FGFR3 
in primary bladder tumours and matched nodal metastases. This data has 
now been published [248]. The TMA was constructed with six tissue cores 
per patient: two each from normal urothelium, primary tumour (centre and 
invasion front), and a nodal metastasis. Biopsies were placed on slides with 
17 columns and 9 rows with one liver biopsy as a control sample.  Unstained 
TMA slides and clinicopathological data for each patient were provided for 
this study by collaborators in Bern (Drs A Fleischmann, G Thalmann and R 
Seiler). 
 
6.1  FGFR3 protein expression in primary tumours and 
metastases 
As described in detail in Materials and Methods, the following scoring 
system was adopted: 0, absent staining; 1, faint but detectable positivity; 2, 
weak but extensive positivity; 3, strong positivity (Figure 6.1). For the 
statistical analysis, tumours with the score 0 and 1 were grouped as low (L) 
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and tumours scored 2 and 3 as high (H). FGFR3 protein was not detected by 
IHC in the normal urothelial samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Immunohistochemistry detection of FGFR3. A – strong 
FGFR3 expression (score 3, High), B – weak but extensive positivity (score 
2, High), C – faint but detectable positivity (score 1, Low), D – absent 
staining (score 0, Low). Scale bar indicates 100µm 
 
In 123 primary tumours (centre core), FGFR3 status was determined by IHC: 
55 tumours (44.7%) with a score H, 68 tumours (55.3%) with a score L. For 
the primary tumours with invasion front core, a total of 110 primary samples 
were available for analysis: 34 tumours (30.9%) with a score H, 76 tumours 
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(69.1%) with a score L. There were 97 tumours where both primary tumour 
cores from the same patient were available for analysis. Seventy-three 
(74.5%) of them were concordant (OR=8.6, p=0.000003, Fisher’s exact test) 
(Table 6.1). 
 
 
! Number!of!
cores!Primary'tumour'invasion'centre/front:' '
!'''Low/low' 48''''Low/high' ''9''''High/low' 15''''High/high' 25'''''''p'Value' ''0.000003'' 'Metastases'core'2/1:' ''''Low/low' 42''''Low/high' ''5''''High/low' 14''''High/high' 29'''''''p'Value' '0.0000002'
! '' '
 
Table 6.1. FGFR3 expression concordance in samples from the same 
primary tumours and metastases 
 
Corresponding numbers from the 102 patients with evaluable metastases 
were 48 (47.1%) score H, 54 (52.9%) score L for the first biopsy, and 104 
patients for the second biopsy with 41 (39.4%) score H, and 63 (60.6%) 
score L. There were 90 patients with both metastases biopsies available. 
Seventy-one (78.9%) of them were concordant (OR=16.7, p=0.0000002, 
Fisher’s exact test). Table 6.1. 
Overall, the levels of FGFR3 protein expression did not differ between 
primary and metastatic lesions (p=0.78, Mann-Whitney test) (Table 6.2). 
FGFR3 protein expression was assessable in 106 matched primary tumours 
and their matched nodal metastases. In the primary tumour, 53 out of 106 
patients showed protein overexpression defined as high and 53 out of 106 
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defined as low. In the metastasis the corresponding numbers were 56 and 
50, respectively.  
For 79 patients, the concordance between FGFR3 expression levels in 
primary tumours and matched metastasis was high (OR=8.45, p=0.000007, 
Fisher’s exact test). In 15 patients the primary tumour had low protein 
expression and the matched nodal metastasis had high expression. The 
converse was observed for 12 patients (Table 6.2). 
 
! Number!of!
cores!Primary'tumour'/'metastases:' '
!'''Low/low' 38''''Low/high' 15''''High/low' 12''''High/high' 41'''''''p'Value' ''0.000007'' '' '
 
Table 6.2. Comparison of primary tumours and corresponding lymph 
node metastases. High concordance was found between FGFR3 
expression levels in primary tumours and matched lymph node metastases. 
 
6.2  FGFR3 relationship to metastatic phenotype, survival 
and adjuvant chemotherapy 
Patients with FGFR3 overexpressed in their metastases had more 
metastases (median: 0.21 vs 0.13; p = 0.31, Mann-Whitney test) (Figure 
6.2), smaller total diameter of metastases (median: 0.79 cm vs 1.04 cm; p = 
0.065) (Figure 6.3), and lower maximum diameter of metastases (median: 
5.09 cm vs  5.59 cm; p = 0.065) than patients without such overexpression; 
however, these differences were not significant. Tumour stage and 
extracapsular extension of lymph node metastases were not associated with 
FGFR3 status. In univariate analyses, OS did not differ significantly for 
patients with FGFR3 overexpression in the primary tumours compared with 
those patients without overexpression (Figure 6.4). This was also the case 
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for patients with FGFR3 overexpression in metastases (p = 0.241) (Figure 
6.5). FGFR3 IHC did not correlate with RFS (Figure 6.6). 
 
Figure 6.2: Patients with FGFR3 overexpressed in their metastases had 
more metastases (median: 0.21 vs 0.13; p = 0.31). Y- axis: fraction of 
lymph nodes with metastasis; X – axis: metastatic FGFR3 expression (low or 
high). 
 
Figure 6.3: Patients with FGFR3 overexpressed in their metastases had 
smaller total diameter of metastases (median: 0.79 cm vs 1.04 cm; p = 
0.065). Y- axis: mean metastasis diameter in cm; X – axis: metastatic 
FGFR3 expression (low or high). 
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Figure 6.4: Immunohistochemically determined FGFR3 status in 
primary tumours does not segregate significantly into low- and high-
risk patients regarding over-all survival, p=0.70 
 
 
 
Figure 6.5: Immunohistochemically determined FGFR3 status in 
metastasis does not segregate significantly into low- and high-risk 
patients regarding over-all survival, p=0.94 
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Figure 6.6: Immunohistochemically determined FGFR3 status in 
metastasis A) and primary tumours B) does not segregate significantly 
into low- and high-risk patients regarding RFS. 
 
In multivariate analyses, advanced primary tumour stage (pT3/4 vs pT1/2; p 
= 0.019) and extracapsular extension of lymph node metastases (p = 0.001) 
were the only independent adverse risk factors for OS. FGFR3 
overexpresion in primary tumours (p = 0.66) and metastases (p = 0.88) 
failed to add independent prognostic information. 
In this series 63 patients received adjuvant chemotherapy, which was 
cisplatin based in 37. We examined the relationship of FGFR3 expression in 
primary and metastatic tissue, and chemotherapy (none, any and cisplatin 
based) to OS and RFS. No significant relationship was found. 
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Chapter 7 
Discussion 
 
Multifocal tumours study 
 
Bladder cancer represents a heterogeneous disease and commonly is 
described by multifocality and high number of recurrences. Detailed 
molecular characterization and comparison of genetic alterations in clinically 
and morphologically distinct multifocal tumour cell populations may provide 
information about the clonal evolution of carcinoma of the urinary bladder. 
Furthermore, enhanced knowledge of the molecular genetic characteristics 
of multifocal bladder tumours may offer a combined molecular and histo-
pathological approach to classification and thus improve clinical 
management and the decision-making process of this common cancer. 
 
In most of the published studies on multifocal bladder cancer, conventional 
CGH, LOH analysis, FISH and mutation scanning of TP53 and FGFR3 have 
been applied to the study of small sets of tumours [184, 242-247]. There 
have been few studies that have applied array-based CGH (aCGH) to the 
study of multifocal bladder cancer and the numbers of tumours analysed in 
these studies have also been low [249-251]. The main advantages of aCGH 
over conventional CGH are its high resolution and throughput. In this study 
we have mutation scanned key genes (FGFR3, PIK3CA and RAS) and used 
aCGH to screen for genome-wide copy number changes in 66 bladder 
tumours from 22 patients with superficial disease. To our knowledge, this 
study is the first to use aCGH to analyse such a large panel of superficial 
multifocal bladder tumours. We have used the combined copy number and 
mutation data to assess whether multifocal tumours from the same patient 
are monoclonal or oligoclonal in origin, to assess the molecular 
heterogeneity of tumours within and between patients, and to identify 
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specific features related to multifocality i.e. is multifocal disease different to 
solitary disease matched for stage and grade.  
 
Sample collection and processing was crucial to the success of this project. 
We were able to successfully collect such a large panel of multifocal tumours 
due to several factors. Tissue collection was carried out at the tertiary 
referring centre that already has a well-established tissue collection program 
and experienced staff. At St James’s University Hospital procedures such as 
TURBT and cystectomies were performed on a daily basis, offering multiple 
opportunities for patients recruitment. Every Friday theatre lists were 
accessed and studied for potential tissue donors. Information on prior 
cystoscopic examination findings enabled selection of patients with 
multifocal tumours suitable for inclusion in the study. All staff (clinicians, 
nurses, theatre staff) involved in the tissue collection process were well 
informed about the on-going study. Two formal departmental meetings were 
organized where the study proposals were presented. On the day of 
operation, the operating surgeon and theatre staff were also informed about 
participants. At that time tissue collection nuances were re-emphasized. We 
think that this informal way of direct communication between a researcher 
and clinician might have had a significant impact on the number of samples 
collected. It also provided a rare opportunity for clinical staff to receive 
continuous updates on the results of the study. The SSO and myself were 
the only people involved in the tissue collection process during the three 
years of the project. This ‘simplicity’ allowed the process to run more 
efficiently and avoided ‘mistakes’ due to miscommunication.  
 
This study identified numerous copy number alterations many of which 
involve regions previously implicated in conventional CGH and LOH studies 
of bladder cancer [252-254]. Copy number gains and losses involving whole 
chromosomes, chromosome arms or smaller regions were identified in our 
study. The most common region gained was 20q (68.2%), and the most 
common region lost was 9q (81.8%). Other common deletions were 
observed on 9p (77.3%), 10q (63.6%), 5q (54.5%), 8p (50%) and 2q (50%). 
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Loss of the whole of chromosome 9 or 9p/9q is the most frequently 
described genetic alteration in TCC of the bladder. Several tumour 
suppressor genes have been previously identified on both arms of 
chromosome 9 with regions involving 9p21 (CDKN2A) [1], 9q12–q31 (PTCH) 
[2], 9q32–q33 (DBC1) [3] and 9q34 (TSC1) [4]. Another commonly identified 
loss was observed on the long arm of chromosome 5 (54.5%). Loss on 5q 
was a common event in grade 3 tumours (72.7%). Previously published 
studies involving conventional CGH of bladder tumours have also found 
frequent deletion of 5q [243-246, 255-258]. Some studies have reported that 
loss of 5q is often associated with concomitant gain of 5p [246, 259]. We 
have detected gains of 5p in 12 patients (54.5%), with associated losses of 
5q being observed in seven of these.  
 
Fifty percent of our tumours had deletions of the short arm of chromosome 8 
and gains of the long arm were detected in 63.6% of patients. The gains of 
long arm of chromosome 8 were associated with stage Ta tumours (57.1%) 
and grade 3 tumours (63.6%). When tumours were assessed by stage and 
grade together it was found that gains of 8q were detected in 63.4% of 
patients with TaG2 disease and gains of 8q in 75% of patients with T1G3 
tumours. More than 60% of patients with TaG3 and 62.5% with T1G3 
tumours exhibit losses of 8p. In the literature, it was reported that the loss of 
8p occurs in 25–30% of urothelial carcinomas and is primarily associated 
with high-grade and stage tumours [260]. Our chromosome 8 alterations 
findings might indicate that multifocal tumours exhibit chromosome 8 copy 
number alterations characteristic of muscle invasive tumours rather than 
superficial tumours. 
 
High-level amplifications involving regions of chromosome 20 and gains of 
20q have been widely reported in various cancers including ovarian, colon, 
breast and bladder [247, 255, 261]. Gain of 20q was the most frequent gain 
observed in our patients (68.2%). Bruch and colleagues reported an 
association of gains of 5p and 20q in carcinomas stage ≥pT2 [262]. In the 
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present study this association has been observed in 7 patients (patient 5, 6, 
10, 13, 14, 16 and 20) the majority of which had grade 3 tumours. 
 
Sixty-nine high-level amplifications were detected in 66 tumours. The most 
frequently amplified regions were 11q13.2 - q13.4 and 6p22.3 - p22.2 
present in ten and eight tumours from 4 and 3 patients, respectively. 
Amplification at 11q13.3 has been previously reported in bladder cancer and 
candidate genes within this amplicon include cyclin D1  [184, 243, 245, 259]. 
Studies applying conventional CGH, detected in bladder tumours and in the 
cell lines amplification at 6p22 [247, 251, 262-265]. Candidate genes within 
this amplicon were OX4, E2F3, PRL and CDKAL1 as reported by Hurst and 
colleagues [5]. The CDKAL1 showed amplicon-related expression in tumour 
cell lines indicating its putative oncogenic role [5]. 
 
In multifocal tumours the most frequent recurrent regions of HD included 
chromosome 3 (p21.2 - p21.1), 7 (p21.1), 10 (q24.32) and chromosome 12 
(q21.31). When we have analysed the frequencies of the recurrent regions 
of HD and recurrent amplicons in our study and in the study of Hurst et al 
(2012) we found no striking similarities. In the study of Hurst et al (2012) the 
most frequent recurrent regions of HD were detected on chromosome 1 
(1p34.1), 2 (2q36.1-q36.3), chromosome 9 (9p21.3), chromosome 11 
(11p11.2), chromosome 18 (18p11.22-p11.21) and chromosome 19 (19q12). 
The region 9p21.3 on chromosome 9 containing MTAP, CDKN2A, CDKN2B, 
ANRIL was homozygously deleted in 16 (50.9%) tumours in the study of 
Hurst et al (2012) and only in 1 (4.5%) tumour (10_2) in the multifocal data 
set.  
 
When chromosomal alterations were assessed according to stage and grade 
we observed that the distribution of these alterations did not significantly 
differ between stages or grades, but the frequencies of events increased 
with stage and grade. Ta and T1 tumours showed alterations on 18% and 
30% of chromosome arms respectively. Grade 2 tumours showed a lower 
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average frequency (10%) than grade 3 tumours (27%). These findings are in 
accordance with other studies. Low-grade and stage tumours have been 
reported to show fewer molecular alterations and these generally include 
deletions on chromosome 9, 11p, 10q and gains of chromosome 17, 1q, 20q 
11q [252, 266]. In our study gains on chromosome 17, 1q, 20q, 11q and 
losses on chromosome 9 and 11p were more frequent in TaG3 patients. 
Increased chromosomal instability may be partially explained in relation to 
stage and grade. As higher stage and grade tumours represent more 
‘aggressive’ disease one might expect higher level of chromosomal 
instability in these tumours. However, our study has shown that 
chromosomal instability of multifocal tumours cannot completely be 
explained by the higher stage and grade of the disease. When we performed 
hierarchical clustering of copy number data from all 66 tumours, four 
tumours, matched for the same stage and grade separated into three 
different clusters. For example, two tumours from patient 5 (both stage 
TaG2) were in Clusters 1 and 3. In cluster 3 tumours were mostly of higher 
stage and/or grade (T1G3s mainly). One tumour from patient 5 belonged to 
FGA group A and the other to group D.  
The knowledge of significant intra-patient heterogeneity could have 
important prognostic and therapeutic implications. At present, we apply a 
limited number of factors from histology results (stage and grade, tumour 
size, number of tumours and presence of CIS) into risk stratification tables 
(e.g. EORTC tables) to quantify individual risk for progression and 
recurrence. Based on the example for patient 5 from our study, this patient 
would be classified as an intermediate-risk patient in conventional risk 
classification. However our results have shown that based on aCGH data, 
one tumour from this patient grouped with highly chromosomally unstable 
tumours in Cluster 3. Therefore from a therapeutic point of view, this patient 
might benefit more from being classified as a high-risk patient for disease 
progression and/or recurrence. If we applied this knowledge into clinical 
practice we could offer this patient closer surveillance or immediate radical 
treatment. It would also be very interesting to further follow up this patient 
and determine subsequent disease associated events such as recurrence, 
progression and mortality. 
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Another interesting observation made from the clustering of merged copy 
number data was that Cluster 1 contained mainly more chromosomally 
stable tumours and that a high proportion of these were from patients with 
recurrent disease. The fact that recurrent tumours were more 
chromosomally stable may support the hypothesis that the chronology of 
tumour presentation is not reflected in the genetic evolution of the tumours. 
In studies by van Tilborg et al and Lindgren et al authors compared the 
chronology of tumour appearance with the chronology of genetic events in 
patients with multiple recurrences and observed that the genetic progression 
trees better reflected the tumour evolution than their chronologic order of 
presentation [214, 251].  
 
A comparison of the merged copy number dataset for the multifocal patients 
with a subset of solitary tumours from the dataset of Hurst et al 2012 
revealed interesting findings that further characterize superficial multifocal 
bladder cancer and also give new insight into the significant complexity of 
this disease. The hierarchical cluster analysis revealed that TaG2 multifocal 
tumours tended to cluster with solitary tumours of higher stage and grade. 
T1G3 multifocal tumours clustered with different subsets of T1G3 solitary 
tumours and interestingly formed the majority in a highly chromosomally 
unstable subset of tumours. Cluster 4, which exhibited the highest level of 
chromosomal instability with all tumours being FGA group D, contained 
mostly multifocal tumours (seven out of ten tumours). Next we made 
comparisons between multifocal and solitary superficial tumours matched for 
stage or grade. Overall, multifocal stage Ta and T1 tumours were more 
chromosomally unstable than stage Ta and T1 solitary tumours. Several 
regions including gains of 8q24.13  (ANXA13, FBXO32, KLHL38), 13q12.11 
- q12.3 and 20q11.23 - q12, and losses of 8p21.2  - p12 (including NRG1), 
9p21.3 (CDKN2A, CDKN2B) and 9q12 - q34.3 (including PTCH, DBC1 and 
TSC1) were more common in multifocal stage Ta patients. Stage T1 
tumours from multifocal patients had a higher prevalence of gains on 1p12 - 
q24.3 (TAGLN2), 2p25.3 - q11.1, 6p22.3 - p22.1 (E2F3, CDKAL1, SOX4, 
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PRL), 7p11.2 - q36.3, 16p12.1 - q11.2, 19q13.11 - q13.2, 20p13 - q13.33 
and losses on 2q33.3 - q37.3 (SGC2, AP1S3, WDFY1, MRPL44, 
SERPINE2, FAM124B, CUL3, DOCK10, KIAA1486), 5q11.2 - q12.3, 6q27, 
8p23.2 - p12, chromosome 10 (q22.3 and q23.1 - q26.3), 3q14.2 - q14.3, 
14q23.1 and 22q11.1 - q13.33. Our study showed that these regions are 
strongly associated with tumour ‘multifocality’. Therefore we could 
hypothesise that mutifocality is characterized by unique features at the 
genomic level which ‘drive’ the tumours development into more aggressive 
disease. By studying further these unique regions and the genes they 
contain targeted therapies for multifocal bladder cancer could be developed.  
 
As multifocal tumours constituted the majority of the highly chromosomally 
unstable tumours present in Cluster 4, we also included ≥ T2 tumours in the 
cluster analysis to see whether the multifocal tumours in this cluster 
exhibited characteristics of muscle invasive disease. As previously 
observed, the same multifocal tumours separated into cluster 4 along with 
T1G3 (n=8) and ≥ T2 (n=7) solitary tumours. Analysis of this cluster revealed 
copy number events characteristic of ≥ T2 tumours. Copy number gains and 
losses were frequent across most chromosomes in tumours from this cluster 
with the most frequent losses involving 2p, 2q, 5q, 6q, 8p, 9p, 9q, 10q, 13p, 
15q, 16q, 17p, and the most frequent gains involving 1p, 1q, 2p, 3p, 3q, 5p, 
7p, 7q, 8q, 17q, 19q, 20p and 20q. One of the interesting features of Cluster 
4 was a high frequency of chromosome 7 gains. One of the oncogenes 
located on chromosome 7 is EGFR. Mutations leading to EGFR upregulation 
have been associated with a number of cancers (lung, colon cancer). 
Currently, various therapeutic approaches are aimed at EGFR including 
afatinib, erlotinib, gefitinib, icotinib in lung cancer and cetuximab in gastro-
intestinal cancer. In our study, it would be of high interest to study EGFR 
expression levels to examine if this correlates with copy number increase as 
this potentially could be considered as a targeted therapy option for these 
patients. 
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One of the most interesting findings of the comparison of the multifocal 
tumour dataset with that of the solitary dataset involved patients with 
TaG1/G2 tumours. Multifocal tumours revealed a higher frequency of gains 
on chromosome 6 (q26), chromosome 9 (p24.3) and losses of regions on 
chromosomes 8 (p23.3 - p11.21), chromosome 9 (p21.3, q12 - q34.12 and 
q34.3), chromosome 10 (q24.32), chromosome 13 (q13.3 - q14.2), 
chromosome 16 (p13.3, q23.3 - q24.1 and q24.3) and chromosome 17 (q12 
- q21.2). Theoretically, these tumours despite being classified as low grade 
and stage might need a different clinical follow up regime and might 
represent disease with a high risk of progression due to the presence of 
these chromosomal aberrations. 
 
We next investigated the diversity of copy number alterations in multifocal 
and solitary disease and compared these to FGFR3 mutation status. FGFR3 
mutation was still associated with low stage and grade tumours. When the 
relationship of FGFR3 mutation status to copy number events in stage and 
grade matched multifocal and solitary tumours was examined, several 
regions of gain and loss were more common in multifocal tumours. FGFR3 
mutant, multifocal tumours commonly exhibited losses on chromosome 5, 
10, 16 and gains on chromosome 1, 6, 8 and 19 whereas their solitary 
counterparts have shown no such events. In a comparison of copy number 
events in FGFR3 mutant TaG1/G2 multifocal and solitary tumours deletions 
on chromosome 5 (q34 - q35.3), chromosome 9 (p21.3 and q21.33), 
chromosome 10 (q24.2 - q25.1) and chromosome 16 (p13.3), and gains on 
chromosome 1 (p12 - q31.3), chromosome 6 (q26), chromosome 8 (q13.2 - 
q13.3), chromosome 13 (q12.11 - q12.3 and q21.32 - q21.33), chromosome 
19 (q12 - q13.43) and chromosome 20 (q11.23 - q13.33) were more frequent 
in mutant FGFR3, TaG2, multifocal tumours.   
 
Most patients presenting with bladder cancer have more than one tumour 
during the course of their treatment. Determination of whether tumours are 
monoclonal or oligoclonal is of paramount importance due to therapeutic 
implications. If tumours are monoclonal in origin, with all tumours (multifocal 
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and recurrent) arising from a single progenitor cell, then application of 
adjuvant treatment post TURBT is more likely to benefit the patient. This 
treatment, in the form of intravesical, topical chemotherapy will potentially 
eradicate all micrometastatic deposits following primary resection. However, 
if bladder tumours arise as a consequence of a ‘field effect’ post global 
exposure to carcinogens present in the urine then tumours are genetically 
unrelated and chemotherapeutic bladder installations could potentially 
increase mutagenic pressures and cause healthy urothelium to develop 
further tumours. Understanding the mechanisms behind tumour multifocality 
and the origin of bladder cancer is important also from a personalized-
medicine and targeted therapies point of view. If we could identify common 
genetic or epigenetic changes in synchronous or metachronous 
development of multifocal tumours then we could ‘’target’ these alterations 
and establish new strategies in bladder cancer treatment and prevention. 
 
In the literature there has been much debate about bladder tumour clonality 
with the majority of these studies favouring the hypothesis of the monoclonal 
origin of multifocal bladder tumours [203, 205, 207, 214, 218, 267, 268]. One 
objective of the current study was to use our copy number and mutation 
status data to determine the relationships between tumours from the same 
patient and to assess tumour clonality. Visualisation of whole genome 
profiles revealed that some patients had tumours that shared all or the 
majority of copy number events (patients 2, 3, 4, 7, 11, 13, 14, 17, 20, 21), 
whilst others had tumours that shared some common copy number events 
but were otherwise highly divergent (patients 6, 10, 12, 15, 18, 19, 22) thus 
suggesting a monoclonal origin for tumours in these patients. However, we 
also identified a group of patients where the evidence for monoclonality of at 
least one tumour could not be determined (patient 1, 5, 8, 9, 13, 16).  
 
We performed one-way unsupervised hierarchical cluster analysis of copy 
number data from all 66 tumours in order to further assess the relationships 
between the individual multifocal tumours of each patient. In the majority of 
cases tumours from the same patient tended to group together. In 3 patients 
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(5, 8, 13) evidence of possible non-clonality was obtained from the 
observation that not all tumours clustered together. In patient 5, two tumours 
had no shared copy number events and grouped in two separate Clusters (1 
and 3). In patient 13 tumour 4 did not share any copy number events with 
the other 3 synchronous tumours and separated into Cluster 1. Tumour 2 
from patient 8 separated into Cluster 2 while other tumours grouped in 
Cluster 1. 
 
The relationships between tumours from the same patient were also 
assessed using phylogenetic analysis. When we reconstructed the probable 
sequence of events that gave rise to each tumour based upon similarities 
and differences in breakpoint regions and copy number events a 
phylogenetic tree was produced for each patient. This phylogenetic tree 
analysis shows all tumours as descendants of common hypothetical 
ancestors. 
 
Common initiating events revealed by phylogenetic tree analysis were 
deletions of chromosome 9 and mutations of FGFR3. Most of the evidence 
currently recorded shows that chromosome 9 genes might participate early 
in tumorigenesis [121-123]. In this study, abnormalities involving partial or 
complete loss of 9q and/or 9p (including small regions of homozygous 
deletion) were detected in majority of tumours and were among the most 
frequent copy number changes detected. Interestingly, it has been shown 
that the reduplication of a single parental homologue of chromosome 9 
appears to be common in more aggressive tumours [5]. Chromosome 9 
deletions have been widely studied in bladder cancer because they are 
present during the earliest stages of urothelial tumorigenesis [269]. Loss of 
heterozygosity studies performed by Spruck et al showed that deletions of 
9q are more prevalent in the low grade non muscle invasive papillary 
tumours than in CIS and muscle invasive tumours [94]. Other studies also 
confirmed association of low stage and grade tumours with chromosome 9 
deletions [270, 271]. Interestingly, these alterations were also observed in 
the normal-appearing urothelium that is adjacent to the tumour lesion [217]. 
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In 16 patients (2, 3, 4, 6, 7, 10, 11, 12, 14, 15, 17, 18, 19, 20, 21, 22) we 
were able to confirm a monoclonal origin for all tumours. The majority of 
these patients had tumours that were descendants of a ’common precursor’. 
Tumours also underwent substantive clonal evolution, often diverging 
significantly from the other synchronous tumours. This could be illustrated in 
patient 19 where all tumours from the patient shared a common precursor 
based on copy number losses on 4q and 9p. Tumour 3 appears to have 
acquired unique characteristics and diverged away from the remaining 
tumours and also lacked an FGFR3 Y375C mutation detected in the other 
two tumours. 
 
In patients 1, 5, 8, 9, 13, 16 we could not determine a clonal origin for all 
tumours based on phylogenetic analysis of the available copy number and 
mutation data.  For two tumours (8_1) and (8_2) from patient 8 we have 
confirmed a monoclonal origin based on shared common copy number gain 
on 22q, and shared FGFR3 (S249C) and PIK3CA (H1047R) mutations. 
Tumour 3 from this patient exhibited no copy number alterations and 
therefore the relatedness of this tumour to the other two tumours could not 
be assessed based on copy number. This tumour did, however, carry both 
mutations seen in tumours 1 and 2 making it more likely that all 3 tumours 
are related and tumour 8_3 represents the precursor for the other 2 tumours. 
In patient 1, two out of three tumours exhibited no copy number alterations. 
Potentially, these tumours were resected at the ‘early’ time of tumorigenesis 
and have not yet acquired any chromosomal changes. When we have 
analysed the mutation status of these tumours, two carried the same 
PIK3CA E545K mutation, which could imply common origin. Mutation status 
data for a limited number of genes should be interpreted with caution when 
analysing clonality. Tumours sharing the same mutations are not necessary 
related as they could acquire common mutations independently. Some of the 
mutations detected in the current study occur frequently in bladder cancer 
(e.g. FGFR3 S249C). In patient 5, none of the tumours shared copy number 
events but all carried FGFR3 S249C mutations. This could be taken as 
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evidence for a monoclonal origin of tumours in this patient but should be 
viewed with caution. None of the tumours in patient 9 carried copy number 
alterations or mutations hence the clonal origin of these tumours could not 
be determined. In patient 13 tumour 4, seemed to be unrelated to the other 
tumours based on copy number data and exhibited characteristic losses on 
10q and 19p. Mutational data could not shed further light on the relatedness 
of tumour 4 to the tumours, as all were wildtype for FGFR3, PIK3CA and the 
3 RAS genes. In patient 16 we have observed the situation where all 
tumours where ‘related’ when mutational data was analysed (all shared 
HRAS G12C mutation) but the same tumours were ‘unrelated’ when copy 
number data was analysed (three tumours did not share copy number 
events and one tumour carried no copy number events). As HRAS mutations 
are relatively infrequent  (~12%, unlike FGFR3), this provides a better 
suggestion that they are related than FGFR3 or PIK3Ca mutations do. 
Whole exome sequencing could possibly be applied on these tumours to 
further assess the clonality in these particular cases. This approach could 
potentially provide additional variants that could be used to assess clonal 
relatedness. 
 
In the majority of tumours, the hypothesis of a monoclonal origin was 
supported by the sharing of chromosome aberrations. Interestingly, in all but 
one case, there was no ‘pure’ linear evolution observed, where one tumour 
could be indicated as the direct descendant of another tumour. Each tumour 
exhibited a sub-set of specific alterations, which occurred after the 
divergence of the tumours. However, in patient 4 tumour 4 appeared to be 
the common precursor. Evidence of significant sub-clonal divergence within 
patients with monoclonal disease may prove that development of targeted 
therapies for these patients might be difficult.  
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Matched primary and metastatic bladder cancer samples 
 
FGFR3 plays an important role in bladder tumour pathogenesis. Recently 
there has been increased interest in analysing the association between 
mutation status of FGFR3 and bladder TCC. It has been revealed that these 
mutations are significantly more frequent in low stage and grade tumours. 
However, our understanding of the role of FGFR3 remains incomplete. 
There have been several studies assessing FGFR3 expression but most of 
these examined only primary tumours of various stages and grades. The aim 
of this study was to examine the relationship of FGFR3 expression between 
primary and matched metastasis from the same patient. One of the earlier 
studies performed by Matsumoto et al. reported at least moderate 
expression in nearly half of the primary tumours [272]. Later, two 
independent investigators reported correlation between protein expression 
levels and lower tumour stage and grade [273, 274].  
 
It has been proposed that FGFR3 could be a valuable therapeutic target in 
bladder cancer. However, in order to evaluate FGFR3 usefulness in targeted 
therapy its expression status needs to be studied in relation to metastasis. 
As a potential therapy would act at the protein level, this study aimed to 
investigate FGFR3 protein status by performing IHC. The most important 
finding of this research is the good correlation between FGFR3 expression in 
primary tumour and its corresponding metastasis. While FGFR3 was highly 
expressed in 44.7% of the primary tumours, this was present in matched 
metastases of 47.1% patients. By analysing expression status of the primary 
tumour it was relatively easy to predict the status of the corresponding 
metastasis. Overall 74.5% of patients had high levels of concordance 
between primary tumours and matched metastasis. Thirty-six percentage of 
patients who had low FGFR3 expression in primary had corresponding low 
expression in matched metastasis and similarly the figure was 38.7% for 
high level of expression. This might indicate high similarity for expression of 
the protein after occurrence in the primary. Also, one might hypothesise that 
the clone of cells with metastatic potential dominates the primary tumour and 
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later spreads to distant lymph nodes. Therefore, tumour cells of the primary 
and metastasis are genetically identical or closely related. This might have 
useful clinical applicability in targeted therapies. The findings of discordant 
cases may also have clinical applicability. This study showed that 14% of 
samples expressed FGFR3 in the metastasis but not in the primary tumour. 
In this scenario the relevant treatment might be withheld in a clinical trial 
setting. Conversely, patients who reveal expression in the primary tumour 
but not in the metastasis might be over-treated. 
 
When planning targeted therapies it is important to have consistent 
expression results in the sampled tissue with little variability depending on 
tumour site.  In this study two biopsies were obtained from the metastatic 
site and two from the primary. Seventy-five percent of patients showed 
concordance at both primary sites with 50% of patients showing low 
expression levels and 25% showing high levels at both sites. Corresponding 
numbers between metastatic samples were 46.7% for low expression and 
32.2% for high expression and overall 79% concordance. These high 
concordance rates between sites of sampled tissue are quite reassuring. It 
might indicate that the specific site of biopsy is less relevant when planning 
treatment options.  
 
In breast cancer, the HER2 status works as a predictor for treatment 
response [275]. However, the choice of assay for HER2 determination 
remains a subject of dispute [275-277]. Some authors consider IHC as a 
method of choice others consider cytogenetic studies (FISH etc.) more 
appropriate. The arguments for using IHC are multiple: the targeted therapy 
works at the protein level, protein expression might not be just the result of 
gene amplification [276] and there is high concordance between IHC and 
cytogenetic testing [276]. In our study we have observed high concordance 
rates between matched primary tumour and metastasis despite the fact that 
samples were paraffin-embedded and thus subject to tissue processing 
artefacts.  
 
-165 - 
 
One of the limitations of IHC is its variability in reporting. It often reflects 
differences in antibodies and kits used, protocols and methods of 
interpretation. In this study the scoring criteria have been simplified by 
grouping samples into only two groups (low and high). If applied in clinical 
practice this might potentially enhance the interpretation of results for 
response to therapy. However, the group of patients with only few cells 
stained, who were labelled as ‘low’, would need to be further examined. It is 
not known if such a small percentage of protein expression could indicate 
positive response to the therapy. Also it is recognised that assessment of a 
therapeutic target has different requirements than assessment of a 
prognostic indicator. Therefore the scoring used in this study based on the 
worst feature or presence of minor cell population in a tumour may be 
inappropriate for application in clinical practice and new scoring criteria may 
be required. 
 
Another interesting analysis would be to determine FGFR3 mutation status. 
As it has been previously shown on primary tumour samples, high FGFR3 
expression, and its relationship to the mutation status, was significantly more 
frequent in non-invasive (pTa) compared to invasive (pT2) tumours and 
more frequent in low grade compared with high grade tumours [62]. 
Additional characteristics of mutation status may contribute to a predictive 
value for progression and overall survival. A recently published study 
examining FGFR3 expression levels and mutation status in primary and 
metastatic urethral carcinoma found high levels of FGFR3 expression in both 
primary tumours and metastasis (29% and 49%, respectively) with low 
FGFR3 mutation rate (2% in primary tumours and 9% in metastases) [278]. 
Similarly to our study, FGFR3 immunohistochemistry staining did not impact 
overall survival (p = 0.89, primary tumours; p = 0.78, metastases). 
 
The role of FGFR3 inhibitors in advanced bladder cancer has not yet been 
fully characterized and awaits results of ongoing clinical trials. Interestingly, 
in this study the survival of the immunohistochemically FGFR3-positive and -
negative subgroups was not significantly different (Figures 6.4 and 6.5). This 
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finding was in contrast to the results of a recently published study on the 
relationship of FGFR3 mutation and expression status to outcome in muscle-
invasive bladder cancer treated by cystectomy with or without adjuvant 
cisplatin-gemcitabine chemotherapy [279]. In this paper researchers 
reported FGFR3 over-expression to be an independent predictor of reduced 
OS and RFS.  
 
An interesting finding of this study is the relationship between FGFR3 
expression and metastatic deposit characteristics. Metastases, which were 
scored low were associated with a higher number of metastasis (lower ratio 
of lymph node positive to total lymph nodes dissected). Also, the diameter of 
metastasis correlated with the level of FGFR3 expression, with metastatic 
deposits of larger diameter scoring low on IHC staining. However, both 
findings were not statistically significant. 
 
This study has some limitations. Despite including large number of matched 
samples it might be still underpowered to show statistical significance 
between different parameters (tumour characteristics etc.). Hence, these 
features merit investigation in a larger sample series. 
 
Suggestions for future work 
 
This work has produced the data that has further added to the evidence of 
the vast complexity of molecular events associated with evolution of 
multifocal and metastatic urothelial cancer.  There are many opportunities to 
further work on this subject. Future work should include: 
 F LOH analysis could be performed to further assess clonal 
relatedness. Patterns of LOH were used as genetic fingerprints in a 
study by Takahashi et al [209] where he confirmed the clonal origin of 
multifocal bladder cancer. The ploidy profiling technique developed by 
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Navin et al [280] could also be used to assess relatedness based the 
ploidy of different multifocal tumours from the same patient. X 
chromosome inactivation analysis of the multifocal tumours used in 
this study could also be used to see if tumours carry the same 
inactivation patterns. By applying this technique, Sidransky et al [203] 
confirmed a monoclonal origin for bladder tumours from four patients. 
However one of the disadvantages of this method is that it can only 
be performed on female patients thus we would only be able to use 
this approach for samples from six of the patients used in the current 
study.  
 F State-of-the-art next generation sequencing (NGS) approaches such 
as whole exome sequencing could also be used to further analyse 
tumours used in this study. Whole exome-sequencing could be 
performed using DNA samples from the multifocal bladder tumours in 
which a monoclonal origin of all tumours could not definitively be 
defined. This approach provides sequence information for all exons in 
the genome and is likely to provide a wealth of variants that could be 
used to assess clonal relatedness.  
Sample validation by NGS. NGS platforms are able to perform 
parallel sequencing, during which millions of fragments of DNA from a 
single sample are sequenced in unison. This technology facilitates 
high-throughput sequencing, which allows an entire genome to be 
sequenced in less than one day. Recently several NGS platforms 
have been developed that provide high-throughput sequencing at low 
cost. It has been also confirmed that this technique can be used to 
interrogate DNA from fresh frozen material, cell lines, and FFPE 
samples, providing highly reproducible results [281]. 
 F Continued collection of mutifocal bladder cancer samples. Despite the 
fact that we have collected one of the largest multifocal bladder 
tumours panels that have been reported, it is still a relatively small 
number of tumours to enable detection of small differences in copy 
number data.  
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F Analysis of copy number changes of the tumours and comparison to 
those in the urothelium adjacent to the tumour or ‘normal’ urothelium, 
distant from the tumour. This could further shed the light on clonal 
relationship or ‘field effect’ changes. In the study performed by Steidl 
et al. authors revealed the occurrence of similar patterns of 
chromosomal aberrations in the tumours and their associated 
urothelium by FISH analysis [216]. 
 
In conclusion, our study suggests that based on mutation and copy number 
data the majority of multifocal tumours are monoclonal in origin but there is 
significant intra-patient sub-clonal divergence, and also inter-patient diversity 
in the extent of chromosomal instability exists in multifocal disease. 
Multifocal tumours are more chromosomally unstable than stage and grade 
matched solitary tumours. These findings may have implications with respect 
to the differential response to treatment of multifocal disease. 
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Appendix 2.1 
Bladder cancer questionnaire 
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Patients were asked to complete this questionnaire prior TURBT.
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Appendix 3.1 Whole genome plots of array CGH data for 3 
tumours from patient 1 
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Whole genome plots of array CGH data for 3 tumours from 
patient 2 
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Whole genome plots of array CGH data for 3 tumours from 
patient 3 
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Whole genome plots of array CGH data for 6 tumours from 
patient 4 
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Whole genome plots of array CGH data for 2 tumours from 
patient 5 
 
 
 
 
 
Whole genome plots of array CGH data for 3 tumours from 
patient 6 
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Whole genome plots of array CGH data for 2 tumours from 
patient 7 
 
 
 
 
 
 
Whole genome plots of array CGH data for 3 tumours from 
patient 8 
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Whole genome plots of array CGH data for 2 tumours from 
patient 9 
 
 
 
 
 
 
 
 
Whole genome plots of array CGH data for 2 tumours from 
patient 10 
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Whole genome plots of array CGH data for 2 tumours from 
patient 11 
 
 
 
 
 
Whole genome plots of array CGH data for 4 tumours from 
patient 12 
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Whole genome plots of array CGH data for 4 tumours from 
patient 13 
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Whole genome plots of array CGH data for 4 tumours from 
patient 14 
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Whole genome plots of array CGH data for 2 tumours from 
patient 15 
 
 
 
 
 
Whole genome plots of array CGH data for 4 tumours from 
patient 16 
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Whole genome plots of array CGH data for 3 tumours from 
patient 17 
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Whole genome plots of array CGH data for 4 tumours from 
patient 18 
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Whole genome plots of array CGH data for 3 tumours from 
patient 19 
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Whole genome plots of array CGH data for 3 tumours from 
patient 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-186 - 
 
 
Whole genome plots of array CGH data for 2 tumours from 
patient 21 
 
 
 
 
 
 
 
Whole genome plots of array CGH data for 2 tumours from 
patient 22 
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Appendix 3.2: Regions showing significant copy number differences in multifocal stage Ta (n=14) versus T1 (n=8) tumours. 
 !
Region1 Cytoband 
Location 
Event Region 
Length 
Freq. in T1 (%) Freq. in Ta (%) Difference p-value 
chr1:50,594,589-50,823,305 p33  Gain 228716 50 7.14 42.86 0.04 
chr1:68,609,865-73,625,895 p31.3 - p31.1  Gain 5016030 50 7.14 42.86 0.04 
chr2:20,215,537-21,280,646 p24.1  Gain 1065109 50 7.14 42.86 0.04 
chr2:224,263-20,037,859 p25.3 - p24.1  Gain 19813596 50 7.14 42.86 0.04 
chr2:232,368,564-232,541,867 q37.1  Loss 173303 75 21.43 53.57 0.03 
chr2:232,987,278-241,796,109 q37.1 - q37.3  Loss 8808831 75 21.43 53.57 0.03 
chr2:25,870,821-52,373,212 p23.3 - p16.3  Gain 26502391 50 7.14 42.86 0.04 
chr2:52,373,212-53,101,240 p16.3 - p16.2  Gain 728028 62.5 7.14 55.36 0.01 
chr2:64,478,283-69,024,185 p14  Gain 4545902 50 7.14 42.86 0.04 
chr2:74,335,462-88,214,979 p13.1 - p11.2  Gain 13879517 50 7.14 42.86 0.04 
chr2:88,214,979-94,782,159 p11.2 - q11.1  Gain 6567180 62.5 7.14 55.36 0.01 
chr2:94,782,159-95,675,764 q11.1  Gain 893605 50 0.00 50.00 0.01 
chr6:146,266,178-162,794,027 q24.3 - q26  Loss 16527849 37.5 0.00 37.50 0.04 
chr6:163,005,402-165,244,688 q26 - q27  Loss 2239286 37.5 0.00 37.50 0.04 
chr6:165,244,688-168,121,846 q27  Loss 2877158 50 7.14 42.86 0.04 
chr6:6,382,300-7,427,280 p25.1 - p24.3  Gain 1044980 50 7.14 42.86 0.04 
chr7:12,919,070-13,079,613 p21.3  Gain 160543 37.5 0.00 37.50 0.04 
chr7:15,056,488-21,588,275 p21.2 - p15.3  Gain 6531787 50 7.14 42.86 0.04 
chr7:26,749,335-29,450,068 p15.2 - p15.1  Gain 2700733 50 7.14 42.86 0.04 
chr7:32,275,005-45,048,865 p14.3 - p13  Gain 12773860 37.5 0.00 37.50 0.04 
chr7:50,617,642-63,102,874 p12.2 - q11.21  Gain 12485232 50 7.14 42.86 0.04 
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chr7:63,102,874-84,591,194 q11.21 - q21.11  Gain 21488320 62.5 7.14 55.36 0.01 
chr7:97,101,588-100,038,722 q21.3 - q22.1  Gain 2937134 62.5 7.14 55.36 0.01 
chr9:84,783,002-89,446,315 q21.32 - q21.33  Gain 4663313 37.5 0.00 37.50 0.04 
chr10:109,290,751-116,774,295 q25.1 - q25.3  Loss 7483544 75 21.43 53.57 0.03 
chr10:78,996,385-80,472,830 q22.3  Loss 1476445 50 7.14 42.86 0.04 
chr10:85,567,652-86,390,131 q23.1  Loss 822479 50 7.14 42.86 0.04 
chr10:86,390,131-88,222,653 q23.1 - q23.2  Loss 1832522 62.5 7.14 55.36 0.01 
chr10:88,222,653-89,694,469 q23.2 - q23.31  Loss 1471816 75 21.43 53.57 0.03 
chr10:89,694,975-93,738,544 q23.31 - q23.32  Loss 4043569 75 21.43 53.57 0.03 
chr10:93,738,544-94,907,303 q23.32 - q23.33  Loss 1168759 75 14.29 60.71 0.01 
chr10:94,907,303-99,781,492 q23.33 - q24.2  Loss 4874189 75 21.43 53.57 0.03 
chr12:33,333,489-40,716,974 p11.1 - q12  Loss 7383485 37.5 0.00 37.50 0.04 
chr12:42,413,160-46,156,911 q12 - q13.11  Loss 3743751 37.5 0.00 37.50 0.04 
chr14:23,749,068-25,757,198 q12  Loss 2008130 37.5 0.00 37.50 0.04 
chr14:65,655,482-66,870,415 q23.3  Loss 1214933 37.5 0.00 37.50 0.04 
chr16:23,756,350-31,190,651 p12.1 - p11.2  Gain 7434301 50 0.00 50.00 0.01 
chr16:31,190,651-45,067,244 p11.2 - q11.2  Gain 13876593 50 7.14 42.86 0.04 
chr16:7,019,846-23,756,350 p13.2 - p12.1  Gain 16736504 37.5 0.00 37.50 0.04 
chr22:16,347,244-16,899,186 q11.21  Loss 551942 50 7.14 42.86 0.04 
chr22:16,899,186-18,151,355 q11.21  Loss 1252169 50 0.00 50.00 0.01 
chr22:18,151,355-18,151,891 q11.21  Loss 536 37.5 0.00 37.50 0.04 
chr22:18,151,891-30,032,831 q11.21 - q12.2  Loss 11880940 50 0.00 50.00 0.01 
chr22:30,032,831-30,535,980 q12.2 - q12.3  Loss 503149 50 7.14 42.86 0.04 
chr22:30,535,980-30,623,768 q12.3  Loss 87788 50 0.00 50.00 0.01 
chr22:30,623,768-30,623,867 q12.3  Loss 99 37.5 0.00 37.50 0.04 
chr22:30,646,302-30,646,401 q12.3  Loss 99 37.5 0.00 37.50 0.04 
chr22:30,646,401-40,803,595 q12.3 - q13.2  Loss 10157194 50 0.00 50.00 0.01 
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chr22:40,803,595-42,473,589 q13.2  Loss 1669994 62.5 0.00 62.50 0.00 
chr22:42,473,589-44,175,906 q13.2 - q13.31  Loss 1702317 50 0.00 50.00 0.01 
chr22:44,175,906-49,453,810 q13.31 - q13.33  Loss 5277904 50 7.14 42.86 0.04 !
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Appendix 3.3: Regions showing significant copy number differences in multifocal grade 2 (n=11) versus grade 3 (n=11) 
tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in G3 (%) Freq. in G2 (%) Difference p-value 
chr2:195,231,804-196,753,496 q32.3  Loss 1521692 45.45 0.00 45.45 0.04 
chr2:20,215,537-21,280,646 p24.1  Gain 1065109 45.45 0.00 45.45 0.04 
chr2:208,876,525-227,205,229 q33.3 - q36.3  Loss 18328704 63.64 9.09 54.55 0.02 
chr2:224,263-20,037,859 p25.3 - p24.1  Gain 19813596 45.45 0.00 45.45 0.04 
chr2:228,542,036-232,368,564 q36.3 - q37.1  Loss 3826528 72.73 18.18 54.55 0.03 
chr2:232,368,564-232,541,867 q37.1  Loss 173303 72.73 9.09 63.64 0.01 
chr2:232,541,867-232,987,278 q37.1  Loss 445411 72.73 18.18 54.55 0.03 
chr2:232,987,278-241,796,109 q37.1 - q37.3  Loss 8808831 72.73 9.09 63.64 0.01 
chr2:25,870,821-52,373,212 p23.3 - p16.3  Gain 26502391 45.45 0.00 45.45 0.04 
chr2:52,373,212-53,101,240 p16.3 - p16.2  Gain 728028 54.55 0.00 54.55 0.01 
chr2:64,478,283-69,024,185 p14  Gain 4545902 45.45 0.00 45.45 0.04 
chr2:74,335,462-88,214,979 p13.1 - p11.2  Gain 13879517 45.45 0.00 45.45 0.04 
chr2:88,214,979-94,782,159 p11.2 - q11.1  Gain 6567180 54.55 0.00 54.55 0.01 
chr3:82,799,401-87,044,540 p12.2 - p12.1  Gain 4245139 45.45 0.00 45.45 0.04 
chr4:26,747,433-45,608,190 p15.2 - p12  Loss 18860757 45.45 0.00 45.45 0.04 
chr4:55,628-1,065,598 p16.3  Loss 1009970 45.45 0.00 45.45 0.04 
chr5:26,353,486-26,539,834 p14.1  Gain 186348 45.45 0.00 45.45 0.04 
chr7:15,056,488-21,588,275 p21.2 - p15.3  Gain 6531787 45.45 0.00 45.45 0.04 
chr7:26,749,335-29,450,068 p15.2 - p15.1  Gain 2700733 45.45 0.00 45.45 0.04 
chr7:50,617,642-63,102,874 p12.2 - q11.21  Gain 12485232 45.45 0.00 45.45 0.04 
chr7:63,102,874-84,591,194 q11.21 - q21.11  Gain 21488320 54.55 0.00 54.55 0.01 
chr7:97,101,588-100,038,722 q21.3 - q22.1  Gain 2937134 54.55 0.00 54.55 0.01 
chr10:78,996,385-80,472,830 q22.3  Loss 1476445 45.45 0.00 45.45 0.04 
chr10:85,567,652-86,390,131 q23.1  Loss 822479 45.45 0.00 45.45 0.04 
chr10:86,390,131-88,222,653 q23.1 - q23.2  Loss 1832522 54.55 0.00 54.55 0.01 
chr11:43,020,941-50,013,069 p12 - p11.12  Loss 6992128 45.45 0.00 45.45 0.04 
chr14:71,308,003-74,588,657 q24.2 - q24.3  Loss 3280654 45.45 0.00 45.45 0.04 
-191 - 
 
chr15:42,756,125-56,535,071 q21.1 - q22.1  Gain 13778946 45.45 0.00 45.45 0.04 
chr16:31,190,651-45,067,244 p11.2 - q11.2  Gain 13876593 45.45 0.00 45.45 0.04 
chr19:211,322-6,523,485 p13.3  Loss 6312163 45.45 0.00 45.45 0.04 
chr20:29,503,014-29,779,350 q11.21  Gain 276336 72.73 18.18 54.55 0.03 
chr22:15,745,966-16,347,244 q11.1 - q11.21  Loss 601278 54.55 0.00 54.55 0.01 
chr22:16,347,244-16,899,186 q11.21  Loss 551942 45.45 0.00 45.45 0.04 
chr22:30,032,831-30,535,980 q12.2 - q12.3  Loss 503149 45.45 0.00 45.45 0.04 
chr22:40,803,595-42,473,589 q13.2  Loss 1669994 45.45 0.00 45.45 0.04 
chr22:44,175,906-49,453,810 q13.31 - q13.33  Loss 5277904 45.45 0.00 45.45 0.04 !
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4 p16.3 - 
p16.1 
0.21- 
7.94 
151 ABCA11P, ADD1, ADRA2C, AFAP1, AFAP1-AS1, ALG1L7P, 
ATP5I, BLOC1S4, C4orf6, C4orf48, C4orf50, CCDC96, 
CFAP99, COX6B1P5, CPLX1, CRIPAK, CRMP1, CTBP1, 
CTBP1-AS2, CYTL1, DGKQ, DOK7, ENPP7P9, EVC, EVC2, 
FAM53A, FAM86EP, FAM193A, FGFR3, FGFRL1, FLJ36777, 
GAK, GRK4, GRPEL1, HAUS3, HGFAC, HTT, HTT-AS, IDUA, 
JAKMIP1, KIAA0232, LDHAP1, LETM1, LINC00955, MIR571, 
MIR943, MIR4274, MIR4798, MIR4800, MRFAP1, 
MRFAP1L1, MSANTD1, MSX1, MXD4, MYL5, NAT8L, 
NELFA, NOP14, NOP14-AS1, NSG1, OR4D12P, OR7E43P, 
OR7E99P, OR7E162P, OTOP1, PCGF3, PDE6B, PIGG, 
POLN, PPP2R2C, PSAPL1, RGS12, RNF4, RNF212, 
RPL7AP29, RPS3AP16, RPS7P15, S100P, SCARNA22, 
SH3BP2, SLBP, SLC26A1, SORCS2, SPON2, STK32B, 
STX18, STX18-AS1, TACC3, TADA2B, TBC1D14, TMED11P, 
TMEM128, TMEM129, TMEM175, TNIP2, TRSUP-TTA3-1, 
UNC93B4, UVSSA, WFS1, WHSC1, ZBTB49, ZFYVE28, 
ZNF141, ZNF721, ZNF732, ZNF876P 
10_2, 
21_2 
4.55 2 
-193 - 
 
5 p14.1 - 
q11.1 
 
26.54 - 
49.91 
172 ADAMTS12, AGXT2, AMACR, ANXA2R, BRIX1, C1QTNF3, 
C1QTNF3-AMACR, C5orf22, C5orf28, C5orf34, C5orf42, 
C5orf51, C6, C7, C9, CAPSL, CARD6, CCDC11P1, 
CCDC152, CCL28, CCNB3P1, CDH6, CDH9, CTD-
2118P12.1, DAB2, DNAJC21, DROSHA, EEF1A1P19, 
EGFLAM, EGFLAM-AS2, EGFLAM-AS4, EMB, FBXO4, 
FGF10, FGF10-AS1, FYB, GDNF, GDNF-AS1, GHR, 
GOLGA5P1, GOLPH3, HCN1, HMGCS1, HPRTP2, IL7R, 
INTS6P1, KCTD9P5, KRT18P31, LIFR, LIFR-AS1, MIR579, 
MIR580, MIR3650, MIR4279, MROH2B, MRPS30, 
MTHFD2P6, MTMR12, NADK2, NIM1K, NIPBL, NIPBL-AS1, 
NNT, NNT-AS1, NPR3, NUP155, OFD1P17, OSMR, OSMR-
AS1, OXCT1, PAIP1, PDZD2, PGBD3P2, PLCXD3, 
PRDX4P2, PRKAA1, PRLR, PSMC6P3, PTGER4, RAD1, 
RAI14, RANBP3L, RICTOR, RNA5SP181, RNU7-75P, 
RPL5P14, RPL9P17, RPL19P11, RPL21P54, RPL21P56, 
RPL27P10, RPL29P12, RPL37, RPL39P22, RPS2P22, 
RPS4XP6, RPS8P8, RPSAP38, RXFP3, SEPP1, SERBP1P6, 
SKP2, SLC1A3, SLC45A2, SNORD72, SPEF2, ST3GAL5P1, 
SUB1, SUCLG2P4, TARS, TCP1P2, TPT1P5, TTC23L, 
TTC33, UBL5P1, UGT3A1, UGT3A2, WDR70, ZFR, ZNF131 
5_2, 
6_2 
4.55 2 
-194 - 
 
6 p22.3 - 
p22.2 
19.13 - 
24.25 
27 CASC14, CASC15, CDKAL1, DCDC2, E2F3, HDGFL1, 
HNRNPA1P58, ID4, KRT18P38, LINC00581, MBOAT1, 
NRSN1, PRL, RNA5SP205, RPL5P20, RPL6P18, RPL21P61, 
RPL29P17, RPL36AP25, SOX4, SPTLC1P2, UQCRFS1P3 
12_1, 
12_2, 
12_3, 
12_4, 
13_1, 
13_2, 
13_3, 
18_2 
4.55 8 
8 q13.2 - 
q13.3 
 
69.61 - 
72.6 
27 BTF3P12, C8orf34, EYA1, H2AFZP2, LACTB2, NCOA2, 
PRDM14, RPL13P11, RPS18P11, SDCBPP2, SLCO5A1, 
SULF1, SUMO2P20, TRAM1, TRAPPC2P2, TRE-CTC14-1, 
XKR9 
3_1, 
19_3 
9.1 2 
-195 - 
 
10 q22.2 - 
q23.1 
 
74.95 - 
83.64 
140 ADK, AGAP5, ANXA7, ANXA11, AP3M1, ATP5G1P8, 
BEND3P3, BMS1P4, C1DP2, C1DP3, C1DP4, C10orf11, 
C10orf55, CAMK2G, CFAP70, CHCHD1, COMTD1, CTSLP6, 
DLG5, DLG5-AS1, DNAJC9, DNAJC9-AS1, DUPD1, DUSP13, 
DYDC1, DYDC2, EIF4A2P2, EIF5AL1, EIF5AP4, FAM32C, 
FAM149B1, FAM213A, FARSBP1, FUT11, GLUD1P3, 
GNAI2P2, H2AFZP5, HMGA1P5, IMPDH1P5, KAT6B, 
KCNMA1, KCNMA1-AS1, KCNMA1-AS2, KCNMA1-AS3, 
LINC00595, LINC00856, LINC00857, MAT1A, MBL1P, 
MBL3P, MIR606, MRPL35P3, MRPS16, MSS51, MYOZ1, 
NDST2, NPAP1P2, NRG3, NUTM2B, NUTM2B-AS1, 
NUTM2E, PGGT1BP2, PLAC9, PLAU, POLR3A, POLR3DP1, 
PPIAP13, PPIF, PPP3CB, PPP3CB-AS1, RAB5CP1, 
RBBP6P1, RNA5SP320, RNA5SP321, RPA2P2, RPL22P18, 
RPL26P6, RPL39P25, RPS7P9, RPS12P2, RPS12P18, 
RPS24, RPS26P41, RPS26P42, RPSAP6, SAMD8, SEC24C, 
SFTPA1, SFTPA2, SFTPA3P, SFTPD, SH2D4B, SPA17P1, 
SYNPO2L, TIMM9P1, TMEM254, TMEM254-AS1, TPRX1P1, 
TSPAN14, USP54, VCL, VDAC2, WARS2P1, ZCCHC24, 
ZMIZ1, ZMIZ1-AS1, ZNF503, ZNF503-AS1, ZNF503-AS2, 
ZNF519P1, ZNRF2P3, ZSWIM8, ZSWIM8-AS1 
12_2, 
20_1, 
20_3 
4.55 3 
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11 q13.2 - 
q13.4 
 
68.28 - 
72.38 
98 ALG1L9P, ANAPC15, ANO1, ANO1-AS2, ART2P, CCND1, 
CLPB, CPT1A, CTTN, DEFB108B, DHCR7, ENPP7P8, FADD, 
FAM86C1, FGF3, FGF4, FGF19, FLJ42102, FOLR1, 
FOLR1P1, FOLR2, FOLR3, FOLR3P1, GAL, H2AFZP4, 
IFITM9P, IGHMBP2, IL18BP, INPPL1, KRTAP5-7, KRTAP5-8, 
KRTAP5-9, KRTAP5-10, KRTAP5-11, KRTAP5-13P, KRTAP5-
14P, LAMTOR1, LINC01488, LINC01537, LRTOMT, MIR139, 
MIR548K, MIR3164, MIR3165, MIR3664, MRGPRD, 
MRGPRF, MRGPRF-AS1, MRPL21, MTL5, MYEOV, 
NADSYN1, NUMA1, OR7E4P, OR7E87P, OR7E126P, 
OR7E128P, ORAOV1, PDE2A, PHOX2A, PPFIA1, PPP6R3, 
RNF121, RPEP6, RPS3AP41, S100A11P3, SHANK2, 
SHANK2-AS1, SHANK2-AS3, SNRPCP14, TPCN2, 
UNC93B6, ZNF705E 
3_1, 
12_1, 
12_2, 
12_3, 
12_4, 
14_1, 
14_2, 
14_3, 
14_4, 
18_3 
4.55 10 
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12 p12.1 - 
p11.21 
 
25.56 - 
33.17 
96 AK4P3, AMN1, ARNTL2, ARNTL2-AS1, ASS1P14, ASUN, 
BHLHE41, BICD1, C12orf71, CAPRIN2, CCDC91, DDX11, 
DDX11-AS1, DENND5B, DENND5B-AS1, DNM1L, DSPA2D, 
ERGIC2, FAM60A, FAR2, FGD4, FGFR1OP2, FLJ13224, 
H3F3C, HMGB1P49, IPO8, ITPR2, KIAA1551, KLHL42, 
LINC00941, LMNTD1,, MANSC4, MED21, METTL20, 
MIR4302, MRPL30P2, MRPS35, OVCH1, OVCH1-AS1, 
OVOS2, PKP2, PPFIBP1, PTHLH, RARSP1, RASSF8, 
RASSF8-AS1, REP15, RNA5SP354, RNA5SP356, RNU5F-
4P, RPL12P32, RPL13AP22, RPL21P99, RPL29P27, 
RPL31P50, RPL35AP27, RPL39P27, RPLP2P4, SMCO2, 
SSPN, STK38L, STMN1P1, TDGP1, TM7SF3, TMTC1, 
TSPAN11, YARS2 
6_3, 
20_2 
4.55 2 
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12 q14.3 - 
q21.1 
 
64.71 - 
73.07 
107 APOOP3, ATP5HP4, ATP6V1E1P3, BEST3, C12orf56, 
CAND1, CCT2, CHCHD3P2, CNOT2, CPM, CPSF6, DYRK2, 
FAHD2P1, FLJ41278, FRS2, GGTA2P, GNS, GRIP1, HELB, 
HMGA2, HNRNPA1P70, IFNG, IFNG-AS1, IL22, IL26, IRAK3, 
KCNMB4, KRT8P39, KRT18P60, LEMD3, LGR5, LINC01479, 
LINC01481, LLPH, LRRC10, LYZ, MDM1, MDM2, MIR548C, 
MIR548Z, MIR1279, MIR3913-1, MIR3913-2, MRPL40P1, 
MRS2P2, MSRB3, MYRFL, NTAN1P3, NUP107, OSBPL9P4, 
PCNPP3, PDCL3P7, PSMC6P2, PTPRB, PTPRR, RAB3IP, 
RAB21, RAP1B, RASSF3, RBMS1P1, RNA5SP362, 
RPL7P39, RPL7P42, RPL10P12, RPL21P18, RPL39P28, 
RPS11P6, RPS26P45, RPSAP12, RPSAP52, SLC35E3, 
SNORA70G, TBC1D15, TBC1D30, TBK1, THAP2, TMBIM4, 
TMEM19, TPH2, TRHDE, TRHDE-AS1, TSPAN8, WIF1, 
XPOT, YEATS4, ZFC3H1 
12_1, 
12_2, 
12_3, 
12_4, 
20_1, 
20_2, 
20_3 
4.55 7 
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17 q11.2 - 
q12 
 
26.58 - 
29.51 
104 ABHD15, ADAP2, ALDOC, ALOX12P1, ANKRD13B, ATAD5, 
BLMH, CORO6, CPD, CRLF3, CRYBA1, DHRS13, DPRXP4, 
EFCAB5, ERAL1, FAM222B, FLOT2, FOXN1, GIT1, GOSR1, 
H3F3BP2, IFT20, KIAA0100, KRT17P3, KRT18P55, MIR144, 
MIR423, MIR451A, MIR451B, MIR3184, MIR4523, MIR4723, 
MIR4732, MIR4733, MYO18A, NARR, NDUFS5P7, NEK8, 
NF1, NSRP1, NUFIP2, PHF12, PIGS, PIPOX, POLDIP2, 
PPY2, PROCA1, RAB34, RNF135, RNY4P13, RPL9P30, 
RPL21P123, RPL23A, RPL31P58, RPL35AP35, RPS7P1, 
RPS12P28, RPS17P3, SARM1, SDF2, SEBOX, SEZ6, 
SGK494, SH3GL1P2, SLC6A4, SLC13A2, SLC46A1, 
SNORD4A, SNORD4B, SNORD42A, SNORD42B, SPAG5, 
SPAG5-AS1, SSH2, STX18P1, SUPT6H, SUZ12P1, TAOK1, 
TBC1D29, TEFM, TIAF1, TLCD1, TMEM97, TMEM199, 
TMIGD1, TNFAIP1, TP53I13, TRAF4, TWF1P1, UNC119, 
VTN 
6_2, 
14_1, 
14_2, 
14_3, 
14_4 
4.55 5 
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Appendix 3.4: Recurrent regions of high-level amplification detected in 
all 66 tumours. 
1Physical position is according to hg19/NCBI build 37. 
2Amplifications were classified as those regions where the normalized log2 
ratio was ≥1.2 detected in 2 or more tumours are listed. 
3The frequency of gain across candidate regions was estimated as the 
percentage of samples with log2ratio ≥0.15 
20 q11.1 - 
q11.22 
28.27 - 
32.56 
94 ACTL10, ASXL1, BAK1P1, BCL2L1, BPIFA1, BPIFA2, 
BPIFA3, BPIFA4P, BPIFB1, BPIFB2, BPIFB3, BPIFB4, 
BPIFB5P, BPIFB6, BPIFB9P, C20orf144, C20orf203, 
CBFA2T2, CCM2L, CD24P3, CDK5RAP1, CHMP4B, 
COMMD7, COX4I2, DEFB115, DEFB116, DEFB117, 
DEFB118, DEFB119, DEFB121, DEFB122, DEFB123, 
DEFB124, DKKL1P1, DNMT3B, DUSP15, E2F1, EFCAB8, 
FOXS1, FRG1B, HAUS6P2, HCK, HDHD1P3, HM13, HM13-
AS1, ID1, KIF3B, LINC00028, MAPRE1, MCTS2P, MIR1825, 
MIR3193, MLLT10P1, MYLK2, NECAB3, NOL4L, PDRG1, 
PIGPP3, PLAGL2, POFUT1, PXMP4, REM1, RNA5SP480, 
RNA5SP481, RPL12P3, RPL31P2, RPL31P3, RSL24D1P6, 
SNTA1, SOCS2P1, SUN5, TM9SF4, TPM3P2, TPX2, TRS-
AGA7-1, TSPY26P, TTLL9, XKR7, ZNF341, ZNF341-AS1 
5_2, 
6_1 
4.55 2 
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Appendix 3.5: Regions showing significant copy number differences in multifocal FGFR3 wildtype (n=14) versus FGFR3 
mutant (n=8) tumours. 
 
 
Region Cytoband 
Location 
Event Region Length Freq. in WT (%) Freq. in Mutant 
(%) 
Difference p-value 
chr7:84,591,194-97,101,588 q21.11 - q21.3  Gain 12510394 57.14 0 57.14 0.02 
chr7:100,038,722-158,625,992 q22.1 - q36.3  Gain 58587270 57.14 0 57.14 0.02 
chr8:132,638,132-133,156,783 q24.22  Gain 518651 64.29 12.5 51.79 0.03 
chr8:134,255,043-142,612,553 q24.22 - q24.3  Gain 8357510 64.29 12.5 51.79 0.03 
chr8:146,003,740-146,133,884 q24.3  Gain 130144 57.14 0 57.14 0.02 
chr20:29,503,014-29,779,350 q11.21  Gain 276336 64.29 12.5 51.79 0.03 
 
 
1Physical position is according to hg19/NCBI build 37 
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Appendix 4.1: Details of samples in the three main clusters obtained by hierarchical cluster analysis of copy number data 
from 66 tumours. 
  
 
Tumour&Number&
&
Stage& &grade&
&
Primary/&Recurrent& FGA&group&
FGFR3%
Mutation&
Status&
PIK3CA%
Mutation&
Status&
RAS&gene&Mutation&
Status&
Cluster&
1_1# Ta#G2# Recurrence# B# WT# MUTANT# WT# 1#
1_2# Ta#G2# Recurrence# A# WT# MUTANT# WT# 1#
1_3# Ta#G2# Recurrence# A# WT# WT# WT# 1#
5_1# Ta#G2# Primary# A# MUTANT# WT# WT# 1#
8_1# Ta#G2# Recurrence# A# MUTANT# MUTANT# WT# 1#
8_3# Ta#G2# Recurrence# A# MUTANT# MUTANT# WT# 1#
9_1# T1#G3# Primary# A# WT# WT# WT# 1#
9_2# T1#G3# Primary# A# WT# WT# WT# 1#
13_4# Ta#G3# Primary# A# WT# WT# WT# 1#
16_3# Ta#G2# Recurrence# A# WT# WT# MUTANT# 1#
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Tumour&Number&
&
Stage& &grade&
&
Primary/&Recurrent& FGA&group&
FGFR3%
Mutation&
Status&
PIK3CA%
Mutation&
Status&
Ras&Mutation&
Status&
Cluster#
16_4# Ta#G2# Recurrence# A# WT# WT# MUTANT# 1#
17_1# Ta#G2# Recurrence# B# MUTANT# MUTANT# WT# 1#
17_2# Ta#G2# Recurrence# B# MUTANT# MUTANT# WT# 1#
17_3# Ta#G2# Recurrence# B# MUTANT# MUTANT# WT# 1#
2_1# Ta#G2# Recurrence# C# MUTANT# WT# WT# 2#
2_2# Ta#G2# Recurrence# B# MUTANT# WT# WT# 2#
2_3# Ta#G2# Recurrence# B# MUTANT# WT# WT# 2#
3_1# T1#G3# Recurrence# C# WT# WT# MUTANT# 2#
3_2# T1#G3# Recurrence# C# WT# WT# MUTANT# 2#
3_3# T1#G3# Recurrence# C# WT# WT# MUTANT# 2#
4_1# Ta#G3# Recurrence# C# MUTANT# MUTANT# WT# 2#
4_2# Ta#G3# Recurrence# B# MUTANT# MUTANT# WT# 2#
4_3# Ta#G3# Recurrence# B# MUTANT# MUTANT# WT# 2#
4_4# Ta#G3# Recurrence# B# MUTANT# MUTANT# WT# 2#
-204 - 
 
Tumour&Number&
&
Stage& &grade&
&
Primary/&Recurrent& FGA&group&
FGFR3%
Mutation&
Status&
PIK3CA%
Mutation&
Status&
Ras&Mutation&
Status&
Cluster#
4_5# Ta#G3# Recurrence# B# MUTANT# MUTANT# WT# 2#
4_6# Ta#G3# Recurrence# B# MUTANT# MUTANT# WT# 2#
7_1# Ta#G2# Recurrence# C# WT# WT# WT# 2#
7_2# Ta#G2# Recurrence# C# WT# WT# WT# 2#
8_2# Ta#G2# Recurrence# C# MUTANT# MUTANT# WT# 2#
11_1# Ta#G2# Recurrence# C# WT# WT# WT# 2#
11_2# T1#G3# Recurrence# C# WT# WT# WT# 2#
15_1# Ta#G2# Primary# C# MUTANT# MUTANT# WT# 2#
15_2# Ta#G2# Primary# B# MUTANT# MUTANT# WT# 2#
16_1# Ta#G2# Recurrence# C# WT# WT# MUTANT# 2#
16_2# Ta#G2# Recurrence# B# WT# WT# MUTANT# 2#
19_1# Ta#G2# Primary# B# MUTANT# WT# WT# 2#
19_2# Ta#G2# Primary# B# MUTANT# WT# WT# 2#
19_3# Ta#G2# Primary# C# WT# WT# WT# 2#
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Tumour&Number&
&
Stage& &grade&
&
Primary/&Recurrent& FGA&group&
FGFR3%
Mutation&
Status&
PIK3CA%
Mutation&
Status&
Ras&Mutation&
Status&
Cluster#
21_1# Ta#G2# Recurrence# C# MUTANT# WT# WT# 2#
21_2# Ta#G2# Recurrence# C# MUTANT# WT# WT# 2#
22_1# Ta#G2# Primary# C# WT# WT# WT# 2#
22_2# Ta#G2# Primary# B# WT# WT# WT# 2#
5_2# Ta#G2# Primary# D# MUTANT# WT# WT# 3#
6_1# T1#G3# Primary# D# WT# WT# WT# 3#
6_2# T1#G3# Primary# D# WT# WT# WT# 3#
6_3# T1#G3# Primary# D# WT# WT# WT# 3#
10_1# Ta#G3# Primary# C# WT# WT# WT# 3#
10_2# Ta#G3# Primary# D# WT# WT# WT# 3#
12_1# T1#G3# Primary# D# WT# WT# WT# 3#
12_2# T1#G3# Primary# D# WT# WT# WT# 3#
12_3# T1#G3# Primary# D# WT# WT# WT# 3#
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Tumour&Number&
&
Stage& &grade&
&
Primary/&Recurrent& FGA&group&
FGFR3%
Mutation&
Status&
PIK3CA%
Mutation&
Status&
Ras&Mutation&
Status&
Cluster#
12_4# Ta#G3# Primary# D# WT# WT# WT# 3#
13_1# Ta#G3# Primary# D# WT# WT# WT# 3#
13_2# Ta#G3# Primary# D# WT# WT# WT# 3#
13_3# Ta#G3# Primary# D# WT# WT# WT# 3#
14_1# Ta#G3# Primary# D# WT# WT# WT# 3#
14_2# Ta#G3# Primary# D# WT# WT# WT# 3#
14_3# Ta#G3# Primary# D# WT# WT# WT# 3#
14_4# Ta#G3# Primary# D# WT# WT# WT# 3#
18_1# T1#G3# Primary# D# WT# WT# WT# 3#
18_2# T1#G3# Primary# D# WT# WT# WT# 3#
18_3# T1#G3# Primary# D# WT# WT# WT# 3#
18_4# T1#G3# Primary# D# WT# WT# WT# 3#
20_1# Ta#G2# Primary# D# WT# WT# WT# 3#
20_2# T1#G3# Primary# D# WT# WT# WT# 3#
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Tumour&Number&
&
Stage& &grade&
&
Primary/&Recurrent& FGA&group&
FGFR3%
Mutation&
Status&
PIK3CA%
Mutation&
Status&
Ras&Mutation&
Status&
Cluster#
20_3# T1#G3# Primary# D# WT# WT# WT# 3#
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Appendix 4.1B: Candidate genes in a minimal region of copy number 
loss extending from 2q24-2q27.3 (214.9-242.1 Mb) in multifocal tumours 
from Cluster 3. 
 
AAMP, ABCA12, ABCB6, ACKR3, ACSL3, AGAP1, AGAP1-IT1, AGFG1, AGXT, ALPI, 
ALPP, ALPPL2, ANKMY1, ANKZF1, AP1S3, AQP12A, AQP12B, ARL4C, ARMC9, ARPC2, 
ASB1, ASB18, ASIC4, ATG9A, ATG12P2, ATG16L1, ATIC, B3GNT7, BANF1P3, BARD1, 
BCS1L, C2orf54, C2orf57, C2orf72, C2orf82, C2orf83, CAB39, CAPN10, CAPN10-AS1, 
CATIP, CATIP-AS1, CCDC108, CCDC140, CCL20, CDK5R2, CHPF, CHRND, CHRNG, 
CNPPD1, COL4A3, COL4A4, COL6A3, COPS7B, COPS8, COX20P2, CRYBA2, CTDSP1, 
CUL3, CXCR1, CXCR2, CXCR2P1, CYP27A1, DAW1, DES, DGKD, DIRC3, DIS3L2, 
DIS3L2P1, DNAJB2, DNAJB3, DNER, DNPEP, DOCK10, DUSP28, ECEL1, ECEL1P2, 
ECEL1P3, EFHD1, EIF4E2, ENSAP3, EPHA4, ESPNL, FABP5P14, FAM124B, FAM132B, 
FAM134A, FARSB, FBXO36, FEV, FLJ43879, FN1, GAMTP1, GAPDHP49, GBX2, 
GIGYF2, GLB1L, GMPPA, GPBAR1, GPC1, GPR35, GPR55, HDAC4, HES6, HIGD1AP4, 
HJURP, HMGB1P3, HMGB1P9, HSPA8P10, HSPA9P1, HTR2B, IGFBP2, IGFBP5, IHH, 
ILKAP, INHA, INPP5D, IQCA1, IRS1, ITM2C, KCNE4, KCNJ13, KIF1A, KLHL30, KRT8P30, 
LINC00471, LINC00607, LINC00608, LINC01107, LINC01280, LINC01494, LRRFIP1, 
MARCH4, MFF, MGC16025, MIR26B, MIR149, MIR153-1, MIR375, MIR562, MIR1244-1, 
MIR1471, MIR2467, MIR3131, MIR3132, MIR4268, MIR4269, MIR4439, MIR4440, 
MIR4441, MIR4777, MIR4786, MIR5001, MIR5702, MIR5703, MLPH, MOGAT1, MREG, 
MROH2A, MRPL44, MSL3P1, MTERF4, MYEOV2, NANOGP2, NCL, NDUFA10, NEU2, 
NGEF, NHEJ1, NMUR1, NPPC, NYAP2, OBSL1, OR5S1P, OR6B2, OR6B3, OR9S24P, 
OTOS, PASK, PAX3, PDE6D, PECR, PER2, PID1, PKI55, PLCD4, PNKD, PP14571, 
PPP1R7, PRKAG3, PRLH, PRR21, PRSS56, PSMB3P2, PSMD1, PTMA, PTPRN, RAB17, 
RAMP1, RBM44, RESP18, RHBDD1, RNA5SP120, RNA5SP121, RNF25, RNPEPL1, 
RNY4P19, RPL3P5, RPL5P8, RPL7L1P9, RPL10P6, RPL17P11, RPL17P14, RPL19P5, 
RPL21P35, RPL23AP26, RPL23AP28, RPL23AP31, RPL23P4, RPL23P5, RPL28P2, 
RPL31P14, RPL31P17, RPL37A, RPS20P12, RPS28P4, RQCD1, RUFY4, SAG, 
SCARNA5, SCARNA6, SCG2, SCLY, SERPINE2, SGPP2, SH3BP4, SLC4A3, SLC11A1, 
SLC16A14, SLC19A3, SLC23A3, SMARCAL1, SNED1, SNORA75, SNORD20, SNORD82, 
SNRPGP8, SP100, SP110, SP140, SP140L, SPAG16, SPATA3, SPATA3-AS1, SPEG, 
SPHKAP, SPP2, STIP1P2, STK11IP, STK16, STK36, TDGF1P2, TIGD1, TM4SF20, 
TMBIM1, TMEM169, TMEM198, TMSB10P1, TNP1, TNS1, TPM3P8, TRAF3IP1, TRIP12, 
TRK-TTT15-1, TRPM8, TRQ-CTG16-1, TRY-ATA1-1, TTLL4, TUBA4A, TUBA4B, TWIST2, 
UBE2F, UBE2F-SCLY, UGT1A, UGT1A1, UGT1A2P, UGT1A3, UGT1A4, UGT1A5, 
UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT1A11P, UGT1A12P, UGT1A13P, 
USP37, USP40, VIL1, VWC2L, VWC2L-IT1, WDFY1, WNT6, WNT10A, XRCC5, 
ZBTB8OSP2, ZFAND2B, ZNF142 
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Appendix 4.2 Regions showing significant copy number differences in multifocal tumours from cluster 1 (n=14) versus 
cluster 2 (n=8). 
 
 
Region1 Cytoband Location Event Region Length Freq. in 
Cluster 2 (%) 
Freq. in Cluster 
1 (%) 
Difference p-value 
chr1:1,144,379-38,051,746 p36.33 - p34.3 Gain 36907367 62.5 7.14 55.36 0.0109 
chr1:113,473,675-119,480,610 p13.2 - p12 Gain 6006935 62.5 0.00 62.50 0.0021 
chr1:119,480,610-119,708,536 p12 Gain 227926 87.5 0.00 87.50 0.0000 
chr1:119,708,536-148,424,834 p12 - q21.2 Gain 28716298 87.5 21.43 66.07 0.0062 
chr1:148,424,834-157,241,521 q21.2 - q23.1 Gain 8816687 75.0 21.43 53.57 0.0260 
chr1:167,621,290-169,324,707 q24.2 - q24.3 Gain 1703417 75.0 21.43 53.57 0.0260 
chr1:185,614,023-191,477,703 q31.1 - q31.2 Loss 5863680 37.5 0.00 37.50 0.0364 
chr1:192,424,789-197,774,987 q31.3 - q32.1 Loss 5350198 37.5 0.00 37.50 0.0364 
chr1:234,285,489-246,181,016 q42.3 - q44 Loss 11895527 37.5 0.00 37.50 0.0364 
chr1:242,491,517-247,029,735 q44 Gain 4538218 50.0 7.14 42.86 0.0393 
chr1:246,181,016-247,164,041 q44 Loss 983025 50.0 0.00 50.00 0.0096 
chr1:38,051,746-48,917,318 p34.3 - p33 Gain 10865572 75.0 7.14 67.86 0.0023 
chr1:48,917,318-50,594,589 p33 Gain 1677271 75.0 0.00 75.00 0.0004 
chr1:50,594,589-50,823,305 p33 Gain 228716 62.5 0.00 62.50 0.0021 
chr1:50,823,305-53,509,194 p33 - p32.3 Gain 2685889 75.0 7.14 67.86 0.0023 
chr1:53,509,194-68,609,865 p32.3 - p31.3 Gain 15100671 75.0 0.00 75.00 0.0004 
chr1:68,609,865-73,625,895 p31.3 - p31.1 Gain 5016030 62.5 0.00 62.50 0.0021 
chr1:73,625,895-83,494,525 p31.1 Gain 9868630 50.0 0.00 50.00 0.0096 
chr1:83,678,458-95,929,212 p31.1 - p21.3 Gain 12250754 37.5 0.00 37.50 0.0364 
chr1:918,164-1,144,379 p36.33 Gain 226215 50.0 7.14 42.86 0.0393 
chr1:95,929,212-113,473,675 p21.3 - p13.2 Gain 17544463 50.0 0.00 50.00 0.0096 
chr10:103,282,021-104,340,398 q24.32 Loss 1058377 87.5 28.57 58.93 0.0237 
chr10:104,340,398-104,342,397 q24.32 Loss 1999 87.5 21.43 66.07 0.0062 
chr10:104,342,397-104,652,460 q24.32 Loss 310063 87.5 28.57 58.93 0.0237 
chr10:104,652,460-109,290,751 q24.32 - q25.1 Loss 4638291 87.5 21.43 66.07 0.0062 
chr10:109,290,751-116,774,295 q25.1 - q25.3 Loss 7483544 87.5 14.29 73.21 0.0015 
chr10:116,774,295-122,467,467 q25.3 - q26.12 Loss 5693172 75.0 14.29 60.71 0.0083 
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chr10:122,467,970-125,057,698 q26.12 - q26.13 Loss 2589728 75.0 14.29 60.71 0.0083 
chr10:125,057,698-130,095,088 q26.13 - q26.2 Loss 5037390 75.0 0.00 75.00 0.0004 
chr10:130,095,088-131,816,154 q26.2 - q26.3 Loss 1721066 75.0 7.14 67.86 0.0023 
chr10:131,816,154-131,982,049 q26.3 Loss 165895 62.5 7.14 55.36 0.0109 
chr10:131,982,049-135,247,831 q26.3 Loss 3265782 75.0 7.14 67.86 0.0023 
chr10:38,812,575-52,328,336 p11.1 - q11.23 Loss 13515761 37.5 0.00 37.50 0.0364 
chr10:52,328,336-56,882,157 q11.23 - q21.1 Loss 4553821 50.0 0.00 50.00 0.0096 
chr10:56,882,157-59,005,947 q21.1 Loss 2123790 50.0 7.14 42.86 0.0393 
chr10:59,005,947-62,853,055 q21.1 - q21.2 Loss 3847108 50.0 0.00 50.00 0.0096 
chr10:62,853,055-68,138,624 q21.2 - q21.3 Loss 5285569 37.5 0.00 37.50 0.0364 
chr10:78,996,385-80,472,830 q22.3 Loss 1476445 50.0 7.14 42.86 0.0393 
chr10:80,472,830-83,637,155 q22.3 - q23.1 Loss 3164325 50.0 0.00 50.00 0.0096 
chr10:83,637,155-84,577,760 q23.1 Loss 940605 50.0 7.14 42.86 0.0393 
chr10:84,577,760-85,567,652 q23.1 Loss 989892 62.5 7.14 55.36 0.0109 
chr10:85,567,652-86,390,131 q23.1 Loss 822479 62.5 0.00 62.50 0.0021 
chr10:86,390,131-88,222,653 q23.1 - q23.2 Loss 1832522 75.0 0.00 75.00 0.0004 
chr10:88,222,653-89,694,469 q23.2 - q23.31 Loss 1471816 87.5 14.29 73.21 0.0015 
chr10:89,694,469-89,694,975 q23.31 Loss 506 87.5 0.00 87.50 0.00005 
chr10:89,694,975-93,738,544 q23.31 - q23.32 Loss 4043569 87.5 14.29 73.21 0.0015 
chr10:93,738,544-94,907,303 q23.32 - q23.33 Loss 1168759 75.0 14.29 60.71 0.0083 
chr10:94,907,303-99,781,492 q23.33 - q24.2 Loss 4874189 87.5 14.29 73.21 0.0015 
chr10:99,781,492-103,282,021 q24.2 - q24.32 Loss 3500529 87.5 21.43 66.07 0.0062 
chr11:1,785,273-9,667,022 p15.5 - p15.4 Loss 7881749 50.0 7.14 42.86 0.0393 
chr11:107,722,054-115,161,463 q22.3 - q23.2 Loss 7439409 50.0 7.14 42.86 0.0393 
chr11:123,449,312-131,065,134 q24.1 - q25 Loss 7615822 50.0 7.14 42.86 0.0393 
chr11:131,065,134-133,984,028 q25 Loss 2918894 62.5 7.14 55.36 0.0109 
chr11:133,984,028-134,156,487 q25 Loss 172459 62.5 0.00 62.50 0.0021 
chr11:178,227-267,210 p15.5 Loss 88983 37.5 0.00 37.50 0.0364 
chr11:24,362,912-37,838,885 p14.3 - p12 Loss 13475973 50.0 0.00 50.00 0.0096 
chr11:37,838,885-40,185,000 p12 Loss 2346115 50.0 7.14 42.86 0.0393 
chr11:40,185,000-43,020,941 p12 Loss 2835941 50.0 0.00 50.00 0.0096 
chr11:43,020,941-50,013,069 p12 - p11.12 Loss 6992128 62.5 0.00 62.50 0.0021 
chr11:50,013,069-60,851,894 p11.12 - q12.2 Loss 10838825 50.0 0.00 50.00 0.0096 
chr11:60,851,894-63,843,056 q12.2 - q13.1 Loss 2991162 37.5 0.00 37.50 0.0364 
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chr11:76,232,396-81,301,979 q13.5 - q14.1 Gain 5069583 37.5 0.00 37.50 0.0364 
chr12:103,714,143-111,697,547 q23.3 - q24.13 Loss 7983404 37.5 0.00 37.50 0.0364 
chr12:11,018,640-14,521,944 p13.2 - p13.1 Gain 3503304 37.5 0.00 37.50 0.0364 
chr12:129,839,417-132,272,931 q24.33 Loss 2433514 37.5 0.00 37.50 0.0364 
chr12:152,534-3,099,629 p13.33 Gain 2947095 37.5 0.00 37.50 0.0364 
chr12:33,333,489-40,716,974 p11.1 - q12 Loss 7383485 37.5 0.00 37.50 0.0364 
chr12:40,716,974-42,413,160 q12 Loss 1696186 50.0 0.00 50.00 0.0096 
chr12:42,413,160-46,156,911 q12 - q13.11 Loss 3743751 37.5 0.00 37.50 0.0364 
chr13:31,870,598-36,083,776 q13.1 - q13.3 Loss 4213178 37.5 0.00 37.50 0.0364 
chr14:26,561,378-26,744,993 q12 Loss 183615 37.5 0.00 37.50 0.0364 
chr14:26,744,993-38,933,843 q12 - q21.1 Loss 12188850 50.0 0.00 50.00 0.0096 
chr14:38,933,843-40,363,695 q21.1 Loss 1429852 50.0 7.14 42.86 0.0393 
chr14:40,363,695-57,420,120 q21.1 - q23.1 Loss 17056425 50.0 0.00 50.00 0.0096 
chr14:57,420,120-58,323,469 q23.1 Loss 903349 75.0 0.00 75.00 0.0004 
chr14:58,323,469-58,470,270 q23.1 Loss 146801 62.5 0.00 62.50 0.0021 
chr14:58,470,270-59,336,011 q23.1 Loss 865741 75.0 0.00 75.00 0.0004 
chr14:59,336,011-65,655,482 q23.1 - q23.3 Loss 6319471 50.0 0.00 50.00 0.0096 
chr14:65,655,482-66,870,415 q23.3 Loss 1214933 37.5 0.00 37.50 0.0364 
chr14:66,870,415-71,308,003 q23.3 - q24.2 Loss 4437588 50.0 0.00 50.00 0.0096 
chr14:71,308,003-74,588,657 q24.2 - q24.3 Loss 3280654 62.5 0.00 62.50 0.0021 
chr14:74,588,657-81,191,238 q24.3 - q31.1 Loss 6602581 50.0 0.00 50.00 0.0096 
chr14:81,191,238-94,901,754 q31.1 - q32.13 Loss 13710516 37.5 0.00 37.50 0.0364 
chr15:20,363,717-22,736,034 q11.2 Gain 2372317 50.0 7.14 42.86 0.0393 
chr15:22,894,833-62,510,397 q11.2 - q22.31 Loss 39615564 37.5 0.00 37.50 0.0364 
chr15:42,756,125-56,535,071 q21.1 - q22.1 Gain 13778946 50.0 7.14 42.86 0.0393 
chr15:62,510,397-82,907,017 q22.31 - q25.2 Loss 20396620 50.0 0.00 50.00 0.0096 
chr15:82,907,017-83,883,618 q25.2 - q25.3 Loss 976601 37.5 0.00 37.50 0.0364 
chr15:83,883,618-87,527,174 q25.3 - q26.1 Loss 3643556 50.0 0.00 50.00 0.0096 
chr15:87,527,174-89,307,983 q26.1 Loss 1780809 50.0 7.14 42.86 0.0393 
chr15:89,307,983-100,022,043 q26.1 - q26.3 Loss 10714060 50.0 0.00 50.00 0.0096 
chr16:23,756,350-31,190,651 p12.1 - p11.2 Gain 7434301 50.0 0.00 50.00 0.0096 
chr16:31,190,651-45,067,244 p11.2 - q11.2 Gain 13876593 62.5 0.00 62.50 0.0021 
chr16:33,715,230-45,231,075 p11.2 - q11.2 Loss 11515845 37.5 0.00 37.50 0.0364 
chr16:45,231,075-63,462,907 q11.2 - q21 Loss 18231832 50.0 0.00 50.00 0.0096 
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chr16:63,462,907-82,569,517 q21 - q23.3 Loss 19106610 37.5 0.00 37.50 0.0364 
chr16:7,019,846-23,756,350 p13.2 - p12.1 Gain 16736504 37.5 0.00 37.50 0.0364 
chr16:88,421,159-88,552,007 q24.3 Loss 130848 37.5 0.00 37.50 0.0364 
chr17:12,108,967-14,364,543 p12 Gain 2255576 37.5 0.00 37.50 0.0364 
chr17:20,230,301-22,465,647 p11.2 - q11.1 Gain 2235346 37.5 0.00 37.50 0.0364 
chr17:26,575,095-28,423,748 q11.2 Gain 1848653 50.0 7.14 42.86 0.0393 
chr17:28,423,748-29,512,898 q11.2 - q12 Gain 1089150 62.5 7.14 55.36 0.0109 
chr17:29,512,898-33,099,942 q12 Gain 3587044 50.0 7.14 42.86 0.0393 
chr17:35,682,018-38,327,610 q21.2 - q21.31 Gain 2645592 37.5 0.00 37.50 0.0364 
chr17:52,172,780-62,246,742 q22 - q24.2 Gain 10073962 50.0 7.14 42.86 0.0393 
chr17:62,246,742-66,194,639 q24.2 - q24.3 Gain 3947897 62.5 7.14 55.36 0.0109 
chr17:66,194,639-67,327,134 q24.3 Gain 1132495 50.0 7.14 42.86 0.0393 
chr17:67,327,134-68,199,396 q24.3 Gain 872262 62.5 7.14 55.36 0.0109 
chr17:68,199,396-76,183,573 q24.3 - q25.3 Gain 7984177 50.0 7.14 42.86 0.0393 
chr17:77,729,550-78,374,103 q25.3 Gain 644553 37.5 0.00 37.50 0.0364 
chr18:130,336-2,479,744 p11.32 Gain 2349408 50.0 0.00 50.00 0.0096 
chr18:2,479,744-6,213,636 p11.32 - p11.31 Gain 3733892 37.5 0.00 37.50 0.0364 
chr18:6,933,612-9,449,205 p11.31 - p11.22 Gain 2515593 37.5 0.00 37.50 0.0364 
chr19:211,322-6,523,485 p13.3 Loss 6312163 50.0 7.14 42.86 0.0393 
chr2:123,095,058-127,253,875 q14.3 Loss 4158817 50.0 7.14 42.86 0.0393 
chr2:127,253,875-136,875,479 q14.3 - q22.1 Loss 9621604 62.5 7.14 55.36 0.0109 
chr2:136,875,479-142,876,374 q22.1 - q22.2 Loss 6000895 62.5 0.00 62.50 0.0021 
chr2:142,876,374-151,825,968 q22.2 - q23.3 Loss 8949594 62.5 7.14 55.36 0.0109 
chr2:151,825,968-152,428,325 q23.3 Loss 602357 50.0 7.14 42.86 0.0393 
chr2:152,428,325-153,751,686 q23.3 Loss 1323361 50.0 0.00 50.00 0.0096 
chr2:153,751,686-156,410,442 q23.3 - q24.1 Loss 2658756 62.5 0.00 62.50 0.0021 
chr2:156,410,442-169,397,061 q24.1 - q24.3 Loss 12986619 50.0 0.00 50.00 0.0096 
chr2:157,250,015-165,687,734 q24.1 - q24.3 Gain 8437719 37.5 0.00 37.50 0.0364 
chr2:169,397,061-175,231,393 q24.3 - q31.1 Loss 5834332 62.5 0.00 62.50 0.0021 
chr2:175,231,393-176,870,358 q31.1 Loss 1638965 75.0 0.00 75.00 0.0004 
chr2:176,870,358-183,311,858 q31.1 - q32.1 Loss 6441500 62.5 0.00 62.50 0.0021 
chr2:183,311,858-195,231,804 q32.1 - q32.3 Loss 11919946 75.0 0.00 75.00 0.0004 
chr2:193,940,783-196,538,333 q32.3 Gain 2597550 37.5 0.00 37.50 0.0364 
chr2:195,231,804-196,753,496 q32.3 Loss 1521692 62.5 0.00 62.50 0.0021 
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chr2:196,753,496-208,876,525 q32.3 - q33.3 Loss 12123029 75.0 0.00 75.00 0.0004 
chr2:20,037,859-20,215,537 p24.1 Gain 177678 50.0 0.00 50.00 0.0096 
chr2:20,215,537-21,280,646 p24.1 Gain 1065109 62.5 0.00 62.50 0.0021 
chr2:208,876,525-227,205,229 q33.3 - q36.3 Loss 18328704 100.0 0.00 100.00 0.000003 
chr2:21,280,646-25,870,821 p24.1 - p23.3 Gain 4590175 50.0 0.00 50.00 0.0096 
chr2:224,263-20,037,859 p25.3 - p24.1 Gain 19813596 62.5 0.00 62.50 0.0021 
chr2:227,205,229-228,542,036 q36.3 Loss 1336807 100.0 7.14 92.86 0.00003 
chr2:228,542,036-232,368,564 q36.3 - q37.1 Loss 3826528 100.0 14.29 85.71 0.0001 
chr2:232,368,564-232,541,867 q37.1 Loss 173303 100.0 7.14 92.86 0.00003 
chr2:232,541,867-232,987,278 q37.1 Loss 445411 100.0 14.29 85.71 0.0001 
chr2:232,987,278-241,796,109 q37.1 - q37.3 Loss 8808831 100.0 7.14 92.86 0.00003 
chr2:25,870,821-52,373,212 p23.3 - p16.3 Gain 26502391 62.5 0.00 62.50 0.0021 
chr2:52,373,212-53,101,240 p16.3 - p16.2 Gain 728028 62.5 7.14 55.36 0.0109 
chr2:64,478,283-69,024,185 p14 Gain 4545902 62.5 0.00 62.50 0.0021 
chr2:69,024,185-71,285,149 p14 - p13.3 Gain 2260964 62.5 7.14 55.36 0.0109 
chr2:74,335,462-88,214,979 p13.1 - p11.2 Gain 13879517 62.5 0.00 62.50 0.0021 
chr2:88,214,979-94,782,159 p11.2 - q11.1 Gain 6567180 75.0 0.00 75.00 0.0004 
chr2:94,782,159-95,675,764 q11.1 Gain 893605 50.0 0.00 50.00 0.0096 
chr2:94,983,765-123,095,058 q11.1 - q14.3 Loss 28111293 50.0 0.00 50.00 0.0096 
chr2:96,200,121-97,472,556 q11.2 Gain 1272435 37.5 0.00 37.50 0.0364 
chr20:26,220,344-29,503,014 p11.1 - q11.21 Gain 3282670 100.0 21.43 78.57 0.0010 
chr20:275,014-26,220,344 p13 - p11.1 Gain 25945330 87.5 21.43 66.07 0.0062 
chr20:29,503,014-29,779,350 q11.21 Gain 276336 87.5 21.43 66.07 0.0062 
chr20:29,779,350-30,102,016 q11.21 Gain 322666 100.0 21.43 78.57 0.0010 
chr20:30,102,016-34,346,661 q11.21 - q11.23 Gain 4244645 100.0 28.57 71.43 0.0017 
chr20:34,346,661-35,931,146 q11.23 Gain 1584485 100.0 35.71 64.29 0.0055 
chr20:35,931,146-37,522,311 q11.23 - q12 Gain 1591165 100.0 42.86 57.14 0.0177 
chr20:37,522,311-37,666,045 q12 Gain 143734 100.0 35.71 64.29 0.0055 
chr20:37,666,045-40,680,814 q12 Gain 3014769 100.0 42.86 57.14 0.0177 
chr20:40,680,814-45,646,214 q12 - q13.12 Gain 4965400 100.0 35.71 64.29 0.0055 
chr20:45,646,214-47,243,628 q13.12 - q13.13 Gain 1597414 87.5 35.71 51.79 0.0310 
chr20:47,243,628-47,383,084 q13.13 Gain 139456 100.0 35.71 64.29 0.0055 
chr20:47,538,301-59,894,661 q13.13 - q13.33 Gain 12356360 100.0 35.71 64.29 0.0055 
chr20:59,894,661-62,392,510 q13.33 Gain 2497849 87.5 35.71 51.79 0.0310 
-214 - 
 
chr22:15,621,248-15,745,966 q11.1 Loss 124718 50.0 0.00 50.00 0.0096 
chr22:15,745,966-16,347,244 q11.1 - q11.21 Loss 601278 62.5 7.14 55.36 0.0109 
chr22:16,347,244-16,899,186 q11.21 Loss 551942 50.0 7.14 42.86 0.0393 
chr22:16,899,186-18,151,355 q11.21 Loss 1252169 50.0 0.00 50.00 0.0096 
chr22:18,151,355-18,151,891 q11.21 Loss 536 37.5 0.00 37.50 0.0364 
chr22:18,151,891-30,032,831 q11.21 - q12.2 Loss 11880940 50.0 0.00 50.00 0.0096 
chr22:30,032,831-30,535,980 q12.2 - q12.3 Loss 503149 62.5 0.00 62.50 0.0021 
chr22:30,535,980-30,623,768 q12.3 Loss 87788 50.0 0.00 50.00 0.0096 
chr22:30,623,768-30,623,867 q12.3 Loss 99 37.5 0.00 37.50 0.0364 
chr22:30,623,867-30,646,302 q12.3 Loss 22435 50.0 7.14 42.86 0.0393 
chr22:30,646,302-30,646,401 q12.3 Loss 99 37.5 0.00 37.50 0.0364 
chr22:30,646,401-40,803,595 q12.3 - q13.2 Loss 10157194 50.0 0.00 50.00 0.0096 
chr22:40,803,595-42,473,589 q13.2 Loss 1669994 50.0 7.14 42.86 0.0393 
chr22:42,473,589-44,175,906 q13.2 - q13.31 Loss 1702317 50.0 0.00 50.00 0.0096 
chr22:44,175,906-49,453,810 q13.31 - q13.33 Loss 5277904 62.5 0.00 62.50 0.0021 
chr3:14,886,339-44,567,516 p24.3 - p21.32 Gain 29681177 50.0 0.00 50.00 0.0096 
chr3:169,732,146-170,729,895 q26.2 Gain 997749 50.0 7.14 42.86 0.0393 
chr3:179,511,139-179,653,380 q26.32 Gain 142241 50.0 7.14 42.86 0.0393 
chr3:180,293,412-181,647,155 q26.32 - q26.33 Gain 1353743 50.0 7.14 42.86 0.0393 
chr3:186,817-958,261 p26.3 Gain 771444 50.0 0.00 50.00 0.0096 
chr3:190,563,330-199,160,165 q28 - q29 Gain 8596835 50.0 7.14 42.86 0.0393 
chr3:44,567,516-54,188,434 p21.32 - p21.1 Gain 9620918 37.5 0.00 37.50 0.0364 
chr3:54,188,434-74,391,234 p21.1 - p12.3 Gain 20202800 50.0 0.00 50.00 0.0096 
chr3:74,391,234-82,655,862 p12.3 - p12.2 Gain 8264628 62.5 0.00 62.50 0.0021 
chr3:82,655,862-82,799,401 p12.2 Gain 143539 50.0 0.00 50.00 0.0096 
chr3:82,799,401-87,044,540 p12.2 - p12.1 Gain 4245139 62.5 0.00 62.50 0.0021 
chr3:87,044,540-169,732,146 p12.1 - q26.2 Gain 82687606 50.0 0.00 50.00 0.0096 
chr3:958,261-14,886,339 p26.3 - p24.3 Gain 13928078 62.5 0.00 62.50 0.0021 
chr4:1,065,598-1,784,503 p16.3 Loss 718905 50.0 0.00 50.00 0.0096 
chr4:1,784,503-10,207,878 p16.3 - p16.1 Loss 8423375 50.0 7.14 42.86 0.0393 
chr4:10,207,878-11,429,778 p16.1 - p15.33 Loss 1221900 50.0 0.00 50.00 0.0096 
chr4:11,429,778-13,655,289 p15.33 Loss 2225511 37.5 0.00 37.50 0.0364 
chr4:113,578,539-182,025,739 q25 - q34.3 Loss 68447200 50.0 0.00 50.00 0.0096 
chr4:13,655,289-26,747,433 p15.33 - p15.2 Loss 13092144 50.0 0.00 50.00 0.0096 
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chr4:182,025,739-184,561,840 q34.3 - q35.1 Loss 2536101 37.5 0.00 37.50 0.0364 
chr4:184,561,840-191,020,215 q35.1 - q35.2 Loss 6458375 50.0 0.00 50.00 0.0096 
chr4:26,747,433-45,608,190 p15.2 - p12 Loss 18860757 62.5 0.00 62.50 0.0021 
chr4:45,608,190-47,677,803 p12 Loss 2069613 50.0 0.00 50.00 0.0096 
chr4:47,677,803-48,524,316 p12 Loss 846513 37.5 0.00 37.50 0.0364 
chr4:55,628-1,065,598 p16.3 Loss 1009970 62.5 0.00 62.50 0.0021 
chr4:80,547,099-113,578,539 q21.21 - q25 Loss 33031440 37.5 0.00 37.50 0.0364 
chr5:107,339,380-136,366,234 q21.3 - q31.2 Loss 29026854 50.0 0.00 50.00 0.0096 
chr5:12,216,435-12,262,939 p15.2 Gain 46504 50.0 7.14 42.86 0.0393 
chr5:12,262,939-13,218,128 p15.2 Gain 955189 62.5 7.14 55.36 0.0109 
chr5:13,218,128-16,546,966 p15.2 - p15.1 Gain 3328838 50.0 7.14 42.86 0.0393 
chr5:136,366,234-148,846,264 q31.2 - q33.1 Loss 12480030 50.0 7.14 42.86 0.0393 
chr5:16,546,966-22,468,834 p15.1 - p14.3 Gain 5921868 62.5 7.14 55.36 0.0109 
chr5:2,570,762-7,530,112 p15.33 - p15.31 Gain 4959350 62.5 0.00 62.50 0.0021 
chr5:22,468,834-25,187,412 p14.3 - p14.1 Gain 2718578 75.0 7.14 67.86 0.0023 
chr5:25,187,412-26,353,486 p14.1 Gain 1166074 75.0 0.00 75.00 0.0004 
chr5:26,353,486-26,539,834 p14.1 Gain 186348 62.5 0.00 62.50 0.0021 
chr5:26,539,834-35,388,213 p14.1 - p13.2 Gain 8848379 75.0 0.00 75.00 0.0004 
chr5:35,388,213-49,907,782 p13.2 - q11.1 Gain 14519569 62.5 0.00 62.50 0.0021 
chr5:50,093,906-50,168,170 q11.1 Loss 74264 50.0 0.00 50.00 0.0096 
chr5:50,168,170-51,232,444 q11.1 - q11.2 Loss 1064274 62.5 0.00 62.50 0.0021 
chr5:51,232,444-65,239,073 q11.2 - q12.3 Loss 14006629 75.0 0.00 75.00 0.0004 
chr5:65,239,073-65,352,862 q12.3 Loss 113789 75.0 7.14 67.86 0.0023 
chr5:65,352,862-66,695,993 q12.3 - q13.1 Loss 1343131 62.5 7.14 55.36 0.0109 
chr5:66,695,993-75,600,638 q13.1 - q13.3 Loss 8904645 62.5 0.00 62.50 0.0021 
chr5:7,530,112-12,216,435 p15.31 - p15.2 Gain 4686323 62.5 7.14 55.36 0.0109 
chr5:75,600,638-79,219,538 q13.3 - q14.1 Loss 3618900 50.0 0.00 50.00 0.0096 
chr5:79,219,538-79,936,331 q14.1 Loss 716793 62.5 0.00 62.50 0.0021 
chr5:79,936,331-97,113,079 q14.1 - q15 Loss 17176748 50.0 0.00 50.00 0.0096 
chr5:97,113,079-99,111,442 q15 - q21.1 Loss 1998363 50.0 7.14 42.86 0.0393 
chr6:146,266,178-162,794,027 q24.3 - q26 Loss 16527849 37.5 0.00 37.50 0.0364 
chr6:163,005,402-165,244,688 q26 - q27 Loss 2239286 37.5 0.00 37.50 0.0364 
chr6:6,382,300-7,427,280 p25.1 - p24.3 Gain 1044980 50.0 7.14 42.86 0.0393 
chr7:100,038,722-158,625,992 q22.1 - q36.3 Gain 58587270 75.0 14.29 60.71 0.0083 
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chr7:12,919,070-13,079,613 p21.3 Gain 160543 37.5 0.00 37.50 0.0364 
chr7:13,079,613-15,056,488 p21.3 - p21.2 Gain 1976875 50.0 0.00 50.00 0.0096 
chr7:15,056,488-21,588,275 p21.2 - p15.3 Gain 6531787 62.5 0.00 62.50 0.0021 
chr7:188,219-12,919,070 p22.3 - p21.3 Gain 12730851 50.0 0.00 50.00 0.0096 
chr7:21,588,275-26,749,335 p15.3 - p15.2 Gain 5161060 50.0 0.00 50.00 0.0096 
chr7:26,749,335-29,450,068 p15.2 - p15.1 Gain 2700733 62.5 0.00 62.50 0.0021 
chr7:29,450,068-32,275,005 p15.1 - p14.3 Gain 2824937 50.0 0.00 50.00 0.0096 
chr7:32,275,005-45,048,865 p14.3 - p13 Gain 12773860 37.5 0.00 37.50 0.0364 
chr7:45,048,865-50,617,642 p13 - p12.2 Gain 5568777 50.0 0.00 50.00 0.0096 
chr7:50,617,642-63,102,874 p12.2 - q11.21 Gain 12485232 62.5 0.00 62.50 0.0021 
chr7:63,102,874-84,591,194 q11.21 - q21.11 Gain 21488320 75.0 0.00 75.00 0.0004 
chr7:84,591,194-97,101,588 q21.11 - q21.3 Gain 12510394 75.0 14.29 60.71 0.0083 
chr7:97,101,588-100,038,722 q21.3 - q22.1 Gain 2937134 75.0 0.00 75.00 0.0004 
chr9:11,341,967-20,172,465 p23 - p21.3 Loss 8830498 87.5 28.57 58.93 0.0237 
chr9:20,172,465-20,351,121 p21.3 Loss 178656 87.5 21.43 66.07 0.0062 
chr9:20,351,121-21,158,452 p21.3 Loss 807331 87.5 28.57 58.93 0.0237 
chr9:24,090,721-25,069,382 p21.3 Loss 978661 87.5 21.43 66.07 0.0062 
chr9:25,069,382-30,699,255 p21.3 - p21.1 Loss 5629873 87.5 28.57 58.93 0.0237 
 
 
1Physical position is according to hg19/NCBI build 37 
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Appendix 4.3: Regions showing significant differences in copy number 
loss (>75% difference) in multifocal tumours from cluster 1 (n=14) 
versus cluster 2 (n=8). 
 
 
1Physical position is according to hg18/NCBI build 37 
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Appendix 4.4: Regions showing significant differences in copy number 
gain (>70% difference) in multifocal tumours from cluster 1 (n=14) 
versus cluster 2 (n=8). 
 
 
1Physical position is according to hg18/NCBI build 37 
  
-222 - 
 
Appendix 4.5 
Phylogenetic tree showing the relationships between 3 tumours from 
patient 3 
 
 
 
 
 
Phylogenetic tree showing the relationships between 2 tumours from 
patient 7 
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Phylogenetic tree showing the relationships between 2 tumours from 
patient 10 
 
 
 
 
Phylogenetic tree showing the relationships between 2 tumours from 
patient 11 
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Phylogenetic tree showing the relationships between 4 tumours from 
patient 12 
 
Phylogenetic tree showing the relationships between 4 tumours from 
patient 14 
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Phylogenetic tree showing the relationships between 2 tumours from 
patient 15 
 
 
 
 
Phylogenetic tree showing the relationships between 3 tumours from 
patient 17 
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Phylogenetic tree showing the relationships between 4 tumours from 
patient 18 
 
 
Phylogenetic tree showing the relationships between 3 tumours from 
patient 20 
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Phylogenetic tree showing the relationships between 2 tumours from 
patient 21 
 
 
 
 
 
Phylogenetic tree showing the relationships between 2 tumours from 
patient 22 
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Appendix 5.1: Details of samples in the four main clusters obtained by 
hierarchical cluster analysis of copy number data from 22 patients with 
multifocal tumours and 74 solitary tumours excluding stage ≥ T2 
tumours. "
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9 T1 G3 Multifocal A WT WT WT 1 
17 Ta G2 Multifocal B Mutant Mutant WT 1 
239 Ta G1 Single A WT WT Mutant 1 
397 Ta G2 Single A Mutant Mutant Mutant 1 
406 Ta G2 Single B Mutant WT WT 1 
489 Ta G3 Single A WT Mutant WT 1 
494 Ta G2 Single A Mutant WT WT 1 
518 Ta G2 Single A Mutant Mutant WT 1 
536 Ta G2 Single A Mutant Mutant WT 1 
575 Ta G2 Single B Mutant Mutant WT 1 
578 Ta G2 Single B Mutant WT WT 1 
584 Ta G3 Single A Mutant WT WT 1 
672 Ta G2 Single A WT WT Mutant 1 
695 Ta G2 Single B WT WT WT 1 
811 Ta G2 Single A Mutant Mutant WT 1 
868 Ta G2 Single A Mutant WT WT 1 
894 Ta G1 Single A WT WT Mutant 1 
924 Ta G2 Single B WT WT Mutant 1 
933 Ta G2 Single B Mutant Mutant WT 1 
961 Ta G2 Single A Mutant WT WT 1 
983 T1 G2 Single B Mutant Mutant WT 1 
989 Ta G3 Single B WT WT WT 1 
1010 T1 G3 Single B WT WT Mutant 1 
1044 Ta G2 Single B WT WT WT 1 
1103 Ta G3 Single A WT Mutant WT 1 
1315 T1 G3 Single A Mutant Mutant WT 1 
2 Ta G2 Multifocal C Mutant WT WT 2 
4 Ta G3 Multifocal C Mutant Mutant WT 2 
8 Ta G2 Multifocal C Mutant Mutant WT 2 
11 T1 G3 Multifocal C WT WT WT 2 
15 Ta G2 Multifocal C Mutant Mutant WT 2 
21 Ta G2 Multifocal C Mutant WT WT 2 
94 T1 G3 Single C Mutant WT WT 2 
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140 T1 G3 Single C WT Mutant WT 2 
243 T1 G3 Single C WT WT WT 2 
418 T1 G3 Single B WT Mutant WT 2 
457 T1 G2 Single C Mutant Mutant WT 2 
461 T1 G3 Single B Mutant WT WT 2 
468 T1 G2 Single B WT WT WT 2 
540 Ta G2 Single C Mutant WT WT 2 
554 T1 G2 Single B Mutant WT WT 2 
572 T1 G3 Single C Mutant WT WT 2 
579 T1 G2 Single B Mutant Mutant WT 2 
675 Ta G2 Single B Mutant WT WT 2 
718 Ta G2 Single C Mutant WT WT 2 
736 Ta G3 Single B Mutant WT Mutant 2 
837 Ta G1 Single B Mutant WT WT 2 
860 Ta G2 Single B Mutant Mutant WT 2 
866 T1 G3 Single B Mutant WT WT 2 
934 Ta G2 Single B Mutant Mutant WT 2 
969 T1 G3 Single B Mutant WT WT 2 
979 T1 G3 Single C Mutant WT WT 2 
1006 Ta G2 Single B Mutant WT WT 2 
1046 Ta G2 Single C Mutant WT WT 2 
1079 Ta G3 Single C Mutant Mutant WT 2 
1082 Ta G3 Single C WT WT WT 2 
1094 T1 G3 Single C Mutant WT WT 2 
1118 T1 G3 Single C Mutant Mutant WT 2 
1161 T1 G3 Single C Mutant Mutant WT 2 
1210 T1 G3 Single C WT WT WT 2 
1230 T1 G3 Single C Mutant WT WT 2 
1342 T1 G2 Single C Mutant WT WT 2 
1 Ta G2 Multifocal B WT Mutant WT 3 
3 T1 G3 Multifocal C WT WT Mutant 3 
7 Ta G2 Multifocal C WT WT WT 3 
14 Ta G3 Multifocal D WT WT WT 3 
16 Ta G2 Multifocal C WT WT Mutant 3 
19 Ta G2 Multifocal C Mutant WT WT 3 
22 Ta G2 Multifocal C WT WT WT 3 
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358 Ta G2 Single C WT WT WT 3 
366 Ta G2 Single C WT WT WT 3 
385 T1 G2 Single B Mutant WT WT 3 
511 Ta G3 Single C Mutant WT WT 3 
519 T1 G3 Single D Mutant WT WT 3 
561 T1 G3 Single C WT Mutant Mutant 3 
589 T1 G3 Single C WT WT WT 3 
657 Ta G2 Single C WT Mutant WT 3 
734 Ta G3 Single D WT WT WT 3 
884 T1 G3 Single C WT WT WT 3 
1021 T1 G3 Single C WT Mutant WT 3 
1072 Ta G3 Single C WT WT WT 3 
1129 T1 G3 Single C WT WT Mutant 3 
1138 T1 G3 Single C WT WT WT 3 
1145 T1 G3 Single C WT WT WT 3 
1229 T1 G3 Single C Mutant WT WT 3 
1264 T1 G3 Single C WT WT WT 3 
5 Ta G2 Multifocal D Mutant WT WT 4 
6 T1 G3 Multifocal D WT WT WT 4 
10 Ta G3 Multifocal D WT WT WT 4 
12 T1 G3 Multifocal D WT WT WT 4 
13 T1 G3 Multifocal D WT WT WT 4 
18 T1 G3 Multifocal D WT WT WT 4 
20 T1 G3 Multifocal D WT WT WT 4 
411 T1 G3 Single D WT WT WT 4 
930 T1 G3 Single D WT WT WT 4 
1320 T1 G3 Single D WT WT WT 4 "
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Appendix 5.2: Regions showing significant copy number differences in stage Ta multifocal (n=14) versus solitary (n=38) 
tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:119,708,536-142,787,183 p12 - q21.1 Gain 23078647 35.71 0.00 35.71 0.001 
chr1:142,787,183-148,424,834 q21.1 - q21.2 Gain 5637651 35.71 2.63 33.08 0.004 
chr1:148,424,834-153,581,460 q21.2 - q22 Gain 5156626 28.57 2.63 25.94 0.015 
chr1:157,241,521-157,953,509 q23.1 - q23.2 Gain 711988 35.71 5.26 30.45 0.011 
chr1:157,953,509-158,150,295 q23.2 Gain 196786 35.71 2.63 33.08 0.004 
chr1:158,150,295-159,891,087 q23.2 - q23.3 Gain 1740792 35.71 5.26 30.45 0.011 
chr1:159,891,087-160,195,246 q23.3 Gain 304159 35.71 7.89 27.82 0.025 
chr1:160,195,246-160,195,822 q23.3 Gain 576 35.71 5.26 30.45 0.011 
chr1:160,195,822-161,212,962 q23.3 Gain 1017140 35.71 7.89 27.82 0.025 
chr1:161,212,962-167,621,290 q23.3 - q24.2 Gain 6408328 35.71 5.26 30.45 0.011 
chr10:103,282,021-104,340,398 q24.32 Loss 1058377 35.71 7.89 27.82 0.025 
chr10:104,342,397-104,652,460 q24.32 Loss 310063 35.71 7.89 27.82 0.025 
chr10:5,844,781-8,219,578 p15.1 - p14 Gain 2374797 28.57 2.63 25.94 0.015 
chr10:71,487,752-73,834,924 q22.1 Gain 2347172 28.57 2.63 25.94 0.015 
chr10:73,834,924-74,954,700 q22.1 - q22.2 Gain 1119776 35.71 2.63 33.08 0.004 
chr10:74,954,700-81,634,066 q22.2 - q22.3 Gain 6679366 28.57 2.63 25.94 0.015 
chr10:8,346,526-11,805,252 p14 Gain 3458726 28.57 2.63 25.94 0.015 
chr10:81,634,066-81,634,692 q22.3 Gain 626 28.57 0.00 28.57 0.004 
chr10:81,634,692-89,597,006 q22.3 - q23.2 Gain 7962314 28.57 2.63 25.94 0.015 
chr13:19,137,297-19,920,905 q12.11 Gain 783608 42.86 5.26 37.59 0.003 
chr13:19,920,905-20,982,693 q12.11 Gain 1061788 42.86 7.89 34.96 0.008 
chr13:20,982,693-22,108,664 q12.11 Gain 1125971 42.86 5.26 37.59 0.003 
chr13:22,108,664-27,824,701 q12.11 - q12.3 Gain 5716037 42.86 2.63 40.23 0.001 
chr13:27,824,701-31,703,968 q12.3 - q13.1 Gain 3879267 35.71 2.63 33.08 0.004 
chr13:31,703,968-44,121,309 q13.1 - q14.11 Gain 12417341 28.57 2.63 25.94 0.015 
chr13:44,301,217-50,471,832 q14.12 - q14.3 Gain 6170615 28.57 2.63 25.94 0.015 
chr13:50,471,832-55,372,320 q14.3 - q21.1 Gain 4900488 35.71 2.63 33.08 0.004 
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chr13:55,372,320-56,523,630 q21.1 Gain 1151310 28.57 2.63 25.94 0.015 
chr13:56,523,630-56,717,407 q21.1 Gain 193777 28.57 0.00 28.57 0.004 
chr13:56,717,407-66,421,707 q21.1 - q21.32 Gain 9704300 28.57 2.63 25.94 0.015 
chr13:66,421,707-67,895,141 q21.32 - q21.33 Gain 1473434 35.71 2.63 33.08 0.004 
chr13:67,895,141-71,256,801 q21.33 Gain 3361660 28.57 2.63 25.94 0.015 
chr13:71,256,801-113,927,980 q21.33 - q34 Gain 42671179 35.71 2.63 33.08 0.004 
chr16:88,552,007-88,552,722 q24.3 Loss 715 28.57 2.63 25.94 0.015 
chr17:30,523,581-33,099,942 q12 Gain 2576361 28.57 2.63 25.94 0.015 
chr17:37,370,848-38,137,289 q21.2 - q21.31 Loss 766441 28.57 2.63 25.94 0.015 
chr17:5,098,018-5,293,177 p13.2 Loss 195159 28.57 0.00 28.57 0.004 
chr17:62,246,742-66,194,639 q24.2 - q24.3 Gain 3947897 28.57 2.63 25.94 0.015 
chr17:67,327,134-68,199,396 q24.3 Gain 872262 28.57 2.63 25.94 0.015 
chr19:33,399,234-36,171,164 q12 Gain 2771930 28.57 0.00 28.57 0.004 
chr19:36,322,238-37,664,852 q12 - q13.11 Gain 1342614 28.57 0.00 28.57 0.004 
chr19:37,664,852-38,091,356 q13.11 Gain 426504 28.57 2.63 25.94 0.015 
chr19:38,091,356-38,091,878 q13.11 Gain 522 28.57 0.00 28.57 0.004 
chr19:38,091,878-40,876,527 q13.11 - q13.12 Gain 2784649 28.57 2.63 25.94 0.015 
chr19:41,059,171-51,988,000 q13.12 - q13.32 Gain 10928829 28.57 2.63 25.94 0.015 
chr19:52,342,137-63,602,791 q13.32 - q13.43 Gain 11260654 28.57 0.00 28.57 0.004 
chr2:127,253,875-136,875,479 q14.3 - q22.1 Loss 9621604 28.57 0.00 28.57 0.004 
chr2:142,876,374-152,428,325 q22.2 - q23.3 Loss 9551951 28.57 0.00 28.57 0.004 
chr20:26,220,344-28,267,569 p11.1 - q11.1 Gain 2047225 35.71 10.53 25.19 0.048 
chr20:30,102,016-34,346,661 q11.21 - q11.23 Gain 4244645 42.86 13.16 29.70 0.050 
chr20:34,346,661-35,931,146 q11.23 Gain 1584485 50.00 13.16 36.84 0.010 
chr20:35,931,146-36,843,266 q11.23 Gain 912120 57.14 13.16 43.98 0.003 
chr20:36,843,266-37,522,311 q11.23 - q12 Gain 679045 57.14 15.79 41.35 0.005 
chr20:37,522,311-39,296,098 q12 Gain 1773787 50.00 15.79 34.21 0.026 
chr20:39,296,098-44,398,282 q12 - q13.12 Gain 5102184 50.00 13.16 36.84 0.010 
chr20:44,398,282-45,646,214 q13.12 Gain 1247932 50.00 15.79 34.21 0.026 
chr20:47,243,628-47,383,084 q13.13 Gain 139456 50.00 15.79 34.21 0.026 
chr20:47,538,301-51,561,551 q13.13 - q13.2 Gain 4023250 50.00 15.79 34.21 0.026 
chr20:51,561,551-59,894,661 q13.2 - q13.33 Gain 8333110 50.00 13.16 36.84 0.010 
chr20:59,894,661-62,392,510 q13.33 Gain 2497849 42.86 13.16 29.70 0.050 
chr3:170,729,895-179,511,139 q26.2 - q26.32 Gain 8781244 28.57 2.63 25.94 0.015 
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chr3:179,653,380-180,293,412 q26.32 Gain 640032 28.57 2.63 25.94 0.015 
chr3:181,647,155-187,914,171 q26.33 - q27.3 Gain 6267016 28.57 2.63 25.94 0.015 
chr3:187,914,171-187,914,682 q27.3 Gain 511 28.57 0.00 28.57 0.004 
chr3:187,914,682-190,563,330 q27.3 - q28 Gain 2648648 28.57 2.63 25.94 0.015 
chr4:2,656,057-2,718,557 p16.3 Gain 62500 28.57 0.00 28.57 0.004 
chr4:207,197-2,656,057 p16.3 Gain 2448860 28.57 2.63 25.94 0.015 
chr6:162,865,542-162,954,569 q26 Gain 89027 28.57 0.00 28.57 0.004 
chr8:120,863,829-124,550,528 q24.12 - q24.13 Gain 3686699 42.86 7.89 34.96 0.008 
chr8:124,550,528-124,718,428 q24.13 Gain 167900 42.86 2.63 40.23 0.001 
chr8:124,718,428-133,156,783 q24.13 - q24.22 Gain 8438355 42.86 7.89 34.96 0.008 
chr8:133,156,783-134,255,043 q24.22 Gain 1098260 35.71 7.89 27.82 0.025 
chr8:134,255,043-146,003,740 q24.22 - q24.3 Gain 11748697 42.86 7.89 34.96 0.008 
chr8:146,003,740-146,133,884 q24.3 Gain 130144 35.71 7.89 27.82 0.025 
chr8:27,277,284-32,530,048 p21.2 - p12 Loss 5252764 42.86 2.63 40.23 0.001 
chr8:32,530,048-32,715,279 p12 Loss 185231 28.57 2.63 25.94 0.015 
chr8:32,715,279-37,204,481 p12 Loss 4489202 35.71 2.63 33.08 0.004 
chr8:37,204,481-38,289,058 p12 Loss 1084577 35.71 0.00 35.71 0.001 
chr8:38,289,058-42,487,636 p12 - p11.21 Loss 4198578 28.57 0.00 28.57 0.004 
chr8:477,653-658,324 p23.3 Loss 180671 35.71 5.26 30.45 0.011 
chr8:658,324-27,277,284 p23.3 - p21.2 Loss 26618960 42.86 5.26 37.59 0.003 
chr8:70,378,901-72,600,219 q13.2 - q13.3 Gain 2221318 35.71 7.89 27.82 0.025 
chr8:96,177,980-120,863,829 q22.1 - q24.12 Gain 24685849 35.71 7.89 27.82 0.025 
chr9:1,101,150-1,340,595 p24.3 Gain 239445 28.57 0.00 28.57 0.004 
chr9:132,631,265-139,523,184 q34.12 - q34.3 Loss 6891919 78.57 36.84 41.73 0.012 
chr9:139,523,184-140,012,327 q34.3 Loss 489143 71.43 36.84 34.59 0.033 
chr9:140,012,327-140,118,015 q34.3 Loss 105688 71.43 31.58 39.85 0.013 
chr9:140,118,015-140,273,252 q34.3 Loss 155237 0.00 31.58 -31.58 0.023 
chr9:21,734,602-21,851,433 p21.3 Loss 116831 71.43 28.95 42.48 0.010 
chr9:21,851,433-21,998,414 p21.3 Loss 146981 64.29 26.32 37.97 0.021 
chr9:21,998,414-22,046,818 p21.3 Loss 48404 57.14 23.68 33.46 0.043 
chr9:22,046,818-22,155,847 p21.3 Loss 109029 71.43 23.68 47.74 0.003 
chr9:22,155,847-22,155,946 p21.3 Loss 99 64.29 23.68 40.60 0.010 
chr9:22,155,946-22,309,530 p21.3 Loss 153584 64.29 26.32 37.97 0.021 
chr9:22,309,530-22,479,595 p21.3 Loss 170065 64.29 23.68 40.60 0.010 
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chr9:22,479,595-23,376,562 p21.3 Loss 896967 64.29 26.32 37.97 0.021 
chr9:23,376,562-24,090,721 p21.3 Loss 714159 57.14 23.68 33.46 0.043 
chr9:68,858,635-70,488,655 q12 - q13 Loss 1630020 78.57 31.58 46.99 0.004 
chr9:70,488,655-82,003,000 q13 - q21.31 Loss 11514345 85.71 31.58 54.14 0.001 
chr9:82,003,000-82,148,095 q21.31 Loss 145095 85.71 13.16 72.56 0.000 
chr9:82,148,095-85,485,840 q21.31 - q21.32 Loss 3337745 85.71 31.58 54.14 0.001 
chr9:85,485,840-87,920,679 q21.32 - q21.33 Loss 2434839 85.71 34.21 51.50 0.001 
chr9:87,920,679-88,054,773 q21.33 Loss 134094 85.71 31.58 54.14 0.001 
chr9:88,054,773-88,787,420 q21.33 Loss 732647 85.71 34.21 51.50 0.001 
chr9:88,787,420-88,883,454 q21.33 Loss 96034 71.43 34.21 37.22 0.027 
chr9:88,883,454-88,940,656 q21.33 Loss 57202 71.43 28.95 42.48 0.010 
chr9:88,940,656-89,058,511 q21.33 Loss 117855 85.71 34.21 51.50 0.001 
chr9:89,058,511-132,631,265 q21.33 - q34.12 Loss 43572754 85.71 36.84 48.87 0.004 !
 
1Physical position is according to hg18/NCBI build 36!!
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Appendix 5.3: Regions showing significant copy number differences in stage T1 multifocal (n=8) versus solitary (n=36) 
tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:113,473,675-117,407,078 p13.2 - p13.1 Gain 3933403 37.5 2.78 34.72 0.0154 
chr1:117,407,078-119,480,610 p13.1 - p12 Gain 2073532 37.5 5.56 31.94 0.0349 
chr1:119,480,610-141,672,545 p12 - q12 Gain 22191935 62.5 5.56 56.94 0.0009 
chr1:141,672,545-142,787,183 q12 - q21.1 Gain 1114638 62.5 8.33 54.17 0.0024 
chr1:142,787,183-143,613,581 q21.1 Gain 826398 62.5 13.89 48.61 0.0092 
chr1:143,613,581-143,614,341 q21.1 Gain 760 62.5 11.11 51.39 0.0049 
chr1:143,614,341-146,342,686 q21.1 Gain 2728345 62.5 13.89 48.61 0.0092 
chr1:146,342,686-154,399,117 q21.1 - q22 Gain 8056431 62.5 16.67 45.83 0.0157 
chr1:154,399,117-156,056,126 q22 - q23.1 Gain 1657009 62.5 22.22 40.28 0.0375 
chr1:156,056,126-160,195,246 q23.1 - q23.3 Gain 4139120 62.5 19.44 43.06 0.0249 
chr1:160,195,246-160,195,822 q23.3 Gain 576 62.5 16.67 45.83 0.0157 
chr1:160,195,822-162,629,394 q23.3 Gain 2433572 62.5 19.44 43.06 0.0249 
chr1:162,629,394-165,523,632 q23.3 - q24.2 Gain 2894238 62.5 22.22 40.28 0.0375 
chr1:166,251,815-169,324,707 q24.2 - q24.3 Gain 3072892 62.5 22.22 40.28 0.0375 
chr1:185,614,023-191,477,703 q31.1 - q31.2 Loss 5863680 25 0.00 25.00 0.0296 
chr1:192,424,789-237,780,877 q31.3 - q43 Loss 45356088 25 0.00 25.00 0.0296 
chr1:241,339,986-247,164,041 q43 - q44 Loss 5824055 25 0.00 25.00 0.0296 
chr1:29,481,197-33,046,828 p35.3 - p35.1 Gain 3565631 37.5 5.56 31.94 0.0349 
chr1:38,051,746-39,307,926 p34.3 Gain 1256180 50 8.33 41.67 0.0140 
chr1:39,307,926-44,062,032 p34.3 - p34.1 Gain 4754106 50 5.56 44.44 0.0065 
chr1:44,062,032-45,524,938 p34.1 Gain 1462906 50 2.78 47.22 0.0024 
chr1:45,524,938-53,077,428 p34.1 - p32.3 Gain 7552490 50 5.56 44.44 0.0065 
chr1:53,077,428-73,625,895 p32.3 - p31.1 Gain 20548467 50 2.78 47.22 0.0024 
chr1:73,625,895-83,494,525 p31.1 Gain 9868630 37.5 2.78 34.72 0.0154 
chr1:918,164-25,159,219 p36.33 - p36.11 Gain 24241055 37.5 5.56 31.94 0.0349 
chr10:104,813,472-108,400,155 q24.32 - q25.1 Loss 3586683 75 11.11 63.89 0.0007 
chr10:108,400,155-114,874,404 q25.1 - q25.2 Loss 6474249 75 8.33 66.67 0.0003 
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chr10:114,874,404-116,774,295 q25.2 - q25.3 Loss 1899891 75 5.56 69.44 0.0001 
chr10:116,774,295-119,495,422 q25.3 - q26.11 Loss 2721127 62.5 5.56 56.94 0.0009 
chr10:119,495,422-120,558,865 q26.11 Loss 1063443 62.5 2.78 59.72 0.0003 
chr10:120,558,865-123,214,100 q26.11 - q26.13 Loss 2655235 62.5 5.56 56.94 0.0009 
chr10:123,214,100-125,057,698 q26.13 Loss 1843598 62.5 2.78 59.72 0.0003 
chr10:125,057,698-126,007,431 q26.13 Loss 949733 50 2.78 47.22 0.0024 
chr10:126,007,431-131,816,154 q26.13 - q26.3 Loss 5808723 50 0.00 50.00 0.0005 
chr10:131,816,154-131,982,049 q26.3 Loss 165895 37.5 0.00 37.50 0.0042 
chr10:131,982,049-135,247,831 q26.3 Loss 3265782 50 0.00 50.00 0.0005 
chr10:34,638,996-38,812,575 p11.21 - p11.1 Loss 4173579 25 0.00 25.00 0.0296 
chr10:72,803,738-79,687,959 q22.1 - q22.3 Gain 6884221 25 0.00 25.00 0.0296 
chr10:76,882,526-78,996,385 q22.2 - q22.3 Loss 2113859 37.5 5.56 31.94 0.0349 
chr10:78,996,385-80,472,830 q22.3 Loss 1476445 50 5.56 44.44 0.0065 
chr10:80,472,830-83,636,464 q22.3 - q23.1 Loss 3163634 37.5 5.56 31.94 0.0349 
chr10:83,636,464-83,637,155 q23.1 Loss 691 37.5 2.78 34.72 0.0154 
chr10:83,637,155-84,577,760 q23.1 Loss 940605 37.5 5.56 31.94 0.0349 
chr10:84,577,760-86,390,131 q23.1 Loss 1812371 50 5.56 44.44 0.0065 
chr10:86,390,131-87,373,214 q23.1 Loss 983083 62.5 5.56 56.94 0.0009 
chr10:87,373,214-88,222,653 q23.1 - q23.2 Loss 849439 62.5 8.33 54.17 0.0024 
chr10:88,222,653-89,694,469 q23.2 - q23.31 Loss 1471816 75 8.33 66.67 0.0003 
chr10:89,694,469-89,694,975 q23.31 Loss 506 62.5 8.33 54.17 0.0024 
chr10:89,694,975-90,596,444 q23.31 Loss 901469 75 8.33 66.67 0.0003 
chr10:90,596,444-95,924,122 q23.31 - q23.33 Loss 5327678 75 5.56 69.44 0.0001 
chr10:95,924,122-104,813,472 q23.33 - q24.32 Loss 8889350 75 8.33 66.67 0.0003 
chr11:50,013,045-54,839,338 p11.12 - q11 Loss 4826293 37.5 5.56 31.94 0.0349 
chr11:54,839,338-59,697,061 q11 - q12.1 Loss 4857723 37.5 0.00 37.50 0.0042 
chr11:59,697,061-60,851,894 q12.1 - q12.2 Loss 1154833 37.5 2.78 34.72 0.0154 
chr12:152,534-152,582 p13.33 Loss 48 37.5 2.78 34.72 0.0154 
chr12:152,582-153,169 p13.33 Loss 587 37.5 0.00 37.50 0.0042 
chr12:153,169-16,742,828 p13.33 - p12.3 Loss 16589659 37.5 2.78 34.72 0.0154 
chr12:16,742,828-25,552,960 p12.3 - p12.1 Loss 8810132 37.5 0.00 37.50 0.0042 
chr12:29,733,366-30,740,646 p11.22 - p11.21 Loss 1007280 25 0.00 25.00 0.0296 
chr12:30,939,600-33,333,489 p11.21 - p11.1 Loss 2393889 25 0.00 25.00 0.0296 
chr12:33,333,489-46,156,911 p11.1 - q13.11 Loss 12823422 37.5 0.00 37.50 0.0042 
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chr12:46,156,911-52,417,126 q13.11 - q13.13 Loss 6260215 25 0.00 25.00 0.0296 
chr12:68,627,676-71,742,532 q15 - q21.1 Loss 3114856 25 0.00 25.00 0.0296 
chr12:91,367,961-121,982,522 q22 - q24.31 Loss 30614561 25 0.00 25.00 0.0296 
chr13:47,794,572-47,964,053 q14.2 Loss 169481 37.5 5.56 31.94 0.0349 
chr13:47,964,053-51,243,111 q14.2 - q14.3 Loss 3279058 50 5.56 44.44 0.0065 
chr13:51,243,111-53,669,880 q14.3 - q21.1 Loss 2426769 37.5 5.56 31.94 0.0349 
chr13:78,112,209-107,482,925 q31.1 - q33.3 Gain 29370716 37.5 5.56 31.94 0.0349 
chr14:23,749,068-26,561,378 q12 Loss 2812310 37.5 2.78 34.72 0.0154 
chr14:26,744,993-33,897,190 q12 - q13.1 Loss 7152197 37.5 2.78 34.72 0.0154 
chr14:33,897,190-34,061,283 q13.1 Loss 164093 37.5 0.00 37.50 0.0042 
chr14:34,061,283-41,500,259 q13.1 - q21.2 Loss 7438976 37.5 2.78 34.72 0.0154 
chr14:41,500,259-57,420,120 q21.2 - q23.1 Loss 15919861 37.5 5.56 31.94 0.0349 
chr14:57,420,120-58,323,469 q23.1 Loss 903349 50 5.56 44.44 0.0065 
chr14:58,323,469-58,470,270 q23.1 Loss 146801 37.5 2.78 34.72 0.0154 
chr14:58,470,270-59,336,011 q23.1 Loss 865741 50 5.56 44.44 0.0065 
chr14:59,336,011-66,870,415 q23.1 - q23.3 Loss 7534404 37.5 5.56 31.94 0.0349 
chr14:73,931,005-74,588,657 q24.3 Loss 657652 37.5 5.56 31.94 0.0349 
chr14:75,833,225-77,328,585 q24.3 Gain 1495360 25 0.00 25.00 0.0296 
chr15:20,363,717-31,975,417 q11.2 - q14 Loss 11611700 25 0.00 25.00 0.0296 
chr15:62,510,397-63,070,265 q22.31 Loss 559868 37.5 2.78 34.72 0.0154 
chr15:63,070,265-82,907,017 q22.31 - q25.2 Loss 19836752 37.5 0.00 37.50 0.0042 
chr15:82,907,017-83,883,618 q25.2 - q25.3 Loss 976601 25 0.00 25.00 0.0296 
chr15:83,883,618-85,362,775 q25.3 Loss 1479157 37.5 0.00 37.50 0.0042 
chr15:85,362,775-87,338,954 q25.3 - q26.1 Loss 1976179 37.5 2.78 34.72 0.0154 
chr15:87,338,954-100,022,043 q26.1 - q26.3 Loss 12683089 37.5 0.00 37.50 0.0042 
chr16:2,267,343-7,019,846 p13.3 - p13.2 Gain 4752503 25 0.00 25.00 0.0296 
chr16:23,756,350-24,856,451 p12.1 Gain 1100101 50 0.00 50.00 0.0005 
chr16:24,856,451-29,550,785 p12.1 - p11.2 Gain 4694334 50 2.78 47.22 0.0024 
chr16:29,550,785-45,067,244 p11.2 - q11.2 Gain 15516459 50 0.00 50.00 0.0005 
chr16:3,918,289-4,131,849 p13.3 Loss 213560 25 0.00 25.00 0.0296 
chr16:33,715,230-45,231,075 p11.2 - q11.2 Loss 11515845 25 0.00 25.00 0.0296 
chr16:45,231,075-63,462,907 q11.2 - q21 Loss 18231832 37.5 0.00 37.50 0.0042 
chr16:63,462,907-88,552,722 q21 - q24.3 Loss 25089815 25 0.00 25.00 0.0296 
chr16:7,019,846-23,756,350 p13.2 - p12.1 Gain 16736504 37.5 0.00 37.50 0.0042 
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chr17:12,108,967-14,364,543 p12 Gain 2255576 25 0.00 25.00 0.0296 
chr19:183,116-211,322 p13.3 Loss 28206 25 0.00 25.00 0.0296 
chr19:21,345,165-22,729,077 p12 Gain 1383912 25 0.00 25.00 0.0296 
chr19:211,322-5,009,897 p13.3 Loss 4798575 37.5 0.00 37.50 0.0042 
chr19:23,732,302-32,891,236 p12 - q12 Gain 9158934 37.5 2.78 34.72 0.0154 
chr19:32,891,236-33,399,234 q12 Gain 507998 37.5 0.00 37.50 0.0042 
chr19:33,399,234-35,629,568 q12 Gain 2230334 37.5 5.56 31.94 0.0349 
chr19:35,629,568-36,171,164 q12 Gain 541596 37.5 2.78 34.72 0.0154 
chr19:36,322,238-36,979,850 q12 Gain 657612 37.5 2.78 34.72 0.0154 
chr19:36,979,850-37,664,852 q12 - q13.11 Gain 685002 37.5 5.56 31.94 0.0349 
chr19:37,664,852-38,091,322 q13.11 Gain 426470 50 5.56 44.44 0.0065 
chr19:38,091,322-38,282,890 q13.11 Gain 191568 50 2.78 47.22 0.0024 
chr19:38,282,890-39,226,664 q13.11 Gain 943774 50 5.56 44.44 0.0065 
chr19:39,226,664-45,806,715 q13.11 - q13.2 Gain 6580051 50 2.78 47.22 0.0024 
chr19:45,806,715-46,479,845 q13.2 Gain 673130 37.5 2.78 34.72 0.0154 
chr19:46,479,845-51,023,195 q13.2 - q13.32 Gain 4543350 37.5 0.00 37.50 0.0042 
chr19:5,009,897-5,549,421 p13.3 Loss 539524 37.5 2.78 34.72 0.0154 
chr19:5,549,421-6,523,485 p13.3 Loss 974064 37.5 0.00 37.50 0.0042 
chr19:51,023,195-58,336,597 q13.32 - q13.41 Gain 7313402 25 0.00 25.00 0.0296 
chr19:59,359,392-59,464,022 q13.42 Gain 104630 25 0.00 25.00 0.0296 
chr19:6,523,485-20,458,451 p13.3 - p12 Loss 13934966 25 0.00 25.00 0.0296 
chr19:63,602,791-63,771,717 q13.43 Gain 168926 25 0.00 25.00 0.0296 
chr2:1,785,220-11,122,011 p25.3 - p25.1 Gain 9336791 50 5.56 44.44 0.0065 
chr2:109,111,217-109,319,695 q13 Gain 208478 25 0.00 25.00 0.0296 
chr2:11,122,011-20,037,859 p25.1 - p24.1 Gain 8915848 50 2.78 47.22 0.0024 
chr2:111,491,810-141,564,023 q13 - q22.1 Gain 30072213 25 0.00 25.00 0.0296 
chr2:143,499,679-143,667,001 q22.2 Gain 167322 25 0.00 25.00 0.0296 
chr2:144,588,986-159,300,999 q22.2 - q24.1 Gain 14712013 25 0.00 25.00 0.0296 
chr2:148,009,604-151,825,968 q22.3 - q23.3 Loss 3816364 25 0.00 25.00 0.0296 
chr2:153,751,686-169,397,061 q23.3 - q24.3 Loss 15645375 25 0.00 25.00 0.0296 
chr2:167,445,852-169,206,769 q24.3 Gain 1760917 25 0.00 25.00 0.0296 
chr2:169,397,061-207,861,345 q24.3 - q33.3 Loss 38464284 37.5 0.00 37.50 0.0042 
chr2:20,037,859-20,215,537 p24.1 Gain 177678 37.5 2.78 34.72 0.0154 
chr2:20,215,537-21,280,646 p24.1 Gain 1065109 50 2.78 47.22 0.0024 
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chr2:207,861,345-208,876,525 q33.3 Loss 1015180 37.5 5.56 31.94 0.0349 
chr2:208,876,525-210,331,732 q33.3 - q34 Loss 1455207 62.5 5.56 56.94 0.0009 
chr2:21,280,646-25,870,821 p24.1 - p23.3 Gain 4590175 37.5 2.78 34.72 0.0154 
chr2:210,331,732-216,402,525 q34 - q35 Loss 6070793 62.5 8.33 54.17 0.0024 
chr2:216,402,525-224,018,802 q35 - q36.1 Loss 7616277 62.5 11.11 51.39 0.0049 
chr2:224,018,802-225,739,791 q36.1 - q36.2 Loss 1720989 62.5 13.89 48.61 0.0092 
chr2:224,263-1,785,220 p25.3 Gain 1560957 50 2.78 47.22 0.0024 
chr2:225,739,791-227,039,805 q36.2 - q36.3 Loss 1300014 62.5 16.67 45.83 0.0157 
chr2:227,039,805-228,542,036 q36.3 Loss 1502231 62.5 13.89 48.61 0.0092 
chr2:228,542,036-230,386,971 q36.3 Loss 1844935 75 13.89 61.11 0.0014 
chr2:230,386,971-230,387,771 q36.3 Loss 800 75 11.11 63.89 0.0007 
chr2:230,387,771-238,252,220 q36.3 - q37.3 Loss 7864449 75 13.89 61.11 0.0014 
chr2:238,252,220-239,091,229 q37.3 Loss 839009 75 16.67 58.33 0.0027 
chr2:239,091,229-241,620,162 q37.3 Loss 2528933 75 19.44 55.56 0.0048 
chr2:241,620,162-241,796,109 q37.3 Loss 175947 75 16.67 58.33 0.0027 
chr2:25,870,821-48,938,583 p23.3 - p16.3 Gain 23067762 50 2.78 47.22 0.0024 
chr2:48,938,583-52,373,212 p16.3 Gain 3434629 50 0.00 50.00 0.0005 
chr2:52,373,212-64,478,283 p16.3 - p14 Gain 12105071 62.5 0.00 62.50 0.0001 
chr2:64,478,283-71,285,149 p14 - p13.3 Gain 6806866 50 0.00 50.00 0.0005 
chr2:71,285,149-74,335,462 p13.3 - p13.1 Gain 3050313 62.5 0.00 62.50 0.0001 
chr2:74,335,462-82,716,433 p13.1 - p12 Gain 8380971 50 0.00 50.00 0.0005 
chr2:82,716,433-83,447,850 p12 Gain 731417 50 2.78 47.22 0.0024 
chr2:83,447,850-88,214,979 p12 - p11.2 Gain 4767129 50 0.00 50.00 0.0005 
chr2:88,214,979-94,782,159 p11.2 - q11.1 Gain 6567180 62.5 0.00 62.50 0.0001 
chr2:94,782,159-95,675,764 q11.1 Gain 893605 50 0.00 50.00 0.0005 
chr2:94,983,765-100,292,273 q11.1 - q11.2 Loss 5308508 25 0.00 25.00 0.0296 
chr2:95,675,764-108,345,037 q11.1 - q12.3 Gain 12669273 25 0.00 25.00 0.0296 
chr20:26,006,126-26,220,344 p11.1 Gain 214218 75 5.56 69.44 0.0001 
chr20:26,220,344-28,267,569 p11.1 - q11.1 Gain 2047225 75 8.33 66.67 0.0003 
chr20:275,014-424,783 p13 Gain 149769 75 5.56 69.44 0.0001 
chr20:28,267,569-29,779,350 q11.1 - q11.21 Gain 1511781 75 19.44 55.56 0.0048 
chr20:29,779,350-30,526,698 q11.21 Gain 747348 75 22.22 52.78 0.0080 
chr20:30,526,698-37,666,045 q11.21 - q12 Gain 7139347 75 19.44 55.56 0.0048 
chr20:37,666,045-40,680,814 q12 Gain 3014769 87.5 19.44 68.06 0.0006 
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chr20:40,680,814-40,792,351 q12 Gain 111537 75 19.44 55.56 0.0048 
chr20:40,792,351-43,889,716 q12 - q13.12 Gain 3097365 75 25.00 50.00 0.0126 
chr20:424,783-26,006,126 p13 - p11.1 Gain 25581343 75 8.33 66.67 0.0003 
chr20:43,889,716-47,383,084 q13.12 - q13.13 Gain 3493368 75 19.44 55.56 0.0048 
chr20:47,383,084-47,538,301 q13.13 Gain 155217 62.5 19.44 43.06 0.0249 
chr20:47,538,301-62,393,015 q13.13 - q13.33 Gain 14854714 75 19.44 55.56 0.0048 
chr22:15,621,248-15,745,966 q11.1 Loss 124718 37.5 0.00 37.50 0.0042 
chr22:15,745,966-18,151,355 q11.1 - q11.21 Loss 2405389 50 0.00 50.00 0.0005 
chr22:18,151,355-18,151,891 q11.21 Loss 536 37.5 0.00 37.50 0.0042 
chr22:18,151,891-24,286,893 q11.21 - q11.23 Loss 6135002 50 2.78 47.22 0.0024 
chr22:24,286,893-28,379,404 q11.23 - q12.2 Loss 4092511 50 5.56 44.44 0.0065 
chr22:28,379,404-30,623,768 q12.2 - q12.3 Loss 2244364 50 2.78 47.22 0.0024 
chr22:30,623,768-30,623,867 q12.3 Loss 99 37.5 2.78 34.72 0.0154 
chr22:30,646,302-30,646,401 q12.3 Loss 99 37.5 2.78 34.72 0.0154 
chr22:30,646,401-40,803,595 q12.3 - q13.2 Loss 10157194 50 2.78 47.22 0.0024 
chr22:40,803,595-42,473,589 q13.2 Loss 1669994 62.5 5.56 56.94 0.0009 
chr22:42,473,589-45,618,622 q13.2 - q13.31 Loss 3145033 50 5.56 44.44 0.0065 
chr22:45,618,622-49,453,810 q13.31 - q13.33 Loss 3835188 50 8.33 41.67 0.0140 
chr3:122,541,183-125,236,945 q13.33 - q21.1 Loss 2695762 25 0.00 25.00 0.0296 
chr3:133,822,599-158,979,197 q22.1 - q25.32 Gain 25156598 25 0.00 25.00 0.0296 
chr3:140,451,428-140,626,759 q23 Loss 175331 25 0.00 25.00 0.0296 
chr3:140,627,376-184,141,428 q23 - q26.33 Loss 43514052 25 0.00 25.00 0.0296 
chr3:54,612,454-71,816,463 p14.3 - p13 Gain 17204009 25 0.00 25.00 0.0296 
chr3:6,636,703-10,788,431 p26.1 - p25.3 Gain 4151728 37.5 5.56 31.94 0.0349 
chr3:77,584,830-79,097,077 p12.3 Gain 1512247 25 0.00 25.00 0.0296 
chr3:82,799,401-83,768,022 p12.2 - p12.1 Gain 968621 37.5 2.78 34.72 0.0154 
chr3:83,768,022-87,044,540 p12.1 Gain 3276518 37.5 0.00 37.50 0.0042 
chr3:87,044,540-111,740,734 p12.1 - q13.13 Gain 24696194 25 0.00 25.00 0.0296 
chr3:958,261-6,636,703 p26.3 - p26.1 Gain 5678442 37.5 2.78 34.72 0.0154 
chr4:113,578,539-152,907,961 q25 - q31.3 Loss 39329422 37.5 0.00 37.50 0.0042 
chr4:152,907,961-179,587,711 q31.3 - q34.3 Loss 26679750 37.5 2.78 34.72 0.0154 
chr4:179,587,711-180,006,495 q34.3 Loss 418784 37.5 5.56 31.94 0.0349 
chr4:184,404,421-185,872,338 q35.1 Gain 1467917 25 0.00 25.00 0.0296 
chr4:185,872,338-190,151,886 q35.1 - q35.2 Loss 4279548 37.5 5.56 31.94 0.0349 
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chr4:2,865,088-11,429,778 p16.3 - p15.33 Loss 8564690 37.5 2.78 34.72 0.0154 
chr4:26,747,433-47,264,023 p15.2 - p12 Loss 20516590 37.5 2.78 34.72 0.0154 
chr4:47,264,023-47,677,803 p12 Loss 413780 37.5 0.00 37.50 0.0042 
chr4:47,677,803-48,524,316 p12 Loss 846513 25 0.00 25.00 0.0296 
chr4:55,628-2,865,088 p16.3 Loss 2809460 37.5 0.00 37.50 0.0042 
chr4:69,912,758-74,866,776 q13.2 - q13.3 Gain 4954018 25 0.00 25.00 0.0296 
chr4:74,866,776-78,196,278 q13.3 - q21.1 Gain 3329502 37.5 0.00 37.50 0.0042 
chr4:80,547,099-113,578,539 q21.21 - q25 Loss 33031440 25 0.00 25.00 0.0296 
chr5:136,366,234-180,626,608 q31.2 - q35.3 Loss 44260374 37.5 2.78 34.72 0.0154 
chr5:3,426,805-3,559,003 p15.33 Gain 132198 37.5 2.78 34.72 0.0154 
chr5:3,559,003-4,533,614 p15.33 - p15.32 Gain 974611 37.5 5.56 31.94 0.0349 
chr5:5,500,139-6,708,632 p15.32 - p15.31 Gain 1208493 37.5 5.56 31.94 0.0349 
chr5:50,168,170-51,232,444 q11.1 - q11.2 Loss 1064274 37.5 5.56 31.94 0.0349 
chr5:51,232,444-65,352,862 q11.2 - q12.3 Loss 14120418 50 5.56 44.44 0.0065 
chr5:65,352,862-75,600,638 q12.3 - q13.3 Loss 10247776 37.5 5.56 31.94 0.0349 
chr5:99,111,442-107,339,380 q21.1 - q21.3 Loss 8227938 37.5 2.78 34.72 0.0154 
chr6:165,244,688-169,488,215 q27 Loss 4243527 50 8.33 41.67 0.0140 
chr6:169,576,118-170,622,773 q27 Loss 1046655 50 8.33 41.67 0.0140 
chr6:170,622,773-170,728,000 q27 Loss 105227 50 5.56 44.44 0.0065 
chr6:19,131,847-20,272,069 p22.3 Gain 1140222 50 11.11 38.89 0.0256 
chr6:20,272,069-22,580,422 p22.3 Gain 2308353 62.5 11.11 51.39 0.0049 
chr6:22,580,422-23,499,391 p22.3 Gain 918969 62.5 5.56 56.94 0.0009 
chr6:23,499,391-27,152,460 p22.3 - p22.1 Gain 3653069 50 5.56 44.44 0.0065 
chr6:27,152,460-32,404,070 p22.1 - p21.32 Gain 5251610 37.5 5.56 31.94 0.0349 
chr6:6,382,300-7,427,280 p25.1 - p24.3 Gain 1044980 50 11.11 38.89 0.0256 
chr6:62,586,405-69,438,735 q11.1 - q12 Gain 6852330 25 0.00 25.00 0.0296 
chr7:142,857,956-144,143,399 q35 Gain 1285443 62.5 11.11 51.39 0.0049 
chr7:144,143,399-147,259,180 q35 Gain 3115781 62.5 8.33 54.17 0.0024 
chr7:147,259,180-148,089,302 q35 - q36.1 Gain 830122 62.5 11.11 51.39 0.0049 
chr7:148,089,302-151,558,264 q36.1 Gain 3468962 62.5 13.89 48.61 0.0092 
chr7:15,056,488-21,588,275 p21.2 - p15.3 Gain 6531787 50 13.89 36.11 0.0422 
chr7:151,558,264-153,901,560 q36.1 - q36.2 Gain 2343296 62.5 11.11 51.39 0.0049 
chr7:153,901,560-158,625,992 q36.2 - q36.3 Gain 4724432 62.5 13.89 48.61 0.0092 
chr7:26,749,335-29,450,068 p15.2 - p15.1 Gain 2700733 50 13.89 36.11 0.0422 
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chr7:50,617,642-52,867,234 p12.2 - p12.1 Gain 2249592 50 11.11 38.89 0.0256 
chr7:52,867,234-56,264,968 p12.1 - p11.2 Gain 3397734 50 13.89 36.11 0.0422 
chr7:56,264,968-63,102,874 p11.2 - q11.21 Gain 6837906 50 8.33 41.67 0.0140 
chr7:63,102,874-67,229,358 q11.21 - q11.22 Gain 4126484 62.5 8.33 54.17 0.0024 
chr7:67,229,358-71,274,704 q11.22 Gain 4045346 62.5 11.11 51.39 0.0049 
chr7:71,274,704-80,528,144 q11.22 - q21.11 Gain 9253440 62.5 13.89 48.61 0.0092 
chr7:80,528,144-81,356,796 q21.11 Gain 828652 62.5 16.67 45.83 0.0157 
chr7:81,356,796-142,857,956 q21.11 - q35 Gain 61501160 62.5 13.89 48.61 0.0092 
chr8:14,461,142-28,432,298 p22 - p21.1 Loss 13971156 62.5 22.22 40.28 0.0375 
chr8:28,432,298-30,816,370 p21.1 - p12 Loss 2384072 62.5 19.44 43.06 0.0249 
chr8:38,289,058-39,836,613 p12 - p11.22 Loss 1547555 37.5 5.56 31.94 0.0349 
chr8:39,836,613-43,315,811 p11.22 - p11.1 Loss 3479198 37.5 2.78 34.72 0.0154 
chr8:4,386,741-14,461,142 p23.2 - p22 Loss 10074401 62.5 19.44 43.06 0.0249 
chr9:124,954,691-140,118,015 q33.2 - q34.3 Gain 15163324 25 0.00 25.00 0.0296 
chr9:13,729,630-21,157,685 p23 - p21.3 Gain 7428055 25 0.00 25.00 0.0296 
chr9:140,118,015-140,273,252 q34.3 Loss 155237 0 41.67 -41.67 0.0368 
chr9:190-336,203 p24.3 Gain 336013 37.5 0.00 37.50 0.0042 
chr9:27,417,088-29,639,053 p21.2 - p21.1 Gain 2221965 25 0.00 25.00 0.0296 
chr9:336,203-991,152 p24.3 Gain 654949 37.5 2.78 34.72 0.0154 
chr9:38,427,196-84,783,002 p13.1 - q21.32 Gain 46355806 25 0.00 25.00 0.0296 
chr9:84,783,002-89,446,315 q21.32 - q21.33 Gain 4663313 37.5 0.00 37.50 0.0042 
chr9:89,446,315-123,651,685 q21.33 - q33.2 Gain 34205370 25 0.00 25.00 0.0296 !
 
1Physical position is according to hg18/NCBI build 36!!!
  
-243 - 
 
Appendix 5.4: Regions showing significant copy number differences in grade 1/2 multifocal (n=11) versus solitary (n=35) 
tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:119,708,536-153,581,460 p12 - q22 Gain 33872924 27.27 0.00 27.27 0.011 
chr1:157,241,521-157,953,509 q23.1 - q23.2 Gain 711988 36.36 2.86 33.51 0.009 
chr1:157,953,509-167,621,290 q23.2 - q24.2 Gain 9667781 36.36 0.00 36.36 0.002 
chr1:167,621,290-193,197,934 q24.2 - q31.3 Gain 25576644 27.27 0.00 27.27 0.011 
chr10:104,342,397-104,652,460 q24.32 Loss 310063 36.36 5.71 30.65 0.023 
chr10:5,844,781-8,219,578 p15.1 - p14 Gain 2374797 27.27 0.00 27.27 0.011 
chr10:71,487,752-73,834,924 q22.1 Gain 2347172 27.27 0.00 27.27 0.011 
chr10:73,834,924-74,954,700 q22.1 - q22.2 Gain 1119776 36.36 0.00 36.36 0.002 
chr10:74,954,700-89,597,006 q22.2 - q23.2 Gain 14642306 27.27 0.00 27.27 0.011 
chr10:8,346,526-11,805,252 p14 Gain 3458726 27.27 0.00 27.27 0.011 
chr13:107,482,925-110,508,381 q33.3 - q34 Gain 3025456 36.36 5.71 30.65 0.023 
chr13:110,508,381-113,927,980 q34 Gain 3419599 36.36 2.86 33.51 0.009 
chr13:19,137,297-19,920,905 q12.11 Gain 783608 45.45 5.71 39.74 0.005 
chr13:19,920,905-20,982,693 q12.11 Gain 1061788 45.45 8.57 36.88 0.013 
chr13:20,982,693-22,108,664 q12.11 Gain 1125971 45.45 5.71 39.74 0.005 
chr13:22,108,664-27,824,701 q12.11 - q12.3 Gain 5716037 45.45 2.86 42.60 0.002 
chr13:27,824,701-31,703,968 q12.3 - q13.1 Gain 3879267 36.36 2.86 33.51 0.009 
chr13:37,218,551-47,794,572 q13.3 - q14.2 Loss 10576021 27.27 0.00 27.27 0.011 
chr13:50,471,832-56,523,630 q14.3 - q21.1 Gain 6051798 36.36 2.86 33.51 0.009 
chr13:56,523,630-56,717,407 q21.1 Gain 193777 36.36 0.00 36.36 0.002 
chr13:56,717,407-66,421,707 q21.1 - q21.32 Gain 9704300 36.36 2.86 33.51 0.009 
chr13:66,421,707-67,895,141 q21.32 - q21.33 Gain 1473434 45.45 2.86 42.60 0.002 
chr13:67,895,141-107,482,925 q21.33 - q33.3 Gain 39587784 36.36 2.86 33.51 0.009 
chr16:193,278-6,165,969 p13.3 Loss 5972691 27.27 0.00 27.27 0.011 
chr16:82,569,517-84,922,020 q23.3 - q24.1 Loss 2352503 27.27 0.00 27.27 0.011 
chr16:87,260,485-88,421,159 q24.3 Loss 1160674 36.36 2.86 33.51 0.009 
chr16:88,552,007-88,552,722 q24.3 Loss 715 36.36 0.00 36.36 0.002 
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chr16:88,552,722-88,643,456 q24.3 Loss 90734 27.27 0.00 27.27 0.011 
chr17:35,227,093-35,920,940 q12 - q21.2 Loss 693847 27.27 0.00 27.27 0.011 
chr19:33,399,234-36,171,164 q12 Gain 2771930 27.27 0.00 27.27 0.011 
chr19:36,322,238-40,876,527 q12 - q13.12 Gain 4554289 27.27 0.00 27.27 0.011 
chr19:41,059,171-51,988,000 q13.12 - q13.32 Gain 10928829 27.27 0.00 27.27 0.011 
chr19:52,342,137-63,602,791 q13.32 - q13.43 Gain 11260654 27.27 0.00 27.27 0.011 
chr20:34,346,661-62,392,510 q11.23 - q13.33 Gain 28045849 45.45 11.43 34.03 0.025 
chr6:162,865,542-162,954,569 q26 Gain 89027 27.27 0.00 27.27 0.011 
chr8:124,550,528-124,718,428 q24.13 Gain 167900 45.45 0.00 45.45 0.000 
chr8:124,718,428-131,641,498 q24.13 - q24.22 Gain 6923070 45.45 5.71 39.74 0.005 
chr8:131,641,498-131,795,149 q24.22 Gain 153651 45.45 2.86 42.60 0.002 
chr8:131,795,149-146,003,740 q24.22 - q24.3 Gain 14208591 45.45 5.71 39.74 0.005 
chr8:146,003,740-146,133,884 q24.3 Gain 130144 36.36 5.71 30.65 0.023 
chr8:28,432,298-38,289,058 p21.1 - p12 Loss 9856760 36.36 0.00 36.36 0.002 
chr8:38,289,058-42,487,636 p12 - p11.21 Loss 4198578 27.27 0.00 27.27 0.011 
chr8:42,674,285-65,551,264 p11.21 - q12.3 Gain 22876979 27.27 0.00 27.27 0.011 
chr8:658,324-28,432,298 p23.3 - p21.1 Loss 27773974 36.36 2.86 33.51 0.009 
chr8:69,616,969-70,378,901 q13.2 Gain 761932 36.36 2.86 33.51 0.009 
chr8:70,378,901-72,600,219 q13.2 - q13.3 Gain 2221318 45.45 2.86 42.60 0.002 
chr8:72,600,219-75,850,345 q13.3 - q21.11 Gain 3250126 36.36 2.86 33.51 0.009 
chr8:96,177,980-124,550,528 q22.1 - q24.13 Gain 28372548 45.45 5.71 39.74 0.005 
chr9:108,208,167-132,631,265 q31.2 - q34.12 Loss 24423098 81.82 40.00 41.82 0.035 
chr9:190-1,340,595 p24.3 Gain 1340405 27.27 0.00 27.27 0.011 
chr9:21,734,602-21,851,433 p21.3 Loss 116831 72.73 28.57 44.16 0.014 
chr9:21,998,414-22,046,818 p21.3 Loss 48404 63.64 25.71 37.92 0.032 
chr9:22,046,818-22,155,847 p21.3 Loss 109029 72.73 25.71 47.01 0.010 
chr9:22,155,847-22,155,946 p21.3 Loss 99 63.64 25.71 37.92 0.032 
chr9:68,858,635-70,488,655 q12 - q13 Loss 1630020 72.73 34.29 38.44 0.038 
chr9:70,488,655-72,637,606 q13 - q21.11 Loss 2148951 81.82 34.29 47.53 0.013 
chr9:72,637,606-82,003,000 q21.11 - q21.31 Loss 9365394 81.82 37.14 44.68 0.015 
chr9:82,003,000-82,148,095 q21.31 Loss 145095 81.82 14.29 67.53 0.001 
chr9:82,148,095-85,485,840 q21.31 - q21.32 Loss 3337745 81.82 37.14 44.68 0.015 
chr9:85,485,840-87,920,679 q21.32 - q21.33 Loss 2434839 81.82 40.00 41.82 0.035 
chr9:87,920,679-88,054,773 q21.33 Loss 134094 81.82 34.29 47.53 0.013 
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chr9:88,054,773-88,787,420 q21.33 Loss 732647 81.82 40.00 41.82 0.035 
chr9:88,940,656-89,058,511 q21.33 Loss 117855 81.82 40.00 41.82 0.035 
chr9:89,058,511-108,208,167 q21.33 - q31.2 Loss 19149656 81.82 42.86 38.96 0.038 !
 
1Physical position is according to hg18/NCBI build 36!!!
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Appendix 5.5: Regions showing significant copy number differences in grade 3 multifocal (n=11) versus solitary (n=39) 
tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:113,473,675-117,407,078 p13.2 - p13.1 Gain 3933403 37.5 2.78 34.72 0.0154 
chr1:113,473,675-117,407,078 p13.2 - p13.1 Gain 3933403 36.36 2.56 33.80 0.00629 
chr1:117,407,078-119,480,610 p13.1 - p12 Gain 2073532 36.36 5.13 31.24 0.01655 
chr1:119,480,610-119,708,536 p12 Gain 227926 54.55 5.13 49.42 0.00066 
chr1:119,708,536-141,672,545 p12 - q12 Gain 21964009 63.64 5.13 58.51 0.00010 
chr1:141,672,545-142,787,183 q12 - q21.1 Gain 1114638 63.64 7.69 55.94 0.00031 
chr1:142,787,183-143,613,581 q21.1 Gain 826398 63.64 15.38 48.25 0.00331 
chr1:143,613,581-143,614,341 q21.1 Gain 760 63.64 12.82 50.82 0.00168 
chr1:143,614,341-146,342,686 q21.1 Gain 2728345 63.64 15.38 48.25 0.00331 
chr1:146,342,686-148,424,834 q21.1 - q21.2 Gain 2082148 63.64 17.95 45.69 0.00602 
chr1:148,424,834-154,399,117 q21.2 - q22 Gain 5974283 54.55 17.95 36.60 0.02334 
chr1:185,614,023-191,477,703 q31.1 - q31.2 Loss 5863680 27.27 0.00 27.27 0.00842 
chr1:192,424,789-197,774,987 q31.3 - q32.1 Loss 5350198 27.27 0.00 27.27 0.00842 
chr1:234,285,489-237,780,877 q42.3 - q43 Loss 3495388 27.27 0.00 27.27 0.00842 
chr1:241,339,986-247,164,041 q43 - q44 Loss 5824055 27.27 0.00 27.27 0.00842 
chr1:25,159,219-29,481,197 p36.11 - p35.3 Gain 4321978 36.36 7.69 28.67 0.03380 
chr1:29,481,197-33,046,828 p35.3 - p35.1 Gain 3565631 36.36 5.13 31.24 0.01655 
chr1:33,046,828-38,051,746 p35.1 - p34.3 Gain 5004918 36.36 7.69 28.67 0.03380 
chr1:38,051,746-39,307,926 p34.3 Gain 1256180 45.45 7.69 37.76 0.00853 
chr1:39,307,926-44,062,032 p34.3 - p34.1 Gain 4754106 45.45 5.13 40.33 0.00361 
chr1:44,062,032-45,524,938 p34.1 Gain 1462906 45.45 2.56 42.89 0.00116 
chr1:45,524,938-50,594,589 p34.1 - p33 Gain 5069651 45.45 5.13 40.33 0.00361 
chr1:50,594,589-50,823,305 p33 Gain 228716 36.36 5.13 31.24 0.01655 
chr1:50,823,305-53,077,428 p33 - p32.3 Gain 2254123 45.45 5.13 40.33 0.00361 
chr1:53,077,428-68,609,865 p32.3 - p31.3 Gain 15532437 45.45 2.56 42.89 0.00116 
chr1:68,609,865-73,625,895 p31.3 - p31.1 Gain 5016030 36.36 2.56 33.80 0.00629 
chr1:918,164-25,159,219 p36.33 - p36.11 Gain 24241055 36.36 5.13 31.24 0.01655 
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chr10:103,282,021-104,340,398 q24.32 Loss 1058377 72.73 10.26 62.47 0.00012 
chr10:104,340,398-104,813,472 q24.32 Loss 473074 63.64 10.26 53.38 0.00077 
chr10:104,813,472-108,400,155 q24.32 - q25.1 Loss 3586683 63.64 12.82 50.82 0.00168 
chr10:108,400,155-114,874,404 q25.1 - q25.2 Loss 6474249 63.64 10.26 53.38 0.00077 
chr10:114,874,404-116,774,295 q25.2 - q25.3 Loss 1899891 63.64 7.69 55.94 0.00031 
chr10:116,774,295-119,495,422 q25.3 - q26.11 Loss 2721127 54.55 7.69 46.85 0.00179 
chr10:119,495,422-120,558,865 q26.11 Loss 1063443 54.55 2.56 51.98 0.00018 
chr10:120,558,865-123,214,100 q26.11 - q26.13 Loss 2655235 54.55 5.13 49.42 0.00066 
chr10:123,214,100-125,057,698 q26.13 Loss 1843598 54.55 2.56 51.98 0.00018 
chr10:125,057,698-126,007,431 q26.13 Loss 949733 45.45 2.56 42.89 0.00116 
chr10:126,007,431-130,095,088 q26.13 - q26.2 Loss 4087657 45.45 0.00 45.45 0.00022 
chr10:130,095,088-131,816,154 q26.2 - q26.3 Loss 1721066 54.55 0.00 54.55 0.00003 
chr10:131,816,154-131,982,049 q26.3 Loss 165895 45.45 0.00 45.45 0.00022 
chr10:131,982,049-135,247,831 q26.3 Loss 3265782 54.55 0.00 54.55 0.00003 
chr10:76,882,526-78,996,385 q22.2 - q22.3 Loss 2113859 36.36 7.69 28.67 0.03380 
chr10:78,996,385-80,472,830 q22.3 Loss 1476445 45.45 7.69 37.76 0.00853 
chr10:80,472,830-83,636,464 q22.3 - q23.1 Loss 3163634 36.36 7.69 28.67 0.03380 
chr10:83,636,464-83,637,155 q23.1 Loss 691 36.36 5.13 31.24 0.01655 
chr10:83,637,155-84,577,760 q23.1 Loss 940605 36.36 7.69 28.67 0.03380 
chr10:84,577,760-86,390,131 q23.1 Loss 1812371 45.45 7.69 37.76 0.00853 
chr10:86,390,131-87,373,214 q23.1 Loss 983083 54.55 7.69 46.85 0.00179 
chr10:87,373,214-88,222,653 q23.1 - q23.2 Loss 849439 54.55 10.26 44.29 0.00400 
chr10:88,222,653-89,694,469 q23.2 - q23.31 Loss 1471816 63.64 10.26 53.38 0.00077 
chr10:89,694,469-89,694,975 q23.31 Loss 506 54.55 10.26 44.29 0.00400 
chr10:89,694,975-90,596,444 q23.31 Loss 901469 63.64 10.26 53.38 0.00077 
chr10:90,596,444-93,738,544 q23.31 - q23.32 Loss 3142100 63.64 7.69 55.94 0.00031 
chr10:93,738,544-94,907,303 q23.32 - q23.33 Loss 1168759 54.55 7.69 46.85 0.00179 
chr10:94,907,303-95,924,122 q23.33 Loss 1016819 63.64 7.69 55.94 0.00031 
chr10:95,924,122-103,282,021 q23.33 - q24.32 Loss 7357899 63.64 10.26 53.38 0.00077 
chr11:107,722,054-108,393,306 q22.3 Loss 671252 36.36 5.13 31.24 0.01655 
chr11:108,393,306-110,510,107 q22.3 - q23.1 Loss 2116801 36.36 7.69 28.67 0.03380 
chr11:123,449,312-124,487,806 q24.1 - q24.2 Loss 1038494 36.36 7.69 28.67 0.03380 
chr11:124,487,806-134,156,487 q24.2 - q25 Loss 9668681 36.36 5.13 31.24 0.01655 
chr11:43,020,941-44,879,168 p12 - p11.2 Loss 1858227 45.45 12.82 32.63 0.02990 
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chr11:44,879,168-46,216,229 p11.2 Loss 1337061 45.45 10.26 35.20 0.01695 
chr11:46,216,229-50,013,045 p11.2 - p11.12 Loss 3796816 45.45 7.69 37.76 0.00853 
chr11:50,013,045-50,013,069 p11.12 Loss 24 45.45 5.13 40.33 0.00361 
chr11:50,013,069-54,839,338 p11.12 - q11 Loss 4826269 36.36 5.13 31.24 0.01655 
chr11:54,839,338-59,697,061 q11 - q12.1 Loss 4857723 36.36 0.00 36.36 0.00143 
chr11:59,697,061-60,851,894 q12.1 - q12.2 Loss 1154833 36.36 2.56 33.80 0.00629 
chr11:68,701,448-69,297,663 q13.2 - q13.3 Gain 596215 45.45 12.82 32.63 0.02990 
chr11:69,297,663-69,323,924 q13.3 Gain 26261 45.45 7.69 37.76 0.00853 
chr11:69,323,924-69,494,896 q13.3 Gain 170972 45.45 10.26 35.20 0.01695 
chr11:69,494,896-70,236,623 q13.3 Gain 741727 45.45 12.82 32.63 0.02990 
chr11:79,636,827-81,301,979 q14.1 Gain 1665152 27.27 0.00 27.27 0.00842 
chr12:103,714,143-111,697,547 q23.3 - q24.13 Loss 7983404 27.27 0.00 27.27 0.00842 
chr12:152,582-153,169 p13.33 Loss 587 27.27 0.00 27.27 0.00842 
chr12:16,742,828-25,552,960 p12.3 - p12.1 Loss 8810132 27.27 0.00 27.27 0.00842 
chr12:33,333,489-40,716,974 p11.1 - q12 Loss 7383485 27.27 0.00 27.27 0.00842 
chr12:40,716,974-42,413,160 q12 Loss 1696186 36.36 0.00 36.36 0.00143 
chr12:42,413,160-46,156,911 q12 - q13.11 Loss 3743751 27.27 0.00 27.27 0.00842 
chr12:46,299,979-46,573,750 q13.11 Loss 273771 36.36 0.00 36.36 0.00143 
chr12:46,573,750-52,417,126 q13.11 - q13.13 Loss 5843376 27.27 0.00 27.27 0.00842 
chr13:108,341,331-113,927,980 q33.3 - q34 Gain 5586649 36.36 7.69 28.67 0.03380 
chr13:47,964,053-51,243,111 q14.2 - q14.3 Loss 3279058 36.36 5.13 31.24 0.01655 
chr13:78,112,209-108,341,331 q31.1 - q33.3 Gain 30229122 36.36 5.13 31.24 0.01655 
chr14:25,757,198-26,561,378 q12 Loss 804180 36.36 5.13 31.24 0.01655 
chr14:26,744,993-32,835,734 q12 - q13.1 Loss 6090741 36.36 5.13 31.24 0.01655 
chr14:32,835,734-33,897,190 q13.1 Loss 1061456 36.36 2.56 33.80 0.00629 
chr14:33,897,190-34,061,283 q13.1 Loss 164093 36.36 0.00 36.36 0.00143 
chr14:34,061,283-44,957,642 q13.1 - q21.3 Loss 10896359 36.36 2.56 33.80 0.00629 
chr14:44,957,642-57,420,120 q21.3 - q23.1 Loss 12462478 36.36 5.13 31.24 0.01655 
chr14:57,420,120-58,323,469 q23.1 Loss 903349 45.45 5.13 40.33 0.00361 
chr14:58,323,469-58,470,270 q23.1 Loss 146801 36.36 2.56 33.80 0.00629 
chr14:58,470,270-59,336,011 q23.1 Loss 865741 45.45 5.13 40.33 0.00361 
chr14:59,336,011-65,655,482 q23.1 - q23.3 Loss 6319471 36.36 5.13 31.24 0.01655 
chr14:66,870,415-71,308,003 q23.3 - q24.2 Loss 4437588 36.36 7.69 28.67 0.03380 
chr14:71,308,003-73,931,005 q24.2 - q24.3 Loss 2623002 45.45 7.69 37.76 0.00853 
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chr14:73,931,005-74,588,657 q24.3 Loss 657652 45.45 5.13 40.33 0.00361 
chr14:74,588,657-81,191,238 q24.3 - q31.1 Loss 6602581 36.36 5.13 31.24 0.01655 
chr15:22,736,020-22,894,833 q11.2 Gain 158813 36.36 5.13 31.24 0.01655 
chr15:22,894,833-42,756,125 q11.2 - q21.1 Gain 19861292 36.36 7.69 28.67 0.03380 
chr15:42,756,125-56,535,071 q21.1 - q22.1 Gain 13778946 45.45 7.69 37.76 0.00853 
chr15:56,535,071-63,070,265 q22.1 - q22.31 Gain 6535194 36.36 7.69 28.67 0.03380 
chr15:63,070,265-82,907,017 q22.31 - q25.2 Loss 19836752 27.27 0.00 27.27 0.00842 
chr15:72,953,319-99,915,007 q24.1 - q26.3 Gain 26961688 36.36 7.69 28.67 0.03380 
chr15:83,883,618-85,362,775 q25.3 Loss 1479157 27.27 0.00 27.27 0.00842 
chr15:87,338,954-100,022,043 q26.1 - q26.3 Loss 12683089 27.27 0.00 27.27 0.00842 
chr16:12,336,699-23,756,350 p13.13 - p12.1 Gain 11419651 27.27 0.00 27.27 0.00842 
chr16:23,756,350-24,856,451 p12.1 Gain 1100101 36.36 0.00 36.36 0.00143 
chr16:24,856,451-29,550,785 p12.1 - p11.2 Gain 4694334 36.36 2.56 33.80 0.00629 
chr16:29,550,785-31,190,651 p11.2 Gain 1639866 36.36 0.00 36.36 0.00143 
chr16:31,190,651-45,067,244 p11.2 - q11.2 Gain 13876593 45.45 0.00 45.45 0.00022 
chr16:7,019,846-12,014,145 p13.2 - p13.13 Gain 4994299 27.27 0.00 27.27 0.00842 
chr19:183,116-211,322 p13.3 Loss 28206 36.36 0.00 36.36 0.00143 
chr19:20,458,451-43,004,473 p12 - q13.13 Loss 22546022 27.27 0.00 27.27 0.00842 
chr19:21,345,165-22,729,077 p12 Gain 1383912 27.27 0.00 27.27 0.00842 
chr19:211,322-5,009,897 p13.3 Loss 4798575 45.45 0.00 45.45 0.00022 
chr19:23,732,302-32,891,236 p12 - q12 Gain 9158934 36.36 2.56 33.80 0.00629 
chr19:32,891,236-33,399,234 q12 Gain 507998 36.36 0.00 36.36 0.00143 
chr19:33,399,234-35,629,568 q12 Gain 2230334 36.36 5.13 31.24 0.01655 
chr19:35,629,568-36,171,164 q12 Gain 541596 36.36 2.56 33.80 0.00629 
chr19:36,322,238-36,979,850 q12 Gain 657612 36.36 2.56 33.80 0.00629 
chr19:36,979,850-37,664,852 q12 - q13.11 Gain 685002 36.36 5.13 31.24 0.01655 
chr19:37,664,852-38,091,322 q13.11 Gain 426470 45.45 7.69 37.76 0.00853 
chr19:38,091,322-38,091,356 q13.11 Gain 34 45.45 5.13 40.33 0.00361 
chr19:38,091,356-38,091,878 q13.11 Gain 522 45.45 2.56 42.89 0.00116 
chr19:38,091,878-38,282,890 q13.11 Gain 191012 45.45 5.13 40.33 0.00361 
chr19:38,282,890-39,226,664 q13.11 Gain 943774 45.45 7.69 37.76 0.00853 
chr19:39,226,664-45,806,715 q13.11 - q13.2 Gain 6580051 45.45 5.13 40.33 0.00361 
chr19:45,806,715-46,479,845 q13.2 Gain 673130 36.36 5.13 31.24 0.01655 
chr19:46,479,845-51,023,195 q13.2 - q13.32 Gain 4543350 36.36 2.56 33.80 0.00629 
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chr19:47,423,994-63,771,717 q13.2 - q13.43 Loss 16347723 27.27 0.00 27.27 0.00842 
chr19:5,009,897-5,549,421 p13.3 Loss 539524 45.45 2.56 42.89 0.00116 
chr19:5,549,421-6,523,485 p13.3 Loss 974064 45.45 0.00 45.45 0.00022 
chr19:51,988,000-58,336,597 q13.32 - q13.41 Gain 6348597 27.27 0.00 27.27 0.00842 
chr19:59,359,392-59,464,022 q13.42 Gain 104630 27.27 0.00 27.27 0.00842 
chr19:6,523,485-20,458,451 p13.3 - p12 Loss 13934966 36.36 0.00 36.36 0.00143 
chr19:63,602,791-63,771,717 q13.43 Gain 168926 27.27 0.00 27.27 0.00842 
chr2:1,785,220-11,122,011 p25.3 - p25.1 Gain 9336791 45.45 5.13 40.33 0.00361 
chr2:11,122,011-20,037,859 p25.1 - p24.1 Gain 8915848 45.45 2.56 42.89 0.00116 
chr2:127,253,875-148,009,604 q14.3 - q22.3 Loss 20755729 36.36 2.56 33.80 0.00629 
chr2:148,009,604-151,825,968 q22.3 - q23.3 Loss 3816364 36.36 0.00 36.36 0.00143 
chr2:151,825,968-153,751,686 q23.3 Loss 1925718 27.27 0.00 27.27 0.00842 
chr2:153,751,686-156,410,442 q23.3 - q24.1 Loss 2658756 36.36 0.00 36.36 0.00143 
chr2:156,410,442-169,397,061 q24.1 - q24.3 Loss 12986619 27.27 0.00 27.27 0.00842 
chr2:157,250,015-159,300,999 q24.1 Gain 2050984 27.27 0.00 27.27 0.00842 
chr2:169,397,061-175,231,393 q24.3 - q31.1 Loss 5834332 36.36 0.00 36.36 0.00143 
chr2:175,231,393-176,870,358 q31.1 Loss 1638965 45.45 0.00 45.45 0.00022 
chr2:176,870,358-183,311,858 q31.1 - q32.1 Loss 6441500 36.36 0.00 36.36 0.00143 
chr2:183,311,858-207,861,345 q32.1 - q33.3 Loss 24549487 45.45 0.00 45.45 0.00022 
chr2:20,037,859-20,215,537 p24.1 Gain 177678 36.36 2.56 33.80 0.00629 
chr2:20,215,537-21,280,646 p24.1 Gain 1065109 45.45 2.56 42.89 0.00116 
chr2:207,861,345-208,876,525 q33.3 Loss 1015180 45.45 2.56 42.89 0.00116 
chr2:208,876,525-210,331,732 q33.3 - q34 Loss 1455207 63.64 2.56 61.07 0.00002 
chr2:21,280,646-25,870,821 p24.1 - p23.3 Gain 4590175 36.36 2.56 33.80 0.00629 
chr2:210,331,732-213,347,177 q34 Loss 3015445 63.64 5.13 58.51 0.00010 
chr2:213,347,177-216,402,525 q34 - q35 Loss 3055348 63.64 7.69 55.94 0.00031 
chr2:216,402,525-225,739,791 q35 - q36.2 Loss 9337266 63.64 10.26 53.38 0.00077 
chr2:224,263-1,785,220 p25.3 Gain 1560957 45.45 2.56 42.89 0.00116 
chr2:225,739,791-228,542,036 q36.2 - q36.3 Loss 2802245 63.64 12.82 50.82 0.00168 
chr2:228,542,036-230,386,971 q36.3 Loss 1844935 72.73 12.82 59.91 0.00028 
chr2:230,386,971-230,387,771 q36.3 Loss 800 72.73 10.26 62.47 0.00012 
chr2:230,387,771-238,252,220 q36.3 - q37.3 Loss 7864449 72.73 12.82 59.91 0.00028 
chr2:238,252,220-239,091,229 q37.3 Loss 839009 72.73 15.38 57.34 0.00061 
chr2:239,091,229-241,620,162 q37.3 Loss 2528933 72.73 17.95 54.78 0.00121 
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chr2:241,620,162-241,796,109 q37.3 Loss 175947 72.73 15.38 57.34 0.00061 
chr2:25,870,821-48,938,583 p23.3 - p16.3 Gain 23067762 45.45 2.56 42.89 0.00116 
chr2:48,938,583-52,373,212 p16.3 Gain 3434629 45.45 0.00 45.45 0.00022 
chr2:52,373,212-64,478,283 p16.3 - p14 Gain 12105071 54.55 0.00 54.55 0.00003 
chr2:64,478,283-71,285,149 p14 - p13.3 Gain 6806866 45.45 0.00 45.45 0.00022 
chr2:71,285,149-74,335,462 p13.3 - p13.1 Gain 3050313 54.55 0.00 54.55 0.00003 
chr2:74,335,462-82,716,433 p13.1 - p12 Gain 8380971 45.45 0.00 45.45 0.00022 
chr2:82,716,433-83,447,850 p12 Gain 731417 45.45 2.56 42.89 0.00116 
chr2:83,447,850-88,214,979 p12 - p11.2 Gain 4767129 45.45 0.00 45.45 0.00022 
chr2:88,214,979-94,782,159 p11.2 - q11.1 Gain 6567180 54.55 0.00 54.55 0.00003 
chr2:94,782,159-95,675,764 q11.1 Gain 893605 36.36 0.00 36.36 0.00143 
chr2:94,983,765-100,292,273 q11.1 - q11.2 Loss 5308508 27.27 0.00 27.27 0.00842 
chr2:96,200,121-97,472,556 q11.2 Gain 1272435 27.27 0.00 27.27 0.00842 
chr20:17,961,951-19,322,167 p11.23 Gain 1360216 63.64 10.26 53.38 0.00077 
chr20:19,322,167-26,006,126 p11.23 - p11.1 Gain 6683959 63.64 12.82 50.82 0.00168 
chr20:26,006,126-26,220,344 p11.1 Gain 214218 63.64 10.26 53.38 0.00077 
chr20:26,220,344-28,267,569 p11.1 - q11.1 Gain 2047225 72.73 12.82 59.91 0.00028 
chr20:275,014-424,783 p13 Gain 149769 63.64 2.56 61.07 0.00002 
chr20:28,267,569-29,503,014 q11.1 - q11.21 Gain 1235445 72.73 23.08 49.65 0.00391 
chr20:29,503,014-29,779,350 q11.21 Gain 276336 72.73 20.51 52.21 0.00224 
chr20:29,779,350-30,526,698 q11.21 Gain 747348 72.73 23.08 49.65 0.00391 
chr20:30,526,698-35,931,146 q11.21 - q11.23 Gain 5404448 72.73 20.51 52.21 0.00224 
chr20:35,931,146-36,843,266 q11.23 Gain 912120 81.82 20.51 61.31 0.00036 
chr20:36,843,266-37,522,311 q11.23 - q12 Gain 679045 81.82 23.08 58.74 0.00068 
chr20:37,522,311-37,666,045 q12 Gain 143734 72.73 23.08 49.65 0.00391 
chr20:37,666,045-39,296,098 q12 Gain 1630053 81.82 23.08 58.74 0.00068 
chr20:39,296,098-40,680,814 q12 Gain 1384716 81.82 20.51 61.31 0.00036 
chr20:40,680,814-40,792,351 q12 Gain 111537 72.73 20.51 52.21 0.00224 
chr20:40,792,351-43,889,716 q12 - q13.12 Gain 3097365 72.73 25.64 47.09 0.00995 
chr20:424,783-9,340,955 p13 - p12.2 Gain 8916172 63.64 5.13 58.51 0.00010 
chr20:43,889,716-44,398,282 q13.12 Gain 508566 72.73 20.51 52.21 0.00224 
chr20:44,398,282-45,646,214 q13.12 Gain 1247932 72.73 23.08 49.65 0.00391 
chr20:45,646,214-47,243,628 q13.12 - q13.13 Gain 1597414 63.64 23.08 40.56 0.02410 
chr20:47,243,628-47,383,084 q13.13 Gain 139456 72.73 23.08 49.65 0.00391 
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chr20:47,538,301-51,561,551 q13.13 - q13.2 Gain 4023250 72.73 23.08 49.65 0.00391 
chr20:51,561,551-59,894,661 q13.2 - q13.33 Gain 8333110 72.73 20.51 52.21 0.00224 
chr20:59,894,661-62,393,015 q13.33 Gain 2498354 63.64 20.51 43.12 0.01023 
chr20:9,340,955-17,961,951 p12.2 - p11.23 Gain 8620996 63.64 7.69 55.94 0.00031 
chr22:15,621,248-15,745,966 q11.1 Loss 124718 36.36 0.00 36.36 0.00143 
chr22:15,745,966-16,347,244 q11.1 - q11.21 Loss 601278 54.55 0.00 54.55 0.00003 
chr22:16,347,244-16,899,186 q11.21 Loss 551942 45.45 0.00 45.45 0.00022 
chr22:16,899,186-18,151,355 q11.21 Loss 1252169 36.36 0.00 36.36 0.00143 
chr22:18,151,355-18,151,891 q11.21 Loss 536 27.27 0.00 27.27 0.00842 
chr22:18,151,891-20,448,350 q11.21 Loss 2296459 36.36 2.56 33.80 0.00629 
chr22:20,448,350-24,286,893 q11.21 - q11.23 Loss 3838543 36.36 5.13 31.24 0.01655 
chr22:24,286,893-24,560,716 q11.23 - q12.1 Loss 273823 36.36 7.69 28.67 0.03380 
chr22:24,560,716-28,379,404 q12.1 - q12.2 Loss 3818688 36.36 5.13 31.24 0.01655 
chr22:28,379,404-30,032,831 q12.2 Loss 1653427 36.36 2.56 33.80 0.00629 
chr22:30,032,831-30,535,980 q12.2 - q12.3 Loss 503149 45.45 2.56 42.89 0.00116 
chr22:30,535,980-30,623,768 q12.3 Loss 87788 36.36 2.56 33.80 0.00629 
chr22:30,623,867-30,646,302 q12.3 Loss 22435 36.36 5.13 31.24 0.01655 
chr22:30,646,401-40,803,595 q12.3 - q13.2 Loss 10157194 36.36 2.56 33.80 0.00629 
chr22:40,803,595-42,473,589 q13.2 Loss 1669994 45.45 5.13 40.33 0.00361 
chr22:42,473,589-44,175,906 q13.2 - q13.31 Loss 1702317 36.36 5.13 31.24 0.01655 
chr22:44,175,906-45,618,622 q13.31 Loss 1442716 45.45 5.13 40.33 0.00361 
chr22:45,618,622-49,453,810 q13.31 - q13.33 Loss 3835188 45.45 7.69 37.76 0.00853 
chr3:111,740,734-121,091,572 q13.13 - q13.33 Gain 9350838 36.36 5.13 31.24 0.01655 
chr3:121,091,572-121,205,097 q13.33 Gain 113525 36.36 2.56 33.80 0.00629 
chr3:121,205,097-133,822,599 q13.33 - q22.1 Gain 12617502 36.36 5.13 31.24 0.01655 
chr3:133,822,599-137,175,189 q22.1 - q22.2 Gain 3352590 36.36 2.56 33.80 0.00629 
chr3:137,175,189-137,175,931 q22.2 Gain 742 36.36 0.00 36.36 0.00143 
chr3:137,175,931-158,979,197 q22.2 - q25.32 Gain 21803266 36.36 2.56 33.80 0.00629 
chr3:158,979,197-181,383,557 q25.32 - q26.33 Gain 22404360 36.36 5.13 31.24 0.01655 
chr3:181,383,557-181,436,285 q26.33 Gain 52728 36.36 2.56 33.80 0.00629 
chr3:181,436,285-187,914,171 q26.33 - q27.3 Gain 6477886 36.36 5.13 31.24 0.01655 
chr3:187,914,171-187,914,682 q27.3 Gain 511 36.36 2.56 33.80 0.00629 
chr3:187,914,682-199,160,165 q27.3 - q29 Gain 11245483 36.36 5.13 31.24 0.01655 
chr3:54,612,454-71,816,463 p14.3 - p13 Gain 17204009 27.27 0.00 27.27 0.00842 
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chr3:6,636,703-10,788,431 p26.1 - p25.3 Gain 4151728 36.36 7.69 28.67 0.03380 
chr3:74,391,234-77,584,830 p12.3 Gain 3193596 36.36 2.56 33.80 0.00629 
chr3:77,584,830-79,097,077 p12.3 Gain 1512247 36.36 0.00 36.36 0.00143 
chr3:79,097,077-82,066,186 p12.3 - p12.2 Gain 2969109 36.36 2.56 33.80 0.00629 
chr3:82,066,186-82,799,401 p12.2 Gain 733215 36.36 5.13 31.24 0.01655 
chr3:82,799,401-83,768,022 p12.2 - p12.1 Gain 968621 45.45 5.13 40.33 0.00361 
chr3:83,768,022-87,044,540 p12.1 Gain 3276518 45.45 2.56 42.89 0.00116 
chr3:87,044,540-111,740,734 p12.1 - q13.13 Gain 24696194 36.36 2.56 33.80 0.00629 
chr3:958,261-6,636,703 p26.3 - p26.1 Gain 5678442 36.36 5.13 31.24 0.01655 
chr4:1,065,598-2,865,088 p16.3 Loss 1799490 36.36 2.56 33.80 0.00629 
chr4:10,207,878-11,429,778 p16.1 - p15.33 Loss 1221900 36.36 5.13 31.24 0.01655 
chr4:113,578,539-152,907,961 q25 - q31.3 Loss 39329422 36.36 0.00 36.36 0.00143 
chr4:13,655,289-26,747,433 p15.33 - p15.2 Loss 13092144 36.36 5.13 31.24 0.01655 
chr4:152,907,961-179,587,711 q31.3 - q34.3 Loss 26679750 36.36 2.56 33.80 0.00629 
chr4:179,587,711-180,006,495 q34.3 Loss 418784 36.36 5.13 31.24 0.01655 
chr4:180,006,495-182,025,739 q34.3 Loss 2019244 36.36 7.69 28.67 0.03380 
chr4:184,404,421-185,872,338 q35.1 Gain 1467917 27.27 0.00 27.27 0.00842 
chr4:184,561,840-185,872,338 q35.1 Loss 1310498 36.36 7.69 28.67 0.03380 
chr4:185,872,338-191,020,215 q35.1 - q35.2 Loss 5147877 36.36 5.13 31.24 0.01655 
chr4:2,865,088-10,207,878 p16.3 - p16.1 Loss 7342790 36.36 7.69 28.67 0.03380 
chr4:207,197-1,065,598 p16.3 Loss 858401 45.45 2.56 42.89 0.00116 
chr4:207,197-7,937,465 p16.3 - p16.1 Gain 7730268 36.36 2.56 33.80 0.00629 
chr4:26,747,433-38,175,739 p15.2 - p14 Loss 11428306 45.45 5.13 40.33 0.00361 
chr4:38,175,739-45,608,190 p14 - p12 Loss 7432451 45.45 2.56 42.89 0.00116 
chr4:45,608,190-47,264,023 p12 Loss 1655833 36.36 2.56 33.80 0.00629 
chr4:47,264,023-47,677,803 p12 Loss 413780 36.36 0.00 36.36 0.00143 
chr4:47,677,803-48,524,316 p12 Loss 846513 27.27 0.00 27.27 0.00842 
chr4:55,628-207,197 p16.3 Loss 151569 45.45 0.00 45.45 0.00022 
chr4:74,866,776-76,733,068 q13.3 - q21.1 Gain 1866292 27.27 0.00 27.27 0.00842 
chr4:77,782,579-78,196,278 q21.1 Gain 413699 27.27 0.00 27.27 0.00842 
chr4:80,547,099-81,510,343 q21.21 Loss 963244 27.27 0.00 27.27 0.00842 
chr4:82,199,002-113,578,539 q21.21 - q25 Loss 31379537 27.27 0.00 27.27 0.00842 
chr5:136,366,234-152,728,888 q31.2 - q33.2 Loss 16362654 36.36 7.69 28.67 0.03380 
chr5:152,728,888-154,417,750 q33.2 Loss 1688862 45.45 7.69 37.76 0.00853 
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chr5:154,417,750-169,611,921 q33.2 - q35.1 Loss 15194171 36.36 7.69 28.67 0.03380 
chr5:169,611,921-169,783,365 q35.1 Loss 171444 36.36 5.13 31.24 0.01655 
chr5:169,783,365-178,243,610 q35.1 - q35.3 Loss 8460245 36.36 7.69 28.67 0.03380 
chr5:178,243,610-178,415,257 q35.3 Loss 171647 36.36 2.56 33.80 0.00629 
chr5:178,415,257-180,512,398 q35.3 Loss 2097141 36.36 7.69 28.67 0.03380 
chr5:180,512,398-180,626,608 q35.3 Loss 114210 36.36 2.56 33.80 0.00629 
chr5:22,468,834-35,388,213 p14.3 - p13.2 Gain 12919379 45.45 10.26 35.20 0.01695 
chr5:3,426,805-3,559,003 p15.33 Gain 132198 36.36 7.69 28.67 0.03380 
chr5:51,232,444-65,352,862 q11.2 - q12.3 Loss 14120418 45.45 10.26 35.20 0.01695 
chr5:99,111,442-107,339,380 q21.1 - q21.3 Loss 8227938 36.36 7.69 28.67 0.03380 
chr6:168,121,846-169,488,215 q27 Loss 1366369 45.45 10.26 35.20 0.01695 
chr6:169,576,118-170,622,773 q27 Loss 1046655 45.45 10.26 35.20 0.01695 
chr6:170,622,773-170,728,000 q27 Loss 105227 45.45 5.13 40.33 0.00361 
chr6:20,272,069-22,580,422 p22.3 Gain 2308353 45.45 10.26 35.20 0.01695 
chr6:22,580,422-23,499,391 p22.3 Gain 918969 45.45 5.13 40.33 0.00361 
chr6:23,499,391-27,152,460 p22.3 - p22.1 Gain 3653069 36.36 5.13 31.24 0.01655 
chr7:142,857,956-144,143,399 q35 Gain 1285443 54.55 10.26 44.29 0.00400 
chr7:144,143,399-147,259,180 q35 Gain 3115781 54.55 7.69 46.85 0.00179 
chr7:147,259,180-148,089,302 q35 - q36.1 Gain 830122 54.55 10.26 44.29 0.00400 
chr7:148,089,302-151,558,264 q36.1 Gain 3468962 54.55 12.82 41.72 0.00789 
chr7:15,056,488-21,588,275 p21.2 - p15.3 Gain 6531787 45.45 12.82 32.63 0.02990 
chr7:151,558,264-153,901,560 q36.1 - q36.2 Gain 2343296 54.55 10.26 44.29 0.00400 
chr7:153,901,560-158,625,992 q36.2 - q36.3 Gain 4724432 54.55 12.82 41.72 0.00789 
chr7:16,205,630-17,756,921 p21.1 Loss 1551291 27.27 0.00 27.27 0.00842 
chr7:188,219-257,533 p22.3 Gain 69314 36.36 7.69 28.67 0.03380 
chr7:26,749,335-29,450,068 p15.2 - p15.1 Gain 2700733 45.45 12.82 32.63 0.02990 
chr7:50,617,642-52,867,234 p12.2 - p12.1 Gain 2249592 45.45 10.26 35.20 0.01695 
chr7:52,867,234-56,264,968 p12.1 - p11.2 Gain 3397734 45.45 12.82 32.63 0.02990 
chr7:56,264,968-63,102,874 p11.2 - q11.21 Gain 6837906 45.45 7.69 37.76 0.00853 
chr7:63,102,874-67,229,358 q11.21 - q11.22 Gain 4126484 54.55 7.69 46.85 0.00179 
chr7:67,229,358-71,274,704 q11.22 Gain 4045346 54.55 10.26 44.29 0.00400 
chr7:71,274,704-80,528,144 q11.22 - q21.11 Gain 9253440 54.55 12.82 41.72 0.00789 
chr7:80,528,144-81,356,796 q21.11 Gain 828652 54.55 15.38 39.16 0.01410 
chr7:81,356,796-142,857,956 q21.11 - q35 Gain 61501160 54.55 12.82 41.72 0.00789 
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chr8:1,128,443-1,706,678 p23.3 Loss 578235 54.55 17.95 36.60 0.02334 
chr8:14,461,142-27,277,284 p22 - p21.2 Loss 12816142 63.64 23.08 40.56 0.02410 
chr8:27,277,284-30,816,370 p21.2 - p12 Loss 3539086 63.64 20.51 43.12 0.01023 
chr8:37,204,481-38,289,058 p12 Loss 1084577 36.36 7.69 28.67 0.03380 
chr8:38,289,058-39,836,613 p12 - p11.22 Loss 1547555 36.36 5.13 31.24 0.01655 
chr8:39,836,613-43,315,811 p11.22 - p11.1 Loss 3479198 36.36 2.56 33.80 0.00629 
chr8:4,386,741-14,461,142 p23.2 - p22 Loss 10074401 63.64 20.51 43.12 0.01023 
chr9:13,729,630-21,157,685 p23 - p21.3 Gain 7428055 27.27 0.00 27.27 0.00842 
chr9:140,118,015-140,273,252 q34.3 Loss 155237 0.00 43.59 -43.59 0.00909 
chr9:190-336,203 p24.3 Gain 336013 27.27 0.00 27.27 0.00842 
chr9:27,417,088-29,639,053 p21.2 - p21.1 Gain 2221965 27.27 0.00 27.27 0.00842 
chr9:38,427,196-44,898,290 p13.1 - p11.2 Gain 6471094 27.27 0.00 27.27 0.00842 
chr9:45,100,371-70,318,675 p11.2 - q13 Gain 25218304 27.27 0.00 27.27 0.00842 
chr9:84,783,002-89,446,315 q21.32 - q21.33 Gain 4663313 27.27 0.00 27.27 0.00842 !
 
1Physical position is according to hg18/NCBI build 36!!!
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Appendix 5.6: Regions showing significant copy number differences in low stage and low grade (TaG1/G2) multifocal (n=11) 
versus solitary (n=28) tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:119,708,536-153,581,460 p12 - q22 Gain 33872924 27.27 0.00 27.27 0.0181 
chr1:157,241,521-157,953,509 q23.1 - q23.2 Gain 711988 36.36 3.57 32.79 0.0169 
chr1:157,953,509-167,621,290 q23.2 - q24.2 Gain 9667781 36.36 0.00 36.36 0.0040 
chr1:167,621,290-193,197,934 q24.2 - q31.3 Gain 25576644 27.27 0.00 27.27 0.0181 
chr10:104,342,397-104,652,460 q24.32 Loss 310063 36.36 7.14 29.22 0.0423 
chr10:5,844,781-8,219,578 p15.1 - p14 Gain 2374797 27.27 0.00 27.27 0.0181 
chr10:71,487,752-73,834,924 q22.1 Gain 2347172 27.27 0.00 27.27 0.0181 
chr10:73,834,924-74,954,700 q22.1 - q22.2 Gain 1119776 36.36 0.00 36.36 0.0040 
chr10:74,954,700-89,597,006 q22.2 - q23.2 Gain 14642306 27.27 0.00 27.27 0.0181 
chr10:8,346,526-11,805,252 p14 Gain 3458726 27.27 0.00 27.27 0.0181 
chr13:19,137,297-19,920,905 q12.11 Gain 783608 45.45 7.14 38.31 0.0122 
chr13:19,920,905-20,982,693 q12.11 Gain 1061788 45.45 10.71 34.74 0.0276 
chr13:20,982,693-22,108,664 q12.11 Gain 1125971 45.45 7.14 38.31 0.0122 
chr13:22,108,664-27,824,701 q12.11 - q12.3 Gain 5716037 45.45 3.57 41.88 0.0041 
chr13:27,824,701-31,703,968 q12.3 - q13.1 Gain 3879267 36.36 3.57 32.79 0.0169 
chr13:37,218,551-47,794,572 q13.3 - q14.2 Loss 10576021 27.27 0.00 27.27 0.0181 
chr13:50,471,832-56,523,630 q14.3 - q21.1 Gain 6051798 36.36 3.57 32.79 0.0169 
chr13:56,523,630-56,717,407 q21.1 Gain 193777 36.36 0.00 36.36 0.0040 
chr13:56,717,407-66,421,707 q21.1 - q21.32 Gain 9704300 36.36 3.57 32.79 0.0169 
chr13:66,421,707-67,895,141 q21.32 - q21.33 Gain 1473434 45.45 3.57 41.88 0.0041 
chr13:67,895,141-113,927,980 q21.33 - q34 Gain 46032839 36.36 3.57 32.79 0.0169 
chr16:193,278-6,165,969 p13.3 Loss 5972691 27.27 0.00 27.27 0.0181 
chr16:82,569,517-84,922,020 q23.3 - q24.1 Loss 2352503 27.27 0.00 27.27 0.0181 
chr16:87,260,485-88,421,159 q24.3 Loss 1160674 36.36 3.57 32.79 0.0169 
chr16:88,552,007-88,552,722 q24.3 Loss 715 36.36 0.00 36.36 0.0040 
chr16:88,552,722-88,643,456 q24.3 Loss 90734 27.27 0.00 27.27 0.0181 
chr17:35,227,093-35,920,940 q12 - q21.2 Loss 693847 27.27 0.00 27.27 0.0181 
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chr19:33,399,234-36,171,164 q12 Gain 2771930 27.27 0.00 27.27 0.0181 
chr19:36,322,238-40,876,527 q12 - q13.12 Gain 4554289 27.27 0.00 27.27 0.0181 
chr19:41,059,171-51,988,000 q13.12 - q13.32 Gain 10928829 27.27 0.00 27.27 0.0181 
chr19:52,342,137-63,602,791 q13.32 - q13.43 Gain 11260654 27.27 0.00 27.27 0.0181 
chr20:34,346,661-62,392,510 q11.23 - q13.33 Gain 28045849 45.45 10.71 34.74 0.0276 
chr6:162,865,542-162,954,569 q26 Gain 89027 27.27 0.00 27.27 0.0181 
chr8:124,550,528-124,718,428 q24.13 Gain 167900 45.45 0.00 45.45 0.0008 
chr8:124,718,428-146,003,740 q24.13 - q24.3 Gain 21285312 45.45 3.57 41.88 0.0041 
chr8:146,003,740-146,133,884 q24.3 Gain 130144 36.36 3.57 32.79 0.0169 
chr8:38,289,058-42,487,636 p12 - p11.21 Loss 4198578 27.27 0.00 27.27 0.0181 
chr8:42,674,285-65,551,264 p11.21 - q12.3 Gain 22876979 27.27 0.00 27.27 0.0181 
chr8:477,653-658,324 p23.3 Loss 180671 27.27 0.00 27.27 0.0181 
chr8:658,324-38,289,058 p23.3 - p12 Loss 37630734 36.36 0.00 36.36 0.0040 
chr8:69,616,969-70,378,901 q13.2 Gain 761932 36.36 3.57 32.79 0.0169 
chr8:70,378,901-72,600,219 q13.2 - q13.3 Gain 2221318 45.45 3.57 41.88 0.0041 
chr8:72,600,219-75,850,345 q13.3 - q21.11 Gain 3250126 36.36 3.57 32.79 0.0169 
chr8:96,177,980-124,550,528 q22.1 - q24.13 Gain 28372548 45.45 3.57 41.88 0.0041 
chr9:140,118,015-140,273,252 q34.3 Loss 155237 0.00 32.14 -32.14 0.0403 
chr9:190-1,340,595 p24.3 Gain 1340405 27.27 0.00 27.27 0.0181 
chr9:21,734,602-21,851,433 p21.3 Loss 116831 72.73 21.43 51.30 0.0072 
chr9:21,851,433-21,998,414 p21.3 Loss 146981 63.64 21.43 42.21 0.0221 
chr9:21,998,414-22,046,818 p21.3 Loss 48404 63.64 17.86 45.78 0.0170 
chr9:22,046,818-22,155,847 p21.3 Loss 109029 72.73 17.86 54.87 0.0021 
chr9:22,155,847-22,155,946 p21.3 Loss 99 63.64 17.86 45.78 0.0170 
chr9:22,155,946-23,376,562 p21.3 Loss 1220616 63.64 21.43 42.21 0.0221 
chr9:23,376,562-24,090,721 p21.3 Loss 714159 54.55 17.86 36.69 0.0443 
chr9:68,858,635-70,488,655 q12 - q13 Loss 1630020 72.73 28.57 44.16 0.0272 
chr9:70,488,655-82,003,000 q13 - q21.31 Loss 11514345 81.82 28.57 53.25 0.0040 
chr9:82,003,000-82,148,095 q21.31 Loss 145095 81.82 10.71 71.10 0.0004 
chr9:82,148,095-85,485,840 q21.31 - q21.32 Loss 3337745 81.82 28.57 53.25 0.0040 
chr9:85,485,840-87,920,679 q21.32 - q21.33 Loss 2434839 81.82 32.14 49.68 0.0107 
chr9:87,920,679-88,054,773 q21.33 Loss 134094 81.82 28.57 53.25 0.0040 
chr9:88,054,773-88,787,420 q21.33 Loss 732647 81.82 32.14 49.68 0.0107 
chr9:88,883,454-88,940,656 q21.33 Loss 57202 63.64 25.00 38.64 0.0331 
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chr9:88,940,656-89,058,511 q21.33 Loss 117855 81.82 32.14 49.68 0.0107 
chr9:89,058,511-132,631,265 q21.33 - q34.12 Loss 43572754 81.82 35.71 46.10 0.0138 !
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Appendix 5.7: Regions showing significant copy number differences in stage T1 and grade 3 (T1G3) multifocal (n=8) versus 
solitary (n=29) tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:113,473,675-117,407,078 p13.2 - p13.1 Gain 3933403 37.5 3.45 34.05 0.0256 
chr1:119,480,610-141,672,545 p12 - q12 Gain 22191935 62.5 6.90 55.60 0.0023 
chr1:141,672,545-142,787,183 q12 - q21.1 Gain 1114638 62.5 10.34 52.16 0.0056 
chr1:142,787,183-143,613,581 q21.1 Gain 826398 62.5 17.24 45.26 0.0211 
chr1:143,613,581-143,614,341 q21.1 Gain 760 62.5 13.79 48.71 0.0115 
chr1:143,614,341-146,342,686 q21.1 Gain 2728345 62.5 17.24 45.26 0.0211 
chr1:146,342,686-154,399,117 q21.1 - q22 Gain 8056431 62.5 20.69 41.81 0.0352 
chr1:160,195,246-160,195,822 q23.3 Gain 576 62.5 20.69 41.81 0.0352 
chr1:185,614,023-191,477,703 q31.1 - q31.2 Loss 5863680 25 0.00 25.00 0.0420 
chr1:192,424,789-237,780,877 q31.3 - q43 Loss 45356088 25 0.00 25.00 0.0420 
chr1:241,339,986-247,164,041 q43 - q44 Loss 5824055 25 0.00 25.00 0.0420 
chr1:38,051,746-39,307,926 p34.3 Gain 1256180 50 10.34 39.66 0.0271 
chr1:39,307,926-44,062,032 p34.3 - p34.1 Gain 4754106 50 6.90 43.10 0.0129 
chr1:44,062,032-45,524,938 p34.1 Gain 1462906 50 3.45 46.55 0.0048 
chr1:45,524,938-53,077,428 p34.1 - p32.3 Gain 7552490 50 6.90 43.10 0.0129 
chr1:53,077,428-73,625,895 p32.3 - p31.1 Gain 20548467 50 3.45 46.55 0.0048 
chr1:73,625,895-83,494,525 p31.1 Gain 9868630 37.5 3.45 34.05 0.0256 
chr10:104,813,472-108,400,155 q24.32 - q25.1 Loss 3586683 75 13.79 61.21 0.0020 
chr10:108,400,155-114,874,404 q25.1 - q25.2 Loss 6474249 75 10.34 64.66 0.0008 
chr10:114,874,404-116,774,295 q25.2 - q25.3 Loss 1899891 75 6.90 68.10 0.0003 
chr10:116,774,295-119,495,422 q25.3 - q26.11 Loss 2721127 62.5 6.90 55.60 0.0023 
chr10:119,495,422-120,558,865 q26.11 Loss 1063443 62.5 3.45 59.05 0.0007 
chr10:120,558,865-123,214,100 q26.11 - q26.13 Loss 2655235 62.5 6.90 55.60 0.0023 
chr10:123,214,100-125,057,698 q26.13 Loss 1843598 62.5 3.45 59.05 0.0007 
chr10:125,057,698-126,007,431 q26.13 Loss 949733 50 3.45 46.55 0.0048 
chr10:126,007,431-131,816,154 q26.13 - q26.3 Loss 5808723 50 0.00 50.00 0.0011 
chr10:131,816,154-131,982,049 q26.3 Loss 165895 37.5 0.00 37.50 0.0072 
-260 - 
 
chr10:131,982,049-135,247,831 q26.3 Loss 3265782 50 0.00 50.00 0.0011 
chr10:34,638,996-38,812,575 p11.21 - p11.1 Loss 4173579 25 0.00 25.00 0.0420 
chr10:72,803,738-79,687,959 q22.1 - q22.3 Gain 6884221 25 0.00 25.00 0.0420 
chr10:78,996,385-80,472,830 q22.3 Loss 1476445 50 6.90 43.10 0.0129 
chr10:83,636,464-83,637,155 q23.1 Loss 691 37.5 3.45 34.05 0.0256 
chr10:84,577,760-86,390,131 q23.1 Loss 1812371 50 6.90 43.10 0.0129 
chr10:86,390,131-87,373,214 q23.1 Loss 983083 62.5 6.90 55.60 0.0023 
chr10:87,373,214-88,222,653 q23.1 - q23.2 Loss 849439 62.5 10.34 52.16 0.0056 
chr10:88,222,653-89,694,469 q23.2 - q23.31 Loss 1471816 75 10.34 64.66 0.0008 
chr10:89,694,469-89,694,975 q23.31 Loss 506 62.5 10.34 52.16 0.0056 
chr10:89,694,975-90,596,444 q23.31 Loss 901469 75 10.34 64.66 0.0008 
chr10:90,596,444-95,924,122 q23.31 - q23.33 Loss 5327678 75 6.90 68.10 0.0003 
chr10:95,924,122-104,813,472 q23.33 - q24.32 Loss 8889350 75 10.34 64.66 0.0008 
chr11:50,013,045-54,839,338 p11.12 - q11 Loss 4826293 37.5 3.45 34.05 0.0256 
chr11:54,839,338-59,697,061 q11 - q12.1 Loss 4857723 37.5 0.00 37.50 0.0072 
chr11:59,697,061-60,851,894 q12.1 - q12.2 Loss 1154833 37.5 3.45 34.05 0.0256 
chr11:76,232,396-78,206,791 q13.5 - q14.1 Gain 1974395 25 0.00 25.00 0.0420 
chr11:79,636,827-81,301,979 q14.1 Gain 1665152 25 0.00 25.00 0.0420 
chr12:152,534-152,582 p13.33 Loss 48 37.5 3.45 34.05 0.0256 
chr12:152,582-153,169 p13.33 Loss 587 37.5 0.00 37.50 0.0072 
chr12:153,169-16,742,828 p13.33 - p12.3 Loss 16589659 37.5 3.45 34.05 0.0256 
chr12:16,742,828-25,552,960 p12.3 - p12.1 Loss 8810132 37.5 0.00 37.50 0.0072 
chr12:29,733,366-30,740,646 p11.22 - p11.21 Loss 1007280 25 0.00 25.00 0.0420 
chr12:30,939,600-33,333,489 p11.21 - p11.1 Loss 2393889 25 0.00 25.00 0.0420 
chr12:33,333,489-46,156,911 p11.1 - q13.11 Loss 12823422 37.5 0.00 37.50 0.0072 
chr12:46,156,911-52,417,126 q13.11 - q13.13 Loss 6260215 25 0.00 25.00 0.0420 
chr12:68,627,676-71,742,532 q15 - q21.1 Loss 3114856 25 0.00 25.00 0.0420 
chr12:91,367,961-121,982,522 q22 - q24.31 Loss 30614561 25 0.00 25.00 0.0420 
chr13:47,964,053-51,243,111 q14.2 - q14.3 Loss 3279058 50 6.90 43.10 0.0129 
chr14:23,749,068-26,561,378 q12 Loss 2812310 37.5 3.45 34.05 0.0256 
chr14:26,744,993-33,897,190 q12 - q13.1 Loss 7152197 37.5 3.45 34.05 0.0256 
chr14:33,897,190-34,061,283 q13.1 Loss 164093 37.5 0.00 37.50 0.0072 
chr14:34,061,283-57,420,120 q13.1 - q23.1 Loss 23358837 37.5 3.45 34.05 0.0256 
chr14:57,420,120-58,323,469 q23.1 Loss 903349 50 3.45 46.55 0.0048 
-261 - 
 
chr14:58,323,469-58,470,270 q23.1 Loss 146801 37.5 0.00 37.50 0.0072 
chr14:58,470,270-59,336,011 q23.1 Loss 865741 50 3.45 46.55 0.0048 
chr14:59,336,011-66,870,415 q23.1 - q23.3 Loss 7534404 37.5 3.45 34.05 0.0256 
chr14:73,931,005-74,588,657 q24.3 Loss 657652 37.5 3.45 34.05 0.0256 
chr14:75,833,225-77,328,585 q24.3 Gain 1495360 25 0.00 25.00 0.0420 
chr15:20,363,717-31,975,417 q11.2 - q14 Loss 11611700 25 0.00 25.00 0.0420 
chr15:62,510,397-63,070,265 q22.31 Loss 559868 37.5 3.45 34.05 0.0256 
chr15:63,070,265-82,907,017 q22.31 - q25.2 Loss 19836752 37.5 0.00 37.50 0.0072 
chr15:82,907,017-83,883,618 q25.2 - q25.3 Loss 976601 25 0.00 25.00 0.0420 
chr15:83,883,618-85,362,775 q25.3 Loss 1479157 37.5 0.00 37.50 0.0072 
chr15:85,362,775-87,338,954 q25.3 - q26.1 Loss 1976179 37.5 3.45 34.05 0.0256 
chr15:87,338,954-100,022,043 q26.1 - q26.3 Loss 12683089 37.5 0.00 37.50 0.0072 
chr16:2,267,343-7,019,846 p13.3 - p13.2 Gain 4752503 25 0.00 25.00 0.0420 
chr16:23,756,350-24,856,451 p12.1 Gain 1100101 50 0.00 50.00 0.0011 
chr16:24,856,451-29,550,785 p12.1 - p11.2 Gain 4694334 50 3.45 46.55 0.0048 
chr16:29,550,785-45,067,244 p11.2 - q11.2 Gain 15516459 50 0.00 50.00 0.0011 
chr16:3,918,289-4,131,849 p13.3 Loss 213560 25 0.00 25.00 0.0420 
chr16:33,715,230-45,231,075 p11.2 - q11.2 Loss 11515845 25 0.00 25.00 0.0420 
chr16:45,231,075-63,462,907 q11.2 - q21 Loss 18231832 37.5 0.00 37.50 0.0072 
chr16:63,462,907-88,552,722 q21 - q24.3 Loss 25089815 25 0.00 25.00 0.0420 
chr16:7,019,846-23,756,350 p13.2 - p12.1 Gain 16736504 37.5 0.00 37.50 0.0072 
chr17:12,108,967-14,364,543 p12 Gain 2255576 25 0.00 25.00 0.0420 
chr19:183,116-211,322 p13.3 Loss 28206 25 0.00 25.00 0.0420 
chr19:21,345,165-22,729,077 p12 Gain 1383912 25 0.00 25.00 0.0420 
chr19:211,322-5,009,897 p13.3 Loss 4798575 37.5 0.00 37.50 0.0072 
chr19:23,732,302-32,891,236 p12 - q12 Gain 9158934 37.5 3.45 34.05 0.0256 
chr19:32,891,236-33,399,234 q12 Gain 507998 37.5 0.00 37.50 0.0072 
chr19:35,629,568-36,171,164 q12 Gain 541596 37.5 3.45 34.05 0.0256 
chr19:36,322,238-36,979,850 q12 Gain 657612 37.5 3.45 34.05 0.0256 
chr19:37,664,852-38,091,322 q13.11 Gain 426470 50 6.90 43.10 0.0129 
chr19:38,091,322-38,282,890 q13.11 Gain 191568 50 3.45 46.55 0.0048 
chr19:38,282,890-39,226,664 q13.11 Gain 943774 50 6.90 43.10 0.0129 
chr19:39,226,664-45,806,715 q13.11 - q13.2 Gain 6580051 50 3.45 46.55 0.0048 
chr19:45,806,715-46,479,845 q13.2 Gain 673130 37.5 3.45 34.05 0.0256 
-262 - 
 
chr19:46,479,845-51,023,195 q13.2 - q13.32 Gain 4543350 37.5 0.00 37.50 0.0072 
chr19:5,009,897-5,549,421 p13.3 Loss 539524 37.5 3.45 34.05 0.0256 
chr19:5,549,421-6,523,485 p13.3 Loss 974064 37.5 0.00 37.50 0.0072 
chr19:51,023,195-58,336,597 q13.32 - q13.41 Gain 7313402 25 0.00 25.00 0.0420 
chr19:59,359,392-59,464,022 q13.42 Gain 104630 25 0.00 25.00 0.0420 
chr19:6,523,485-20,458,451 p13.3 - p12 Loss 13934966 25 0.00 25.00 0.0420 
chr19:63,602,791-63,771,717 q13.43 Gain 168926 25 0.00 25.00 0.0420 
chr2:1,785,220-11,122,011 p25.3 - p25.1 Gain 9336791 50 6.90 43.10 0.0129 
chr2:109,111,217-109,319,695 q13 Gain 208478 25 0.00 25.00 0.0420 
chr2:11,122,011-20,037,859 p25.1 - p24.1 Gain 8915848 50 3.45 46.55 0.0048 
chr2:111,491,810-159,300,999 q13 - q24.1 Gain 47809189 25 0.00 25.00 0.0420 
chr2:148,009,604-151,825,968 q22.3 - q23.3 Loss 3816364 25 0.00 25.00 0.0420 
chr2:153,751,686-169,397,061 q23.3 - q24.3 Loss 15645375 25 0.00 25.00 0.0420 
chr2:167,445,852-169,206,769 q24.3 Gain 1760917 25 0.00 25.00 0.0420 
chr2:169,397,061-207,861,345 q24.3 - q33.3 Loss 38464284 37.5 0.00 37.50 0.0072 
chr2:20,037,859-20,215,537 p24.1 Gain 177678 37.5 3.45 34.05 0.0256 
chr2:20,215,537-21,280,646 p24.1 Gain 1065109 50 3.45 46.55 0.0048 
chr2:207,861,345-208,876,525 q33.3 Loss 1015180 37.5 3.45 34.05 0.0256 
chr2:208,876,525-210,331,732 q33.3 - q34 Loss 1455207 62.5 3.45 59.05 0.0007 
chr2:21,280,646-25,870,821 p24.1 - p23.3 Gain 4590175 37.5 3.45 34.05 0.0256 
chr2:210,331,732-216,402,525 q34 - q35 Loss 6070793 62.5 6.90 55.60 0.0023 
chr2:216,402,525-225,739,791 q35 - q36.2 Loss 9337266 62.5 10.34 52.16 0.0056 
chr2:224,263-1,785,220 p25.3 Gain 1560957 50 3.45 46.55 0.0048 
chr2:225,739,791-228,542,036 q36.2 - q36.3 Loss 2802245 62.5 13.79 48.71 0.0115 
chr2:228,542,036-230,386,971 q36.3 Loss 1844935 75 13.79 61.21 0.0020 
chr2:230,386,971-230,387,771 q36.3 Loss 800 75 10.34 64.66 0.0008 
chr2:230,387,771-238,252,220 q36.3 - q37.3 Loss 7864449 75 13.79 61.21 0.0020 
chr2:238,252,220-239,091,229 q37.3 Loss 839009 75 17.24 57.76 0.0041 
chr2:239,091,229-241,620,162 q37.3 Loss 2528933 75 20.69 54.31 0.0077 
chr2:241,620,162-241,796,109 q37.3 Loss 175947 75 17.24 57.76 0.0041 
chr2:25,870,821-48,938,583 p23.3 - p16.3 Gain 23067762 50 3.45 46.55 0.0048 
chr2:48,938,583-52,373,212 p16.3 Gain 3434629 50 0.00 50.00 0.0011 
chr2:52,373,212-64,478,283 p16.3 - p14 Gain 12105071 62.5 0.00 62.50 0.0001 
chr2:64,478,283-71,285,149 p14 - p13.3 Gain 6806866 50 0.00 50.00 0.0011 
-263 - 
 
chr2:71,285,149-74,335,462 p13.3 - p13.1 Gain 3050313 62.5 0.00 62.50 0.0001 
chr2:74,335,462-82,716,433 p13.1 - p12 Gain 8380971 50 0.00 50.00 0.0011 
chr2:82,716,433-83,447,850 p12 Gain 731417 50 3.45 46.55 0.0048 
chr2:83,447,850-88,214,979 p12 - p11.2 Gain 4767129 50 0.00 50.00 0.0011 
chr2:88,214,979-94,782,159 p11.2 - q11.1 Gain 6567180 62.5 0.00 62.50 0.0001 
chr2:94,782,159-95,675,764 q11.1 Gain 893605 50 0.00 50.00 0.0011 
chr2:94,983,765-100,292,273 q11.1 - q11.2 Loss 5308508 25 0.00 25.00 0.0420 
chr2:95,675,764-108,345,037 q11.1 - q12.3 Gain 12669273 25 0.00 25.00 0.0420 
chr20:26,006,126-26,220,344 p11.1 Gain 214218 75 3.45 71.55 0.0001 
chr20:26,220,344-28,267,569 p11.1 - q11.1 Gain 2047225 75 6.90 68.10 0.0003 
chr20:275,014-424,783 p13 Gain 149769 75 3.45 71.55 0.0001 
chr20:28,267,569-29,779,350 q11.1 - q11.21 Gain 1511781 75 20.69 54.31 0.0077 
chr20:29,779,350-30,526,698 q11.21 Gain 747348 75 24.14 50.86 0.0134 
chr20:30,526,698-37,666,045 q11.21 - q12 Gain 7139347 75 20.69 54.31 0.0077 
chr20:37,666,045-40,680,814 q12 Gain 3014769 87.5 20.69 66.81 0.0011 
chr20:40,680,814-40,792,351 q12 Gain 111537 75 20.69 54.31 0.0077 
chr20:40,792,351-43,889,716 q12 - q13.12 Gain 3097365 75 27.59 47.41 0.0345 
chr20:424,783-26,006,126 p13 - p11.1 Gain 25581343 75 6.90 68.10 0.0003 
chr20:43,889,716-47,383,084 q13.12 - q13.13 Gain 3493368 75 20.69 54.31 0.0077 
chr20:47,383,084-47,538,301 q13.13 Gain 155217 62.5 20.69 41.81 0.0352 
chr20:47,538,301-62,393,015 q13.13 - q13.33 Gain 14854714 75 20.69 54.31 0.0077 
chr22:15,621,248-15,745,966 q11.1 Loss 124718 37.5 0.00 37.50 0.0072 
chr22:15,745,966-18,151,355 q11.1 - q11.21 Loss 2405389 50 0.00 50.00 0.0011 
chr22:18,151,355-18,151,891 q11.21 Loss 536 37.5 0.00 37.50 0.0072 
chr22:18,151,891-24,286,893 q11.21 - q11.23 Loss 6135002 50 3.45 46.55 0.0048 
chr22:24,286,893-28,379,404 q11.23 - q12.2 Loss 4092511 50 6.90 43.10 0.0129 
chr22:28,379,404-30,623,768 q12.2 - q12.3 Loss 2244364 50 3.45 46.55 0.0048 
chr22:30,623,768-30,623,867 q12.3 Loss 99 37.5 3.45 34.05 0.0256 
chr22:30,646,302-30,646,401 q12.3 Loss 99 37.5 3.45 34.05 0.0256 
chr22:30,646,401-40,803,595 q12.3 - q13.2 Loss 10157194 50 3.45 46.55 0.0048 
chr22:40,803,595-42,473,589 q13.2 Loss 1669994 62.5 6.90 55.60 0.0023 
chr22:42,473,589-45,618,622 q13.2 - q13.31 Loss 3145033 50 6.90 43.10 0.0129 
chr22:45,618,622-49,453,810 q13.31 - q13.33 Loss 3835188 50 10.34 39.66 0.0271 
chr3:122,541,183-125,236,945 q13.33 - q21.1 Loss 2695762 25 0.00 25.00 0.0420 
-264 - 
 
chr3:133,822,599-158,979,197 q22.1 - q25.32 Gain 25156598 25 0.00 25.00 0.0420 
chr3:140,451,428-140,626,759 q23 Loss 175331 25 0.00 25.00 0.0420 
chr3:140,627,376-184,141,428 q23 - q26.33 Loss 43514052 25 0.00 25.00 0.0420 
chr3:54,612,454-71,816,463 p14.3 - p13 Gain 17204009 25 0.00 25.00 0.0420 
chr3:77,584,830-79,097,077 p12.3 Gain 1512247 25 0.00 25.00 0.0420 
chr3:82,799,401-83,768,022 p12.2 - p12.1 Gain 968621 37.5 3.45 34.05 0.0256 
chr3:83,768,022-87,044,540 p12.1 Gain 3276518 37.5 0.00 37.50 0.0072 
chr3:87,044,540-111,740,734 p12.1 - q13.13 Gain 24696194 25 0.00 25.00 0.0420 
chr3:958,261-6,636,703 p26.3 - p26.1 Gain 5678442 37.5 3.45 34.05 0.0256 
chr4:113,578,539-152,907,961 q25 - q31.3 Loss 39329422 37.5 0.00 37.50 0.0072 
chr4:152,907,961-179,587,711 q31.3 - q34.3 Loss 26679750 37.5 3.45 34.05 0.0256 
chr4:184,404,421-185,872,338 q35.1 Gain 1467917 25 0.00 25.00 0.0420 
chr4:2,865,088-11,429,778 p16.3 - p15.33 Loss 8564690 37.5 3.45 34.05 0.0256 
chr4:26,747,433-47,264,023 p15.2 - p12 Loss 20516590 37.5 3.45 34.05 0.0256 
chr4:47,264,023-47,677,803 p12 Loss 413780 37.5 0.00 37.50 0.0072 
chr4:47,677,803-48,524,316 p12 Loss 846513 25 0.00 25.00 0.0420 
chr4:55,628-2,865,088 p16.3 Loss 2809460 37.5 0.00 37.50 0.0072 
chr4:69,912,758-74,866,776 q13.2 - q13.3 Gain 4954018 25 0.00 25.00 0.0420 
chr4:74,866,776-78,196,278 q13.3 - q21.1 Gain 3329502 37.5 0.00 37.50 0.0072 
chr4:80,547,099-113,578,539 q21.21 - q25 Loss 33031440 25 0.00 25.00 0.0420 
chr5:136,366,234-180,626,608 q31.2 - q35.3 Loss 44260374 37.5 3.45 34.05 0.0256 
chr5:3,426,805-3,559,003 p15.33 Gain 132198 37.5 3.45 34.05 0.0256 
chr5:51,232,444-65,352,862 q11.2 - q12.3 Loss 14120418 50 6.90 43.10 0.0129 
chr5:99,111,442-107,339,380 q21.1 - q21.3 Loss 8227938 37.5 3.45 34.05 0.0256 
chr6:165,244,688-169,488,215 q27 Loss 4243527 50 10.34 39.66 0.0271 
chr6:169,576,118-170,622,773 q27 Loss 1046655 50 10.34 39.66 0.0271 
chr6:170,622,773-170,728,000 q27 Loss 105227 50 6.90 43.10 0.0129 
chr6:19,131,847-20,272,069 p22.3 Gain 1140222 50 10.34 39.66 0.0271 
chr6:20,272,069-22,580,422 p22.3 Gain 2308353 62.5 10.34 52.16 0.0056 
chr6:22,580,422-23,499,391 p22.3 Gain 918969 62.5 3.45 59.05 0.0007 
chr6:23,499,391-27,152,460 p22.3 - p22.1 Gain 3653069 50 3.45 46.55 0.0048 
chr6:27,152,460-32,404,070 p22.1 - p21.32 Gain 5251610 37.5 3.45 34.05 0.0256 
chr6:6,382,300-7,427,280 p25.1 - p24.3 Gain 1044980 50 10.34 39.66 0.0271 
chr6:62,586,405-69,438,735 q11.1 - q12 Gain 6852330 25 0.00 25.00 0.0420 
-265 - 
 
chr7:142,857,956-144,143,399 q35 Gain 1285443 62.5 13.79 48.71 0.0115 
chr7:144,143,399-147,259,180 q35 Gain 3115781 62.5 10.34 52.16 0.0056 
chr7:147,259,180-148,089,302 q35 - q36.1 Gain 830122 62.5 13.79 48.71 0.0115 
chr7:148,089,302-151,558,264 q36.1 Gain 3468962 62.5 17.24 45.26 0.0211 
chr7:151,558,264-153,901,560 q36.1 - q36.2 Gain 2343296 62.5 13.79 48.71 0.0115 
chr7:153,901,560-158,625,992 q36.2 - q36.3 Gain 4724432 62.5 17.24 45.26 0.0211 
chr7:50,617,642-52,867,234 p12.2 - p12.1 Gain 2249592 50 13.79 36.21 0.0487 
chr7:56,264,968-63,102,874 p11.2 - q11.21 Gain 6837906 50 10.34 39.66 0.0271 
chr7:63,102,874-67,229,358 q11.21 - q11.22 Gain 4126484 62.5 10.34 52.16 0.0056 
chr7:67,229,358-71,274,704 q11.22 Gain 4045346 62.5 13.79 48.71 0.0115 
chr7:71,274,704-80,528,144 q11.22 - q21.11 Gain 9253440 62.5 17.24 45.26 0.0211 
chr7:80,528,144-81,356,796 q21.11 Gain 828652 62.5 20.69 41.81 0.0352 
chr7:81,356,796-142,857,956 q21.11 - q35 Gain 61501160 62.5 17.24 45.26 0.0211 
chr8:39,836,613-43,315,811 p11.22 - p11.1 Loss 3479198 37.5 3.45 34.05 0.0256 
chr8:4,386,741-14,461,142 p23.2 - p22 Loss 10074401 62.5 20.69 41.81 0.0352 
chr9:124,954,691-140,118,015 q33.2 - q34.3 Gain 15163324 25 0.00 25.00 0.0420 
chr9:13,729,630-21,157,685 p23 - p21.3 Gain 7428055 25 0.00 25.00 0.0420 
chr9:140,118,015-140,273,252 q34.3 Loss 155237 0 48.28 -48.28 0.0148 
chr9:190-336,203 p24.3 Gain 336013 37.5 0.00 37.50 0.0072 
chr9:27,417,088-29,639,053 p21.2 - p21.1 Gain 2221965 25 0.00 25.00 0.0420 
chr9:336,203-991,152 p24.3 Gain 654949 37.5 3.45 34.05 0.0256 
chr9:38,427,196-84,783,002 p13.1 - q21.32 Gain 46355806 25 0.00 25.00 0.0420 
chr9:84,783,002-89,446,315 q21.32 - q21.33 Gain 4663313 37.5 0.00 37.50 0.0072 
chr9:89,446,315-123,651,685 q21.33 - q33.2 Gain 34205370 25 0.00 25.00 0.0420 !
 
1Physical position is according to hg18/NCBI build 36!!!
  
-266 - 
 
Appendix 5.8: Regions showing significant copy number differences in FGFR3 mutant TaG1/G2 multifocal (n=7) versus 
solitary (n=19) tumours. 
 
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:119,708,536-193,197,934 p12 - q31.3 Gain 73489398 42.86 0.00 42.86 0.013 
chr10:104,342,397-104,652,460 q24.32 Loss 310063 57.14 0.00 57.14 0.002 
chr10:104,652,460-109,290,751 q24.32 - q25.1 Loss 4638291 42.86 0.00 42.86 0.013 
chr10:99,781,492-104,342,397 q24.2 - q24.32 Loss 4560905 42.86 0.00 42.86 0.013 
chr13:22,108,664-27,824,701 q12.11 - q12.3 Gain 5716037 42.86 5.26 37.59 0.047 
chr13:66,421,707-67,895,141 q21.32 - q21.33 Gain 1473434 42.86 5.26 37.59 0.047 
chr16:193,278-6,165,969 p13.3 Loss 5972691 42.86 0.00 42.86 0.013 
chr19:33,399,234-36,171,164 q12 Gain 2771930 42.86 0.00 42.86 0.013 
chr19:36,322,238-40,876,527 q12 - q13.12 Gain 4554289 42.86 0.00 42.86 0.013 
chr19:41,059,171-51,988,000 q13.12 - q13.32 Gain 10928829 42.86 0.00 42.86 0.013 
chr19:52,342,137-63,602,791 q13.32 - q13.43 Gain 11260654 42.86 0.00 42.86 0.013 
chr20:30,102,016-34,346,661 q11.21 - q11.23 Gain 4244645 42.86 5.26 37.59 0.047 
chr20:34,346,661-62,392,510 q11.23 - q13.33 Gain 28045849 57.14 5.26 51.88 0.010 
chr20:62,392,510-62,393,015 q13.33 Gain 505 42.86 5.26 37.59 0.047 
chr5:162,296,397-171,159,864 q34 - q35.1 Loss 8863467 42.86 0.00 42.86 0.013 
chr5:171,159,864-173,800,904 q35.1 - q35.2 Loss 2641040 42.86 5.26 37.59 0.047 
chr5:173,800,904-178,243,610 q35.2 - q35.3 Loss 4442706 42.86 0.00 42.86 0.013 
chr6:162,865,542-162,954,569 q26 Gain 89027 42.86 0.00 42.86 0.013 
chr8:70,378,901-72,600,219 q13.2 - q13.3 Gain 2221318 42.86 0.00 42.86 0.013 
chr9:21,734,602-21,851,433 p21.3 Loss 116831 100.00 26.32 73.68 0.001 
chr9:21,851,433-21,998,414 p21.3 Loss 146981 85.71 26.32 59.40 0.021 
chr9:21,998,414-22,046,818 p21.3 Loss 48404 85.71 21.05 64.66 0.005 
chr9:22,046,818-22,155,847 p21.3 Loss 109029 100.00 21.05 78.95 0.001 
chr9:22,155,847-22,155,946 p21.3 Loss 99 85.71 21.05 64.66 0.005 
chr9:22,155,946-23,376,562 p21.3 Loss 1220616 85.71 26.32 59.40 0.021 
chr9:82,003,000-82,148,095 q21.31 Loss 145095 85.71 10.53 75.19 0.001 
1Physical position is according to hg18/NCBI build 36 
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Appendix 5.9: Regions showing significant copy number differences in FGFR3  wildtype TaG1/2  multifocal (n=4) versus 
solitary (n=9) tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr8:96,177,980-124,550,528 q22.1 - q24.13 Gain 28372548 100 11.1 88.9 0.007 
chr8:124,718,428-146,133,884 q24.13 - q24.3 Gain 21415456 100 11.1 88.9 0.007 
chr8:124,550,528-124,718,428 q24.13 Gain 167900 100 0.0 100.0 0.001 
chr9:30,699,255-68,858,635 p21.1 - q12 Loss 38159380 75 0.0 75.0 0.014 
chr17:35,227,093-35,920,940 q12 - q21.2 Loss 693847 75 0.0 75.0 0.014 !
 
1Physical position is according to hg18/NCBI build 36!!!
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Appendix 5.10: Regions showing significant copy number differences in FGFR3 wildtype T1G3 multifocal (n=8) versus 
solitary (n=16) tumours. 
 !
Region1 Cytoband Location Event Region Length Freq. in 
Multifocal (%) 
Freq. in 
Solitary (%) 
Difference p-value 
chr1:119,480,610-141,672,545 p12 - q12 Gain 22191935 62.5 12.5 50 0.0207 
chr1:44,062,032-45,524,938 p34.1 Gain 1462906 50 6.25 43.75 0.0277 
chr1:53,077,428-73,625,895 p32.3 - p31.1 Gain 20548467 50 6.25 43.75 0.0277 
chr10:116,774,295-125,057,698 q25.3 - q26.13 Loss 8283403 62.5 0 62.5 0.0013 
chr10:125,057,698-131,816,154 q26.13 - q26.3 Loss 6758456 50 0 50 0.0066 
chr10:131,816,154-131,982,049 q26.3 Loss 165895 37.5 0 37.5 0.0277 
chr10:131,982,049-135,247,831 q26.3 Loss 3265782 50 0 50 0.0066 
chr10:78,996,385-80,472,830 q22.3 Loss 1476445 50 6.25 43.75 0.0277 
chr10:84,577,760-86,390,131 q23.1 Loss 1812371 50 6.25 43.75 0.0277 
chr10:86,390,131-88,222,653 q23.1 - q23.2 Loss 1832522 62.5 6.25 56.25 0.0069 
chr10:88,222,653-89,694,469 q23.2 - q23.31 Loss 1471816 75 6.25 68.75 0.0013 
chr10:89,694,469-89,694,975 q23.31 Loss 506 62.5 6.25 56.25 0.0069 
chr10:89,694,975-90,596,444 q23.31 Loss 901469 75 6.25 68.75 0.0013 
chr10:90,596,444-116,774,295 q23.31 - q25.3 Loss 26177851 75 0 75 0.0002 
chr11:44,879,168-59,697,061 p11.2 - q12.1 Loss 14817893 37.5 0 37.5 0.0277 
chr12:152,534-25,552,960 p13.33 - p12.1 Loss 25400426 37.5 0 37.5 0.0277 
chr12:33,333,489-46,156,911 p11.1 - q13.11 Loss 12823422 37.5 0 37.5 0.0277 
chr13:47,964,053-51,243,111 q14.2 - q14.3 Loss 3279058 50 6.25 43.75 0.0277 
chr14:33,897,190-34,061,283 q13.1 Loss 164093 37.5 0 37.5 0.0277 
chr14:57,420,120-58,323,469 q23.1 Loss 903349 50 6.25 43.75 0.0277 
chr14:58,323,469-58,470,270 q23.1 Loss 146801 37.5 0 37.5 0.0277 
chr14:58,470,270-59,336,011 q23.1 Loss 865741 50 6.25 43.75 0.0277 
chr15:63,070,265-82,907,017 q22.31 - q25.2 Loss 19836752 37.5 0 37.5 0.0277 
chr15:83,883,618-85,362,775 q25.3 Loss 1479157 37.5 0 37.5 0.0277 
chr15:87,338,954-100,022,043 q26.1 - q26.3 Loss 12683089 37.5 0 37.5 0.0277 
chr16:23,756,350-45,067,244 p12.1 - q11.2 Gain 21310894 50 0 50 0.0066 
chr16:45,231,075-63,462,907 q11.2 - q21 Loss 18231832 37.5 0 37.5 0.0277 
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chr16:7,019,846-23,756,350 p13.2 - p12.1 Gain 16736504 37.5 0 37.5 0.0277 
chr19:211,322-6,523,485 p13.3 Loss 6312163 37.5 0 37.5 0.0277 
chr19:32,891,236-33,399,234 q12 Gain 507998 37.5 0 37.5 0.0277 
chr19:38,091,322-38,282,890 q13.11 Gain 191568 50 6.25 43.75 0.0277 
chr19:39,226,664-45,806,715 q13.11 - q13.2 Gain 6580051 50 6.25 43.75 0.0277 
chr19:46,479,845-51,023,195 q13.2 - q13.32 Gain 4543350 37.5 0 37.5 0.0277 
chr2:1,785,220-20,037,859 p25.3 - p24.1 Gain 18252639 50 6.25 43.75 0.0277 
chr2:169,397,061-208,876,525 q24.3 - q33.3 Loss 39479464 37.5 0 37.5 0.0277 
chr2:20,215,537-21,280,646 p24.1 Gain 1065109 50 6.25 43.75 0.0277 
chr2:208,876,525-210,331,732 q33.3 - q34 Loss 1455207 62.5 0 62.5 0.0013 
chr2:210,331,732-228,542,036 q34 - q36.3 Loss 18210304 62.5 6.25 56.25 0.0069 
chr2:224,263-1,785,220 p25.3 Gain 1560957 50 0 50 0.0066 
chr2:228,542,036-238,252,220 q36.3 - q37.3 Loss 9710184 75 6.25 68.75 0.0013 
chr2:238,252,220-241,796,109 q37.3 Loss 3543889 75 12.5 62.5 0.0047 
chr2:25,870,821-48,938,583 p23.3 - p16.3 Gain 23067762 50 6.25 43.75 0.0277 
chr2:48,938,583-52,373,212 p16.3 Gain 3434629 50 0 50 0.0066 
chr2:52,373,212-64,478,283 p16.3 - p14 Gain 12105071 62.5 0 62.5 0.0013 
chr2:64,478,283-71,285,149 p14 - p13.3 Gain 6806866 50 0 50 0.0066 
chr2:71,285,149-74,335,462 p13.3 - p13.1 Gain 3050313 62.5 0 62.5 0.0013 
chr2:74,335,462-82,716,433 p13.1 - p12 Gain 8380971 50 0 50 0.0066 
chr2:82,716,433-83,447,850 p12 Gain 731417 50 6.25 43.75 0.0277 
chr2:83,447,850-88,214,979 p12 - p11.2 Gain 4767129 50 0 50 0.0066 
chr2:88,214,979-94,782,159 p11.2 - q11.1 Gain 6567180 62.5 0 62.5 0.0013 
chr2:94,782,159-95,675,764 q11.1 Gain 893605 50 0 50 0.0066 
chr20:26,006,126-26,220,344 p11.1 Gain 214218 75 0 75 0.0002 
chr20:26,220,344-28,267,569 p11.1 - q11.1 Gain 2047225 75 6.25 68.75 0.0013 
chr20:275,014-424,783 p13 Gain 149769 75 0 75 0.0002 
chr20:28,267,569-29,779,350 q11.1 - q11.21 Gain 1511781 75 18.75 56.25 0.0215 
chr20:29,779,350-30,526,698 q11.21 Gain 747348 75 25 50 0.0324 
chr20:30,526,698-37,666,045 q11.21 - q12 Gain 7139347 75 18.75 56.25 0.0215 
chr20:37,666,045-40,680,814 q12 Gain 3014769 87.5 18.75 68.75 0.0023 
chr20:40,680,814-40,792,351 q12 Gain 111537 75 18.75 56.25 0.0215 
chr20:40,792,351-43,889,716 q12 - q13.12 Gain 3097365 75 25 50 0.0324 
chr20:424,783-26,006,126 p13 - p11.1 Gain 25581343 75 6.25 68.75 0.0013 
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chr20:43,889,716-47,383,084 q13.12 - q13.13 Gain 3493368 75 18.75 56.25 0.0215 
chr20:47,538,301-62,393,015 q13.13 - q13.33 Gain 14854714 75 18.75 56.25 0.0215 
chr22:15,621,248-15,745,966 q11.1 Loss 124718 37.5 0 37.5 0.0277 
chr22:15,745,966-18,151,355 q11.1 - q11.21 Loss 2405389 50 0 50 0.0066 
chr22:18,151,355-18,151,891 q11.21 Loss 536 37.5 0 37.5 0.0277 
chr22:18,151,891-24,286,893 q11.21 - q11.23 Loss 6135002 50 6.25 43.75 0.0277 
chr22:28,379,404-30,623,768 q12.2 - q12.3 Loss 2244364 50 6.25 43.75 0.0277 
chr22:30,646,401-40,803,595 q12.3 - q13.2 Loss 10157194 50 6.25 43.75 0.0277 
chr22:40,803,595-42,473,589 q13.2 Loss 1669994 62.5 12.5 50 0.0207 
chr3:83,768,022-87,044,540 p12.1 Gain 3276518 37.5 0 37.5 0.0277 
chr4:113,578,539-179,587,711 q25 - q34.3 Loss 66009172 37.5 0 37.5 0.0277 
chr4:26,747,433-47,677,803 p15.2 - p12 Loss 20930370 37.5 0 37.5 0.0277 
chr4:55,628-11,429,778 p16.3 - p15.33 Loss 11374150 37.5 0 37.5 0.0277 
chr4:74,866,776-78,196,278 q13.3 - q21.1 Gain 3329502 37.5 0 37.5 0.0277 
chr5:51,232,444-65,352,862 q11.2 - q12.3 Loss 14120418 50 6.25 43.75 0.0277 
chr6:170,622,773-170,728,000 q27 Loss 105227 50 6.25 43.75 0.0277 
chr6:20,272,069-22,580,422 p22.3 Gain 2308353 62.5 12.5 50 0.0207 
chr6:22,580,422-23,499,391 p22.3 Gain 918969 62.5 6.25 56.25 0.0069 
chr6:23,499,391-27,152,460 p22.3 - p22.1 Gain 3653069 50 6.25 43.75 0.0277 
chr7:142,857,956-147,259,180 q35 Gain 4401224 62.5 12.5 50 0.0207 
chr7:63,102,874-67,229,358 q11.21 - q11.22 Gain 4126484 62.5 12.5 50 0.0207 
chr9:190-336,203 p24.3 Gain 336013 37.5 0 37.5 0.0277 
chr9:84,783,002-89,446,315 q21.32 - q21.33 Gain 4663313 37.5 0 37.5 0.0277 !
 
1Physical position is according to hg18/NCBI build 36!!!
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Appendix 5.11: Details of samples in the four main clusters obtained by 
hierarchical cluster analysis of copy number data from 22 patients with 
multifocal tumours and 103 solitary tumours including stage ≥ T2 
tumours (n=29). 
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Appendix 5.12: Suppliers and manufacturers 
 
 
Amersham Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA 
www.amersham.com 
 
Amity Ltd Libra House, Spring Park, Clayburn Road, Park Springs, Barnsley, 
South Yorkshire, S72 7FD www.amityinternational.com 
 
Applied Biosystems (AB) Lingley House, 120 Birchwood Boulevard, 
Warrington, WA3 7QH www.appliedbiosystems.com 
 
BD Biosciences The Danby Building, Edmund Halley Road, Oxford science 
park, Oxford, OX4 4DQ www.bpeurope.com 
 
Beckman Coulter Oakley Court, Kingsmead Business Park, London Road, 
High Wycombe, Buckinghamshire, HP11 1JU www.beckmancoulter.com 
 
Bioline Ltd 16 The Edge Business Centre, Humber Road, London, NW62 
6EW www.bioline.com 
 
BIO-RAD Bio-Rad house, Maxted Road, Hemel Hempstead, Hertfordshire, 
HP2 7DX www.bio-rad.com 
 
Cambridge Bioscience Munro House, Trafalgar Way, Cambridge, CB23 8SQ 
www.bioscience.co.uk 
 
Corning Supplied by Sigma www.corning.com 
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Falcon Supplied by SLS 
 
Fisher Scientific Ltd Bishop Meadow Road, Loughborough, Leicestershire, 
LE11 5RG 
 
GE Healthcare Supplied by Fisher Scientific 
 
Guava Technologies 10 Torkington Street, Stamford, Lincolnshire, PE9 2UY 
www.guavatechnologies.com 
 
Insight Biotechnology Ltd PO Box 520, Wembley, HA9 7YN 
www.insightbio.com 
 
Integra Biosciences Supplied by SLS www.integra-biosciences.com 
 
Medical Air Technology (MAT) Independent House, Broadway Business 
Park, Gateway Crescent, Chadderton, Oldham, OL9 9XB 
www.medicalairtechnology.com 
 
Medichem PO Box 237, Sevenoaks, Kent, TN15 0ZJ www.medi-chem.com 
 
Mirus Supplied by Cambridge Bioscience 
 
Nalgene Unit 1a, Thorn Business Park, Hereford, HR2 6JT 
www.nalgenelabware.com 
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National Diagnostics Unit 4 Fleet Business Park, Itlings Lane, Hessle, 
Yorkshire, HU13 9LX www.nationaldiagnostics.com 
 
New England Biolabs (NEB) 75-77 Knowl Place, Wilbury Way, Hitchin, 
Hertfordshire, SG4 0TY www.neb.com 
 
NUNC supplied by SLS 
 
PALL Life sciences Europa House, Havant Street, Portsmouth, Hampshire, 
PO1 3PD www.pall.com 
 
Qiagen Fleming Way, Crawley, West Sussex, RH10 9NQ www.qiagen.com 
 
Santa Cruz Biotechnology Supplied by Insight Biotechnology www.scbt.com 
 
Sarstedt 68 Boston Road, Beaumont Leys, Leicester, LE4 1AW 
www.sarstedt.com 
 
Scientific Laboratory Supplies (SLS) Ruddington Lane, Wilford Industrial 
Estate, Nottingham, NG11 7EP www.scientific-labs.com 
 
Sigma-Aldrich Company Ltd. Fancy Road, Poole, Dorset, BH12 4QH 
www.sigmaaldrich.com 
 
Stratagene Europe Gebouw California, Hogehilweg 15 1101 CB Amsterdam, 
The Netherlands www.stratagene.com 
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Thermo Scientific 93-96 Chadwick Road, Astmoor, Runcorn, Cheshire, WA7 
1PR www.thermo.com 
 
Zeiss Carl Zeiss Ltd., 5-20 Woodfield Road, Welwyn Garden City, 
Hertfordshire, AL7 1JQ www.zeiss.co.uk 
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bladder)cancer."Cancer"Res,"1992."52(6):"p."1393C8."94." Spruck,"C.H.,"3rd,"et"al.,"Two)molecular)pathways)to)transitional)cell)
carcinoma)of)the)bladder."Cancer"Res,"1994."54(3):"p."784C8."95." Goebell,"P.J.,"S.G."Groshen,"and"B.J."SchmitzCDrager,"p53)
immunohistochemistry)in)bladder)cancer;;a)new)approach)to)an)old)
question."Urol"Oncol,"2010."28(4):"p."377C88."96." Malats,"N.,"et"al.,"P53)as)a)prognostic)marker)for)bladder)cancer:)a)meta;
analysis)and)review."Lancet"Oncol,"2005."6(9):"p."678C86."97." George,"B.,"et"al.,"p53)gene)and)protein)status:)the)role)of)p53)alterations)
in)predicting)outcome)in)patients)with)bladder)cancer."J"Clin"Oncol,"2007."
25(34):"p."5352C8."98." Benedict,"W.F.,"et"al.,"Level)of)retinoblastoma)protein)expression)correlates)
with)p16)(MTS;1/INK4A/CDKN2))status)in)bladder)cancer."Oncogene,"1999."18(5):"p."1197C203."99." Shariat,"S.F.,"et"al.,"p53,)p21,)pRB,)and)p16)expression)predict)clinical)
outcome)in)cystectomy)with)bladder)cancer."J"Clin"Oncol,"2004."22(6):"p."1014C24."100." Logothetis,"C.J.,"et"al.,"Altered)expression)of)retinoblastoma)protein)and)
known)prognostic)variables)in)locally)advanced)bladder)cancer."J"Natl"Cancer"Inst,"1992."84(16):"p."1256C61."101." CordonCCardo,"C.,"et"al.,"Altered)expression)of)the)retinoblastoma)gene)
product:)prognostic)indicator)in)bladder)cancer."J"Natl"Cancer"Inst,"1992."
84(16):"p."1251C6."102." Hurst,"C.D.,"et"al.,"Inactivation)of)the)Rb)pathway)and)overexpression)of)
both)isoforms)of)E2F3)are)obligate)events)in)bladder)tumours)with)6p22)
amplification."Oncogene,"2008."27(19):"p."2716C27."103." Steinthorsdottir,"V.,"et"al.,"A)variant)in)CDKAL1)influences)insulin)response)
and)risk)of)type)2)diabetes."Nat"Genet,"2007."39(6):"p."770C5."104." Oeggerli,"M.,"et"al.,"E2F3)amplification)and)overexpression)is)associated)
with)invasive)tumor)growth)and)rapid)tumor)cell)proliferation)in)urinary)
bladder)cancer."Oncogene,"2004."23(33):"p."5616C23."105." Feber,"A.,"et"al.,"Amplification)and)overexpression)of)E2F3)in)human)
bladder)cancer."Oncogene,"2004."23(8):"p."1627C30."106." Xu,"H.J.,"et"al.,"Loss)of)RB)protein)expression)in)primary)bladder)cancer)
correlates)with)loss)of)heterozygosity)at)the)RB)locus)and)tumor)
progression."Int"J"Cancer,"1993."53(5):"p."781C4."107." Takle,"L.A."and"M.A."Knowles,"Deletion)mapping)implicates)two)tumor)
suppressor)genes)on)chromosome)8p)in)the)development)of)bladder)cancer."Oncogene,"1996."12(5):"p."1083C7."
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108." Stoehr,"R.,"et"al.,"Deletions)of)chromosome)8p)and)loss)of)sFRP1)expression)
are)progression)markers)of)papillary)bladder)cancer."Lab"Invest,"2004."
84(4):"p."465C78."109." Choi,"C.,"et"al.,"Loss)of)heterozygosity)at)chromosome)segments)8p22)and)
8p11.2;21.1)in)transitional;cell)carcinoma)of)the)urinary)bladder."Int"J"Cancer,"2000."86(4):"p."501C5."110." Adams,"J.,"et"al.,"Loss)of)heterozygosity)analysis)and)DNA)copy)number)
measurement)on)8p)in)bladder)cancer)reveals)two)mechanisms)of)allelic)
loss."Cancer"Res,"2005."65(1):"p."66C75."111." Kagan,"J.,"et"al.,"Cluster)of)allele)losses)within)a)2.5)cM)region)of)
chromosome)10)in)high;grade)invasive)bladder)cancer."Oncogene,"1998."
16(7):"p."909C13."112." Cappellen,"D.,"et"al.,"Frequent)loss)of)heterozygosity)on)chromosome)10q)in)
muscle;invasive)transitional)cell)carcinomas)of)the)bladder."Oncogene,"1997."14(25):"p."3059C66."113." Aveyard,"J.S.,"et"al.,"Somatic)mutation)of)PTEN)in)bladder)carcinoma."Br"J"Cancer,"1999."80(5C6):"p."904C8."114." Gildea,"J.J.,"et"al.,"PTEN)can)inhibit)in)vitro)organotypic)and)in)vivo)
orthotopic)invasion)of)human)bladder)cancer)cells)even)in)the)absence)of)
its)lipid)phosphatase)activity."Oncogene,"2004."23(40):"p."6788C97."115." Simon,"R.,"et"al.,"HER;2)and)TOP2A)coamplification)in)urinary)bladder)
cancer."Int"J"Cancer,"2003."107(5):"p."764C72."116." Sauter,"G.,"et"al.,"Heterogeneity)of)erbB;2)gene)amplification)in)bladder)
cancer."Cancer"Res,"1993."53(10"Suppl):"p."2199C203."117." Miyamoto,"H.,"et"al.,"C;ERBB;2)gene)amplification)as)a)prognostic)marker)
in)human)bladder)cancer."Urology,"2000."55(5):"p."679C83."118." Lonn,"U.,"et"al.,"Prognostic)value)of)amplification)of)c;erb;B2)in)bladder)
carcinoma."Clin"Cancer"Res,"1995."1(10):"p."1189C94."119." Coombs,"L.M.,"et"al.,"Amplification)and)over;expression)of)c;erbB;2)in)
transitional)cell)carcinoma)of)the)urinary)bladder."Br"J"Cancer,"1991."
63(4):"p."601C8."120." Hirao,"S.,"et"al.,"Loss)of)heterozygosity)on)chromosome)9q)and)p53)
alterations)in)human)bladder)cancer."Cancer,"2005."104(9):"p."1918C23."121." Tsai,"Y.C.,"et"al.,"Allelic)losses)of)chromosomes)9,)11,)and)17)in)human)
bladder)cancer."Cancer"Res,"1990."50(1):"p."44C7."122." Linnenbach,"A.J.,"et"al.,"Characterization)of)chromosome)9)deletions)in)
transitional)cell)carcinoma)by)microsatellite)assay."Hum"Mol"Genet,"1993."
2(9):"p."1407C11."123." Cairns,"P.,"et"al.,"Rates)of)p16)(MTS1))mutations)in)primary)tumors)with)9p)
loss."Science,"1994."265(5170):"p."415C7."124." Williamson,"M.P.,"et"al.,"p16)(CDKN2))is)a)major)deletion)target)at)9p21)in)
bladder)cancer."Hum"Mol"Genet,"1995."4(9):"p."1569C77."125." Orlow,"I.,"et"al.,"Deletion)of)the)p16)and)p15)genes)in)human)bladder)
tumors."J"Natl"Cancer"Inst,"1995."87(20):"p."1524C9."126." Devlin,"J.,"A.J."Keen,"and"M.A."Knowles,"Homozygous)deletion)mapping)at)
9p21)in)bladder)carcinoma)defines)a)critical)region)within)2cM)of)IFNA."Oncogene,"1994."9(9):"p."2757C60."127." Berggren,"P.,"et"al.,"Detecting)homozygous)deletions)in)the)
CDKN2A(p16(INK4a))/ARF(p14(ARF)))gene)in)urinary)bladder)cancer)
using)real;time)quantitative)PCR."Clin"Cancer"Res,"2003."9(1):"p."235C42."
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128." Chapman,"E.J.,"et"al.,"Comprehensive)analysis)of)CDKN2A)status)in)
microdissected)urothelial)cell)carcinoma)reveals)potential)
haploinsufficiency,)a)high)frequency)of)homozygous)co;deletion)and)
associations)with)clinical)phenotype."Clin"Cancer"Res,"2005."11(16):"p."5740C7."129." Luo,"J.,"N.L."Solimini,"and"S.J."Elledge,"Principles)of)cancer)therapy:)
oncogene)and)non;oncogene)addiction."Cell,"2009."136(5):"p."823C37."130." Inoue,"K.,"et"al.,"Paclitaxel)enhances)the)effects)of)the)anti;epidermal)
growth)factor)receptor)monoclonal)antibody)ImClone)C225)in)mice)with)
metastatic)human)bladder)transitional)cell)carcinoma."Clin"Cancer"Res,"2000."6(12):"p."4874C84."131." Sriplakich,"S.,"S."Jahnson,"and"M.G."Karlsson,"Epidermal)growth)factor)
receptor)expression:)predictive)value)for)the)outcome)after)cystectomy)for)
bladder)cancer?"BJU"Int,"1999."83(4):"p."498C503."132." NCT00645593,"Phase)II)Randomized)Trial)of)Gemcitabine)and)Cisplatin)
With)or)Without)Cetuximab)in)Patients)With)Urothelial)Carcinoma."2008."133." Philips,"G.K.,"et"al.,"A)phase)II)trial)of)cisplatin)(C),)gemcitabine)(G))and)
gefitinib)for)advanced)urothelial)tract)carcinoma:)results)of)Cancer)and)
Leukemia)Group)B)(CALGB))90102."Ann"Oncol,"2009."20(6):"p."1074C9."134." Wulfing,"C.,"et"al.,"A)single;arm,)multicenter,)open;label)phase)2)study)of)
lapatinib)as)the)second;line)treatment)of)patients)with)locally)advanced)or)
metastatic)transitional)cell)carcinoma."Cancer,"2009."115(13):"p."2881C90."135." NCT00949455,"LaMB);)maintenance)lapatinib)versus)placebo)after)first;
line)chemotherapy)in)patients)with)locally)advanced)or)metastatic)bladder)
cancer."2011."136." Matsubara,"H.,"et"al.,"Potential)for)HER;2/neu)molecular)targeted)therapy)
for)invasive)bladder)carcinoma:)comparative)study)of)
immunohistochemistry)and)fluorescent)in)situ)hybridization."Oncol"Rep,"2008."19(1):"p."57C63."137." Hansel,"D.E.,"et"al.,"HER2)overexpression)and)amplification)in)urothelial)
carcinoma)of)the)bladder)is)associated)with)MYC)coamplification)in)a)
subset)of)cases."Am"J"Clin"Pathol,"2008."130(2):"p."274C81."138." Park,"K.,"et"al.,"c;myc)amplification)is)associated)with)HER2)amplification)
and)closely)linked)with)cell)proliferation)in)tissue)microarray)of)
nonselected)breast)cancers."Hum"Pathol,"2005."36(6):"p."634C9."139." Sonpavde,"G.,"et"al.,"Sunitinib)malate)is)active)against)human)urothelial)
carcinoma)and)enhances)the)activity)of)cisplatin)in)a)preclinical)model."Urol"Oncol,"2009."27(4):"p."391C9."140." Takeuchi,"A.,"et"al.,"Sunitinib)enhances)antitumor)effects)against)
chemotherapy;resistant)bladder)cancer)through)suppression)of)ERK1/2)
phosphorylation."Int"J"Oncol,"2012."40(5):"p."1691C6."141." Gallagher,"D.J.,"et"al.,"Phase)II)study)of)sunitinib)in)patients)with)metastatic)
urothelial)cancer."J"Clin"Oncol,"2010."28(8):"p."1373C9."142." Multicentre,"A)Multicentre)Phase)II)Trial)to)Determine)the)Efficacy)of)the)
Anti;Tyrosine)Kinase)Sunitinib)(Sutent®))as)Second)Line)Therapy)in)
Patients)With)Transitional)Cell)Carcinoma)(TCC))of)the)Urothelium)Which)
Failed)or)Progressed)After)First)Line)Chemotherapy)for)Advanced)or)
Metastatic)Disease."2011."
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143." Unit,"W.C.T.,"A)Phase)II)Single;Arm)Trial)to)Evaluate)Cisplatin)and)
Gemcitabine)Chemotherapy)in)Combination)With)Sunitinib)for)First;Line)
Treatment)of)Patients)With)Advanced)Transitional)Carcinoma)of)the)
Urothelium."2010."144." Galsky,"M.D.,"et"al.,"Gemcitabine,)Cisplatin,)and)sunitinib)for)metastatic)
urothelial)carcinoma)and)as)preoperative)therapy)for)muscle;invasive)
bladder)cancer."Clin"Genitourin"Cancer,"2013."11(2):"p."175C81."145." Zhu,"Z."and"L."Witte,"Inhibition)of)tumor)growth)and)metastasis)by)
targeting)tumor;associated)angiogenesis)with)antagonists)to)the)receptors)
of)vascular)endothelial)growth)factor."Invest"New"Drugs,"1999."17(3):"p."195C212."146." von"Hardenberg,"J.,"et"al.,"Expression)and)predictive)value)of)lymph;
specific)markers)in)urothelial)carcinoma)of)the)bladder."Urol"Oncol,"2014."
32(1):"p."54.e9C17."147." Kopparapu,"P.K.,"et"al.,"Expression)of)VEGF)and)its)receptors)
VEGFR1/VEGFR2)is)associated)with)invasiveness)of)bladder)cancer."Anticancer"Res,"2013."33(6):"p."2381C90."148." HenriquezCHernandez,"L.A.,"et"al.,"Polymorphisms)of)glutathione)S;
transferase)mu)and)theta,)MDR1)and)VEGF)genes)as)risk)factors)of)bladder)
cancer:)a)case;control)study."Urol"Oncol,"2012."30(5):"p."660C5."149." Cheng,"D.,"B."Liang,"and"Y."Li,"Clinical)value)of)vascular)endothelial)growth)
factor)and)endostatin)in)urine)for)diagnosis)of)bladder)cancer."Tumori,"2012."98(6):"p."762C7."150." Bernardini,"S.,"et"al.,"Serum)levels)of)vascular)endothelial)growth)factor)as)
a)prognostic)factor)in)bladder)cancer."J"Urol,"2001."166(4):"p."1275C9."151." Bellmunt,"J.,"et"al.,"Phase)II)study)of)sunitinib)as)first;line)treatment)of)
urothelial)cancer)patients)ineligible)to)receive)cisplatin;based)
chemotherapy:)baseline)interleukin;8)and)tumor)contrast)enhancement)as)
potential)predictive)factors)of)activity."Ann"Oncol,"2011."22(12):"p."2646C53."152." Inoue,"K.,"et"al.,"Treatment)of)human)metastatic)transitional)cell)
carcinoma)of)the)bladder)in)a)murine)model)with)the)anti;vascular)
endothelial)growth)factor)receptor)monoclonal)antibody)DC101)and)
paclitaxel."Clin"Cancer"Res,"2000."6(7):"p."2635C43."153." Sonpavde,"G.,"et"al.,"Novel)agents)for)muscle;invasive)and)advanced)
urothelial)cancer."BJU"Int,"2008."101(8):"p."937C43."154." Tomlinson,"D.C.,"et"al.,"Fibroblast)growth)factor)receptor)1)promotes)
proliferation)and)survival)via)activation)of)the)mitogen;activated)protein)
kinase)pathway)in)bladder)cancer."Cancer"Res,"2009."69(11):"p."4613C20."155." Zhu,"L.,"et"al.,"Fibroblast)growth)factor)receptor)3)inhibition)by)short)
hairpin)RNAs)leads)to)apoptosis)in)multiple)myeloma."Mol"Cancer"Ther,"2005."4(5):"p."787C98."156." Trudel,"S.,"et"al.,"The)inhibitory)anti;FGFR3)antibody,)PRO;001,)is)cytotoxic)
to)t(4;14))multiple)myeloma)cells."Blood,"2006."107(10):"p."4039C46."157." Qing,"J.,"et"al.,"Antibody;based)targeting)of)FGFR3)in)bladder)carcinoma)
and)t(4;14);positive)multiple)myeloma)in)mice."J"Clin"Invest,"2009."
119(5):"p."1216C29."158." Hadari,"Y."and"J."Schlessinger,"FGFR3;targeted)mAb)therapy)for)bladder)
cancer)and)multiple)myeloma."J"Clin"Invest,"2009."119(5):"p."1077C9."
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159." di"Martino,"E.,"D.C."Tomlinson,"and"M.A."Knowles,"A)Decade)of)FGF)
Receptor)Research)in)Bladder)Cancer:)Past,)Present,)and)Future)
Challenges."Adv"Urol,"2012."2012:"p."429213."160." Mohammadi,"M.,"et"al.,"Crystal)structure)of)an)angiogenesis)inhibitor)
bound)to)the)FGF)receptor)tyrosine)kinase)domain."EMBO"J,"1998."17(20):"p."5896C904."161." Mohammadi,"M.,"et"al.,"Structures)of)the)tyrosine)kinase)domain)of)
fibroblast)growth)factor)receptor)in)complex)with)inhibitors."Science,"1997."276(5314):"p."955C60."162." Sarker,"D.,"et"al.,"A)phase)I)pharmacokinetic)and)pharmacodynamic)study)
of)TKI258,)an)oral,)multitargeted)receptor)tyrosine)kinase)inhibitor)in)
patients)with)advanced)solid)tumors."Clin"Cancer"Res,"2008."14(7):"p."2075C81."163." Lamont,"F.R.,"et"al.,"Small)molecule)FGF)receptor)inhibitors)block)FGFR;
dependent)urothelial)carcinoma)growth)in)vitro)and)in)vivo."Br"J"Cancer,"2011."104(1):"p."75C82."164." Miyake,"M.,"et"al.,"1;tert;butyl;3;[6;(3,5;dimethoxy;phenyl);2;(4;
diethylamino;butylamino);pyrido[2,3);d]pyrimidin;7;yl];urea)
(PD173074),)a)selective)tyrosine)kinase)inhibitor)of)fibroblast)growth)
factor)receptor;3)(FGFR3),)inhibits)cell)proliferation)of)bladder)cancer)
carrying)the)FGFR3)gene)mutation)along)with)up;regulation)of)p27/Kip1)
and)G1/G0)arrest."J"Pharmacol"Exp"Ther,"2010."332(3):"p."795C802."165." GU12C157,"Dovitinib)in)BCG)Refractory)Urothelial)Carcinoma)With)FGFR3)
Mutations)or)Over;expression."2012."166." Andre,"F.,"et"al.,"Targeting)FGFR)with)Dovitinib)(TKI258):)Preclinical)and)
Clinical)Data)in)Breast)Cancer."Clin"Cancer"Res,"2013."19(13):"p."3693C3702."167." NCT00790426,"A)Phase)II)Multi;center,)Non;randomized,)Open)Label)
Study)of)TKI258)in)FGFR3)Mutated)and)FGFR3)Wild)Type)Advanced)
Urothelial)Carcinoma."2013."168." Ciardiello,"F."and"G."Tortora,"EGFR)antagonists)in)cancer)treatment."N"Engl"J"Med,"2008."358(11):"p."1160C74."169." SartoreCBianchi,"A.,"et"al.,"PIK3CA)mutations)in)colorectal)cancer)are)
associated)with)clinical)resistance)to)EGFR;targeted)monoclonal)
antibodies."Cancer"Res,"2009."69(5):"p."1851C7."170." Antonescu,"C.R.,"Targeted)therapy)of)cancer:)new)roles)for)pathologists)in)
identifying)GISTs)and)other)sarcomas."Mod"Pathol,"2008."21&Suppl&2:"p."S31C6."171." PiccartCGebhart,"M.J.,"et"al.,"Trastuzumab)after)adjuvant)chemotherapy)in)
HER2;positive)breast)cancer."N"Engl"J"Med,"2005."353(16):"p."1659C72."172." Romond,"E.H.,"et"al.,"Trastuzumab)plus)adjuvant)chemotherapy)for)
operable)HER2;positive)breast)cancer."N"Engl"J"Med,"2005."353(16):"p."1673C84."173." Orndal,"C.,"et"al.,"Cytogenetic)evolution)in)primary)tumors,)local)
recurrences,)and)pulmonary)metastases)of)two)soft)tissue)sarcomas."Clin"Exp"Metastasis,"1993."11(5):"p."401C8."174." Levin,"N.A.,"et"al.,"Identification)of)novel)regions)of)altered)DNA)copy)
number)in)small)cell)lung)tumors."Genes"Chromosomes"Cancer,"1995."
13(3):"p."175C85."
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175." Gagos,"S.,"et"al.,"Chromosomal)markers)associated)with)metastasis)in)two)
colon)cancer)cell)lines)established)from)the)same)patient."Anticancer"Res,"1995."15(2):"p."369C78."176." Baffa,"R.,"et"al.,"MicroRNA)expression)profiling)of)human)metastatic)
cancers)identifies)cancer)gene)targets."J"Pathol,"2009."219(2):"p."214C21."177." Bergeron,"A.,"et"al.,"High)frequency)of)MAGE;A4)and)MAGE;A9)expression)
in)high;risk)bladder)cancer."Int"J"Cancer,"2009."125(6):"p."1365C71."178." Bellmunt,"J.,"M."Hussain,"and"C.P."Dinney,"Novel)approaches)with)targeted)
therapies)in)bladder)cancer.)Therapy)of)bladder)cancer)by)blockade)of)the)
epidermal)growth)factor)receptor)family."Crit"Rev"Oncol"Hematol,"2003."
46&Suppl:"p."S85C104."179." Dovedi,"S.J."and"B.R."Davies,"Emerging)targeted)therapies)for)bladder)
cancer:)a)disease)waiting)for)a)drug."Cancer"Metastasis"Rev,"2009."28(3C4):"p."355C67."180." Evans,"C.P.,"Identification)of)molecular)targets)in)urologic)oncology."World"J"Urol,"2009."27(1):"p."3C8."181." Fidler,"I.J."and"M.L."Kripke,"Metastasis)results)from)preexisting)variant)
cells)within)a)malignant)tumor."Science,"1977."197(4306):"p."893C5."182." Clark,"E.A.,"et"al.,"Genomic)analysis)of)metastasis)reveals)an)essential)role)
for)RhoC."Nature,"2000."406(6795):"p."532C5."183." Ramaswamy,"S.,"et"al.,"A)molecular)signature)of)metastasis)in)primary)
solid)tumors."Nat"Genet,"2003."33(1):"p."49C54."184." Hovey,"R.M.,"et"al.,"Genetic)alterations)in)primary)bladder)cancers)and)
their)metastases."Cancer"Res,"1998."58(16):"p."3555C60."185." Bernards,"R."and"R.A."Weinberg,"A)progression)puzzle."Nature,"2002."
418(6900):"p."823."186." Weigelt,"B.,"J.L."Peterse,"and"L.J."van"'t"Veer,"Breast)cancer)metastasis:)
markers)and)models."Nat"Rev"Cancer,"2005."5(8):"p."591C602."187." Klein,"C.A.,"Parallel)progression)of)primary)tumours)and)metastases."Nat"Rev"Cancer,"2009."9(4):"p."302C12."188." Scheel,"C.,"et"al.,"Adaptation)versus)selection:)the)origins)of)metastatic)
behavior."Cancer"Res,"2007."67(24):"p."11476C9;"discussion"11479C80."189." Jones,"T.D.,"et"al.,"Clonal)origin)of)lymph)node)metastases)in)bladder)
carcinoma."Cancer,"2005."104(9):"p."1901C10."190." Cheng,"L.,"et"al.,"Conserved)genetic)findings)in)metastatic)bladder)cancer:)a)
possible)utility)of)allelic)loss)of)chromosomes)9p21)and)17p13)in)diagnosis."Arch"Pathol"Lab"Med,"2001."125(9):"p."1197C9."191." Miyao,"N.,"et"al.,"Role)of)chromosome)9)in)human)bladder)cancer."Cancer"Res,"1993."53(17):"p."4066C70."192." Shariat,"S.F.,"et"al.,"Cooperative)effect)of)cell;cycle)regulators)expression)on)
bladder)cancer)development)and)biologic)aggressiveness."Mod"Pathol,"2007."20(4):"p."445C59."193." Byrne,"R.R.,"et"al.,"E;cadherin)immunostaining)of)bladder)transitional)cell)
carcinoma,)carcinoma)in)situ)and)lymph)node)metastases)with)long;term)
followup."J"Urol,"2001."165(5):"p."1473C9."194." Malmstrom,"P.U.,"et"al.,"Early)metastatic)progression)of)bladder)
carcinoma:)molecular)profile)of)primary)tumor)and)sentinel)lymph)node."J"Urol,"2002."168(5):"p."2240C4."195." Jimenez,"R.E.,"et"al.,"Her;2/neu)overexpression)in)muscle;invasive)
urothelial)carcinoma)of)the)bladder:)prognostic)significance)and)
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comparative)analysis)in)primary)and)metastatic)tumors."Clin"Cancer"Res,"2001."7(8):"p."2440C7."196." Gardmark,"T.,"et"al.,"Analysis)of)HER2)expression)in)primary)urinary)
bladder)carcinoma)and)corresponding)metastases."BJU"Int,"2005."95(7):"p."982C6."197." Fleischmann,"A.,"et"al.,"Her2)amplification)is)significantly)more)frequent)in)
lymph)node)metastases)from)urothelial)bladder)cancer)than)in)the)
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